EP2736514B1 - Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors - Google Patents
Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors Download PDFInfo
- Publication number
- EP2736514B1 EP2736514B1 EP12737280.3A EP12737280A EP2736514B1 EP 2736514 B1 EP2736514 B1 EP 2736514B1 EP 12737280 A EP12737280 A EP 12737280A EP 2736514 B1 EP2736514 B1 EP 2736514B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- chloro
- pyrrole
- ethynyl
- methylphenyl
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title description 16
- 108091000080 Phosphotransferase Proteins 0.000 title description 15
- 102000020233 phosphotransferase Human genes 0.000 title description 15
- 125000000304 alkynyl group Chemical group 0.000 title description 8
- BAJCRPRPWGNRKM-UHFFFAOYSA-N 2-(1h-pyrrol-2-yl)pyrimidine Chemical class C1=CNC(C=2N=CC=CN=2)=C1 BAJCRPRPWGNRKM-UHFFFAOYSA-N 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 335
- -1 alkyne compound Chemical group 0.000 claims description 282
- 238000000034 method Methods 0.000 claims description 113
- 238000006243 chemical reaction Methods 0.000 claims description 79
- 239000001257 hydrogen Substances 0.000 claims description 53
- 229910052739 hydrogen Inorganic materials 0.000 claims description 53
- 150000002431 hydrogen Chemical group 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 37
- 238000002360 preparation method Methods 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 238000005859 coupling reaction Methods 0.000 claims description 28
- 125000000623 heterocyclic group Chemical group 0.000 claims description 25
- 230000008569 process Effects 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 22
- 125000006239 protecting group Chemical group 0.000 claims description 20
- 125000003107 substituted aryl group Chemical group 0.000 claims description 20
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 19
- 108010087686 src-Family Kinases Proteins 0.000 claims description 19
- 102000009076 src-Family Kinases Human genes 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 18
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 17
- 150000001412 amines Chemical class 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 14
- 150000003857 carboxamides Chemical class 0.000 claims description 13
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 238000005658 halogenation reaction Methods 0.000 claims description 13
- 150000002367 halogens Chemical group 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 13
- 150000001345 alkine derivatives Chemical class 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 230000007062 hydrolysis Effects 0.000 claims description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 230000009435 amidation Effects 0.000 claims description 8
- 238000007112 amidation reaction Methods 0.000 claims description 8
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 8
- 238000010511 deprotection reaction Methods 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 7
- AAMATCKFMHVIDO-UHFFFAOYSA-N azane;1h-pyrrole Chemical compound N.C=1C=CNC=1 AAMATCKFMHVIDO-UHFFFAOYSA-N 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052740 iodine Chemical group 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000011630 iodine Chemical group 0.000 claims description 6
- QNZRMHXKTDXPQK-UHFFFAOYSA-N 5-[2-amino-5-(2-phenylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC=CC=2)N1 QNZRMHXKTDXPQK-UHFFFAOYSA-N 0.000 claims description 5
- CDJMHEULFWGCON-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-(4-methylpiperazin-1-yl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)C=C1 CDJMHEULFWGCON-UHFFFAOYSA-N 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- FQRDYEAQJMHOQI-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-[2-(methylamino)-5-[2-[4-(4-methylpiperazin-1-yl)phenyl]ethynyl]pyrimidin-4-yl]-1h-pyrrole-3-carboxamide Chemical compound C=1C(C(N)=O)=C(C=2C(=CC=C(Cl)C=2)C)NC=1C1=NC(NC)=NC=C1C#CC(C=C1)=CC=C1N1CCN(C)CC1 FQRDYEAQJMHOQI-UHFFFAOYSA-N 0.000 claims description 4
- BVMXWYDFXOCJRK-UHFFFAOYSA-N 5-[2-amino-5-[2-(4-formylphenyl)ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC(C=O)=CC=2)N1 BVMXWYDFXOCJRK-UHFFFAOYSA-N 0.000 claims description 4
- DHIKRVHXPYRGSK-UHFFFAOYSA-N 5-[2-amino-5-[2-[3-(azetidin-3-ylmethylamino)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=C(NCC3CNC3)C=CC=2)N1 DHIKRVHXPYRGSK-UHFFFAOYSA-N 0.000 claims description 4
- NMUZFIGCXAOWPE-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-(4-methylpiperazin-1-yl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-ethylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC(=CC=2)N2CCN(C)CC2)N1 NMUZFIGCXAOWPE-UHFFFAOYSA-N 0.000 claims description 4
- CCIYWQFXOGSMKI-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-(4-methylpiperazine-1-carbonyl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)C=C1 CCIYWQFXOGSMKI-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- CYGZWVOOUOWEDS-UHFFFAOYSA-N tert-butyl 3-[[3-[2-[2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1h-pyrrol-2-yl]pyrimidin-5-yl]ethynyl]anilino]methyl]azetidine-1-carboxylate Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=C(NCC3CN(C3)C(=O)OC(C)(C)C)C=CC=2)N1 CYGZWVOOUOWEDS-UHFFFAOYSA-N 0.000 claims description 4
- JXNWLPGCIODVGM-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-4-[2-[4-(4-methylpiperazin-1-yl)phenyl]ethynyl]-5-(2-methylpyrimidin-4-yl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C#CC=2C(=C(NC=2C=2N=C(C)N=CC=2)C=2C(=CC=C(Cl)C=2)C)C(N)=O)C=C1 JXNWLPGCIODVGM-UHFFFAOYSA-N 0.000 claims description 3
- MMVRILXRWKCFNO-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-4-[2-[4-(4-methylpiperazin-1-yl)phenyl]ethynyl]-5-pyrimidin-4-yl-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C#CC=2C(=C(NC=2C=2N=CN=CC=2)C=2C(=CC=C(Cl)C=2)C)C(N)=O)C=C1 MMVRILXRWKCFNO-UHFFFAOYSA-N 0.000 claims description 3
- RNIKKWZQPLUDLO-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-[2-(methylamino)pyrimidin-4-yl]-4-[2-[4-(4-methylpiperazin-1-yl)phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound CNC1=NC=CC(C2=C(C(C(N)=O)=C(N2)C=2C(=CC=C(Cl)C=2)C)C#CC=2C=CC(=CC=2)N2CCN(C)CC2)=N1 RNIKKWZQPLUDLO-UHFFFAOYSA-N 0.000 claims description 3
- FBZIYCWGEYMDDE-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-[2-methyl-5-[2-[4-(4-methylpiperazin-1-yl)phenyl]ethynyl]pyrimidin-4-yl]-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C#CC=2C(=NC(C)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)C=C1 FBZIYCWGEYMDDE-UHFFFAOYSA-N 0.000 claims description 3
- AGDMUVUWKFUUKX-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-[5-[2-[4-(4-methylpiperazin-1-yl)phenyl]ethynyl]pyrimidin-4-yl]-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C#CC=2C(=NC=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)C=C1 AGDMUVUWKFUUKX-UHFFFAOYSA-N 0.000 claims description 3
- WIKZRWPFRBDEBJ-UHFFFAOYSA-N 4-[2-(2-aminophenyl)ethynyl]-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide Chemical compound NC1=C(C=CC=C1)C#CC=1C(=C(NC=1C1=NC(=NC=C1)N)C1=C(C=CC(=C1)Cl)C)C(=O)N WIKZRWPFRBDEBJ-UHFFFAOYSA-N 0.000 claims description 3
- ROZFRLLDGJNCQO-UHFFFAOYSA-N 4-[2-(3-aminophenyl)ethynyl]-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(C#CC=2C=C(N)C=CC=2)=C(C=2N=C(N)N=CC=2)N1 ROZFRLLDGJNCQO-UHFFFAOYSA-N 0.000 claims description 3
- ZVANMEKWCUDSEJ-UHFFFAOYSA-N 4-[2-(4-amino-2-methoxyphenyl)ethynyl]-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound COC1=CC(N)=CC=C1C#CC1=C(C=2N=C(N)N=CC=2)NC(C=2C(=CC=C(Cl)C=2)C)=C1C(N)=O ZVANMEKWCUDSEJ-UHFFFAOYSA-N 0.000 claims description 3
- ABNVQBBIXUZBID-UHFFFAOYSA-N 4-[2-(4-aminophenyl)ethynyl]-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(C#CC=2C=CC(N)=CC=2)=C(C=2N=C(N)N=CC=2)N1 ABNVQBBIXUZBID-UHFFFAOYSA-N 0.000 claims description 3
- UIGKKAFZRNACTD-UHFFFAOYSA-N 4-[2-(5-amino-2-methoxyphenyl)ethynyl]-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound COC1=CC=C(N)C=C1C#CC1=C(C=2N=C(N)N=CC=2)NC(C=2C(=CC=C(Cl)C=2)C)=C1C(N)=O UIGKKAFZRNACTD-UHFFFAOYSA-N 0.000 claims description 3
- LEAWKSCQBGJGLM-UHFFFAOYSA-N 4-[2-[3-(2-aminoethylamino)phenyl]ethynyl]-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(C#CC=2C=C(NCCN)C=CC=2)=C(C=2N=C(N)N=CC=2)N1 LEAWKSCQBGJGLM-UHFFFAOYSA-N 0.000 claims description 3
- ASQOTNDBNNPICQ-UHFFFAOYSA-N 5-(2-amino-5-ethynylpyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#C)N1 ASQOTNDBNNPICQ-UHFFFAOYSA-N 0.000 claims description 3
- NRDUEVYFZGTQMF-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-4-[2-[2-[2-(dimethylamino)ethylamino]phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(C#CC=2C(=CC=CC=2)NCCN(C)C)=C(C=2N=C(N)N=CC=2)N1 NRDUEVYFZGTQMF-UHFFFAOYSA-N 0.000 claims description 3
- BREFSVQFPXDDGQ-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-4-[2-[3-(1-methylpiperidin-4-yl)oxyphenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(C#CC=2C=C(OC3CCN(C)CC3)C=CC=2)=C(C=2N=C(N)N=CC=2)N1 BREFSVQFPXDDGQ-UHFFFAOYSA-N 0.000 claims description 3
- OJLQPYDPMSUVPU-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-4-[2-[4-(4-methylpiperazin-1-yl)phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(C#CC=2C=CC(=CC=2)N2CCN(C)CC2)=C(C=2N=C(N)N=CC=2)N1 OJLQPYDPMSUVPU-UHFFFAOYSA-N 0.000 claims description 3
- VVVNQWGBSPVXPJ-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-(2-phenylethynyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(C#CC=2C=CC=CC=2)=C(C=2N=C(N)N=CC=2)N1 VVVNQWGBSPVXPJ-UHFFFAOYSA-N 0.000 claims description 3
- TXUZWBPKEPIRRF-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-(2-methoxyphenyl)ethynyl]-1h-pyrrole-3-carboxamide Chemical compound COC1=CC=CC=C1C#CC1=C(C=2N=C(N)N=CC=2)NC(C=2C(=CC=C(Cl)C=2)C)=C1C(N)=O TXUZWBPKEPIRRF-UHFFFAOYSA-N 0.000 claims description 3
- NJHXSBMXAOHXLI-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-(2-methylphenyl)ethynyl]-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=CC=C1C#CC1=C(C=2N=C(N)N=CC=2)NC(C=2C(=CC=C(Cl)C=2)C)=C1C(N)=O NJHXSBMXAOHXLI-UHFFFAOYSA-N 0.000 claims description 3
- KHKFDBOHKSRMLM-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-(3-hydroxyphenyl)ethynyl]-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(C#CC=2C=C(O)C=CC=2)=C(C=2N=C(N)N=CC=2)N1 KHKFDBOHKSRMLM-UHFFFAOYSA-N 0.000 claims description 3
- XXXBTEVZAWYFMT-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-(4-fluorophenyl)ethynyl]-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(C#CC=2C=CC(F)=CC=2)=C(C=2N=C(N)N=CC=2)N1 XXXBTEVZAWYFMT-UHFFFAOYSA-N 0.000 claims description 3
- NRYVEWWHPRYWMV-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-(4-methoxyphenyl)ethynyl]-1h-pyrrole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C#CC1=C(C=2N=C(N)N=CC=2)NC(C=2C(=CC=C(Cl)C=2)C)=C1C(N)=O NRYVEWWHPRYWMV-UHFFFAOYSA-N 0.000 claims description 3
- PJCRXSDWOFPSFD-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-(4-piperazin-1-ylphenyl)ethynyl]-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(C#CC=2C=CC(=CC=2)N2CCNCC2)=C(C=2N=C(N)N=CC=2)N1 PJCRXSDWOFPSFD-UHFFFAOYSA-N 0.000 claims description 3
- IALWOEOBLQYVCL-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[2-(2-hydroxyethylamino)phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(C#CC=2C(=CC=CC=2)NCCO)=C(C=2N=C(N)N=CC=2)N1 IALWOEOBLQYVCL-UHFFFAOYSA-N 0.000 claims description 3
- JRAIXPLLYMOSFX-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[2-[(1-methylpiperidin-4-yl)amino]phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCC1NC1=CC=CC=C1C#CC1=C(C=2N=C(N)N=CC=2)NC(C=2C(=CC=C(Cl)C=2)C)=C1C(N)=O JRAIXPLLYMOSFX-UHFFFAOYSA-N 0.000 claims description 3
- HKYDUPVOAMPTRS-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[2-[2-(dimethylamino)ethylamino]phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound CN(C)CCNC1=CC=CC=C1C#CC1=C(C=2N=C(N)N=CC=2)NC(C=2C(=CC=C(Cl)C=2)C)=C1C(N)=O HKYDUPVOAMPTRS-UHFFFAOYSA-N 0.000 claims description 3
- CKBXKKSPQLNPSU-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C(C=C1F)=CC=C1C#CC1=C(C=2N=C(N)N=CC=2)NC(C=2C(=CC=C(Cl)C=2)C)=C1C(N)=O CKBXKKSPQLNPSU-UHFFFAOYSA-N 0.000 claims description 3
- GMPBJTZHXMHHRS-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[2-fluoro-5-(4-methylpiperazin-1-yl)phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(F)C(C#CC=2C(=C(NC=2C=2N=C(N)N=CC=2)C=2C(=CC=C(Cl)C=2)C)C(N)=O)=C1 GMPBJTZHXMHHRS-UHFFFAOYSA-N 0.000 claims description 3
- KMONNBAZYLYRKM-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1C#CC(C=1C(N)=O)=C(C=2N=C(N)N=CC=2)NC=1C1=CC(Cl)=CC=C1C KMONNBAZYLYRKM-UHFFFAOYSA-N 0.000 claims description 3
- MLXWNIJQSVUPJQ-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[2-methoxy-5-(4-methylpiperazin-1-yl)phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound COC1=CC=C(N2CCN(C)CC2)C=C1C#CC(C=1C(N)=O)=C(C=2N=C(N)N=CC=2)NC=1C1=CC(Cl)=CC=C1C MLXWNIJQSVUPJQ-UHFFFAOYSA-N 0.000 claims description 3
- XDECTOCGQOQAPN-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[3-(1-methylpiperidin-4-yl)oxyphenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC=CC(C#CC=2C(=C(NC=2C=2N=C(N)N=CC=2)C=2C(=CC=C(Cl)C=2)C)C(N)=O)=C1 XDECTOCGQOQAPN-UHFFFAOYSA-N 0.000 claims description 3
- BTMFITFOCNJDNV-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[3-(4-methylpiperazin-1-yl)phenyl]ethynyl]-1H-pyrrole-3-carboxamide Chemical compound CN1CCN(CC1)c1cccc(c1)C#Cc1c([nH]c(c1C(N)=O)-c1cc(Cl)ccc1C)-c1ccnc(N)n1 BTMFITFOCNJDNV-UHFFFAOYSA-N 0.000 claims description 3
- VGDHCNDXRCQRCE-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[3-[(1-methylpiperidin-4-yl)amino]phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCC1NC1=CC=CC(C#CC=2C(=C(NC=2C=2N=C(N)N=CC=2)C=2C(=CC=C(Cl)C=2)C)C(N)=O)=C1 VGDHCNDXRCQRCE-UHFFFAOYSA-N 0.000 claims description 3
- FZXIKXHCXVJKAN-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1CC1=CC=CC(C#CC=2C(=C(NC=2C=2N=C(N)N=CC=2)C=2C(=CC=C(Cl)C=2)C)C(N)=O)=C1 FZXIKXHCXVJKAN-UHFFFAOYSA-N 0.000 claims description 3
- QQWPOLYXMCDGHK-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[4-(1-methylpiperidin-4-yl)oxyphenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC=C(C#CC=2C(=C(NC=2C=2N=C(N)N=CC=2)C=2C(=CC=C(Cl)C=2)C)C(N)=O)C=C1 QQWPOLYXMCDGHK-UHFFFAOYSA-N 0.000 claims description 3
- CWTYLYIKWGKONV-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[4-(4-methylpiperazin-1-yl)phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C#CC=2C(=C(NC=2C=2N=C(N)N=CC=2)C=2C(=CC=C(Cl)C=2)C)C(N)=O)C=C1 CWTYLYIKWGKONV-UHFFFAOYSA-N 0.000 claims description 3
- GPYJJJVWGCFDSM-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[4-(4-methylpiperazine-1-carbonyl)phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C#CC=2C(=C(NC=2C=2N=C(N)N=CC=2)C=2C(=CC=C(Cl)C=2)C)C(N)=O)C=C1 GPYJJJVWGCFDSM-UHFFFAOYSA-N 0.000 claims description 3
- RVYDGFLZIUHFIG-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[4-(4-piperidin-1-ylpiperidin-1-yl)phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(C#CC=2C=CC(=CC=2)N2CCC(CC2)N2CCCCC2)=C(C=2N=C(N)N=CC=2)N1 RVYDGFLZIUHFIG-UHFFFAOYSA-N 0.000 claims description 3
- DQEVGPLTYXLMTI-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(C#CC=2C=CC(=CC=2)N2CCC(CC2)N2CCCC2)=C(C=2N=C(N)N=CC=2)N1 DQEVGPLTYXLMTI-UHFFFAOYSA-N 0.000 claims description 3
- PXXIDHLXQHXQAT-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C1CCN(C=2C=CC(=CC=2)C#CC=2C(=C(NC=2C=2N=C(N)N=CC=2)C=2C(=CC=C(Cl)C=2)C)C(N)=O)CC1 PXXIDHLXQHXQAT-UHFFFAOYSA-N 0.000 claims description 3
- OCGGBYPBXYLXQF-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[2-[4-[4-(dimethylamino)piperidin-1-yl]phenyl]ethynyl]-1h-pyrrole-3-carboxamide Chemical compound C1CC(N(C)C)CCN1C1=CC=C(C#CC=2C(=C(NC=2C=2N=C(N)N=CC=2)C=2C(=CC=C(Cl)C=2)C)C(N)=O)C=C1 OCGGBYPBXYLXQF-UHFFFAOYSA-N 0.000 claims description 3
- UDMOHJNZUQKNPI-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[3-(dimethylamino)prop-1-ynyl]-1H-pyrrole-3-carboxamide Chemical compound CN(C)CC#Cc1c([nH]c(c1C(N)=O)-c1cc(Cl)ccc1C)-c1ccnc(N)n1 UDMOHJNZUQKNPI-UHFFFAOYSA-N 0.000 claims description 3
- LURQAELGOPNKCE-UHFFFAOYSA-N 5-[2-amino-5-(2-cyclohexylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC2CCCCC2)N1 LURQAELGOPNKCE-UHFFFAOYSA-N 0.000 claims description 3
- MIDGJYCYCJNYLK-UHFFFAOYSA-N 5-[2-amino-5-(2-cyclopropylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC2CC2)N1 MIDGJYCYCJNYLK-UHFFFAOYSA-N 0.000 claims description 3
- DBRQRLLVZWNWNI-UHFFFAOYSA-N 5-[2-amino-5-(2-phenylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-ethylphenyl)-n-methyl-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(=O)NC)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC=CC=2)N1 DBRQRLLVZWNWNI-UHFFFAOYSA-N 0.000 claims description 3
- XEMDZQVTEDNKOX-UHFFFAOYSA-N 5-[2-amino-5-(2-phenylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-n-methyl-1h-pyrrole-3-carboxamide Chemical compound CNC(=O)C=1C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC=CC=2)NC=1C1=CC(Cl)=CC=C1C XEMDZQVTEDNKOX-UHFFFAOYSA-N 0.000 claims description 3
- OCXRCFLPLNWLLS-UHFFFAOYSA-N 5-[2-amino-5-(2-pyridin-3-ylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=NC=CC=2)N1 OCXRCFLPLNWLLS-UHFFFAOYSA-N 0.000 claims description 3
- AGTGWWWVAFOXPI-UHFFFAOYSA-N 5-[2-amino-5-(3,3-dimethylbut-1-ynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC(C)(C)C)N1 AGTGWWWVAFOXPI-UHFFFAOYSA-N 0.000 claims description 3
- SGMSQZXIOWKROP-UHFFFAOYSA-N 5-[2-amino-5-(3-hydroxy-3-methylbut-1-ynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC(C)(C)O)N1 SGMSQZXIOWKROP-UHFFFAOYSA-N 0.000 claims description 3
- AFNCSCZZBSTOST-UHFFFAOYSA-N 5-[2-amino-5-(3-hydroxybut-1-ynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC(O)C#CC1=CN=C(N)N=C1C1=CC(C(N)=O)=C(C=2C(=CC=C(Cl)C=2)C)N1 AFNCSCZZBSTOST-UHFFFAOYSA-N 0.000 claims description 3
- ZZJSNZJYFMNXHU-UHFFFAOYSA-N 5-[2-amino-5-[2-(2,4-difluorophenyl)ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C(=CC(F)=CC=2)F)N1 ZZJSNZJYFMNXHU-UHFFFAOYSA-N 0.000 claims description 3
- ZFFVAZIJYNEROW-UHFFFAOYSA-N 5-[2-amino-5-[2-(2-aminophenyl)ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C(=CC=CC=2)N)N1 ZFFVAZIJYNEROW-UHFFFAOYSA-N 0.000 claims description 3
- KMICEXPUSDENAX-UHFFFAOYSA-N 5-[2-amino-5-[2-(2-methoxyphenyl)ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound COC1=CC=CC=C1C#CC1=CN=C(N)N=C1C1=CC(C(N)=O)=C(C=2C(=CC=C(Cl)C=2)C)N1 KMICEXPUSDENAX-UHFFFAOYSA-N 0.000 claims description 3
- XBCRWUHIWQAAIY-UHFFFAOYSA-N 5-[2-amino-5-[2-(3-aminophenyl)ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=C(N)C=CC=2)N1 XBCRWUHIWQAAIY-UHFFFAOYSA-N 0.000 claims description 3
- QCTBPHGWMSUYMP-UHFFFAOYSA-N 5-[2-amino-5-[2-(3-hydroxyphenyl)ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=C(O)C=CC=2)N1 QCTBPHGWMSUYMP-UHFFFAOYSA-N 0.000 claims description 3
- BWTFOLVMKWRQHO-UHFFFAOYSA-N 5-[2-amino-5-[2-(4-amino-2-methoxyphenyl)ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound COC1=CC(N)=CC=C1C#CC1=CN=C(N)N=C1C1=CC(C(N)=O)=C(C=2C(=CC=C(Cl)C=2)C)N1 BWTFOLVMKWRQHO-UHFFFAOYSA-N 0.000 claims description 3
- WVUBNVYVYKPGAE-UHFFFAOYSA-N 5-[2-amino-5-[2-(4-aminophenyl)ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC(N)=CC=2)N1 WVUBNVYVYKPGAE-UHFFFAOYSA-N 0.000 claims description 3
- LPZWRNYRRGDWPK-UHFFFAOYSA-N 5-[2-amino-5-[2-(4-bromo-2-fluorophenyl)ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C(=CC(Br)=CC=2)F)N1 LPZWRNYRRGDWPK-UHFFFAOYSA-N 0.000 claims description 3
- FBFGOQVXIZFFEY-UHFFFAOYSA-N 5-[2-amino-5-[2-(4-bromophenyl)ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC(Br)=CC=2)N1 FBFGOQVXIZFFEY-UHFFFAOYSA-N 0.000 claims description 3
- DHFKXDOTRSTHLT-UHFFFAOYSA-N 5-[2-amino-5-[2-(4-methoxyphenyl)ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C#CC1=CN=C(N)N=C1C1=CC(C(N)=O)=C(C=2C(=CC=C(Cl)C=2)C)N1 DHFKXDOTRSTHLT-UHFFFAOYSA-N 0.000 claims description 3
- MFWYNIOSZSKTLB-UHFFFAOYSA-N 5-[2-amino-5-[2-(5-amino-2-methoxyphenyl)ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound COC1=CC=C(N)C=C1C#CC1=CN=C(N)N=C1C1=CC(C(N)=O)=C(C=2C(=CC=C(Cl)C=2)C)N1 MFWYNIOSZSKTLB-UHFFFAOYSA-N 0.000 claims description 3
- IASGMQUZCQBTGB-UHFFFAOYSA-N 5-[2-amino-5-[2-(5-bromo-2-methoxyphenyl)ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound COC1=CC=C(Br)C=C1C#CC1=CN=C(N)N=C1C1=CC(C(N)=O)=C(C=2C(=CC=C(Cl)C=2)C)N1 IASGMQUZCQBTGB-UHFFFAOYSA-N 0.000 claims description 3
- NGYNEBJCEIVJEL-UHFFFAOYSA-N 5-[2-amino-5-[2-[2-(2-hydroxyethylamino)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C(=CC=CC=2)NCCO)N1 NGYNEBJCEIVJEL-UHFFFAOYSA-N 0.000 claims description 3
- JFYUPEHSWVGOIJ-UHFFFAOYSA-N 5-[2-amino-5-[2-[2-[2-(dimethylamino)ethylamino]phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CN(C)CCNC1=CC=CC=C1C#CC1=CN=C(N)N=C1C1=CC(C(N)=O)=C(C=2C(=CC=C(Cl)C=2)C)N1 JFYUPEHSWVGOIJ-UHFFFAOYSA-N 0.000 claims description 3
- ZGCDOHJSVFCRQK-UHFFFAOYSA-N 5-[2-amino-5-[2-[2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C(C=C1F)=CC=C1C#CC1=CN=C(N)N=C1C1=CC(C(N)=O)=C(C=2C(=CC=C(Cl)C=2)C)N1 ZGCDOHJSVFCRQK-UHFFFAOYSA-N 0.000 claims description 3
- VAODXOFVKPVGTF-UHFFFAOYSA-N 5-[2-amino-5-[2-[2-fluoro-5-(4-methylpiperazin-1-yl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(F)C(C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)=C1 VAODXOFVKPVGTF-UHFFFAOYSA-N 0.000 claims description 3
- YEULBSRTKQEAHZ-UHFFFAOYSA-N 5-[2-amino-5-[2-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1C#CC1=CN=C(N)N=C1C(N1)=CC(C(N)=O)=C1C1=CC(Cl)=CC=C1C YEULBSRTKQEAHZ-UHFFFAOYSA-N 0.000 claims description 3
- AWUZDPHVZPFBLC-UHFFFAOYSA-N 5-[2-amino-5-[2-[2-methoxy-4-(4-methylpiperazine-1-carbonyl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound COC1=CC(C(=O)N2CCN(C)CC2)=CC=C1C#CC1=CN=C(N)N=C1C(N1)=CC(C(N)=O)=C1C1=CC(Cl)=CC=C1C AWUZDPHVZPFBLC-UHFFFAOYSA-N 0.000 claims description 3
- RXZJNOKWZFFSIR-UHFFFAOYSA-N 5-[2-amino-5-[2-[2-methoxy-4-[(1-methylpiperidin-4-yl)amino]phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C=1C=C(C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)C(OC)=CC=1NC1CCN(C)CC1 RXZJNOKWZFFSIR-UHFFFAOYSA-N 0.000 claims description 3
- PNUMSMUZHUYYBE-UHFFFAOYSA-N 5-[2-amino-5-[2-[2-methoxy-5-(4-methylpiperazin-1-yl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound COC1=CC=C(N2CCN(C)CC2)C=C1C#CC1=CN=C(N)N=C1C(N1)=CC(C(N)=O)=C1C1=CC(Cl)=CC=C1C PNUMSMUZHUYYBE-UHFFFAOYSA-N 0.000 claims description 3
- JPIORFJZJJBQHL-UHFFFAOYSA-N 5-[2-amino-5-[2-[2-methoxy-5-[(1-methylpiperidin-4-yl)amino]phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1=C(C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)C(OC)=CC=C1NC1CCN(C)CC1 JPIORFJZJJBQHL-UHFFFAOYSA-N 0.000 claims description 3
- UDMLMLMZAQLMGN-UHFFFAOYSA-N 5-[2-amino-5-[2-[3-(1-methylpiperidin-4-yl)oxyphenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC=CC(C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)=C1 UDMLMLMZAQLMGN-UHFFFAOYSA-N 0.000 claims description 3
- ARGFGGXENPGMMR-UHFFFAOYSA-N 5-[2-amino-5-[2-[3-(2-aminoethylamino)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=C(NCCN)C=CC=2)N1 ARGFGGXENPGMMR-UHFFFAOYSA-N 0.000 claims description 3
- YHBQDGQQSDHVSF-UHFFFAOYSA-N 5-[2-amino-5-[2-[3-(2-hydroxyethylamino)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=C(NCCO)C=CC=2)N1 YHBQDGQQSDHVSF-UHFFFAOYSA-N 0.000 claims description 3
- LHPIRYRWMYOYKK-UHFFFAOYSA-N 5-[2-amino-5-[2-[3-(4-methylpiperazin-1-yl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=CC(C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)=C1 LHPIRYRWMYOYKK-UHFFFAOYSA-N 0.000 claims description 3
- KWZVSDZJMDDQLM-UHFFFAOYSA-N 5-[2-amino-5-[2-[3-(4-methylpiperazine-1-carbonyl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC(C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)=C1 KWZVSDZJMDDQLM-UHFFFAOYSA-N 0.000 claims description 3
- GEZMROUETCAABI-UHFFFAOYSA-N 5-[2-amino-5-[2-[3-(oxan-4-ylamino)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=C(NC3CCOCC3)C=CC=2)N1 GEZMROUETCAABI-UHFFFAOYSA-N 0.000 claims description 3
- VGTHMMPUFZHHTD-UHFFFAOYSA-N 5-[2-amino-5-[2-[3-[(1-methylazetidin-3-yl)methylamino]phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1N(C)CC1CNC1=CC=CC(C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)=C1 VGTHMMPUFZHHTD-UHFFFAOYSA-N 0.000 claims description 3
- YTGROQSDLKKFLO-UHFFFAOYSA-N 5-[2-amino-5-[2-[3-[(1-methylpiperidin-4-yl)amino]phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCC1NC1=CC=CC(C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)=C1 YTGROQSDLKKFLO-UHFFFAOYSA-N 0.000 claims description 3
- NMYQECINFQOFJW-UHFFFAOYSA-N 5-[2-amino-5-[2-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1CC1=CC=CC(C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)=C1 NMYQECINFQOFJW-UHFFFAOYSA-N 0.000 claims description 3
- FDWDQUIQROTAJT-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-(1-methylpiperidin-4-yl)oxyphenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC=C(C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)C=C1 FDWDQUIQROTAJT-UHFFFAOYSA-N 0.000 claims description 3
- FHNZPXCIRCGEIJ-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-(2-hydroxyethylamino)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC(NCCO)=CC=2)N1 FHNZPXCIRCGEIJ-UHFFFAOYSA-N 0.000 claims description 3
- FQGLEGOGSDVRMI-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-(4-hydroxypiperidin-1-yl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC(=CC=2)N2CCC(O)CC2)N1 FQGLEGOGSDVRMI-UHFFFAOYSA-N 0.000 claims description 3
- XMWSFBCDNZGDIH-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-(4-methylpiperazin-1-yl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-ethylphenyl)-n-methyl-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(=O)NC)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC(=CC=2)N2CCN(C)CC2)N1 XMWSFBCDNZGDIH-UHFFFAOYSA-N 0.000 claims description 3
- YHFRHHSUDZBILQ-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-(4-methylpiperazin-1-yl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-n-methyl-1h-pyrrole-3-carboxamide Chemical compound CNC(=O)C=1C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC(=CC=2)N2CCN(C)CC2)NC=1C1=CC(Cl)=CC=C1C YHFRHHSUDZBILQ-UHFFFAOYSA-N 0.000 claims description 3
- QYYWUIFBOAQTHZ-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC(=CC=2)N2CCC(CC2)N2CCCC2)N1 QYYWUIFBOAQTHZ-UHFFFAOYSA-N 0.000 claims description 3
- MOLQBEWKMIQQFX-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-(azetidin-3-ylmethylamino)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC(NCC3CNC3)=CC=2)N1 MOLQBEWKMIQQFX-UHFFFAOYSA-N 0.000 claims description 3
- XEMLFHSMLZIDBQ-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-(oxan-4-ylamino)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC(NC3CCOCC3)=CC=2)N1 XEMLFHSMLZIDBQ-UHFFFAOYSA-N 0.000 claims description 3
- NYUKSFQOXCMWDG-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-(piperidin-1-ylmethyl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC(CN3CCCCC3)=CC=2)N1 NYUKSFQOXCMWDG-UHFFFAOYSA-N 0.000 claims description 3
- NNJQLVPSXKFQPF-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-(pyrrolidin-1-ylmethyl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC(CN3CCCC3)=CC=2)N1 NNJQLVPSXKFQPF-UHFFFAOYSA-N 0.000 claims description 3
- GABVWEOSQCESLR-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-[(1-methylpiperidin-4-yl)amino]phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCC1NC1=CC=C(C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)C=C1 GABVWEOSQCESLR-UHFFFAOYSA-N 0.000 claims description 3
- MLWJFIYHMRGVON-SANMLTNESA-N 5-[2-amino-5-[2-[4-[(2s)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC(=CC=2)N2[C@@H](CCC2)CN2CCCC2)N1 MLWJFIYHMRGVON-SANMLTNESA-N 0.000 claims description 3
- XMKAHJVAXLNGKF-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1CC1=CC=C(C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)C=C1 XMKAHJVAXLNGKF-UHFFFAOYSA-N 0.000 claims description 3
- IBUJLWZJGISWIT-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C1CCN(C=2C=CC(=CC=2)C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)CC1 IBUJLWZJGISWIT-UHFFFAOYSA-N 0.000 claims description 3
- HEWIFRAYPUUMHL-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-[4-(dimethylamino)piperidin-1-yl]phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CC(N(C)C)CCN1C1=CC=C(C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)C=C1 HEWIFRAYPUUMHL-UHFFFAOYSA-N 0.000 claims description 3
- CHHWRZLNBSBSGL-UHFFFAOYSA-N 5-[2-amino-5-[3-(1,1-dioxo-1,4-thiazinan-4-yl)prop-1-ynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CCN2CCS(=O)(=O)CC2)N1 CHHWRZLNBSBSGL-UHFFFAOYSA-N 0.000 claims description 3
- HDGKCIGPLBBRIV-UHFFFAOYSA-N 5-[2-amino-5-[3-(1-methylpiperidin-4-yl)oxyprop-1-ynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCC1OCC#CC1=CN=C(N)N=C1C1=CC(C(N)=O)=C(C=2C(=CC=C(Cl)C=2)C)N1 HDGKCIGPLBBRIV-UHFFFAOYSA-N 0.000 claims description 3
- QKBFJRNOZSZOCE-UHFFFAOYSA-N 5-[2-amino-5-[3-(4-methylpiperazin-1-yl)prop-1-ynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1CC#CC1=CN=C(N)N=C1C1=CC(C(N)=O)=C(C=2C(=CC=C(Cl)C=2)C)N1 QKBFJRNOZSZOCE-UHFFFAOYSA-N 0.000 claims description 3
- SBTQKLGTZSOLDL-UHFFFAOYSA-N 5-[2-amino-5-[3-(dimethylamino)prop-1-ynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CN(C)CC#CC1=CN=C(N)N=C1C1=CC(C(N)=O)=C(C=2C(=CC=C(Cl)C=2)C)N1 SBTQKLGTZSOLDL-UHFFFAOYSA-N 0.000 claims description 3
- QYTBOUFFFUNNAK-UHFFFAOYSA-N 5-[2-amino-5-[3-[benzyl(methyl)amino]prop-1-ynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1CN(C)CC#CC1=CN=C(N)N=C1C(N1)=CC(C(N)=O)=C1C1=CC(Cl)=CC=C1C QYTBOUFFFUNNAK-UHFFFAOYSA-N 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- BUZSTEXJRAVVRI-UHFFFAOYSA-N n-[3-[2-[2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1h-pyrrol-2-yl]pyrimidin-5-yl]ethynyl]-4-methoxyphenyl]-1-methylpiperidine-4-carboxamide Chemical compound C1=C(C#CC=2C(=NC(N)=NC=2)C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)C(OC)=CC=C1NC(=O)C1CCN(C)CC1 BUZSTEXJRAVVRI-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 3
- SXWNFFKZZNPPSL-UHFFFAOYSA-N tert-butyl 3-[[4-[2-[2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1h-pyrrol-2-yl]pyrimidin-5-yl]ethynyl]anilino]methyl]azetidine-1-carboxylate Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC(NCC3CN(C3)C(=O)OC(C)(C)C)=CC=2)N1 SXWNFFKZZNPPSL-UHFFFAOYSA-N 0.000 claims description 3
- WGIDVXUEKOPWMA-UHFFFAOYSA-N tert-butyl n-[2-[3-[2-[2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1h-pyrrol-2-yl]pyrimidin-5-yl]ethynyl]anilino]ethyl]carbamate Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=C(NCCNC(=O)OC(C)(C)C)C=CC=2)N1 WGIDVXUEKOPWMA-UHFFFAOYSA-N 0.000 claims description 3
- KIHMCBUAJIJJFJ-UHFFFAOYSA-N tert-butyl n-[2-[4-[2-[2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1h-pyrrol-2-yl]pyrimidin-5-yl]ethynyl]anilino]ethyl]carbamate Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)C#CC=2C=CC(NCCNC(=O)OC(C)(C)C)=CC=2)N1 KIHMCBUAJIJJFJ-UHFFFAOYSA-N 0.000 claims description 3
- 238000011319 anticancer therapy Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 213
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 189
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 163
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 105
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 96
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 67
- 229910001868 water Inorganic materials 0.000 description 66
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 65
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 57
- 239000000243 solution Substances 0.000 description 55
- 239000007787 solid Substances 0.000 description 54
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 52
- 239000000203 mixture Substances 0.000 description 52
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 51
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 50
- 239000002904 solvent Substances 0.000 description 50
- 238000003818 flash chromatography Methods 0.000 description 45
- 229910052938 sodium sulfate Inorganic materials 0.000 description 45
- 239000000741 silica gel Substances 0.000 description 44
- 229910002027 silica gel Inorganic materials 0.000 description 44
- WAMLVFZHLCKDJV-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-1-[2-ethyl-5-(trifluoromethyl)phenyl]-N-(2-hydroxyethyl)pyrrole-3-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1N1C(C=2C(=CN=C(N)N=2)Cl)=CC(C(=O)NCCO)=C1 WAMLVFZHLCKDJV-UHFFFAOYSA-N 0.000 description 43
- 235000011152 sodium sulphate Nutrition 0.000 description 43
- 235000019439 ethyl acetate Nutrition 0.000 description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 34
- 239000011541 reaction mixture Substances 0.000 description 33
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 239000012267 brine Substances 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 25
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 23
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 23
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 22
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 19
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 18
- 238000003556 assay Methods 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- 102000042838 JAK family Human genes 0.000 description 17
- 108091082332 JAK family Proteins 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 17
- 239000012071 phase Substances 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- 0 Cc1nccc(-c2cc(C(O)=O)c(*)[n]2)n1 Chemical compound Cc1nccc(-c2cc(C(O)=O)c(*)[n]2)n1 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- FSAKMKWHGFOEAQ-UHFFFAOYSA-N ethyl 5-(2-aminopyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C=2N=C(N)N=CC=2)NC=1C1=CC(C(F)(F)F)=CC=C1C FSAKMKWHGFOEAQ-UHFFFAOYSA-N 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- VCFNACFHPVBJDZ-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylic acid Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=C(C(O)=O)C=C(C=2C(=CN=C(N)N=2)Cl)N1 VCFNACFHPVBJDZ-UHFFFAOYSA-N 0.000 description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 239000000460 chlorine Substances 0.000 description 13
- INBGDKOFOZXJNP-UHFFFAOYSA-N ethyl 5-(2-amino-5-chloropyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C=2C(=CN=C(N)N=2)Cl)NC=1C1=CC(C(F)(F)F)=CC=C1C INBGDKOFOZXJNP-UHFFFAOYSA-N 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 12
- 229910052786 argon Inorganic materials 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 101150058160 Lyn gene Proteins 0.000 description 11
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 239000011347 resin Substances 0.000 description 11
- 229920005989 resin Polymers 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 10
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 10
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 9
- KTMBMMHFDRPOSJ-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-4-iodo-5-[2-(methylamino)pyrimidin-4-yl]-1h-pyrrole-3-carboxamide Chemical compound CNC1=NC=CC(C2=C(C(C(N)=O)=C(N2)C=2C(=CC=C(Cl)C=2)C)I)=N1 KTMBMMHFDRPOSJ-UHFFFAOYSA-N 0.000 description 9
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 9
- IJZJLSWAJQATQF-UHFFFAOYSA-N 5-(2-amino-5-ethynylpyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C(N1COCC[Si](C)(C)C)=C(C(N)=O)C=C1C1=NC(N)=NC=C1C#C IJZJLSWAJQATQF-UHFFFAOYSA-N 0.000 description 9
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 9
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 102000001253 Protein Kinase Human genes 0.000 description 9
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 9
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 108060006633 protein kinase Proteins 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- QJUFORLAWANGCT-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-(4-methylpiperazine-1-carbonyl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C#CC=2C(=NC(N)=NC=2)C=2N(C(C=3C(=CC=C(Cl)C=3)C)=C(C(N)=O)C=2)COCC[Si](C)(C)C)C=C1 QJUFORLAWANGCT-UHFFFAOYSA-N 0.000 description 8
- 101150028321 Lck gene Proteins 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 239000003643 water by type Substances 0.000 description 8
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 7
- RRNMEWYBTLSMLT-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-[5-iodo-2-(methylamino)pyrimidin-4-yl]-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carboxamide Chemical compound CNC1=NC=C(I)C(C=2N(C(C=3C(=CC=C(Cl)C=3)C)=C(C(N)=O)C=2)COCC[Si](C)(C)C)=N1 RRNMEWYBTLSMLT-UHFFFAOYSA-N 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 7
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 230000002452 interceptive effect Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 239000003039 volatile agent Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 6
- 229960004132 diethyl ether Drugs 0.000 description 6
- FKDABFUMZJIQGX-UHFFFAOYSA-N ethyl 5-(2-amino-5-iodopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carboxylate Chemical compound C[Si](C)(C)CCOCN1C(C=2C(=CC=C(Cl)C=2)C)=C(C(=O)OCC)C=C1C1=NC(N)=NC=C1I FKDABFUMZJIQGX-UHFFFAOYSA-N 0.000 description 6
- NIVWPASFISOKSG-UHFFFAOYSA-N ethyl 5-[2-amino-5-(2-trimethylsilylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carboxylate Chemical compound C[Si](C)(C)CCOCN1C(C=2C(=CC=C(Cl)C=2)C)=C(C(=O)OCC)C=C1C1=NC(N)=NC=C1C#C[Si](C)(C)C NIVWPASFISOKSG-UHFFFAOYSA-N 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 125000000168 pyrrolyl group Chemical group 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 6
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 5
- LBNJXLZNUPHGBU-UHFFFAOYSA-N 5-[2-amino-5-(2-phenylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C(N1COCC[Si](C)(C)C)=C(C(N)=O)C=C1C1=NC(N)=NC=C1C#CC1=CC=CC=C1 LBNJXLZNUPHGBU-UHFFFAOYSA-N 0.000 description 5
- MLIQYVXZXLKUPN-UHFFFAOYSA-N 5-[2-amino-5-[2-[4-(4-methylpiperazin-1-yl)phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C#CC=2C(=NC(N)=NC=2)C=2N(C(C=3C(=CC=C(Cl)C=3)C)=C(C(N)=O)C=2)COCC[Si](C)(C)C)C=C1 MLIQYVXZXLKUPN-UHFFFAOYSA-N 0.000 description 5
- 108010024121 Janus Kinases Proteins 0.000 description 5
- 102000015617 Janus Kinases Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 206010052779 Transplant rejections Diseases 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- NDRTTXKEIAXGLT-UHFFFAOYSA-N ethyl 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C=2N=C(N)N=CC=2)NC=1C1=CC(Cl)=CC=C1CC NDRTTXKEIAXGLT-UHFFFAOYSA-N 0.000 description 5
- GPVDRKQWPCQIRO-UHFFFAOYSA-N ethyl 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C=2N=C(N)N=CC=2)NC=1C1=CC(Cl)=CC=C1C GPVDRKQWPCQIRO-UHFFFAOYSA-N 0.000 description 5
- GBXNNAGODXQQTA-UHFFFAOYSA-N ethyl 5-(2-aminopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C=2N=C(N)N=CC=2)NC=1C1=CC(C(F)(F)F)=CC=C1CC GBXNNAGODXQQTA-UHFFFAOYSA-N 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000000021 kinase assay Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 239000012047 saturated solution Substances 0.000 description 5
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- VSRLIXHYPWDUSU-UHFFFAOYSA-N 1-(4-ethynylphenyl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CC=C(C#C)C=C1 VSRLIXHYPWDUSU-UHFFFAOYSA-N 0.000 description 4
- WHLXHZTZZNKUQG-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-[2-(methylamino)pyrimidin-4-yl]-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carboxamide Chemical compound CNC1=NC=CC(C=2N(C(C=3C(=CC=C(Cl)C=3)C)=C(C(N)=O)C=2)COCC[Si](C)(C)C)=N1 WHLXHZTZZNKUQG-UHFFFAOYSA-N 0.000 description 4
- BGPKIRZIIRONDF-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-[2-(methylamino)pyrimidin-4-yl]-1h-pyrrole-3-carboxamide Chemical compound CNC1=NC=CC(C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)=N1 BGPKIRZIIRONDF-UHFFFAOYSA-N 0.000 description 4
- DQDASFFHMDSYAZ-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2N=C(N)N=CC=2)N1 DQDASFFHMDSYAZ-UHFFFAOYSA-N 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000003951 Erythropoietin Human genes 0.000 description 4
- 108090000394 Erythropoietin Proteins 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 150000001502 aryl halides Chemical class 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 229940105423 erythropoietin Drugs 0.000 description 4
- WOJPHHDXQRDJAW-UHFFFAOYSA-N ethyl 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carboxylate Chemical compound C[Si](C)(C)CCOCN1C(C=2C(=CC=C(Cl)C=2)C)=C(C(=O)OCC)C=C1C1=CC=NC(N)=N1 WOJPHHDXQRDJAW-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 4
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- YKPQUSLRUFLVDA-UHFFFAOYSA-N $l^{2}-azanylmethane Chemical group [NH]C YKPQUSLRUFLVDA-UHFFFAOYSA-N 0.000 description 3
- JLBZLLVRABGGJU-UHFFFAOYSA-N (4-ethynylphenyl)-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C#C)C=C1 JLBZLLVRABGGJU-UHFFFAOYSA-N 0.000 description 3
- LZCNTAMUBXUJBQ-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-[2-(methylamino)pyrimidin-4-yl]-1h-pyrrole-3-carbonitrile Chemical compound CNC1=NC=CC(C=2NC(=C(C#N)C=2)C=2C(=CC=C(Cl)C=2)C)=N1 LZCNTAMUBXUJBQ-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- WRFYIYOXJWKONR-UHFFFAOYSA-N 4-bromo-2-methoxyaniline Chemical compound COC1=CC(Br)=CC=C1N WRFYIYOXJWKONR-UHFFFAOYSA-N 0.000 description 3
- WJFONHTWLNQSTP-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxylic acid Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(O)=O)C=C(C=2N=C(N)N=CC=2)N1 WJFONHTWLNQSTP-UHFFFAOYSA-N 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 3
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 3
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 3
- 229910020700 Na3VO4 Inorganic materials 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 102000036693 Thrombopoietin Human genes 0.000 description 3
- 108010041111 Thrombopoietin Proteins 0.000 description 3
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 3
- 208000017733 acquired polycythemia vera Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 150000001543 aryl boronic acids Chemical class 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000010256 biochemical assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000001952 enzyme assay Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940076264 interleukin-3 Drugs 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 208000037244 polycythemia vera Diseases 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 3
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QCTXFSBQYDYHDX-UHFFFAOYSA-N (3-ethynylphenyl)-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC(C#C)=C1 QCTXFSBQYDYHDX-UHFFFAOYSA-N 0.000 description 2
- IUAPGQYWUCARQY-UHFFFAOYSA-N (4-ethynyl-3-methoxyphenyl)-(4-methylpiperazin-1-yl)methanone Chemical compound C1=C(C#C)C(OC)=CC(C(=O)N2CCN(C)CC2)=C1 IUAPGQYWUCARQY-UHFFFAOYSA-N 0.000 description 2
- YHTZZPNGBKRMJG-UHFFFAOYSA-N (4-hydroxy-3-methoxyphenyl)-(4-methylpiperazin-1-yl)methanone Chemical compound C1=C(O)C(OC)=CC(C(=O)N2CCN(C)CC2)=C1 YHTZZPNGBKRMJG-UHFFFAOYSA-N 0.000 description 2
- RIMIYENGLBYFAV-UHFFFAOYSA-N (4-methylpiperazin-1-yl)-[3-(2-trimethylsilylethynyl)phenyl]methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC(C#C[Si](C)(C)C)=C1 RIMIYENGLBYFAV-UHFFFAOYSA-N 0.000 description 2
- BSRYQHOVRGVFSO-UHFFFAOYSA-N (4-methylpiperazin-1-yl)-[4-(2-trimethylsilylethynyl)phenyl]methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C#C[Si](C)(C)C)C=C1 BSRYQHOVRGVFSO-UHFFFAOYSA-N 0.000 description 2
- FDOLAMRYHDWRIS-UHFFFAOYSA-N (4-methylpiperazin-1-yl)methanone Chemical compound CN1CCN([C]=O)CC1 FDOLAMRYHDWRIS-UHFFFAOYSA-N 0.000 description 2
- KHQUXEAMRHNRCB-UHFFFAOYSA-N (5-chloro-2-ethylphenyl)boronic acid Chemical compound CCC1=CC=C(Cl)C=C1B(O)O KHQUXEAMRHNRCB-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- QKSUWWYRUQPPRL-UHFFFAOYSA-N 1-(4-ethynyl-3-methoxyphenyl)-4-methylpiperazine Chemical compound C1=C(C#C)C(OC)=CC(N2CCN(C)CC2)=C1 QKSUWWYRUQPPRL-UHFFFAOYSA-N 0.000 description 2
- WDLPPOOUQBAGQD-UHFFFAOYSA-N 1-[1-(4-ethynylphenyl)piperidin-4-yl]-4-methylpiperazine Chemical compound C1CN(C)CCN1C1CCN(C=2C=CC(=CC=2)C#C)CC1 WDLPPOOUQBAGQD-UHFFFAOYSA-N 0.000 description 2
- APUYKEADZUPAJE-UHFFFAOYSA-N 1-dicyclohexylphosphanyl-n,n-dimethyl-2-phenylcyclohexa-2,4-dien-1-amine Chemical group C1CCCCC1P(C1CCCCC1)C1(N(C)C)CC=CC=C1C1=CC=CC=C1 APUYKEADZUPAJE-UHFFFAOYSA-N 0.000 description 2
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- PNHLARBVOWZUBE-UHFFFAOYSA-N 2-(4-bromo-2-methoxyphenyl)ethynyl-trimethylsilane Chemical compound COC1=CC(Br)=CC=C1C#C[Si](C)(C)C PNHLARBVOWZUBE-UHFFFAOYSA-N 0.000 description 2
- MQYAMXVUTQSBMT-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-4-iodo-5-(2-methylpyrimidin-4-yl)-1h-pyrrole-3-carboxamide Chemical compound CC1=NC=CC(C2=C(C(C(N)=O)=C(N2)C=2C(=CC=C(Cl)C=2)C)I)=N1 MQYAMXVUTQSBMT-UHFFFAOYSA-N 0.000 description 2
- SBUNPCFLMBISGG-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-4-iodo-5-pyrimidin-4-yl-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(I)=C(C=2N=CN=CC=2)N1 SBUNPCFLMBISGG-UHFFFAOYSA-N 0.000 description 2
- YPBDHHDMOYAYHZ-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-(2-methylpyrimidin-4-yl)-1h-pyrrole-3-carboxamide Chemical compound CC1=NC=CC(C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)=N1 YPBDHHDMOYAYHZ-UHFFFAOYSA-N 0.000 description 2
- HPMWSWIAEPBWJR-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-[2-(methylamino)-5-[2-[4-(4-methylpiperazin-1-yl)phenyl]ethynyl]pyrimidin-4-yl]-1-(3-trimethylsilylpropoxymethyl)pyrrole-3-carboxamide Chemical compound C=1C(C(N)=O)=C(C=2C(=CC=C(Cl)C=2)C)N(COCCC[Si](C)(C)C)C=1C1=NC(NC)=NC=C1C#CC(C=C1)=CC=C1N1CCN(C)CC1 HPMWSWIAEPBWJR-UHFFFAOYSA-N 0.000 description 2
- AOUBZGNTXINLBC-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-pyrimidin-4-yl-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2N=CN=CC=2)N1 AOUBZGNTXINLBC-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- VNKQFIYZNJIRFN-UHFFFAOYSA-N 2-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]ethynyl-trimethylsilane Chemical compound C1=C(C#C[Si](C)(C)C)C(OC)=CC(N2CCN(C)CC2)=C1 VNKQFIYZNJIRFN-UHFFFAOYSA-N 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- DNYQTXQFWBCZJU-UHFFFAOYSA-N 3-ethynyl-4-methoxyaniline Chemical compound COC1=CC=C(N)C=C1C#C DNYQTXQFWBCZJU-UHFFFAOYSA-N 0.000 description 2
- RTFXXJOKXAMQQO-UHFFFAOYSA-N 3-methoxy-4-(2-trimethylsilylethynyl)aniline Chemical compound COC1=CC(N)=CC=C1C#C[Si](C)(C)C RTFXXJOKXAMQQO-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- ZQPKPGBEEFOTEK-UHFFFAOYSA-N 4-bromo-1-iodo-2-methoxybenzene Chemical compound COC1=CC(Br)=CC=C1I ZQPKPGBEEFOTEK-UHFFFAOYSA-N 0.000 description 2
- LQNNJVRJHRFWIK-UHFFFAOYSA-N 4-chloro-1-ethyl-2-iodobenzene Chemical compound CCC1=CC=C(Cl)C=C1I LQNNJVRJHRFWIK-UHFFFAOYSA-N 0.000 description 2
- OMUKKKXYZROBAI-UHFFFAOYSA-N 4-ethynyl-3-methoxyaniline Chemical compound COC1=CC(N)=CC=C1C#C OMUKKKXYZROBAI-UHFFFAOYSA-N 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- GJCMIDMYFOSDQW-UHFFFAOYSA-N 5-(2-amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)Br)N1 GJCMIDMYFOSDQW-UHFFFAOYSA-N 0.000 description 2
- YEUSSIFOLUNMSW-UHFFFAOYSA-N 5-(2-amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1h-pyrrole-3-carboxylic acid Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(O)=O)C=C(C=2C(=CN=C(N)N=2)Br)N1 YEUSSIFOLUNMSW-UHFFFAOYSA-N 0.000 description 2
- WSOPLCRVBHZPFC-UHFFFAOYSA-N 5-(2-amino-5-iodopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-n-methyl-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(=O)NC)C=C(C=2C(=CN=C(N)N=2)I)N1 WSOPLCRVBHZPFC-UHFFFAOYSA-N 0.000 description 2
- ZWMHJJAWKGXMEE-UHFFFAOYSA-N 5-(2-amino-5-iodopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C(N1COCC[Si](C)(C)C)=C(C(N)=O)C=C1C1=NC(N)=NC=C1I ZWMHJJAWKGXMEE-UHFFFAOYSA-N 0.000 description 2
- WIMCZYCFQZXGED-UHFFFAOYSA-N 5-(2-amino-5-iodopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)I)N1 WIMCZYCFQZXGED-UHFFFAOYSA-N 0.000 description 2
- QGLCJVSHRUMCTH-UHFFFAOYSA-N 5-(2-amino-5-iodopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxylic acid Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(O)=O)C=C(C=2C(=CN=C(N)N=2)I)N1 QGLCJVSHRUMCTH-UHFFFAOYSA-N 0.000 description 2
- ZROJLLQAMBUISU-UHFFFAOYSA-N 5-(2-amino-5-iodopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-n-methyl-1h-pyrrole-3-carboxamide Chemical compound CNC(=O)C=1C=C(C=2C(=CN=C(N)N=2)I)NC=1C1=CC(Cl)=CC=C1C ZROJLLQAMBUISU-UHFFFAOYSA-N 0.000 description 2
- HSJHSMCJXBFBOZ-UHFFFAOYSA-N 5-(2-amino-5-iodopyrimidin-4-yl)-2-phenyl-1h-pyrrole-3-carboxylic acid Chemical compound NC1=NC=C(I)C(C=2NC(=C(C(O)=O)C=2)C=2C=CC=CC=2)=N1 HSJHSMCJXBFBOZ-UHFFFAOYSA-N 0.000 description 2
- UUIIORWTIROASH-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-4-iodo-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(I)=C(C=2N=C(N)N=CC=2)N1 UUIIORWTIROASH-UHFFFAOYSA-N 0.000 description 2
- VUGLIOCWEQMJNV-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-iodo-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(I)=C(C=2N=C(N)N=CC=2)N1 VUGLIOCWEQMJNV-UHFFFAOYSA-N 0.000 description 2
- WYGJEGAJIXXDDQ-UHFFFAOYSA-N 5-[2-amino-5-[2-(4-bromophenyl)ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C(N1COCC[Si](C)(C)C)=C(C(N)=O)C=C1C1=NC(N)=NC=C1C#CC1=CC=C(Br)C=C1 WYGJEGAJIXXDDQ-UHFFFAOYSA-N 0.000 description 2
- HLWPQVLVLDZPQP-UHFFFAOYSA-N 5-acetyl-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carbonitrile Chemical compound N1C(C(=O)C)=CC(C#N)=C1C1=CC(Cl)=CC=C1C HLWPQVLVLDZPQP-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 2
- 108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 description 2
- 102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 102100024819 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000004280 Sodium formate Substances 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 2
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- SUGGFNUSFCFSCP-UHFFFAOYSA-N [2-methoxy-4-(4-methylpiperazine-1-carbonyl)phenyl] trifluoromethanesulfonate Chemical compound C1=C(OS(=O)(=O)C(F)(F)F)C(OC)=CC(C(=O)N2CCN(C)CC2)=C1 SUGGFNUSFCFSCP-UHFFFAOYSA-N 0.000 description 2
- ZXBAKLVTEDIODI-UHFFFAOYSA-N [3-methoxy-4-(2-trimethylsilylethynyl)phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1=C(C#C[Si](C)(C)C)C(OC)=CC(C(=O)N2CCN(C)CC2)=C1 ZXBAKLVTEDIODI-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 230000002942 anti-growth Effects 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N beta-hydroxyethanesulfonic acid Natural products OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 239000007819 coupling partner Substances 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- DICAPHPCQXAWMZ-UHFFFAOYSA-N ethyl 5-(2-amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C=2C(=CN=C(N)N=2)Br)NC=1C1=CC(Cl)=CC=C1CC DICAPHPCQXAWMZ-UHFFFAOYSA-N 0.000 description 2
- DSAGLQCJKNIMFW-UHFFFAOYSA-N ethyl 5-(2-amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C=2C(=CN=C(N)N=2)Br)NC=1C1=CC(Cl)=CC=C1C DSAGLQCJKNIMFW-UHFFFAOYSA-N 0.000 description 2
- OGSVJRMWGAVFJT-UHFFFAOYSA-N ethyl 5-(2-amino-5-bromopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C=2C(=CN=C(N)N=2)Br)NC=1C1=CC(C(F)(F)F)=CC=C1CC OGSVJRMWGAVFJT-UHFFFAOYSA-N 0.000 description 2
- FZXHOUUXFCQHHZ-UHFFFAOYSA-N ethyl 5-(2-amino-5-bromopyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C=2C(=CN=C(N)N=2)Br)NC=1C1=CC(C(F)(F)F)=CC=C1C FZXHOUUXFCQHHZ-UHFFFAOYSA-N 0.000 description 2
- ABUZNAWXSKTBMR-UHFFFAOYSA-N ethyl 5-(2-amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C=2C(=CN=C(N)N=2)Cl)NC=1C1=CC(Cl)=CC=C1CC ABUZNAWXSKTBMR-UHFFFAOYSA-N 0.000 description 2
- FBAYJJJFCOGIDK-UHFFFAOYSA-N ethyl 5-(2-amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C=2C(=CN=C(N)N=2)Cl)NC=1C1=CC(Cl)=CC=C1C FBAYJJJFCOGIDK-UHFFFAOYSA-N 0.000 description 2
- BPUXIFCFWVOENK-UHFFFAOYSA-N ethyl 5-(2-amino-5-chloropyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C=2C(=CN=C(N)N=2)Cl)NC=1C1=CC(C(F)(F)F)=CC=C1CC BPUXIFCFWVOENK-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 description 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 2
- 229940125697 hormonal agent Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000000677 immunologic agent Substances 0.000 description 2
- 229940124541 immunological agent Drugs 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- HPHIKPWBMAXXFP-UHFFFAOYSA-N n-(2-chloroethyl)-2-ethynylaniline Chemical compound ClCCNC1=CC=CC=C1C#C HPHIKPWBMAXXFP-UHFFFAOYSA-N 0.000 description 2
- VLZFYHAEFRAVME-UHFFFAOYSA-N n-(3-ethynyl-4-methoxyphenyl)-1-methylpiperidin-4-amine Chemical compound C1=C(C#C)C(OC)=CC=C1NC1CCN(C)CC1 VLZFYHAEFRAVME-UHFFFAOYSA-N 0.000 description 2
- CAGFZFNFLKDLPA-UHFFFAOYSA-N n-(3-iodo-4-methoxyphenyl)-1-methylpiperidin-4-amine Chemical compound C1=C(I)C(OC)=CC=C1NC1CCN(C)CC1 CAGFZFNFLKDLPA-UHFFFAOYSA-N 0.000 description 2
- RJGXQVKJOMYMSK-UHFFFAOYSA-N n-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-3-ethynylaniline Chemical compound CC(C)(C)[Si](C)(C)OCCNC1=CC=CC(C#C)=C1 RJGXQVKJOMYMSK-UHFFFAOYSA-N 0.000 description 2
- INICRHHUNJSTIY-UHFFFAOYSA-N n-[4-methoxy-3-(2-trimethylsilylethynyl)phenyl]-1-methylpiperidin-4-amine Chemical compound C1=C(C#C[Si](C)(C)C)C(OC)=CC=C1NC1CCN(C)CC1 INICRHHUNJSTIY-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- ZOUWOGOTHLRRLS-UHFFFAOYSA-N palladium;phosphane Chemical class P.[Pd] ZOUWOGOTHLRRLS-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 2
- 235000019254 sodium formate Nutrition 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000003277 telomerase inhibitor Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- BSIIIHPONCJUDM-UHFFFAOYSA-N tert-butyl 3-[(3-ethynylanilino)methyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC1CNC1=CC=CC(C#C)=C1 BSIIIHPONCJUDM-UHFFFAOYSA-N 0.000 description 2
- FUBNVIXPJQAKJB-UHFFFAOYSA-N tert-butyl 3-[(4-ethynylanilino)methyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC1CNC1=CC=C(C#C)C=C1 FUBNVIXPJQAKJB-UHFFFAOYSA-N 0.000 description 2
- ZZSHMTBRCSCOIR-UHFFFAOYSA-N tert-butyl n-[2-(3-ethynylanilino)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCNC1=CC=CC(C#C)=C1 ZZSHMTBRCSCOIR-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- LHJCZOXMCGQVDQ-UHFFFAOYSA-N tri(propan-2-yl)silyl trifluoromethanesulfonate Chemical compound CC(C)[Si](C(C)C)(C(C)C)OS(=O)(=O)C(F)(F)F LHJCZOXMCGQVDQ-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- DDSCJGAOIJNYMD-UHFFFAOYSA-N trimethyl-[2-[4-(4-methylpiperazin-1-yl)phenyl]ethynyl]silane Chemical compound C1CN(C)CCN1C1=CC=C(C#C[Si](C)(C)C)C=C1 DDSCJGAOIJNYMD-UHFFFAOYSA-N 0.000 description 2
- WJZLURKPEYOSLE-UHFFFAOYSA-N trimethyl-[2-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]ethynyl]silane Chemical compound C1CN(C)CCN1C1CCN(C=2C=CC(=CC=2)C#C[Si](C)(C)C)CC1 WJZLURKPEYOSLE-UHFFFAOYSA-N 0.000 description 2
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- XFQNWPYGEGCIMF-HCUGAJCMSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].[Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 XFQNWPYGEGCIMF-HCUGAJCMSA-N 0.000 description 1
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
- ZWISORBZYIXION-KRWDZBQOSA-N (2s)-1-(4-ethynylphenyl)-2-(pyrrolidin-1-ylmethyl)pyrrolidine Chemical compound C1=CC(C#C)=CC=C1N1[C@H](CN2CCCC2)CCC1 ZWISORBZYIXION-KRWDZBQOSA-N 0.000 description 1
- QWTHTSAWMJFMOV-UHFFFAOYSA-N (5-chloro-2-methylphenyl)boronic acid Chemical compound CC1=CC=C(Cl)C=C1B(O)O QWTHTSAWMJFMOV-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- VVKMHTWFAUCCOD-UHFFFAOYSA-N 1-(3-aminopropyl)-8-[3-[2-(dimethylamino)-2-oxoethyl]anilino]-n-[(2-methylpyridin-4-yl)methyl]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide Chemical group CN(C)C(=O)CC1=CC=CC(NC=2N=C3C=4N(CCCN)N=C(C=4CCC3=CN=2)C(=O)NCC=2C=C(C)N=CC=2)=C1 VVKMHTWFAUCCOD-UHFFFAOYSA-N 0.000 description 1
- YZOSQGDLSDWJCO-UHFFFAOYSA-N 1-(3-ethynyl-4-fluorophenyl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CC=C(F)C(C#C)=C1 YZOSQGDLSDWJCO-UHFFFAOYSA-N 0.000 description 1
- AQLPVYSUZJPXMA-UHFFFAOYSA-N 1-(3-ethynyl-4-methoxyphenyl)-4-methylpiperazine Chemical compound C1=C(C#C)C(OC)=CC=C1N1CCN(C)CC1 AQLPVYSUZJPXMA-UHFFFAOYSA-N 0.000 description 1
- LJIXIPLSLLBIQE-UHFFFAOYSA-N 1-(3-ethynylphenyl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CC=CC(C#C)=C1 LJIXIPLSLLBIQE-UHFFFAOYSA-N 0.000 description 1
- PQWHTOJSGWOQNZ-UHFFFAOYSA-N 1-(4-ethynyl-3-fluorophenyl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CC=C(C#C)C(F)=C1 PQWHTOJSGWOQNZ-UHFFFAOYSA-N 0.000 description 1
- NYOIIKUDGGKIAQ-UHFFFAOYSA-N 1-(4-ethynylphenyl)-4-piperidin-1-ylpiperidine Chemical compound C1=CC(C#C)=CC=C1N1CCC(N2CCCCC2)CC1 NYOIIKUDGGKIAQ-UHFFFAOYSA-N 0.000 description 1
- DLPJZQAVLUGAMC-UHFFFAOYSA-N 1-(4-ethynylphenyl)-4-pyrrolidin-1-ylpiperidine Chemical compound C1=CC(C#C)=CC=C1N1CCC(N2CCCC2)CC1 DLPJZQAVLUGAMC-UHFFFAOYSA-N 0.000 description 1
- UWKKCOYDKYDJSX-UHFFFAOYSA-N 1-(4-ethynylphenyl)-n,n-dimethylpiperidin-4-amine Chemical compound C1CC(N(C)C)CCN1C1=CC=C(C#C)C=C1 UWKKCOYDKYDJSX-UHFFFAOYSA-N 0.000 description 1
- KVPRBHZXBAWDRJ-UHFFFAOYSA-N 1-(4-ethynylphenyl)piperazine Chemical compound C1=CC(C#C)=CC=C1N1CCNCC1 KVPRBHZXBAWDRJ-UHFFFAOYSA-N 0.000 description 1
- FZDYPDHAQBBYLW-UHFFFAOYSA-N 1-(4-ethynylphenyl)piperidin-4-ol Chemical compound C1CC(O)CCN1C1=CC=C(C#C)C=C1 FZDYPDHAQBBYLW-UHFFFAOYSA-N 0.000 description 1
- BQBRGOQCWAXXLR-UHFFFAOYSA-N 1-(chloromethyl)-2,4-dimethoxybenzene Chemical compound COC1=CC=C(CCl)C(OC)=C1 BQBRGOQCWAXXLR-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- VJQCNCOGZPSOQZ-UHFFFAOYSA-N 1-Methylguanidine hydrochloride Chemical compound [Cl-].C[NH2+]C(N)=N VJQCNCOGZPSOQZ-UHFFFAOYSA-N 0.000 description 1
- BFMQKBKYZXDOEI-UHFFFAOYSA-N 1-[(3-ethynylphenyl)methyl]-4-methylpiperazine Chemical compound C1CN(C)CCN1CC1=CC=CC(C#C)=C1 BFMQKBKYZXDOEI-UHFFFAOYSA-N 0.000 description 1
- OADGXVJJFMETJI-UHFFFAOYSA-N 1-[4-(2-trimethylsilylethynyl)phenyl]piperidin-4-ol Chemical compound C1=CC(C#C[Si](C)(C)C)=CC=C1N1CCC(O)CC1 OADGXVJJFMETJI-UHFFFAOYSA-N 0.000 description 1
- ZOZNCAMOIPYYIK-UHFFFAOYSA-N 1-aminoethylideneazanium;acetate Chemical compound CC(N)=N.CC(O)=O ZOZNCAMOIPYYIK-UHFFFAOYSA-N 0.000 description 1
- MHZBKGCHHRDTGK-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione;n,n-dimethylformamide Chemical compound CN(C)C=O.BrN1C(=O)CCC1=O MHZBKGCHHRDTGK-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- MRYYJGQKVGZGSB-UHFFFAOYSA-N 1-methyl-4-piperidin-4-ylpiperazine Chemical compound C1CN(C)CCN1C1CCNCC1 MRYYJGQKVGZGSB-UHFFFAOYSA-N 0.000 description 1
- QLMIVIKAQZJDBP-UHFFFAOYSA-N 1-methyl-4-prop-2-ynoxypiperidine Chemical compound CN1CCC(OCC#C)CC1 QLMIVIKAQZJDBP-UHFFFAOYSA-N 0.000 description 1
- NOXAORINZJERRC-UHFFFAOYSA-N 1-methyl-4-prop-2-ynylpiperazine Chemical compound CN1CCN(CC#C)CC1 NOXAORINZJERRC-UHFFFAOYSA-N 0.000 description 1
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 1
- IPVYMXZYXFFDGW-UHFFFAOYSA-N 1-methylpiperidin-4-ol;hydrochloride Chemical compound Cl.CN1CCC(O)CC1 IPVYMXZYXFFDGW-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- ZEMZPXWZVTUONV-UHFFFAOYSA-N 2-(2-dicyclohexylphosphanylphenyl)-n,n-dimethylaniline Chemical group CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 ZEMZPXWZVTUONV-UHFFFAOYSA-N 0.000 description 1
- PNDGAVAVJCLNHO-UHFFFAOYSA-N 2-(3-ethynylanilino)ethanol Chemical compound OCCNC1=CC=CC(C#C)=C1 PNDGAVAVJCLNHO-UHFFFAOYSA-N 0.000 description 1
- GGYOONXTHJGLEG-UHFFFAOYSA-N 2-(4-bromo-2-fluorophenyl)ethynyl-trimethylsilane Chemical compound C[Si](C)(C)C#CC1=CC=C(Br)C=C1F GGYOONXTHJGLEG-UHFFFAOYSA-N 0.000 description 1
- RNMSGCJGNJYDNS-UHFFFAOYSA-N 2-(4-bromophenyl)ethynyl-trimethylsilane Chemical compound C[Si](C)(C)C#CC1=CC=C(Br)C=C1 RNMSGCJGNJYDNS-UHFFFAOYSA-N 0.000 description 1
- MMMKGMYXVUKOSN-UHFFFAOYSA-N 2-(4-ethynylanilino)ethanol Chemical compound OCCNC1=CC=C(C#C)C=C1 MMMKGMYXVUKOSN-UHFFFAOYSA-N 0.000 description 1
- FWJLJBKOWCTDTA-UHFFFAOYSA-N 2-(5-bromo-2-fluorophenyl)ethynyl-trimethylsilane Chemical compound C[Si](C)(C)C#CC1=CC(Br)=CC=C1F FWJLJBKOWCTDTA-UHFFFAOYSA-N 0.000 description 1
- MYTLCGRKOCYDAQ-UHFFFAOYSA-N 2-(5-bromo-2-methoxyphenyl)ethynyl-trimethylsilane Chemical compound COC1=CC=C(Br)C=C1C#C[Si](C)(C)C MYTLCGRKOCYDAQ-UHFFFAOYSA-N 0.000 description 1
- OREYNGKUHGWZPQ-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carbonitrile Chemical compound CC1=CC=C(Cl)C=C1C1=C(C#N)C=CN1 OREYNGKUHGWZPQ-UHFFFAOYSA-N 0.000 description 1
- NYHJIWWXILOJLC-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-(2-methylpyrimidin-4-yl)-1h-pyrrole-3-carbonitrile Chemical compound CC1=NC=CC(C=2NC(=C(C#N)C=2)C=2C(=CC=C(Cl)C=2)C)=N1 NYHJIWWXILOJLC-UHFFFAOYSA-N 0.000 description 1
- YZHCJRSXAYFWSV-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-pyrimidin-4-yl-1h-pyrrole-3-carbonitrile Chemical compound CC1=CC=C(Cl)C=C1C1=C(C#N)C=C(C=2N=CN=CC=2)N1 YZHCJRSXAYFWSV-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- OQVIOPIJLDSGNX-UHFFFAOYSA-N 2-[2,3-bis(cyclohexylphosphanyl)phenyl]-n,n-dimethylaniline Chemical group CN(C)C1=CC=CC=C1C1=CC=CC(PC2CCCCC2)=C1PC1CCCCC1 OQVIOPIJLDSGNX-UHFFFAOYSA-N 0.000 description 1
- NKISGXFNFOEBIM-UHFFFAOYSA-N 2-[2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]ethynyl-trimethylsilane Chemical compound C1CN(C)CCN1C1=CC=C(C#C[Si](C)(C)C)C(F)=C1 NKISGXFNFOEBIM-UHFFFAOYSA-N 0.000 description 1
- JSQWXXWRCKQYAO-UHFFFAOYSA-N 2-[2-fluoro-5-(4-methylpiperazin-1-yl)phenyl]ethynyl-trimethylsilane Chemical compound C1CN(C)CCN1C1=CC=C(F)C(C#C[Si](C)(C)C)=C1 JSQWXXWRCKQYAO-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- KBQBNJHOTNIGDD-UHFFFAOYSA-N 2-iodo-1-methoxy-4-nitrobenzene Chemical compound COC1=CC=C([N+]([O-])=O)C=C1I KBQBNJHOTNIGDD-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- BLPMCIWDCRGIJV-UHFFFAOYSA-N 2-trimethylsilylethanesulfonyl chloride Chemical compound C[Si](C)(C)CCS(Cl)(=O)=O BLPMCIWDCRGIJV-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- NNKQLUVBPJEUOR-UHFFFAOYSA-N 3-ethynylaniline Chemical compound NC1=CC=CC(C#C)=C1 NNKQLUVBPJEUOR-UHFFFAOYSA-N 0.000 description 1
- IGIUWNVGCVCNPV-UHFFFAOYSA-N 3-ethynylbenzaldehyde Chemical compound O=CC1=CC=CC(C#C)=C1 IGIUWNVGCVCNPV-UHFFFAOYSA-N 0.000 description 1
- AODMJIOEGCBUQL-UHFFFAOYSA-N 3-ethynylphenol Chemical compound OC1=CC=CC(C#C)=C1 AODMJIOEGCBUQL-UHFFFAOYSA-N 0.000 description 1
- UHPNLGCUIGEZRB-UHFFFAOYSA-N 3-iodo-4-methoxyaniline Chemical compound COC1=CC=C(N)C=C1I UHPNLGCUIGEZRB-UHFFFAOYSA-N 0.000 description 1
- KVBWBCRPWVKFQT-UHFFFAOYSA-N 3-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC(I)=C1 KVBWBCRPWVKFQT-UHFFFAOYSA-N 0.000 description 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
- QRSDRPFQDQCMLZ-UHFFFAOYSA-N 4,5-dibromo-2-methoxyaniline Chemical compound COC1=CC(Br)=C(Br)C=C1N QRSDRPFQDQCMLZ-UHFFFAOYSA-N 0.000 description 1
- GUFYYXWHDBOLBG-UHFFFAOYSA-N 4-(2-trimethylsilylethynyl)benzoic acid Chemical compound C[Si](C)(C)C#CC1=CC=C(C(O)=O)C=C1 GUFYYXWHDBOLBG-UHFFFAOYSA-N 0.000 description 1
- VETPHGNARZBXSN-UHFFFAOYSA-N 4-(3-ethynylphenoxy)-1-methylpiperidine Chemical compound C1CN(C)CCC1OC1=CC=CC(C#C)=C1 VETPHGNARZBXSN-UHFFFAOYSA-N 0.000 description 1
- WSCQIFSEWJSJAZ-UHFFFAOYSA-N 4-(4-ethynylphenoxy)-1-methylpiperidine Chemical compound C1CN(C)CCC1OC1=CC=C(C#C)C=C1 WSCQIFSEWJSJAZ-UHFFFAOYSA-N 0.000 description 1
- XRGDFZULQRHDCY-UHFFFAOYSA-N 4-amino-3-pyrimidin-2-yl-1h-pyrrole-2-carboxylic acid Chemical class NC1=CNC(C(O)=O)=C1C1=NC=CC=N1 XRGDFZULQRHDCY-UHFFFAOYSA-N 0.000 description 1
- ZSZIITDRDIHDAY-UHFFFAOYSA-N 4-bromo-1-ethynyl-2-fluorobenzene Chemical compound FC1=CC(Br)=CC=C1C#C ZSZIITDRDIHDAY-UHFFFAOYSA-N 0.000 description 1
- FIOBRFLMQFJRIN-UHFFFAOYSA-N 4-bromo-1-ethynyl-2-methoxybenzene Chemical compound COC1=CC(Br)=CC=C1C#C FIOBRFLMQFJRIN-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- RSXICCZXXOLXIG-UHFFFAOYSA-N 4-bromo-2-ethynyl-1-fluorobenzene Chemical compound FC1=CC=C(Br)C=C1C#C RSXICCZXXOLXIG-UHFFFAOYSA-N 0.000 description 1
- AWJJYCOBHKTAKV-UHFFFAOYSA-N 4-bromo-2-ethynyl-1-methoxybenzene Chemical compound COC1=CC=C(Br)C=C1C#C AWJJYCOBHKTAKV-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 102100022681 40S ribosomal protein S27 Human genes 0.000 description 1
- PFMIHYCMBAJYIC-UHFFFAOYSA-N 5-(2-amino-5-bromopyrimidin-4-yl)-1-[2-ethyl-5-(trifluoromethyl)phenyl]-N-(2-hydroxyethyl)pyrrole-3-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1N1C(C=2C(=CN=C(N)N=2)Br)=CC(C(=O)NCCO)=C1 PFMIHYCMBAJYIC-UHFFFAOYSA-N 0.000 description 1
- HDFKXZUPUFPCSO-UHFFFAOYSA-N 5-(2-amino-5-bromopyrimidin-4-yl)-1-[2-ethyl-5-(trifluoromethyl)phenyl]-N-methylpyrrole-3-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1N1C(C=2C(=CN=C(N)N=2)Br)=CC(C(=O)NC)=C1 HDFKXZUPUFPCSO-UHFFFAOYSA-N 0.000 description 1
- HCWXRJLQXLDWBT-UHFFFAOYSA-N 5-(2-amino-5-bromopyrimidin-4-yl)-1-[2-ethyl-5-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1N1C(C=2C(=CN=C(N)N=2)Br)=CC(C(N)=O)=C1 HCWXRJLQXLDWBT-UHFFFAOYSA-N 0.000 description 1
- IMRCLYLYUZIEKE-UHFFFAOYSA-N 5-(2-amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-(2-hydroxyethyl)-1H-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(=O)NCCO)C=C(C=2C(=CN=C(N)N=2)Br)N1 IMRCLYLYUZIEKE-UHFFFAOYSA-N 0.000 description 1
- JYSRBGCPRISBIS-UHFFFAOYSA-N 5-(2-amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-ethyl-1H-pyrrole-3-carboxamide Chemical compound CCNC(=O)C=1C=C(C=2C(=CN=C(N)N=2)Br)NC=1C1=CC(Cl)=CC=C1CC JYSRBGCPRISBIS-UHFFFAOYSA-N 0.000 description 1
- RWWHXYIFEBYJMH-UHFFFAOYSA-N 5-(2-amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-methyl-1H-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(=O)NC)C=C(C=2C(=CN=C(N)N=2)Br)N1 RWWHXYIFEBYJMH-UHFFFAOYSA-N 0.000 description 1
- LVGXFHCJSGKYRI-UHFFFAOYSA-N 5-(2-amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)Br)N1 LVGXFHCJSGKYRI-UHFFFAOYSA-N 0.000 description 1
- DYBQFBOPZDQBOO-UHFFFAOYSA-N 5-(2-amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-N-methyl-1H-pyrrole-3-carboxamide Chemical compound CNC(=O)C=1C=C(C=2C(=CN=C(N)N=2)Br)NC=1C1=CC(Cl)=CC=C1C DYBQFBOPZDQBOO-UHFFFAOYSA-N 0.000 description 1
- KFOPWXCNTMAZAG-UHFFFAOYSA-N 5-(2-amino-5-bromopyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)Br)N1 KFOPWXCNTMAZAG-UHFFFAOYSA-N 0.000 description 1
- MWDZZKZEHVYKNQ-UHFFFAOYSA-N 5-(2-amino-5-bromopyrimidin-4-yl)-N-ethyl-1-[2-ethyl-5-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound C=1C(C(F)(F)F)=CC=C(CC)C=1N1C=C(C(=O)NCC)C=C1C1=NC(N)=NC=C1Br MWDZZKZEHVYKNQ-UHFFFAOYSA-N 0.000 description 1
- WXYMUSFZSGHIIT-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-1-[2-ethyl-5-(trifluoromethyl)phenyl]-N-methylpyrrole-3-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1N1C(C=2C(=CN=C(N)N=2)Cl)=CC(C(=O)NC)=C1 WXYMUSFZSGHIIT-UHFFFAOYSA-N 0.000 description 1
- VSFFGMDFWVILFW-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-1-[2-ethyl-5-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1N1C(C=2C(=CN=C(N)N=2)Cl)=CC(C(N)=O)=C1 VSFFGMDFWVILFW-UHFFFAOYSA-N 0.000 description 1
- ZJEBJMIPEYOXHG-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)Cl)N1 ZJEBJMIPEYOXHG-UHFFFAOYSA-N 0.000 description 1
- PZHMWEWFZWEOAB-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxylic acid Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(O)=O)C=C(C=2C(=CN=C(N)N=2)Cl)N1 PZHMWEWFZWEOAB-UHFFFAOYSA-N 0.000 description 1
- ORLMHQPMGWTFPB-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-(2-hydroxyethyl)-1H-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(=O)NCCO)C=C(C=2C(=CN=C(N)N=2)Cl)N1 ORLMHQPMGWTFPB-UHFFFAOYSA-N 0.000 description 1
- SVZYDIHOXRRNIC-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-ethyl-1H-pyrrole-3-carboxamide Chemical compound CCNC(=O)C=1C=C(C=2C(=CN=C(N)N=2)Cl)NC=1C1=CC(Cl)=CC=C1CC SVZYDIHOXRRNIC-UHFFFAOYSA-N 0.000 description 1
- VLSJSSBRWUWQCG-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-methyl-1H-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(=O)NC)C=C(C=2C(=CN=C(N)N=2)Cl)N1 VLSJSSBRWUWQCG-UHFFFAOYSA-N 0.000 description 1
- ICKVVANNEOYGTJ-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)Cl)N1 ICKVVANNEOYGTJ-UHFFFAOYSA-N 0.000 description 1
- VMEDFDYCBKBVLH-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxylic acid Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(O)=O)C=C(C=2C(=CN=C(N)N=2)Cl)N1 VMEDFDYCBKBVLH-UHFFFAOYSA-N 0.000 description 1
- RJHXFQHOJLNUOL-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-N-(2-hydroxyethyl)-1H-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(=O)NCCO)C=C(C=2C(=CN=C(N)N=2)Cl)N1 RJHXFQHOJLNUOL-UHFFFAOYSA-N 0.000 description 1
- LNEDNJPYOZBIND-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-N-methyl-1H-pyrrole-3-carboxamide Chemical compound CNC(=O)C=1C=C(C=2C(=CN=C(N)N=2)Cl)NC=1C1=CC(Cl)=CC=C1C LNEDNJPYOZBIND-UHFFFAOYSA-N 0.000 description 1
- XNRNSGRKZNQTJI-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)Cl)N1 XNRNSGRKZNQTJI-UHFFFAOYSA-N 0.000 description 1
- KGUWVCZKOZQIII-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-N-ethyl-1-[2-ethyl-5-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound C=1C(C(F)(F)F)=CC=C(CC)C=1N1C=C(C(=O)NCC)C=C1C1=NC(N)=NC=C1Cl KGUWVCZKOZQIII-UHFFFAOYSA-N 0.000 description 1
- ZGLWRKNQZGXCGA-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-N-ethyl-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide Chemical compound CCNC(=O)C=1C=C(C=2C(=CN=C(N)N=2)Cl)NC=1C1=CC(C(F)(F)F)=CC=C1C ZGLWRKNQZGXCGA-UHFFFAOYSA-N 0.000 description 1
- GNIQBTVBQCRIQS-UHFFFAOYSA-N 5-(2-amino-5-chloropyrimidin-4-yl)-N-methyl-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide Chemical compound CNC(=O)C=1C=C(C=2C(=CN=C(N)N=2)Cl)NC=1C1=CC(C(F)(F)F)=CC=C1C GNIQBTVBQCRIQS-UHFFFAOYSA-N 0.000 description 1
- MPCNTUNXLYJNGO-UHFFFAOYSA-N 5-(2-amino-5-ethynylpyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carboxylic acid Chemical compound CC1=CC=C(Cl)C=C1C(N1COCC[Si](C)(C)C)=C(C(O)=O)C=C1C1=NC(N)=NC=C1C#C MPCNTUNXLYJNGO-UHFFFAOYSA-N 0.000 description 1
- VTJALODLOSXTFO-UHFFFAOYSA-N 5-(2-amino-5-iodopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)I)N1 VTJALODLOSXTFO-UHFFFAOYSA-N 0.000 description 1
- AIIOVKJZNGCYPJ-UHFFFAOYSA-N 5-(2-amino-5-iodopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)I)N1 AIIOVKJZNGCYPJ-UHFFFAOYSA-N 0.000 description 1
- XYUIBTVGCVWAJS-UHFFFAOYSA-N 5-(2-amino-5-iodopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-N-methyl-1H-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=C(C(=O)NC)C=C(C=2C(=CN=C(N)N=2)I)N1 XYUIBTVGCVWAJS-UHFFFAOYSA-N 0.000 description 1
- DCHWKBATPUHCEO-UHFFFAOYSA-N 5-(2-amino-5-iodopyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=C(C(N)=O)C=C(C=2C(=CN=C(N)N=2)I)N1 DCHWKBATPUHCEO-UHFFFAOYSA-N 0.000 description 1
- WYHJNFWIDSLICQ-UHFFFAOYSA-N 5-(2-amino-5-iodopyrimidin-4-yl)-2-phenyl-1H-pyrrole-3-carboxamide Chemical compound NC(=O)C=1C=C(C=2C(=CN=C(N)N=2)I)NC=1C1=CC=CC=C1 WYHJNFWIDSLICQ-UHFFFAOYSA-N 0.000 description 1
- KEOLKSUGMDFFCC-UHFFFAOYSA-N 5-(2-amino-5-iodopyrimidin-4-yl)-N-methyl-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide Chemical compound CNC(=O)C=1C=C(C=2C(=CN=C(N)N=2)I)NC=1C1=CC(C(F)(F)F)=CC=C1C KEOLKSUGMDFFCC-UHFFFAOYSA-N 0.000 description 1
- ISUVXHMMMMUOKF-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C(N1COCC[Si](C)(C)C)=C(C(N)=O)C=C1C1=CC=NC(N)=N1 ISUVXHMMMMUOKF-UHFFFAOYSA-N 0.000 description 1
- NPKUNTFKYWHZGQ-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carbonitrile Chemical compound CC1=CC=C(Cl)C=C1C1=C(C#N)C=C(C=2N=C(N)N=CC=2)N1 NPKUNTFKYWHZGQ-UHFFFAOYSA-N 0.000 description 1
- LOQQUSGOWBJVOC-UHFFFAOYSA-N 5-[2-amino-5-[2-[2-[(1-methylpiperidin-4-yl)amino]phenyl]ethynyl]pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound C1CN(C)CCC1NC1=CC=CC=C1C#CC1=CN=C(N)N=C1C1=CC(C(N)=O)=C(C=2C(=CC=C(Cl)C=2)C)N1 LOQQUSGOWBJVOC-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- GXMFLLVURQXDPD-UHFFFAOYSA-N 5-chloro-2-ethylaniline Chemical compound CCC1=CC=C(Cl)C=C1N GXMFLLVURQXDPD-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- 101150064299 AUR1 gene Proteins 0.000 description 1
- 102100028247 Abl interactor 1 Human genes 0.000 description 1
- 108050004693 Abl interactor 1 Proteins 0.000 description 1
- 102100036409 Activated CDC42 kinase 1 Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101000783817 Agaricus bisporus lectin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 101100381333 Arabidopsis thaliana AUR2 gene Proteins 0.000 description 1
- 101000995861 Arabidopsis thaliana Regulatory protein NPR1 Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102000043139 CK2 family Human genes 0.000 description 1
- 108091054872 CK2 family Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 102100034744 Cell division cycle 7-related protein kinase Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- FVIGODVHAVLZOO-UHFFFAOYSA-N Dixanthogen Chemical compound CCOC(=S)SSC(=S)OCC FVIGODVHAVLZOO-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 1
- 102100021808 Eukaryotic elongation factor 2 kinase Human genes 0.000 description 1
- 102100034174 Eukaryotic translation initiation factor 2-alpha kinase 3 Human genes 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 101100273645 Gallus gallus CCNA2 gene Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 101100297762 Gibberella zeae (strain ATCC MYA-4620 / CBS 123657 / FGSC 9075 / NRRL 31084 / PH-1) PKS12 gene Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 101150017137 Haspin gene Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000678466 Homo sapiens 40S ribosomal protein S27 Proteins 0.000 description 1
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 1
- 101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 description 1
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 description 1
- 101000945740 Homo sapiens Cell division cycle 7-related protein kinase Proteins 0.000 description 1
- 101000659223 Homo sapiens Dual specificity protein kinase TTK Proteins 0.000 description 1
- 101000895759 Homo sapiens Eukaryotic elongation factor 2 kinase Proteins 0.000 description 1
- 101100066427 Homo sapiens FCGR1A gene Proteins 0.000 description 1
- 101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 description 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 1
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 1
- 101000588130 Homo sapiens Microsomal triglyceride transfer protein large subunit Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101000896657 Homo sapiens Mitotic checkpoint serine/threonine-protein kinase BUB1 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000721172 Homo sapiens Protein DBF4 homolog A Proteins 0.000 description 1
- 101001051767 Homo sapiens Protein kinase C beta type Proteins 0.000 description 1
- 101000606502 Homo sapiens Protein-tyrosine kinase 6 Proteins 0.000 description 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 1
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000701393 Homo sapiens Serine/threonine-protein kinase 26 Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 101000600885 Homo sapiens Serine/threonine-protein kinase NIM1 Proteins 0.000 description 1
- 101000588540 Homo sapiens Serine/threonine-protein kinase Nek6 Proteins 0.000 description 1
- 101000987297 Homo sapiens Serine/threonine-protein kinase PAK 4 Proteins 0.000 description 1
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 1
- 101001001648 Homo sapiens Serine/threonine-protein kinase pim-2 Proteins 0.000 description 1
- 101000637847 Homo sapiens Serine/threonine-protein kinase tousled-like 2 Proteins 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 description 1
- 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 208000009388 Job Syndrome Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 101710138999 MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 description 1
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 102100024299 Maternal embryonic leucine zipper kinase Human genes 0.000 description 1
- 101710154611 Maternal embryonic leucine zipper kinase Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102100021691 Mitotic checkpoint serine/threonine-protein kinase BUB1 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108091008010 PERKs Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000031951 Primary immunodeficiency Diseases 0.000 description 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100025198 Protein DBF4 homolog A Human genes 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102100024923 Protein kinase C beta type Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100039810 Protein-tyrosine kinase 6 Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 1
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 108091008118 SFKs Proteins 0.000 description 1
- 102000038012 SFKs Human genes 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 102100030617 Serine/threonine-protein kinase 26 Human genes 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 102100037345 Serine/threonine-protein kinase NIM1 Human genes 0.000 description 1
- 102100031401 Serine/threonine-protein kinase Nek6 Human genes 0.000 description 1
- 102100027940 Serine/threonine-protein kinase PAK 4 Human genes 0.000 description 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 1
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 1
- 102100036120 Serine/threonine-protein kinase pim-2 Human genes 0.000 description 1
- 102100032014 Serine/threonine-protein kinase tousled-like 2 Human genes 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000008036 Suppressor of Cytokine Signaling Proteins Human genes 0.000 description 1
- 108010075383 Suppressor of Cytokine Signaling Proteins Proteins 0.000 description 1
- 101150110875 Syk gene Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000011176 T-cell adult acute lymphocytic leukemia Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- NNTGAOLTGGLLPE-UHFFFAOYSA-N [Zn+2].[C-]#[C-] Chemical class [Zn+2].[C-]#[C-] NNTGAOLTGGLLPE-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
- 125000004948 alkyl aryl alkyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000005120 alkyl cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 238000005905 alkynylation reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000005141 aryl amino sulfonyl group Chemical group 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- URQAMACHHWVNRD-UHFFFAOYSA-O azanium;1-hydroxybenzotriazole Chemical compound [NH4+].C1=CC=C2N(O)N=NC2=C1 URQAMACHHWVNRD-UHFFFAOYSA-O 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- DIOLOCSXUMYFJN-UHFFFAOYSA-N calcium;azane Chemical compound N.[Ca+2] DIOLOCSXUMYFJN-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- STIAPHVBRDNOAJ-UHFFFAOYSA-N carbamimidoylazanium;carbonate Chemical compound NC(N)=N.NC(N)=N.OC(O)=O STIAPHVBRDNOAJ-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000006364 cellular survival Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 239000003426 co-catalyst Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000004465 cycloalkenyloxy group Chemical group 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 description 1
- 125000004986 diarylamino group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- DWLBERAZRYIZEO-UHFFFAOYSA-N ethyl 5-(2-aminopyrimidin-4-yl)-2-bromo-1h-pyrrole-3-carboxylate Chemical compound N1C(Br)=C(C(=O)OCC)C=C1C1=CC=NC(N)=N1 DWLBERAZRYIZEO-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- NVUYWKBRSRPYMH-UHFFFAOYSA-N hydron;piperidine-4-carboxylic acid;chloride Chemical compound Cl.OC(=O)C1CCNCC1 NVUYWKBRSRPYMH-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000005191 hydroxyalkylamino group Chemical group 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical class [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- XOZZATXWQMOVHL-UHFFFAOYSA-N n,n-dimethyl-1,1-di(propan-2-yloxy)methanamine Chemical compound CC(C)OC(N(C)C)OC(C)C XOZZATXWQMOVHL-UHFFFAOYSA-N 0.000 description 1
- NOMNLVFJDJQTRY-UHFFFAOYSA-N n,n-dimethyl-1-[4-(2-trimethylsilylethynyl)phenyl]piperidin-4-amine Chemical compound C1CC(N(C)C)CCN1C1=CC=C(C#C[Si](C)(C)C)C=C1 NOMNLVFJDJQTRY-UHFFFAOYSA-N 0.000 description 1
- WCXWFJWYYUSDJS-UHFFFAOYSA-N n-(2-ethynylphenyl)-1-methylpiperidin-4-amine Chemical compound C1CN(C)CCC1NC1=CC=CC=C1C#C WCXWFJWYYUSDJS-UHFFFAOYSA-N 0.000 description 1
- HRNNMHQSHWGOMP-UHFFFAOYSA-N n-(2-ethynylphenyl)-n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCNC1=CC=CC=C1C#C HRNNMHQSHWGOMP-UHFFFAOYSA-N 0.000 description 1
- MCQLXKMVZUFGQG-UHFFFAOYSA-N n-(3-ethynyl-4-methoxyphenyl)-1-methylpiperidine-4-carboxamide Chemical compound C1=C(C#C)C(OC)=CC=C1NC(=O)C1CCN(C)CC1 MCQLXKMVZUFGQG-UHFFFAOYSA-N 0.000 description 1
- DATRTKSOCIPKBX-UHFFFAOYSA-N n-(3-ethynylphenyl)-1-methylpiperidin-4-amine Chemical compound C1CN(C)CCC1NC1=CC=CC(C#C)=C1 DATRTKSOCIPKBX-UHFFFAOYSA-N 0.000 description 1
- MLVFLAHYIMSDQN-UHFFFAOYSA-N n-(3-ethynylphenyl)oxan-4-amine Chemical compound C#CC1=CC=CC(NC2CCOCC2)=C1 MLVFLAHYIMSDQN-UHFFFAOYSA-N 0.000 description 1
- AXHHKNVFTIXCLB-UHFFFAOYSA-N n-(4-ethynyl-3-methoxyphenyl)-1-methylpiperidin-4-amine Chemical compound C1=C(C#C)C(OC)=CC(NC2CCN(C)CC2)=C1 AXHHKNVFTIXCLB-UHFFFAOYSA-N 0.000 description 1
- SDWAFTCWRBPVGQ-UHFFFAOYSA-N n-(4-ethynylphenyl)-1-methylpiperidin-4-amine Chemical compound C1CN(C)CCC1NC1=CC=C(C#C)C=C1 SDWAFTCWRBPVGQ-UHFFFAOYSA-N 0.000 description 1
- QCYJARASYJWSQA-UHFFFAOYSA-N n-(4-ethynylphenyl)oxan-4-amine Chemical compound C1=CC(C#C)=CC=C1NC1CCOCC1 QCYJARASYJWSQA-UHFFFAOYSA-N 0.000 description 1
- FZLNSANIVMRSLH-UHFFFAOYSA-N n-(4-iodo-3-methoxyphenyl)-1-methylpiperidin-4-amine Chemical compound C1=C(I)C(OC)=CC(NC2CCN(C)CC2)=C1 FZLNSANIVMRSLH-UHFFFAOYSA-N 0.000 description 1
- WDEVDFDRJJDYKX-UHFFFAOYSA-N n-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-ethynylaniline Chemical compound CC(C)(C)[Si](C)(C)OCCNC1=CC=C(C#C)C=C1 WDEVDFDRJJDYKX-UHFFFAOYSA-N 0.000 description 1
- CEBUICWCXCNNKK-UHFFFAOYSA-N n-[3-methoxy-4-(2-trimethylsilylethynyl)phenyl]-1-methylpiperidin-4-amine Chemical compound C1=C(C#C[Si](C)(C)C)C(OC)=CC(NC2CCN(C)CC2)=C1 CEBUICWCXCNNKK-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- GKMHNICUWXRSMF-UHFFFAOYSA-N n-[5-(4-chlorophenyl)-7-(4-fluorophenyl)-1,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]-4-fluorobenzamide Chemical compound C1=CC(F)=CC=C1C1N2NC(NC(=O)C=3C=CC(F)=CC=3)=NC2=NC(C=2C=CC(Cl)=CC=2)=C1 GKMHNICUWXRSMF-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- BXJPDSYWRJBHOS-UHFFFAOYSA-N non-2-ynamide Chemical compound CCCCCCC#CC(N)=O BXJPDSYWRJBHOS-UHFFFAOYSA-N 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000021962 pH elevation Effects 0.000 description 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 108010056274 polo-like kinase 1 Proteins 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000015846 regulation of osteoclast proliferation Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 102200087780 rs77375493 Human genes 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000002805 secondary assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- KZJPVUDYAMEDRM-UHFFFAOYSA-M silver;2,2,2-trifluoroacetate Chemical compound [Ag+].[O-]C(=O)C(F)(F)F KZJPVUDYAMEDRM-UHFFFAOYSA-M 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- QGXFDKHOSNJQKE-UHFFFAOYSA-N sulfuric acid;2,2,2-trifluoroacetic acid Chemical compound OS(O)(=O)=O.OC(=O)C(F)(F)F QGXFDKHOSNJQKE-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- NZOPQQBHHPWQDI-UHFFFAOYSA-N tert-butyl N-[2-(4-ethynylanilino)ethyl]carbamate Chemical group CC(C)(C)OC(=O)NCCNc1ccc(cc1)C#C NZOPQQBHHPWQDI-UHFFFAOYSA-N 0.000 description 1
- IOBDWTVOJRRLGK-UHFFFAOYSA-N tert-butyl N-[2-[3-[2-[2-(2-aminopyrimidin-4-yl)-4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-3-yl]ethynyl]anilino]ethyl]carbamate Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C(C#CC=2C=C(NCCNC(=O)OC(C)(C)C)C=CC=2)=C(C=2N=C(N)N=CC=2)N1 IOBDWTVOJRRLGK-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940073455 tetraethylammonium hydroxide Drugs 0.000 description 1
- LRGJRHZIDJQFCL-UHFFFAOYSA-M tetraethylazanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)CC LRGJRHZIDJQFCL-UHFFFAOYSA-M 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- PHCBRBWANGJMHS-UHFFFAOYSA-J tetrasodium;disulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O PHCBRBWANGJMHS-UHFFFAOYSA-J 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
- HFBLMGNRROBTGW-UHFFFAOYSA-N trimethyl-[2-(4-piperazin-1-ylphenyl)ethynyl]silane Chemical compound C1=CC(C#C[Si](C)(C)C)=CC=C1N1CCNCC1 HFBLMGNRROBTGW-UHFFFAOYSA-N 0.000 description 1
- IKCYWHINDMJPMW-UHFFFAOYSA-N trimethyl-[2-[4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]ethynyl]silane Chemical compound C1=CC(C#C[Si](C)(C)C)=CC=C1N1CCC(N2CCCC2)CC1 IKCYWHINDMJPMW-UHFFFAOYSA-N 0.000 description 1
- QOPRFKKULRUZAH-FQEVSTJZSA-N trimethyl-[2-[4-[(2s)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]phenyl]ethynyl]silane Chemical compound C1=CC(C#C[Si](C)(C)C)=CC=C1N1[C@H](CN2CCCC2)CCC1 QOPRFKKULRUZAH-FQEVSTJZSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 102000042287 type II cytokine receptor family Human genes 0.000 description 1
- 108091052254 type II cytokine receptor family Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to certain alkynyl substituted pyrimidinyl-pyrrole compounds, which modulate the activity of protein kinases.
- the compounds of this invention are therefore useful in treating diseases related to dysregulated kinases activity, for example cancer, cell proliferative disorders, viral infections, immune disorders, neurodegenerative disorders, cardiovascular diseases and bone related diseases.
- the present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and discloses methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.
- Protein kinases mediate intracellular signaling by affecting a phosphoryl transfer from a nucleoside triphosphate to a protein acceptor that is involved in a signaling pathway. These phosphorylation events act as molecular on/off switches that can modulate or regulate the target protein's biological function and are ultimately triggered in response to a variety of extracellular and other stimuli.
- Examples of such stimuli include environmental and chemical stress signals (e.g., osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxin, and H 2 O 2 ), cytokines (e.g., interleukin-3 (IL-3), IL-2) and growth factors (e.g., granulocyte macrophage-colony-stimulating factor (GM-CSF), fibroblast growth factor (FGF) and Erythropoietin (EPO)).
- cytokines e.g., interleukin-3 (IL-3), IL-2
- growth factors e.g., granulocyte macrophage-colony-stimulating factor (GM-CSF), fibroblast growth factor (FGF) and Erythropoietin (EPO)
- An extracellular stimulus may affect one or more cellular responses related to cell growth, migration, differentiation, secretion of hormones, activation of transcription factors, muscle contraction, glucose metabolism, control of protein synthesis and regulation of the cell
- PKs protein kinases
- the enhanced activities of PKs are also implicated in many non-malignant diseases that include, but are not limited to, autoimmune diseases, inflammatory diseases, psoriasis, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cardiovascular diseases, allergies and asthma, Alzheimer's disease, and hormone-related diseases. Accordingly, there has been a substantial effort in medicinal chemistry to find protein kinase inhibitors that are effective as therapeutic agents.
- PKs malfunctioning or deregulation see Current Opinions in Chemical Biology 1999, 3: 459 - 465 ; Nature Rev. Drug Discov. 2002, 1:309-315 and Carcinogenesis 2008, 29:1087-191 .
- JAKs are a family of non-receptor tyrosine kinases consisting of JAK1, JAK2, JAK3 and TYK2. Whereas JAK1, JAK2 and TYK2 are expressed ubiquitously in mammals, JAK3 is primarily expressed in hematopoietic cells. The JAKs play a crucial role in hematopoietic cytokine and growth factors signaling ( Nature 1995; 377: 591-594 , Annu. Rev. Immunol. 1998; 16: 293-322 ) and are critically involved in cell growth, survival, development and differentiation of myeloid and immune cells.
- JAK/STAT signaling has been implicated in the mediation of many abnormal immune responses such as allergies, asthma, autoimmune diseases, transplant rejection, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis as well as in solid and hematological malignancies like leukemias and lymphomas ( Immunol Rev. 2009, 228: 273-287 ).
- JAK2 kinase is exclusively involved in the signal transduction mediated by Erythropoietin (EPO), Thrombopoietin (TPO), Growth Hormone (GH), Prolactin (PR) and by cytokines that signal through the common beta chain receptor IL-3, granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-5.
- EPO Erythropoietin
- TPO Thrombopoietin
- GH Growth Hormone
- PR Prolactin
- JAK2 together with JAK1 and/or TYK2 are important for the cytokines that signal through gp130 receptors (e.g.
- JAK3 kinase is primarily expressed in hematopoietic cells and is selectively associated with the common ⁇ chain ( ⁇ c), which is a shared component of the receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 that are cytokines involved in lymphoid development and function, and homeostasis of the immune system.
- ⁇ c common ⁇ chain
- TYK2 is primarily associated with Interferons, IL-12 and IL-23, but also with IL-10 and IL-6 signalling. All these growth factors and cytokines are mainly involved in proliferation and differentiation of Myeloid cells, inflammatory response and cancer ( Blood. 2009; 114: 1289-1298 , Clin Cancer Res. 2006; 12:6270s-6273s , J Leukoc Biol. 2010; 88:1145-1156 , Eur J Cancer. 2010; 46:1223 ).
- STAT Signal Transducers and Activators of Transcription proteins
- JAKs are responsible for transducing a signal from the cell surface to the nucleus through a tyrosine phosphorylation signalling mechanism ( J. Immun. 2007, 178: 2623-2629 , Oncogene 2007, 26: 6724-6737 and Cell Biochem Biophys. 2006, 44: 213-222 ).
- JAKs are characterized by 7 distinct JAK homology regions (JH1 to JH7), among these the JH1 regions form the kinase domain and is immediately adjacent to the pseudo-kinase domain (JH2) within the C-terminal half of the protein.
- JH2 pseudo-kinase domain
- the function of the pseudo-kinase domain is to negatively regulate the activity of the kinase domain ( N. Engl. J. Med 2006, 355: 2452-2466 ). It should be pointed out that the majority of JAK activating mutations identified in tumors are in pseudo-kinase domain.
- JAK2 Valine to Phenylalanine substitution, JAK2-V617F
- JAK2-V617F Valine to Phenylalanine substitution
- MPLW515L/K TPO Receptor
- JAK2 is a suitable target for the development of a MPD specific therapy ( Curr. Onc. Reports 2009, 11: 117-124 ).
- JAK/STAT pathway has been shown to be activated not only by mutation but also by amplification, translocation, silencing of JAK/STAT pathway inhibitors SOCS proteins and overexpression of cytokines in solid and hematological malignancies like, but not limited to, AML, ALL, Hodgkin's Lymphoma, Diffuse large B cell Lymphoma and Mediastinal large B-Cell Lymphoma, Lung, Prostate, Colon and Breast cancer.
- JAK3 or TYK2 results in defined clinical disorders, which are also evident in mouse models.
- a striking phenotype associated with inactivating JAK3 mutations is severe combined immunodeficiency syndrome, whereas mutation of TYK2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.
- JAK inhibitors in several different diseases such as abnormal immune responses like allergies, asthma, autoimmune diseases, transplant rejection, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis as well as in solid and hematological malignancies like MPD, leukemias and lymphomas.
- J. Leukoc Biol. 2010; 88:1145-1156 Eur J. Cancer. 2010; 46:1223-1231 , Immunol Rev. 2009; 228: 273-287, Trends Blood. 2009; 114: 1289-1298 , Clin Cancer Res. 2008; 14:3716-3721 , Biochem.
- Src family kinases are non-receptor protein tyrosine kinases (PTKs) ubiquitously expressed and highly conserved throughout evolution. Based on their amino acidic sequences, SFK can be clustered into two subfamilies. The first group includes Src, Fyn, and Yes which are ubiquitously expressed, even though with quantitative differences.
- the second group includes Blk, Fgr, Hck, Lck, and Lyn which are found primarily in haematopoietic cells ( Cancer 2010; 116: 1629-1637 ; Oncogene 2004; 23:7918-7927 ). All SFKs play pivotal roles in transducing signals triggered by a variety of surface receptors to downstream molecules to regulate cellular events, such as cell growth, adhesion and migration. Changes in SFK protein expression and/or activity have been causally linked to human carcinogenesis, as described for hematological and solid malignancies ( Cancer Treat Rev., 2010; 36: 492-500 ).
- SFK Src Knockout mice
- Src inhibition could have an effect in tumours that preferentially metastasize to bone
- cytokine receptors associate with members of the Src family kinase (SFK) and JAKs and SFK work in concert to activate many of the signalling molecules, with both kinase families required for optimal transmission of intracellular signals ( Oncogene 2002; 21: 3334-3358 ; Growth Factors 2006; 24: 89-95 ).
- SFK In addition SFK, have been shown to be involved in the signaling of T and B cell receptors respectively, support the potential use of specific inhibitors in immune disorders. All of this information supports the use of SFK in solid and hemathological tumors, to control bone metastasis and for the treatment of T-cell-mediated autoimmune and inflammatory disorders and/or organ transplant rejection.
- a first object of the present invention is to provide an alkynyl substituted pyrimidinyl-pyrrole compound represented by formula (I), wherein:
- the present invention also provides methods of preparing the alkynyl substituted pyrimidinyl-pyrrole compounds, represented by formula (I), prepared through a process consisting of standard synthetic transformations.
- the present invention also provides a compound of formula (I) for use in a method for treating diseases caused by and/or associated with a dysregulated protein kinase activity, particularly ABL, ACK1, AKT1, ALK, AUR1, AUR2, BRK, BUB1, CDC7/DBF4, CDK2/CYCA, CHK1, CK2, EEF2K, EGFR1, EphA2, EphB4, ERK2, FAK, FGFR1, FLT3, GSK3beta, Haspin, IGFR1, IKK2, IR, JAK1, JAK2, JAK3, KIT, Lck, Lyn, MAPKAPK2, MELK, MET, MNK2, MPS1, MST4, NEK6, NIM1, P38alpha, PAK4, PDGFR, PDK1, PERK, PIM1, PIM2, PKAalpha, PKCbeta, PLK1, RET, ROS1, SULU1, Syk, TLK2, TRKA, TYK2, VEGFR2, VEGFR3, Z
- a preferred object of the present invention is to provide a compound of formula (I) for use in a method for treating a disease caused by and/or associated with a dysregulated protein kinase activity selected from the group consisting of cancer, cell proliferative disorders, viral infections, immune-related disorders, neurodegenerative disorders, cardiovascular diseases and bone related diseases.
- a dysregulated protein kinase activity selected from the group consisting of cancer, cell proliferative disorders, viral infections, immune-related disorders, neurodegenerative disorders, cardiovascular diseases and bone related diseases.
- Another preferred object of the present invention is to provide a compound of formula (I) for use in a method for treating specific types of cancer including but not limited to: carcinoma such as bladder, breast, brain, colon, kidney, liver, lung, including small cell lung cancer, head and neck, esophagus, gall-bladder, ovary, uterine, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukaemia, T and B acute lymphoblastic leukemia (ALL), including DS-ALL, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Multiple Myeloma, hairy cell lymphoma, Burkitt's lymphoma and mantle cell lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogen
- Another preferred object of the present invention is to provide a compound of formula (I) for use in a method for treating specific types of cell proliferative disorders including but not limited to: benign prostate hyperplasia, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.
- Another preferred object of the present invention is to provide a compound of formula (I) for use in a method for treating viral infections comprising the prevention of AIDS development in HIV-infected individuals.
- a preferred object of the present invention is to provide a compound of formula (I) for use in a method for treating immune-related disorders including but not limited to: transplant rejection, skin disorders like psoriasis, allergies, asthma and autoimmune-mediated diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Crohn's disease and amyotrophic lateral sclerosis.
- immune-related disorders including but not limited to: transplant rejection, skin disorders like psoriasis, allergies, asthma and autoimmune-mediated diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Crohn's disease and amyotrophic lateral sclerosis.
- Another preferred object of the present invention is to provide a compound of formula (I) for use in a method for treating neurodegenerative disorders including but not limited to: Alzheimer's disease, degenerative nerve diseases, encephalitis, Stroke, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Huntington's Disease and Pick's Disease.
- neurodegenerative disorders including but not limited to: Alzheimer's disease, degenerative nerve diseases, encephalitis, Stroke, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Huntington's Disease and Pick's Disease.
- Another preferred object of the present invention is to provide a compound of formula (I) for use in a method for treating cardiovascular diseases including but not limited to: atherosclerosis primary or secondary to diabetes, heart attack and stroke.
- Another preferred object of the present invention is to provide a compound of formula (I) for use in a method for treating bone loss diseases including but not limited to osteoporosis and bone metastasis.
- the present invention also provides a compound of formula (I) for use in tumor angiogenesis and metastasis inhibition as well as in the treatment of organ transplant rejection and host versus graft disease.
- the method disclosed by the present invention further comprises subjecting the mammal in need thereof to a radiation therapy or chemotherapy regimen in combination with at least one cytostatic or cytotoxic agent.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, and at least one pharmaceutically acceptable excipient, carrier and/or diluent.
- the present invention provides a pharmaceutical composition of a compound of the formula (I) further comprising one or more chemotherapeutic - e.g. cytostatic or cytotoxic - agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents like anti-HER agents, anti-EGFR agents, anti-Abl, anti-angiogenesis agents (e.g.
- chemotherapeutic e.g. cytostatic or cytotoxic - agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, telomerase inhibitors,
- angiogenesis inhibitors farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, Akt pathway inhibitors, cell cycle inhibitors, other CDK inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and the like.
- the present invention further provides an in vitro method for inhibiting JAK and/or Src family kinase proteins activity which comprises contacting the said protein with an effective amount of a compound of formula (I) as defined above. Additionally, the invention provides a product comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
- the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, for use as a medicament.
- the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, for use in a method of treating cancer.
- the present disclosure includes all of the hydrates, solvates, complexes, metabolites, pharmaceutically acceptable prodrugs, pharmaceutically acceptable bio-precursors, carriers, N -oxides and pharmaceutically acceptable salts of the compounds.
- a metabolite of a compound of the formula (I) is any compound into which this same compound of the formula (I) is converted in vivo, for instance upon administration to a mammal in need thereof.
- this same derivative may be converted into a variety of compounds, for instance including more soluble derivatives like hydroxylated derivatives, which are easily excreted.
- any of these hydroxylated derivatives may be regarded as a metabolite of the compounds of the formula (I).
- “Pharmaceutically acceptable prodrug” and “pharmaceutically acceptable bio-precursors” are any covalently bonded compounds, which release in vivo the active parent drug according to the formula (I).
- prodrug and “pharmaceutically acceptable bio-precursors” as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
- prodrug refers to compounds that are rapidly transformed in vivo to yield the active parent drug, according to formula (I), in vivo, for example by hydrolysis in blood.
- N -oxides are compounds of the formula (I) wherein nitrogen and oxygen are tethered through a dative bond.
- Pharmaceutically acceptable salts of the compounds of the formula (I) include the acid addition salts with inorganic or organic acids, e.g., nitric, hydrochloric, hydrobromic, sulfuric, perchloric, phosphoric, acetic, trifluoroacetic, propionic, glycolic, fumaric, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulphonic, isethionic and salicylic acid.
- inorganic or organic acids e.g., nitric, hydrochloric, hydrobromic, sulfuric, perchloric, phosphoric, acetic, trifluoroacetic, propionic, glycolic, fumaric, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulphonic, isethionic and sal
- Pharmaceutically acceptable salts of the compounds of the formula (I) also include the salts with inorganic or organic bases, e.g., alkali or alkaline-earth metals, especially sodium, potassium, calcium ammonium or magnesium hydroxides, carbonates or bicarbonates, acyclic or cyclic amines.
- inorganic or organic bases e.g., alkali or alkaline-earth metals, especially sodium, potassium, calcium ammonium or magnesium hydroxides, carbonates or bicarbonates, acyclic or cyclic amines.
- stereogenic center or another form of an isomeric center is present in a compound of the present invention, all forms of such isomer or isomers, including enantiomers and diastereomers, are intended to be covered herein.
- Compounds containing a stereogenic center may be used as a racemic mixture, an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone. In cases in which compounds have unsaturated carbon-carbon double bonds, both the cis (Z) and trans (E) isomers are within the scope of this invention.
- each tautomeric form is contemplated as being included within this invention whether existing in equilibrium or predominantly in one form.
- aryl includes carbocyclic or heterocyclic hydrocarbons with from 1 to 2 ring moieties, either fused or linked to each other by single bonds, wherein at least one of the rings is aromatic; if present, any aromatic heterocyclic hydrocarbon also referred to as heteroaryl group, comprises a 5 to 6 membered ring with from 1 to 3 heteroatoms selected from N, O and S.
- aryl groups are, for instance, phenyl, biphenyl, ⁇ - or ⁇ -naphthyl, dihydronaphthyl, thienyl, benzothienyl, furyl, benzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, isoindolyl, purinyl, quinolyl, isoquinolyl, dihydroquinolinyl, quinoxalinyl, benzodioxolyl, indanyl, indenyl, triazolyl, and the like.
- heterocyclyl also known as “heterocycloalkyl”
- heterocyclyl we intend a 3- to 7-membered, saturated or partially unsaturated carbocyclic ring where one or more carbon atoms are replaced by heteroatoms such as nitrogen, oxygen and sulfur.
- heterocyclyl groups are, for instance, pyrane, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazolidine, pyrazoline, thiazoline, thiazolidine, dihydrofuran, tetrahydrofuran, 1,3-dioxolane, piperidine, piperazine, morpholine and the like.
- straight or branched C 1 -C 6 alkyl we intend any of the groups such as, for instance, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutul, tert-butyl, sec-butyl, n-pentyl, n-hexyl, and the like.
- C 3 -C 7 cycloalkyl we intend, unless otherwise provided, 3- to 7-membered all-carbon monocyclic ring, which may contain one or more double bonds but does not have a completely conjugated ⁇ -electron system.
- cycloalkyl groups without limitation, are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexadiene, cycloeptane, cycloeptene, cycloeptadiene.
- straight or branched C 2 -C 6 alkenyl we intend any of the groups such as, for instance, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 1-hexenyl, and the like.
- straight or branched C 2 -C 6 alkynyl we intend any of the groups such as, for instance, ethynyl, 2-propynyl, 4-pentynyl, and the like.
- each of the above substituent may be further substituted by one or more of the aforementioned groups.
- halogen atom we intend a fluorine, chlorine, bromine or iodine atom.
- polyfluorinated alkyl or alkoxy we intend any of the above straight or branched C 1 -C 6 alkyl or alkoxy groups which are substituted by more than one fluorine atom such as, for instance, trifluoromethyl, trifluoroethyl, 1,1,1,3,3,3-hexafluoropropyl, trifluoromethoxy and the like.
- alkoxy alkoxy
- cyclyloxy aryloxy
- heterocyclyloxy any of the above C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl or heterocyclyl groups linked to the rest of the molecule through an oxygen atom (-O-).
- any group which name is a composite name such as, for instance, arylamino has to be intended as conventionally construed by the parts from which it derives, e.g. by an amino group which is further substituted by aryl, wherein aryl is as above defined.
- any of the terms such as, for instance, alkylthio, alkylamino, dialkylamino, alkoxycarbonyl, alkoxycarbonylamino, heterocyclylcarbonyl, heterocyclylcarbonylamino, cycloalkyloxycarbonyl and the like, include groups wherein the alkyl, alkoxy, aryl, C 3 -C 7 cycloalkyl and heterocyclyl moieties are as above defined.
- a compound of the formula (I) is characterized in that R1 is ethynyl-R7, R2 is hydrogen, and R3, R4, R5, R6 and R7 are as defined above.
- a compound of the formula (I) is characterized in that R1 is hydrogen, R2 is ethynyl-R7, and R3, R4, R5, R6 and R7 are as defined above.
- a compound of the formula (I) is characterized in that R1 is ethynyl-R7, R2 is hydrogen, R3 and R4 are independently hydrogen or an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heterocyclyl and heterocyclyl-alkyl, and R5, R6 and R7 are as defined above.
- a compound of the formula (I) is characterized in that R1 is hydrogen, R2 is ethynyl-R7, R3 and R4 are independently hydrogen or an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heterocyclyl and heterocyclyl-alkyl, and R5, R6, and R7 are as defined above.
- a compound of the formula (I) is characterized in that R1 is ethynyl-R7, wherein R7 is an optionally substituted aryl, R2 is hydrogen, and R3, R4, R5 and R6 are as defined above.
- a compound of the formula (I) is characterized in that R1 is hydrogen, R2 is ethynyl-R7, wherein R7 is an optionally substituted aryl, and R3, R4, R5 and R6 are as defined above.
- a compound of the formula (I) is characterized in that R1 is ethynyl-R7, wherein R7 is an optionally substituted aryl, R2 is hydrogen, R5 is optionally substituted phenyl, and R3, R4 and R6 are as defined above.
- a compound of the formula (I) is characterized in that R1 is hydrogen, R2 is ethynyl-R7, wherein R7 is an optionally substituted aryl, R5 is optionally substituted phenyl, R3, R4 and R6 are as defined above.
- the present invention also provides a process for the preparation of a compound of formula (I) as defined above, by using the reaction routes and synthetic schemes described below, employing the techniques available in the art and starting materials readily available.
- the preparation of certain embodiments of the present invention is described in the examples that follow, but those of ordinary skill in the art will recognize that the preparations described may be readily adapted to prepare other embodiments of the present invention.
- the synthesis of non-exemplified compounds according to the invention may be performed by modifications apparent to those skilled in the art, for instance by appropriately protecting interfering groups, by changing to other suitable reagents known in the art, or by making routine modifications of reaction conditions.
- other reactions referred to herein or known in the art will be recognized as having adaptability for preparing other compounds of the invention.
- the compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures. Unless otherwise indicated, the starting materials are known compounds or may be prepared from known compounds according to well known procedures. It will be appreciated that, where typical or preferred process conditions (i.e. , reaction temperatures, times, mole ratios of reactants, solvents, pressures) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions.
- process conditions i.e. , reaction temperatures, times, mole ratios of reactants, solvents, pressures
- Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T.W. Greene and P.G.M. Wuts, Protecting Groups in Organic Synthesis, Second Edition, Wiley, New York, 1991 , and references cited therein.
- a compound of formula (I) can be prepared according to the general synthetic processes described hereafter in schemes A, B, C, D, E and F.
- R1 is ethynyl-R7
- R2 is hydrogen
- R3, R4, R5, R6 and R7 are as defined above
- X is halogen
- a process of the present invention comprises the following steps:
- a halo derivative of general formula (II) into a compound of formula (IV) can be accomplished in a variety of ways.
- a compound of formula (II) can be reacted by metal-catalyzed coupling reactions with an optionally substituted aryl boronic acid of formula (IIIa) or an optionally substituted aryl boronic-ester of formula (IIIb).
- a compound of formula (IV) can be prepared from an intermediate of formula (II) by Pd-catalyzed Suzuki-Miyaura coupling with an optionally substituted aryl boronic acid of formula (IIIa) or an optionally substituted aryl boronic-ester of formula (IIIb).
- Transition metal-catalyzed couplings of (hetero)aryl halides with aryl boronic acids or boronic-esters are well known to the person skilled in the art, see references: a) Miyaura, Norio; Suzuki, Akira (1979). "Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds".
- Phosphine-palladium complexes such as tetrakis(triphenylphosphine)palladium(0) are used for this reaction but also bis(triphenylphosphine)palladium(II) chloride, [1,1'-bis(diphenylphosphino) ferrocene] dichloro palladium(II) may be employed.
- a base such as potassium phosphate, sodium carbonate, cesium carbonate, potassium carbonate, potassium t-butoxide, tetraethyl ammonium hydroxide, triethylamine is added and tetrahydrofurane, dioxane, N,N-dimethylformamide, ethanol and toluene may be used as reaction media.
- temperatures range from room temperature to 150 °C.
- Conventional heating along with microwave irradiation may be employed.
- Reaction duration ranges from about 30 min to about 96 hours.
- Pd-catalyst/base/solvent combinations have been described in the literature, which allow the fine-tuning of the reaction conditions in order to allow for a broad set of additional functional groups on both coupling partners.
- the hydrolysis of a derivative of formula (IV) into a carboxylic acid of formula (V) can be accomplished in a variety of ways. Typically NaOH or KOH in alcoholic solution is used, at a temperature ranging from room temperature to 150 °C, for a time ranging from about 30 min to about 96 hours.
- the introduction of halogens on a compound of formula (V) may be carried out in a variety of ways and experimental conditions, which are widely known in the art.
- the reagents that are commonly employed are: NCS, NBS or NIS in solvents such as DMF, THF, AcOH, TFA; CF 3 COOAg/Br 2 or I 2 in TFA, DMF, acetonitrile; Phl(OAc) 2 , I 2 in DCM; ICI in AcOH. Temperature ranging from about-40 °C to 100 °C and for a period of time varying from about 1 hour to about 24 hours.
- a carboxylic acid of formula (VI) into an amide of formula (VIII) can be accomplished in a variety of ways and experimental conditions, which are widely known in the art for the preparation of carboxamides.
- a compound of formula (VI) can be converted into its corresponding acyl chloride in the presence of thionyl chloride or oxalyl chloride, in a suitable solvent, such as toluene, dichloromethane, chloroform, diethyl ether, tetrahydrofuran, dioxane, at a temperature ranging from about -10 °C to reflux and for a period of time varying from about 1 hour to about 96 hours.
- a suitable solvent such as toluene, dichloromethane, chloroform, diethyl ether, tetrahydrofuran, dioxane
- the acyl chloride can be isolated by evaporation of the solvent and further reacted with 33% ammonium hydroxide solution or with an amine NHR3R4 (VII) in a suitable solvent, such as toluene, dichloromethane, chloroform, diethyl ether, tetrahydrofuran, dioxane, at a temperature ranging from about -10 °C to reflux and for a period of time varying from about 1 hour to about 96 hours.
- a suitable solvent such as toluene, dichloromethane, chloroform, diethyl ether, tetrahydrofuran, dioxane
- a compound of formula (VI) can be reacted with the ammonium salt of 1-hydroxybenzotriazole or with an amine NHR3R4 (VII) in the presence of a carbodiimide such as dicyclohexyl carbodiimide, diisopropyl carbodiimide, 1-ethyl-3-(3'-dimethylamino)carbodiimide hydrochloric acid salt and hydroxybenzotriazole.
- a carbodiimide such as dicyclohexyl carbodiimide, diisopropyl carbodiimide, 1-ethyl-3-(3'-dimethylamino)carbodiimide hydrochloric acid salt and hydroxybenzotriazole.
- this reaction is carried out in a suitable solvent such as, for instance, tetrahydrofuran, dichloromethane, toluene, dioxane, N,N -dimethylformamide and in the presence of a proton scavenger such as, for example, triethylamine, N,N -diisopropylethylamine, at a temperature ranging from room temperature to reflux, for a time ranging from about 30 min to about 96 hours.
- a suitable solvent such as, for instance, tetrahydrofuran, dichloromethane, toluene, dioxane, N,N -dimethylformamide
- a proton scavenger such as, for example, triethylamine, N,N -diisopropylethylamine
- Step 5 of Scheme A the transformation of a compound of formula (VIII) into a compound of formula (I) can be accomplished in a variety of ways and experimental conditions, which are widely known in the art.
- compounds (VIII) can be reacted to give compounds of formula (I) by metal-catalyzed coupling reactions with respectively substituted alkynes of general formula (IX).
- compounds of formula (I) can be prepared from intermediates of formula (VIII) by Pd-catalyzed Sonogashira-Hagihara coupling and Sonogashira-type coupling reactions (including Stephen-Castro couplings and Heck-Cassar alkynylations) with alkynes of general formula (IX).
- Transition metal-catalyzed couplings of (hetero)aryl halides with alkynes are well known to the person skilled in the art (see references: a) Sonogashira, Y. T.; Hagihara, N. Tetrahedron Lett. 1975, 16, 4467 ; b) Chinchilla, R.; Najera, C. Chem. Rev. 2007, 107, 874 ).
- Sonogashira reaction coupling reaction of terminal alkynes with (hetero)aryl halides is typically triggered by a zerovalent palladium complex and a halide salt of copper(I).
- Phosphine-palladium complexes such as tetrakis(triphenylphosphine)palladium(0) are used for this reaction but also bis(triphenylphosphine)palladium(II) chloride may be employed.
- An amine is added such as triethylamine or diisopropylethylamine and DMF, acetonitrile or even ether may be used as reaction media.
- temperatures range from room temperature to 150 °C. Conventional heating along with microwave irradiation may be employed. Reaction duration ranges from about 30 min to about 96 hours.
- the present invention further provides an alternative process for the preparation of a compound of formula (I), wherein R1 is ethynyl-R7, R2 is hydrogen, R3, R4, R5, R6 and R7 are as defined above, which is shown in Scheme B below.
- R1 is ethynyl-R7
- R2 is hydrogen
- R3, R4, R5, R6 and R7 are as defined above
- X is halogen
- PG is a protecting group such as SEM, Boc.
- Another process of the present invention comprises the following steps:
- Step 7 of Scheme B the regioselective introduction of the protecting group PG on the pyrrole nitrogen of a compound of general formula (X) is possible by carefully controlling the reaction conditions.
- a wide set of protecting groups is available, which are well known to the person skilled in the art (see for example Green, Theodora W. and Wuts, Peter G.M. - Protective Groups in Organic Synthesis, Third Edition, John Wily & Sons Inc., New York (NY), 1999 ; Jolicoeur,B.; Chapman, E. E.; Thommpson, A.; Lubell, W. D. Tetrahedron 2006, 62, 11531 ).
- Strong bases such as NaH or KH in solvents such as THF, DCM or DMF as well as trialkylamines in DCM or MeCN, sometimes in the presence of DMAP or phase transfer catalysts, are usually employed at temperatures ranging from -40 °C to 50 °C.
- the pyrrole nitrogen reacts then with an activated source of the protecting group such as benzenesulfonyl chloride (BsCI), toluensulfonyl chloride (TsCI), trimethylsilylethylsulfonyl chloride (SESCI), di-tert-butyldicarbonate (Boc) 2 O, benzyl bromide (BnBr), 2-(trimethylsilyl)ethoxymethyl chloride (SEMCI), triisopropylsilyltrifluoromethane sulfonate (TIPSOTf), 4-methoxy-benzyl chloride and 2,4-dimethoxybenzyl chloride.
- BsCI benzenesulfonyl chloride
- TsCI toluensulfonyl chloride
- SESCI trimethylsilylethylsulfonyl chloride
- Boc di-tert-butyldicarbonate
- SEMCI
- the mono-halogenation of the compound of formula (XI) to give a halo derivative of formula (XII) may be carried out under the variety of conditions already described in Step 3 of Scheme A.
- Step 9 of Scheme B the conversion of the halo derivative of formula (XII) into a compound of formula (XIII) may be carried out under the variety of conditions already described in Step 5 of Scheme A.
- the removal of the protecting group PG on the pyrrole ring of a compound of formula (XIII) may be carried out following procedures which are well known in the art ( Jolicoeur,B.; Chapman, E. E.; Thommpson, A.; Lubell, W. D. Tetrahedron 2006, 62, 11531 ).
- benzenesulfonyl (Bs) and toluensulfonyl (Ts) groups may be removed with KOH , NaOH, K 2 CO 3 , Triton B, magnesium also in the presence of ammonium chloride in solvents such as MeOH, dioxane at temperatures ranging from room temperature to reflux; trimethylsilylethylsulfonyl (SES) group may be removed using TBAF in THF at room temperature; tert -butoxycarbonyl (Boc) may be removed in the presence of TFA in DCM or by Na 2 CO 3 in DME, DMF at a temperature ranging from room temperature to 130 °C; 4-methoxy-benzyl (MB) and 2,4-dimethoxybenzyl (DMB) groups may be removed by exposure to acid in the presence of anisole to trap the benzyl carbonium ion (e.g.
- the present invention further provides an alternative process for the preparation of a compound of formula (I), wherein R1 is ethynyl or optionally substituted aryl-ethynyl, R2 is hydrogen, R3, R4, R5 and R6 are as defined above, which is shown in Scheme C below.
- R1 is ethynyl or optionally substituted aryl-ethynyl
- R2 is hydrogen
- R3, R4, R5, R6, X and PG are as defined above
- R7' is trialkylsylyl
- R7" is optionally substituted aryl
- X' is bromine or iodine.
- Another process of the present invention comprises the following steps:
- Step 11 of Scheme C the regioselective introduction of protecting group PG on the pyrrole nitrogen of a compound of formula (IV) can be accomplished in a variety of ways and experimental conditions, already described in the Step 7 of Scheme B.
- the mono-halogenation of a compound of formula (XIV) to give a halo derivative of formula (XV) may be carried out under the variety of conditions already described in Step 3 of Scheme A.
- Step 13 of Scheme C the conversion of a halo derivative of formula (XV) into a compound of formula (XVI) may be carried out under the variety of conditions already described in Step 5 of Scheme A.
- Step 14 of Scheme C the hydrolysis of a derivative of formula (XVI) into a carboxylic acid of formula (XVII) can be accomplished in a variety of ways, already described in Step 2 of Scheme A. In the mean time removal of trialkylsilyl-protecting group occurs.
- Step 17 of Scheme C the removal of the protecting group PG on the pyrrole ring of a compound of general formula (XX) may be carried out following procedures already described in Step 10 of Scheme B.
- Step 17a of Scheme C the removal of the protecting group PG on the pyrrole ring of a compound of general formula (XVIII) may be carried out following procedures already described in Step 10 of Scheme B.
- the present invention further provides an alternative process for the preparation of a compound of formula (I) wherein R1 is amino-aryl-ethynyl, R2 is hydrogen, R3, R4, R5 and R6 are as defined above, which is shown in Scheme D below.
- R1 is amino-aryl-ethynyl
- R2 is hydrogen
- R3, R4, R5, R6, X and PG are as defined above
- R10 and R11 are independently hydrogen or an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, cycloalkyl-alkyl, heterocyclyl and heterocyclyl-alkyl, or R10 and R11, taken together with the nitrogen atom to which they are bonded, may form an optionally substituted 5 to 7 membered heterocyclyl group optionally containing one additional heteroatom selected from N, O and S.
- Another process of the present invention comprises the following steps:
- metal-catalyzed coupling reactions of a halo derivative of formula (XXI) with an amine of formula NHR10R11 (XXII) may be carried out in a suitable solvent such as THF or dioxane, and in the presence of catalytic amounts of Pd 2 (dba) 3 , 2-dicyclohexylphosphino-2'-( N,N -dimethylamino)-biphenyl and a base such as LiN(TMS) 2 at a temperature ranging from room temperature to reflux and for a time ranging from 1 to about 24 hours.
- a suitable solvent such as THF or dioxane
- Pd 2 (dba) 3 2-dicyclohexylphosphino-2'-( N,N -dimethylamino)-biphenyl
- a base such as LiN(TMS) 2
- Step 19 of Scheme D the removal of the protecting group PG on the pyrrole ring of a compound of formula (XXIII) may be carried out following procedures already described in Step 10 of Scheme B.
- the present invention further provides an alternative process for the preparation of a compound of formula (I) wherein R1 is hydrogen, R2 is ethynyl-R7, R3, R4, R5 and R6 are as defined above, which is shown in Scheme E below.
- R1 is hydrogen
- R2 ethynyl-R7, and R3, R4, R5, R6, R7 and X are as defined above.
- Another process of the present invention comprises the following steps:
- Step 21 of Scheme E the conversion of a halo derivative of general formula (XXIV) into a compound of formula (I) may be carried out under the variety of conditions already described in Step 5 of Scheme A.
- the present invention further provides an alternative process for the preparation of a compound of formula (I) wherein R1 is ethynyl-R7, R2 is hydrogen, R3, R4, R5, R6 and R7 are as defined above, which is shown in Scheme F below.
- R1 is ethynyl-R7
- R2 is hydrogen
- R3, R4, R5, R6 and R7 are as defined above
- X is halogen
- Another process of the present invention comprises the following steps:
- the mono-halogenation of a compound of formula (IV) to give a halo derivative of formula (XXV) may be carried out under the variety of conditions already described in Step 3 of Scheme A.
- any of the intermediates of the above described processes could be converted into a different intermediate, if wanted and necessary, by operating in an analogous way as in any one of the conversion reaction here above described.
- the final compounds may be isolated and purified using conventional procedures, for example chromatography and/or crystallization and salt formation.
- the carboxamides of the formula (I) as defined above can be converted into pharmaceutically acceptable salts.
- the carboxamides of the formula (I) as defined above, or the pharmaceutically acceptable salts thereof, can be subsequently formulated with a pharmaceutically acceptable carrier or diluent to provide a pharmaceutical composition.
- the synthesis of a compound of formula (I), according to the synthetic process described above, can be conducted in a stepwise manner, whereby each intermediate is isolated and purified by standard purification techniques, like, for example, column chromatography, before carrying out the subsequent reaction.
- two or more steps of the synthetic sequence can be carried out in a so-called “one-pot” procedure, as known in the art, whereby only the compound resultant from the two or more steps is isolated and purified.
- a compound of formula (I) contains one or more asymmetric centers
- said compound can be separated into the single isomers by procedures known to those skilled in the art. Such procedures comprise standard chromatographic techniques, including chromatography using a chiral stationary phase, or crystallization. General methods for separation of compounds containing one or more asymmetric centers are reported, for instance, in Jacques, Jean; Collet, André; Wilen, Samuel H., - Enantiomers, Racemates, and Resolutions, John Wiley & Sons Inc., New York (NY), 1981 .
- the starting materials and any other reactants are known or easily prepared according to known methods.
- the starting materials of the formula (II) can be prepared as described in WO2007/110344 .
- the compounds of the formula (IIIa), (IIIb), (VII), (IX), (IX)', (X), (XIX) and (XXII) are either commercially available or can be prepared with known methods; the compounds of the formula (IIIa) can also be prepared as described in the experimental part below (Preparation A); the compounds of the formula (IX) can also be prepared as described in the experimental part below (Preparations B to P); the compounds of the formula (X) can also be prepared as described in the experimental part below (Preparations Q).
- the compounds of the present invention can be administered either as single agents or, alternatively, in combination with known anticancer treatments such as radiation therapy or chemotherapy regimen in combination with cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents (e.g.
- cytostatic or cytotoxic agents antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti
- angiogenesis inhibitors farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and the like.
- such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent within the approved dosage range.
- the compounds of the formula (I) of the present invention suitable for administration to a mammal, e.g., to humans, can be administered by the usual routes and the dosage level depends upon the age, weight, conditions of the patient and administration route.
- a suitable dosage adopted for oral administration of a compound of the formula (I) may range from about 10 to about 500 mg per dose, from 1 to 5 times daily.
- the compounds of the invention can be administered in a variety of dosage forms, e.g., orally, in the form tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form suppositories; parenterally, e.g., intramuscularly, or through intravenous and/or intrathecal and/or intraspinal injection or infusion.
- the present invention also includes pharmaceutical compositions comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient, which may be a carrier or a diluent.
- a pharmaceutically acceptable excipient which may be a carrier or a diluent.
- compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a suitable pharmaceutical form.
- the solid oral forms may contain, together with the active compound, diluents, e.g., lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g., silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g., starches, arabic gum, gelatine methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disintegrating agents, e.g., starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations.
- the liquid dispersions for oral administration may be, e.g., syrups, emulsions and suspensions.
- the syrups may contain, as carrier, saccharose or saccharose with glycerine and/or mannitol and sorbitol.
- the suspensions and the emulsions may contain, as examples of carriers, natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
- the suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., sterile water, olive oil, ethyl oleate, glycols, e.g., propylene glycol and, if desired, a suitable amount of lidocaine hydrochloride.
- the solutions for intravenous injections or infusions may contain, as a carrier, sterile water or preferably they may be in the form of sterile, aqueous, isotonic, saline solutions or they may contain propylene glycol as a carrier.
- the suppositories may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
- a pharmaceutically acceptable carrier e.g., cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
- UV detection at 220 nm and 254 nm Flow rate 1 mL/min. Injection volume 10 microL. Full scan, mass range from 100 to 800 amu. Capillary voltage was 2.5 KV; source temperature was 120 °C; cone was 10 V. Retention times (HPLC r.t.) are given in minutes at 220 nm or at 254 nm. Mass are given as m/z ratio.
- N -(2- ⁇ [ tert -Butyl(dimethyl)silyl]oxy ⁇ ethyl)-3-ethynylaniline (335 mg, 1.22 mmol) was treated with 1M TBAF in THF (1.5 mL, 1.5 mmol) at room temperature for 5 min. The volatiles were removed and the crude was dissolved in EtOAc (30 mL). The organic phase was washed with water (20 mL) and finally with brine, dried over sodium sulfate and evaporated to give the corresponding alcohol as brownish oil.
- N -(2-Chloroethyl)-2-ethynylaniline (0.5 g, 2.79 mmol) in ACN (16 mL) was treated with 2M dimethylamine in THF (4.2 mL, 8.37 mmol), sodium iodide (1.25 g, 8.37 mmol), sodium carbonate (887 mg, 8.37 mmol) and heated in a sealed tube at 80 °C (oil bath temperature) for 15 h, with stirring. EtOAc was added (100 mL) and the organic phase was washed first with water (100 mL) and then with brine.
- Step 3 ⁇ 3-Methoxy-4-[(trimethylsilyl)ethynyl]phenyl ⁇ (4-methylpiperazin-1-yl)methanone
- N -(3-iodo-4-methoxyphenyl)-1-methylpiperidin-4-amine 180 mg, 0.52 mmol
- CuI 9.9 mg, 0.052 mmol
- Pd(Ph 3 P)Cl 2 36.5 mg, 0.052 mmol
- TEA 0.725 mL, 526 mg, 5.2 mmol
- (ethynyl)trimethylsilane (0.147 mL, 0.102 mg, 1.04 mmol) were added with a syringe and the solution was stirred at room temperature for 75 min. The volatiles were evaporated and the residue was taken up with EtOAc (30 mL), washed with water (3 x 5 mL), dried over sodium sulfate and the solvent was removed under vacuum.
- Step 2 2-(5-Chloro-2-methyl-phenyl)-5-( E )-3-dimethylamino-acryloyl)-1 H -pyrrole-3-carbonitrile
- Step 3 2-(5-Chloro-2-methyl-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1 H -pyrrole-3-carbonitrile
- Step 4 2-(5-Chloro-2-methyl-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1 H -pyrrole-3-carboxamide
- reaction was then either refluxed or heated under microwave irradiation at 80 °C until full conversion of the starting material was observed (typically from 1 to several h were required). If precipitation of the product occurred upon cooling, the solid was filtered, washed in sequence with ACN (3 x 1 mL), H 2 O/MeOH 9/1 (2 x 1 mL) and finally dried under vacuum at 50 °C. Conversely, the reaction was diluted with DCM (20 mL), washed with water (5 mL), dried over sodium sulfate and evaporated.
- Step 7 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1- ⁇ [2-trimethylsilyl)ethoxy]methyl ⁇ -1 H -pyrrole-3-carboxamide (XI)
- Step 8 5-(2-Amino-5-iodopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1- ⁇ [2-(trimethylsilyl) ethoxy]methyl ⁇ -1 H- pyrrole-3-carboxamide (XII)
- N -iodosuccinimide (720 mg, 3.2 mmol) was added to a solution of 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -1 H -pyrrole-3-carboxamide (1.39 g, 3.0 mmol) in dry DMF (6 mL).
- the reaction mixture was heated at 65 °C for 7 h, allowed to cool to room temperature and then diluted with EtOAc (30 mL), washed with water (2 x 20 mL) brine, dried over sodium sulphate, and evaporated.
- Step 9 5-[2-Amino-5-( ⁇ 4-[(4-methylpiperazin-1-yl)carbonyl]phenyl ⁇ ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -1 H -pyrrole-3-carboxamide (XIII)
- Step 10 5-[2-Amino-5-( ⁇ 4-[(4-methylpiperazin-1-yl)carbonyl]phenyl ⁇ ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1 H -pyrrole-3-carboxamide
- Trifluoroacetic acid (1.4 mL) was added to a solution of 5-[2-amino-5-( ⁇ 4-[(4-methylpiperazin-1-yl)carbonyl]phenyl ⁇ ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -1 H -pyrrole-3-carboxamide (0.110 g, 0.14 mmol) in dry DCM (2.8 mL) and stirred for 4 h at room temperature. After solvent removal, the residue was treated with EtOH (3 mL), 33% NH 4 OH (0.4 mL) and stirred for 0.5 h.
- Step 12 Ethyl 5-(2-amino-5-iodopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1- ⁇ [2-(trimethylsilyl) ethoxy] methyl ⁇ -1 H -pyrrole-3-carboxylate (XV)
- N -iodosuccinimide (356 mg, 1.58 mmol) was added to a solution of ethyl 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1- ⁇ [2-(trimethylsilyl)ethoxy]methyl)-1 H -pyrrole-3-carboxylate (700 mg, 1.44 mmol) in DMF (15 mL). The reaction mixture was heated at 60 °C for 4 h, allowed to cool to room temperature, concentrated and then diluted with EtOAc (30 mL).
- Step 13 Ethyl 5- ⁇ 2-amino-5-[(trimethylsilyl)ethynyl]pyrimidin-4-yl ⁇ -2-(5-chloro-2-methylphenyl)-1- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -1 H -pyrrole-3-carboxylate (XVI)
- Step 14 5-(2-Amino-5-ethynylpyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1- ⁇ [2-(trimethyisilyl)ethoxy]methyl)-1 H -pyrrole-3-carboxylic acid (XVII)
- Step 16 5-[2-Amino-5-(phenylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -1 H -pyrrole-3-carboxamide (XX)
- Trifluoroacetic acid (1.4 mL) was added to a solution of 5-[2-amino-5-(phenylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -1 H -pyrrole-3-carboxamide (78 mg, 0.14 mmol) in dry DCM (2.8 mL) and stirred for 4 h at room temperature. After solvent removal, the residue was treated with EtOH (3 mL), 33% NH 4 OH (0.4 mL) and stirred for 0.5 h.
- Trifluoroacetic acid (1.4 mL) was added to a solution of 5-(2-amino-5-ethynylpyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -1 H -pyrrole-3-carboxamide (67 mg, 0.14 mmol) in dry DCM (2.8 mL) and stirred for 4 h at room temperature. After solvent removal, the residue was treated with EtOH (3 mL), 33% NH 4 OH (0.4 mL) and stirred for 0.5 h.
- Step 18 5-(2-Amino-5- ⁇ [4-(4-methylpiperazin-1-yl)phenyl]ethynyl ⁇ pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -1 H -pyrrole-3-carboxamide (XXIII)
- Step 19 5-(2-Amino-5- ⁇ [4-(4-methylpiperazin-1-yl)phenyl]ethynyl ⁇ pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide
- R1 [4-(4-methylpiperazin-1-yl)phenyl]ethynyl
- R5 5-chloro-2-methylphenyl
- R6 NH 2 ] (compd. 11)
- Trifluoroacetic acid (1.4 mL) was added to a solution of 5-(2-amino-5- ⁇ [4-(4-methylpiperazin-1-yl)phenyl]ethynyl ⁇ pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -1 H -pyrrole-3-carboxamide (92 mg, 0.14 mmol) in dry DCM (2.8 mL) and stirred for 4 h at room temperature. After solvent removal, the residue was treated with EtOH (3 mL), 33% NH 4 OH (0.4 mL) and stirred for 0.5 h.
- reaction was then either refluxed or heated under microwave irradiation at 80 °C until full conversion of the starting material was observed (typically from 1 to several hours were required). If precipitation of the product occurred upon cooling, the solid was filtered, washed in sequence with ACN (3 x 1 mL), H 2 O/MeOH 9/1 (2 x 1 mL) and finally dried under vacuum at 50 °C. Conversely, the reaction was diluted with DCM (20 mL), washed with water (5 mL), dried over sodium sulfate and evaporated. The residue was then purified by flash chromatography. Typically, DCM/MeOH 95/5 under gradient conditions or reverse phase purification (Phase A: 0.05 NH 4 OH/ACN 95/5; Phase B: ACN/H 2 O 95/5 Gradient: 10-70 in 10 CV).
- Step 8 2-(5-Chloro-2-methyl-phenyl)-5-[5-iodo-2-(methylamino)pyrimidin-4-yl]-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrrole-3-carboxamide (XII)
- N -iodosuccinimide (301 mg, 1.34 mmol) was added to a solution of 2-(5-chloro-2-methyl-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1 H -pyrrole-3-carboxamide (600 mg, 1.27 mmol) in dry DMF (5 mL).
- the reaction mixture was heated at 65 °C for 7 h, allowed to cool to room temperature and then diluted with EtOAc (10 mL), washed with water (2x5 mL) brine, dried over sodium sulphate, and evaporated.
- the crude was purified by flash chromatography on silica gel (DCM/MeOH 97/3) to afford the title compound as yellow solid (520 mg, 65%).
- Step 9 2-(5-Chloro-2-methylphenyl)-5-[2-(methylamino)-5- ⁇ [4-(4-methylpiperazin-1-yl)phenyl]ethynyl ⁇ pyrimidin-4-yl]-1- ⁇ [3-(trimethylsilyl)propoxy]methyl ⁇ -1 H -pyrrole-3-carboxamide (XIII)
- Step 10 2-(5-Chloro-2-methylphenyl)-5-[2-(methylamino)-5- ⁇ [4-(4-methylpiperazin-1-yl)phenyl]ethynyl ⁇ pyrimidin-4-yl]-1 H -pyrrole-3-carboxamide
- R1 [4-(4-methylpiperazin-1-yl)phenyl]ethynyl
- R2 H
- R5 5-chloro-2-methylphenyl
- Trifluoroacetic acid (1.4 mL) was added to a solution of 2-(5-chloro-2-methylphenyl)-5-[2-(methylamino)-5- ⁇ [4-(4-methylpiperazin-1-yl)phenyl]ethynyl ⁇ pyrimidin-4-yl]-1- ⁇ [3-(trimethylsilyl)propoxy]methyl ⁇ -1 H -pyrrole-3-carboxamide (96 mg, 0.14 mmol) in dry DCM (2.8 mL) and stirred for 4 h at room temperature. After solvent removal, the residue was treated with EtOH (3 mL), 33% NH 4 OH (0.4 mL) and stirred for 0.5 h.
- N -iodosuccinimide (301 mg, 1.34 mmol) was added to a solution of 2-(5-chloro-2-methylphenyl)-5-[2-(methylamino)pyrimidin-4-yl]-1 H -pyrrole-3-carboxamide (433 mg, 1.27 mmol) in dry DMF (5 mL).
- the reaction mixture was stirred at room temperature for 5 h and poured into iced water (50 mL). The solid was then filtered with suction, washed thoroughly with water, dried in an oven under vacuum at 50 °C and purified by flash chromatography over silica gel (DCM/MeOH/7 N NH 3 in MeOH 95/5/0.5) to afford the title compound (344 mg, 58%).
- Step 22 Ethyl 5-(2-amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1 H -pyrrole-3-carboxylate (XXV)
- Step 25 5-(2-Amino-5- ⁇ [4-(4-methylpiperazin-1-yl)phenyl]ethynyl ⁇ pyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1 H -pyrrole-3-carboxamide
- R1 [4-(4-methylpiperazin-1-yl)phenyl]ethynyl
- R5 5-chloro-2-ethylphenyl
- R6 NH 2 ] (compd. 110)
- JAK2, JAK1 or JAK3 peptide subtrates are trans-phosphorylated by JAK kinases in the presence of ATP traced with 33 P- ⁇ -ATP.
- the unreacted ATP, cold and radioactive is captured by an excess of dowex ion exchange resin that eventually settles by gravity to the bottom of the reaction plate.
- the supernatant is subsequently withdrawn and transferred into a counting plate that is then evaluated by ⁇ -counting.
- Dowex resin preparation - 500 g of wet resin (SIGMA, custom prepared resin DOWEX 1x8 200-400 mesh, 2.5 Kg) are weighed out and diluted 2 to 1 in 150 mM sodium formate, pH 3.00. The resin is allowed to settle down overnight and then the supernatant is discarded. After three washes as above over a couple of days, the resin is allowed to settle and two volumes (with respect to the resin volume) of 150 mM sodium formate buffer are added.
- Kinase Buffer (KB) - Kinase buffer was composed of 50 mM HEPES pH 7.5 containing 10 mM MgCl 2 , 2.5 mM DTT, 10 ( ⁇ M Na 3 VO 4 and 0.2 mg/mL BSA.
- Enzyme - Assays were performed with the commercially available JAK2 kinase domain (Invitrogen, Eugene, OR) that showed a linear kinetic without prephosphorylation.
- the JAK2 kinase assay was run with a final enzyme concentration of 1 nM, in the presence of 60 ⁇ M ATP, 3 nM 33 P- ⁇ -ATP and 64 ⁇ M of substrate BioDBn*306 (Aminoacid sequence: LPLDKDYYWREPGO - SEQ ID NO: 1).
- the peptidic substrate was purchased from American Peptide Company (Sunnyvale, CA).
- Enzyme - Assays were performed with the JAK1 kinase domain (residues 861-1152 of the 1154 amino acid long full-length sequence, accession number P23458 of UniProtKB/Swiss-Prot database).
- the JAK1 kinase domain was preactivated with ATP for 1 h at 28 °C in order to obtain a linear kinetic.
- the JAK1 kinase assay was run with a final pre activated enzyme concentration of 2.5 nM, in the presence of 100 ⁇ M ATP, 2 nM 33 P- ⁇ -ATP and 154 ⁇ M of substrate BioDBn*333 (Aminoacid sequence: KKHTDDGYMPMSPGVA - SEQ ID NO: 2).
- the peptidic substrate was purchased from American Peptide Company (Sunnyvale, CA).
- Enzyme - Assays were performed with the JAK3 kinase domain (residues 781-1124 of the 1124 amino acid long full-length sequence, accession number P52333 of UniProtKB/Swiss-Prot databse) that showed a linear kinetic without prephosphorylation.
- the JAK3 kinase assay was run with a final enzyme concentration of 1 nM, in the presence of 22 ⁇ M ATP, 1 nM 33 P- ⁇ -ATP and 40 ⁇ M of substrate BioDBn*306 (Aminoacid sequence: LPLDKDYYWREPGO - SEQ ID NO: 1).
- the peptidic substrate was purchased from American Peptide Company (Sunnyvale, CA).
- Lck and Lyn subtrates are trans-phosphorylated by Lck and Lyn kinases in the presence of ATP traced with 33 P- ⁇ -ATP.
- the unreacted ATP, cold and radioactive is captured by an excess of dowex ion exchange resin that eventually settles by gravity to the bottom of the reaction plate.
- the supernatant is subsequently withdrawn and transferred into a counting plate that is then evaluated by ⁇ -counting.
- Enzyme - The assay has been performed using Lck full length (accession number P06239 of UniProtKB/Swiss-Prot database).
- Lck full-length protein showed a linear kinetic without prephosphorylation.
- Lck Kinase Buffer (KB) - Kinase buffer was composed of 50 mM HEPES pH 7.5 containing 3 mM MgCl 2 , 3 mM MnCl 2 , 1 mM DTT, 3 ⁇ M Na 3 VO 4 , and 0.2 mg/mL BSA.
- the Lck kinase assay was run with a final enzyme concentration of 1.4 nM, in the presence of 6 ⁇ M ATP, 3 nM 33 P- ⁇ -ATP and 5 ⁇ M of substrate Myelin Basic Protein (MBP).
- MBP Myelin Basic Protein
- Enzyme - The assay has been performed using Lyn full length (accession number P07948 of UniProtKB/Swiss-Prot database).
- Lyn full-length protein showed a linear kinetic without prephosphorylation.
- Lyn Kinase Buffer (KB) - Kinase buffer was composed of 50 mM HEPES pH 7.5 containing 3 mM MgCl 2 , 1 mM DTT, 3 ⁇ M Na 3 VO 4 , and 0.2 mg/mL BSA.
- the Lyn kinase assay was run with a final enzyme concentration of 1 nM, in the presence of 25 ⁇ M ATP, 1.5 nM 33 P- ⁇ -ATP and 250 ⁇ M of substrate ABI 1 (Aminoacid sequence: EAIYAAPFAKKK- SEQ ID NO: 3).
- the peptidic substrate was purchased from American Peptide Company (Sunnyvale, CA).
- test compounds are received as a 1 mM solution in 100% DMSO, distributed into 96 well plates: compounds are then plated into the first column of a microtiter plate (A1 to G1), 100 ⁇ L/well.
- An automated station for serial dilutions (Biomek FX, Beckman) is used for producing 1:3 dilutions in 100 % DMSO, from line A1 to A10, and for all the compounds in the column. Moreover, 4-5 copies of daughter plates are prepared by reformatting 5 ⁇ L of this first set of 100% DMSO dilution plates into 384 deep well-plates: one of these plates with the serial dilutions of test compounds will be thawed the day of the experiments, reconstituted at a 3X concentration with water and used in the IC 50 determination assays. In a standard experiment, the highest concentration (3X) of all compounds is 30 ⁇ M, while the lowest one is 1.5 nM. Each 384 well-plate will contain at least one curve of the standard inhibitor staurosporine and reference wells (total enzyme activity vs. no enzymatic activity) for the Z' and signal to background evaluation.
- Assay Scheme - 384-well plates V bottom (test plates) are prepared with 5 ⁇ L of the compound dilution (3X) and then placed onto a PlateTrak 12 robotized station (Perkin Elmer; the robot has one 384-tip pipetting head for starting the assay plus one 96-tip head for dispensing the resin) together with one reservoir for the Enzyme mix (3X) and one for the ATP mix (3X).
- the robot Aspirates 5 ⁇ L of ATP mix, makes an air gap inside the tips (3 ⁇ l) and aspirates 5 ⁇ L of JAK2 mix.
- the robot incubates the plates for 60 minutes at room temperature, and then stops the reaction by pipetting 60 ⁇ L of dowex resin suspension into the reaction mix. In order to avoid tip clogging, wide bore tips are used to dispense the resin suspension. Three cycles of mixing are done immediately after the addition of the resin. Another mixing cycle is performed after all the plates are stopped, this time using normal tips: the plates are then allowed to rest for about one hour in order to allow resin sedimentation.
- Data Fitting - Data are analyzed by an internally customized version of the SW package "Assay Explorer" that provides sigmoidal fitting of the ten-dilutions curves for IC 50 determination in the secondary assays/hit confirmation routines.
- the JAK2 dependent human megakaryoblastic leukemia cell line SET-2 (DSMZ, Braunschweig GERMANY) and the JAK2 independent human chronic myelogenous leukaemia cell line K562 (ECACC, Wiltshire, UK) were cultured in RPMI-1640 medium-Glutamax (Gibco BRL, Gaithesburg, MD, USA), supplemented with 10% fetal bovine serum (FBS) at 37 °C and 5% CO 2 .
- FBS fetal bovine serum
- Cell proliferation assay Approximately 5x10 3 cells were plated into 384 microtiter plate wells in 50 ⁇ L of growth media with different concentrations of inhibitors. The cells were incubated at 37 °C and 5 % CO 2 for 72 hours, then the plates were processed using CellTiter-Glo assay (Promega, Madison, WI, USA) following the manufacturer's instruction. Briefly 25 ⁇ L/well reagent solution is added to each well and after 5 minutes shaking the micro-plates are read by Envision luminometer (PerkinElmer, Waltham, MA, USA).
- Data Fitting - Data are analyzed by Symix Assay Explorer software (Symix Technologies Inc.) that provides sigmoidal fitting algorithm of the 8 points dilutions curves for IC 50 determination.
- the compounds of formula (I) tested as described above demonstrate a remarkably potent JAK and SFK inhibitory activity, typically lower than 0.1 ⁇ M. See, as an example, the following Table A wherein are reported experimental data (IC 50 ) of the compounds of the invention obtained for representative enzymes of JAK (i.e. JAK2) and Src (i.e. Lyn) family Kinases.
- novel compounds of the invention are endowed with a potent JAK and Src family kinases inhibitory activity and are thus particularly advantageous, in therapy, against cancer and metastasis, cell proliferative disorders, viral infections, immune disorders, neurodegenerative disorders, cardiovascular diseases and bone related diseases.
Description
- The present invention relates to certain alkynyl substituted pyrimidinyl-pyrrole compounds, which modulate the activity of protein kinases. The compounds of this invention are therefore useful in treating diseases related to dysregulated kinases activity, for example cancer, cell proliferative disorders, viral infections, immune disorders, neurodegenerative disorders, cardiovascular diseases and bone related diseases.
- The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and discloses methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.
- Protein kinases mediate intracellular signaling by affecting a phosphoryl transfer from a nucleoside triphosphate to a protein acceptor that is involved in a signaling pathway. These phosphorylation events act as molecular on/off switches that can modulate or regulate the target protein's biological function and are ultimately triggered in response to a variety of extracellular and other stimuli. Examples of such stimuli include environmental and chemical stress signals (e.g., osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxin, and H2O2), cytokines (e.g., interleukin-3 (IL-3), IL-2) and growth factors (e.g., granulocyte macrophage-colony-stimulating factor (GM-CSF), fibroblast growth factor (FGF) and Erythropoietin (EPO)). An extracellular stimulus may affect one or more cellular responses related to cell growth, migration, differentiation, secretion of hormones, activation of transcription factors, muscle contraction, glucose metabolism, control of protein synthesis and regulation of the cell cycle.
- The malfunction of protein kinases (PKs) is the hallmark of numerous diseases. A large share of the oncogenes and proto-oncogenes involved in human cancers encode for PKs. The enhanced activities of PKs are also implicated in many non-malignant diseases that include, but are not limited to, autoimmune diseases, inflammatory diseases, psoriasis, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cardiovascular diseases, allergies and asthma, Alzheimer's disease, and hormone-related diseases. Accordingly, there has been a substantial effort in medicinal chemistry to find protein kinase inhibitors that are effective as therapeutic agents. For a general reference to PKs malfunctioning or deregulation see Current Opinions in Chemical Biology 1999, 3: 459 - 465; Nature Rev. Drug Discov. 2002, 1:309-315 and Carcinogenesis 2008, 29:1087-191.
- The JAKs are a family of non-receptor tyrosine kinases consisting of JAK1, JAK2, JAK3 and TYK2. Whereas JAK1, JAK2 and TYK2 are expressed ubiquitously in mammals, JAK3 is primarily expressed in hematopoietic cells. The JAKs play a crucial role in hematopoietic cytokine and growth factors signaling (Nature 1995; 377: 591-594, Annu. Rev. Immunol. 1998; 16: 293-322) and are critically involved in cell growth, survival, development and differentiation of myeloid and immune cells. Effective innate and adaptive immune responses require functional JAK signaling to protect the organism from infections or tumors and mutations leading to loss of function make up some of the most common inherited severe immunodeficiencies. As a consequence JAK/STAT signaling has been implicated in the mediation of many abnormal immune responses such as allergies, asthma, autoimmune diseases, transplant rejection, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis as well as in solid and hematological malignancies like leukemias and lymphomas (Immunol Rev. 2009, 228: 273-287).
- In particular JAK2 kinase is exclusively involved in the signal transduction mediated by Erythropoietin (EPO), Thrombopoietin (TPO), Growth Hormone (GH), Prolactin (PR) and by cytokines that signal through the common beta chain receptor IL-3, granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-5. In addition, JAK2 together with JAK1 and/or TYK2 are important for the cytokines that signal through gp130 receptors (e.g. IL-6, IL-11), Type II cytokine receptors like IL-10, IL-19, IL-20 and IL-22, p40-containing containing cytokine receptors IL-12 and IL-23 and for the signal of Type I and II IFNs receptors (Immunol Rev. 2009; 228: 273-287). JAK3 kinase is primarily expressed in hematopoietic cells and is selectively associated with the common γ chain (γc), which is a shared component of the receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 that are cytokines involved in lymphoid development and function, and homeostasis of the immune system. TYK2 is primarily associated with Interferons, IL-12 and IL-23, but also with IL-10 and IL-6 signalling. All these growth factors and cytokines are mainly involved in proliferation and differentiation of Myeloid cells, inflammatory response and cancer (Blood. 2009; 114: 1289-1298, Clin Cancer Res. 2006; 12:6270s-6273s, J Leukoc Biol. 2010; 88:1145-1156, Eur J Cancer. 2010; 46:1223).
- The binding of the ligand to the specific receptor seems to induce a conformational change in the receptor that allows trans- and/or autophosphorylation of the two bound JAK molecules. Activated JAK then phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptors, creating docking sites for the SH2 domain of Signal Transducers and Activators of Transcription proteins (STAT). Once bound to the receptors, STATs are themselves phosphorylated by JAK on tyrosine residues. Phosphorylated STATs dimerize and translocate into the nucleus, where they regulate gene transcription. Thus, JAKs are responsible for transducing a signal from the cell surface to the nucleus through a tyrosine phosphorylation signalling mechanism (J. Immun. 2007, 178: 2623-2629, Oncogene 2007, 26: 6724-6737 and Cell Biochem Biophys. 2006, 44: 213-222).
- JAKs are characterized by 7 distinct JAK homology regions (JH1 to JH7), among these the JH1 regions form the kinase domain and is immediately adjacent to the pseudo-kinase domain (JH2) within the C-terminal half of the protein. The function of the pseudo-kinase domain is to negatively regulate the activity of the kinase domain (N. Engl. J. Med 2006, 355: 2452-2466). It should be pointed out that the majority of JAK activating mutations identified in tumors are in pseudo-kinase domain. For example an activating point mutation of JAK2 (Valine to Phenylalanine substitution, JAK2-V617F) in the pseudo-kinase domain together with other activating mutations, in the JAK2 exon12 and in the TPO Receptor (MPLW515L/K), have been identified in Hematopoietic cells of patients with myeloproliferative disorders or MPD (Nature 2005; 434: 1144-8, N Engl J Med 2005; 352: 1779-90, Lancet 2005; 365: 1054-61, Cancer Cell 2005; 7: 387-97, Blood 2006, 108: 1427-1428 and Leukemia 2008, 22: 87-95). All of this data suggests that JAK2 is a suitable target for the development of a MPD specific therapy (Curr. Onc. Reports 2009, 11: 117-124). In addition, the JAK/STAT pathway has been shown to be activated not only by mutation but also by amplification, translocation, silencing of JAK/STAT pathway inhibitors SOCS proteins and overexpression of cytokines in solid and hematological malignancies like, but not limited to, AML, ALL, Hodgkin's Lymphoma, Diffuse large B cell Lymphoma and Mediastinal large B-Cell Lymphoma, Lung, Prostate, Colon and Breast cancer. General observation about the role of JAK in cancer refer to Science 1997, 278:1309-1312; Oncogene 2007; 26: 6724-6737; Trends in Biochemical Sciences 2007; 33: 122-131, PNAS, 2009; 106: 9414-9418, Anti-Cancer Agents Med Chem, 2007, 7, 643-650.
- Data from experimental mice and clinical observations have unraveled multiple signaling events mediated by JAKs in innate and adaptive immunity. Deficiency of JAK3 or TYK2 results in defined clinical disorders, which are also evident in mouse models. A striking phenotype associated with inactivating JAK3 mutations is severe combined immunodeficiency syndrome, whereas mutation of TYK2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.
- Combined this data supports the use of JAK inhibitors in several different diseases such as abnormal immune responses like allergies, asthma, autoimmune diseases, transplant rejection, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis as well as in solid and hematological malignancies like MPD, leukemias and lymphomas. General observations about the pharmaceutical intervention in the JAK/STAT pathway have been reviewed in J. Leukoc Biol. 2010; 88:1145-1156, Eur J. Cancer. 2010; 46:1223-1231, Immunol Rev. 2009; 228: 273-287, Trends Blood. 2009; 114: 1289-1298, Clin Cancer Res. 2008; 14:3716-3721, Biochem. Sciences, 2007; 33: 122-131, Clin Cancer Res. 2006; 12: 6270s-6273s, Cancer Res 2006; 66: 3162-3168 and AJP 2004; 165: 1449-146. The Src family kinases (SFK) are non-receptor protein tyrosine kinases (PTKs) ubiquitously expressed and highly conserved throughout evolution. Based on their amino acidic sequences, SFK can be clustered into two subfamilies. The first group includes Src, Fyn, and Yes which are ubiquitously expressed, even though with quantitative differences. The second group includes Blk, Fgr, Hck, Lck, and Lyn which are found primarily in haematopoietic cells (Cancer 2010; 116: 1629-1637; Oncogene 2004; 23:7918-7927). All SFKs play pivotal roles in transducing signals triggered by a variety of surface receptors to downstream molecules to regulate cellular events, such as cell growth, adhesion and migration. Changes in SFK protein expression and/or activity have been causally linked to human carcinogenesis, as described for hematological and solid malignancies (Cancer Treat Rev., 2010; 36: 492-500). Another important role of SFK is regulation of osteoclast proliferation and function, as shown in Src Knockout mice (Cell, 1991; 64: 693-702). Since excessive osteoclast activity is detectable in bone metastasis, Src inhibition could have an effect in tumours that preferentially metastasize to bone (Nat. Rev. Clin. Oncol., 2010; 7: 641-651). In addition, cytokine receptors associate with members of the Src family kinase (SFK) and JAKs and SFK work in concert to activate many of the signalling molecules, with both kinase families required for optimal transmission of intracellular signals (Oncogene 2002; 21: 3334-3358; Growth Factors 2006; 24: 89-95). Moreover SFK have been found to induce activation of STAT protein in solid tumors, thus affecting cellular proliferation and survival and JAK are able to revert inhibition of STAT activation mediated by SFK inhibitors. These observations support the possibility to combine SFK and JAK inhibitors as therapeutical approach diseases like solid and haematological tumors (Cancer Res. 2009; 69: 1958-1965).
- In addition SFK, have been shown to be involved in the signaling of T and B cell receptors respectively, support the potential use of specific inhibitors in immune disorders. All of this information supports the use of SFK in solid and hemathological tumors, to control bone metastasis and for the treatment of T-cell-mediated autoimmune and inflammatory disorders and/or organ transplant rejection. (Cancer Treat Rev., 2010; 36: 492-500; Curr. Med. Chem., 2008; 15:1154-1165; Clin Cancer Res, 2007; 13: 7232-7236)
- The present inventors have discovered that the alkynyl substituted pyrimidinyl-pyrrole of formula (I), described below, are potent JAK and Src family kinases inhibitors and are thus useful in therapy of cancer, cell proliferative disorders, viral infections, immune disorders, neurodegenerative disorders, cardiovascular diseases and bone related diseases. Accordingly, a first object of the present invention is to provide an alkynyl substituted pyrimidinyl-pyrrole compound represented by formula (I),
- one selected from R1 and R2 is hydrogen and the other is ethynyl-R7, wherein:
- R7 is hydrogen, trialkylsylyl or an optionally substituted group selected from straight or branched C1-C6 alkyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heterocyclyl and heterocyclyl-alkyl;
- R3 and R4 are independently hydrogen or an optionally substituted group selected from straight or branched C1-C6 alkyl, straight or branched C2-C6 alkenyl, straight or branched C2-C6 alkynyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heterocyclyl and heterocyclyl-alkyl, or R3 and R4, taken together with the nitrogen atom to which they are bonded, may form an optionally substituted 5- to 7- membered heterocyclyl group optionally containing one additional heteroatom selected from N, O and S;
- R5 is an optionally substituted aryl;
- R6 is hydrogen, an optionally substituted straight or branched C1-C6 alkyl or NR8R9, wherein:
- R8 and R9 are independently hydrogen or an optionally substituted group selected from straight or branched C1-C6 alkyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, heterocyclyl and heterocyclyl-alkyl, or R8 and R9, taken together with the nitrogen atom to which they are bonded, may form an optionally substituted 5- to 7-membered heterocyclyl group optionally containing one additional heteroatom selected from N, O and S;
- or a pharmaceutically acceptable salt thereof.
- The present invention also provides methods of preparing the alkynyl substituted pyrimidinyl-pyrrole compounds, represented by formula (I), prepared through a process consisting of standard synthetic transformations.
- The present invention also provides a compound of formula (I) for use in a method for treating diseases caused by and/or associated with a dysregulated protein kinase activity, particularly ABL, ACK1, AKT1, ALK, AUR1, AUR2, BRK, BUB1, CDC7/DBF4, CDK2/CYCA, CHK1, CK2, EEF2K, EGFR1, EphA2, EphB4, ERK2, FAK, FGFR1, FLT3, GSK3beta, Haspin, IGFR1, IKK2, IR, JAK1, JAK2, JAK3, KIT, Lck, Lyn, MAPKAPK2, MELK, MET, MNK2, MPS1, MST4, NEK6, NIM1, P38alpha, PAK4, PDGFR, PDK1, PERK, PIM1, PIM2, PKAalpha, PKCbeta, PLK1, RET, ROS1, SULU1, Syk, TLK2, TRKA, TYK2, VEGFR2, VEGFR3, ZAP70, more particularly JAK and/or Src family kinases, which comprises administering to a mammal in need thereof, more particularly a human, an effective amount of an alkynyl substituted pyrimidinyl-pyrrole compound represented by formula (I) as defined above.
- A preferred object of the present invention is to provide a compound of formula (I) for use in a method for treating a disease caused by and/or associated with a dysregulated protein kinase activity selected from the group consisting of cancer, cell proliferative disorders, viral infections, immune-related disorders, neurodegenerative disorders, cardiovascular diseases and bone related diseases.
- Another preferred object of the present invention is to provide a compound of formula (I) for use in a method for treating specific types of cancer including but not limited to: carcinoma such as bladder, breast, brain, colon, kidney, liver, lung, including small cell lung cancer, head and neck, esophagus, gall-bladder, ovary, uterine, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukaemia, T and B acute lymphoblastic leukemia (ALL), including DS-ALL, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Multiple Myeloma, hairy cell lymphoma, Burkitt's lymphoma and mantle cell lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukaemias, acute megakaryoblastic leukaemia, myelodysplastic syndrome and promyelocytic leukaemia, myeloproliferative disorders like Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary myelofibrosis and myelofibrosis secondary to PV and ET, chronic myelomonocytic leukaemia; tumors of mesenchymal origin, including sarcoma, fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer, Kaposi's sarcoma, mesothelioma.
- Another preferred object of the present invention is to provide a compound of formula (I) for use in a method for treating specific types of cell proliferative disorders including but not limited to: benign prostate hyperplasia, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.
- Another preferred object of the present invention is to provide a compound of formula (I) for use in a method for treating viral infections comprising the prevention of AIDS development in HIV-infected individuals.
- A preferred object of the present invention is to provide a compound of formula (I) for use in a method for treating immune-related disorders including but not limited to: transplant rejection, skin disorders like psoriasis, allergies, asthma and autoimmune-mediated diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Crohn's disease and amyotrophic lateral sclerosis.
- Another preferred object of the present invention is to provide a compound of formula (I) for use in a method for treating neurodegenerative disorders including but not limited to: Alzheimer's disease, degenerative nerve diseases, encephalitis, Stroke, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Huntington's Disease and Pick's Disease.
- Another preferred object of the present invention is to provide a compound of formula (I) for use in a method for treating cardiovascular diseases including but not limited to: atherosclerosis primary or secondary to diabetes, heart attack and stroke.
- Another preferred object of the present invention is to provide a compound of formula (I) for use in a method for treating bone loss diseases including but not limited to osteoporosis and bone metastasis.
- In addition, the present invention also provides a compound of formula (I) for use in tumor angiogenesis and metastasis inhibition as well as in the treatment of organ transplant rejection and host versus graft disease.
- Moreover, the method disclosed by the present invention further comprises subjecting the mammal in need thereof to a radiation therapy or chemotherapy regimen in combination with at least one cytostatic or cytotoxic agent.
- The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, and at least one pharmaceutically acceptable excipient, carrier and/or diluent.
- In addition the present invention provides a pharmaceutical composition of a compound of the formula (I) further comprising one or more chemotherapeutic - e.g. cytostatic or cytotoxic - agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents like anti-HER agents, anti-EGFR agents, anti-Abl, anti-angiogenesis agents (e.g. angiogenesis inhibitors), farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, Akt pathway inhibitors, cell cycle inhibitors, other CDK inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and the like.
- The present invention further provides an in vitro method for inhibiting JAK and/or Src family kinase proteins activity which comprises contacting the said protein with an effective amount of a compound of formula (I) as defined above. Additionally, the invention provides a product comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
- In yet another aspect the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, for use as a medicament.
- Moreover the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, for use in a method of treating cancer.
- Unless otherwise specified, when referring to the compounds of the formula (I) per se as well as to any pharmaceutical composition thereof or to any therapeutic treatment comprising them, the present disclosure includes all of the hydrates, solvates, complexes, metabolites, pharmaceutically acceptable prodrugs, pharmaceutically acceptable bio-precursors, carriers, N-oxides and pharmaceutically acceptable salts of the compounds.
- A metabolite of a compound of the formula (I) is any compound into which this same compound of the formula (I) is converted in vivo, for instance upon administration to a mammal in need thereof. Typically, without however representing a limiting example, upon administration of a compound of the formula (I), this same derivative may be converted into a variety of compounds, for instance including more soluble derivatives like hydroxylated derivatives, which are easily excreted. Hence, depending upon the metabolic pathway thus occurring, any of these hydroxylated derivatives may be regarded as a metabolite of the compounds of the formula (I).
- "Pharmaceutically acceptable prodrug" and "pharmaceutically acceptable bio-precursors" are any covalently bonded compounds, which release in vivo the active parent drug according to the formula (I).
- The terms "pharmaceutically acceptable prodrug" and "pharmaceutically acceptable bio-precursors" as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term "prodrug" refers to compounds that are rapidly transformed in vivo to yield the active parent drug, according to formula (I), in vivo, for example by hydrolysis in blood. A discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987.
- N-oxides are compounds of the formula (I) wherein nitrogen and oxygen are tethered through a dative bond.
- Pharmaceutically acceptable salts of the compounds of the formula (I) include the acid addition salts with inorganic or organic acids, e.g., nitric, hydrochloric, hydrobromic, sulfuric, perchloric, phosphoric, acetic, trifluoroacetic, propionic, glycolic, fumaric, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulphonic, isethionic and salicylic acid.
- Pharmaceutically acceptable salts of the compounds of the formula (I) also include the salts with inorganic or organic bases, e.g., alkali or alkaline-earth metals, especially sodium, potassium, calcium ammonium or magnesium hydroxides, carbonates or bicarbonates, acyclic or cyclic amines.
- If a stereogenic center or another form of an isomeric center is present in a compound of the present invention, all forms of such isomer or isomers, including enantiomers and diastereomers, are intended to be covered herein. Compounds containing a stereogenic center may be used as a racemic mixture, an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone. In cases in which compounds have unsaturated carbon-carbon double bonds, both the cis (Z) and trans (E) isomers are within the scope of this invention.
- In cases wherein compounds may exist in tautomeric forms, such as keto-enol tautomers, each tautomeric form is contemplated as being included within this invention whether existing in equilibrium or predominantly in one form.
- In the present description, unless otherwise specified, the following terms have the following meanings.
- The term "aryl" includes carbocyclic or heterocyclic hydrocarbons with from 1 to 2 ring moieties, either fused or linked to each other by single bonds, wherein at least one of the rings is aromatic; if present, any aromatic heterocyclic hydrocarbon also referred to as heteroaryl group, comprises a 5 to 6 membered ring with from 1 to 3 heteroatoms selected from N, O and S.
- Examples of aryl groups according to the invention are, for instance, phenyl, biphenyl, α- or β-naphthyl, dihydronaphthyl, thienyl, benzothienyl, furyl, benzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, isoindolyl, purinyl, quinolyl, isoquinolyl, dihydroquinolinyl, quinoxalinyl, benzodioxolyl, indanyl, indenyl, triazolyl, and the like.
- With the term "heterocyclyl" (also known as "heterocycloalkyl") we intend a 3- to 7-membered, saturated or partially unsaturated carbocyclic ring where one or more carbon atoms are replaced by heteroatoms such as nitrogen, oxygen and sulfur. Non limiting examples of heterocyclyl groups are, for instance, pyrane, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazolidine, pyrazoline, thiazoline, thiazolidine, dihydrofuran, tetrahydrofuran, 1,3-dioxolane, piperidine, piperazine, morpholine and the like.
- With the term "straight or branched C1-C6 alkyl", we intend any of the groups such as, for instance, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutul, tert-butyl, sec-butyl, n-pentyl, n-hexyl, and the like.
- With the term "C3-C7 cycloalkyl", we intend, unless otherwise provided, 3- to 7-membered all-carbon monocyclic ring, which may contain one or more double bonds but does not have a completely conjugated π-electron system. Examples of cycloalkyl groups, without limitation, are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexadiene, cycloeptane, cycloeptene, cycloeptadiene.
- With the term "straight or branched C2-C6 alkenyl" we intend any of the groups such as, for instance, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 1-hexenyl, and the like.
- With the term "straight or branched C2-C6 alkynyl" we intend any of the groups such as, for instance, ethynyl, 2-propynyl, 4-pentynyl, and the like.
- According to the present invention and unless otherwise provided, any of the above R1, R2, R3, R4, R5, R6, R7 group may be optionally substituted, in any of their free positions, by one or more groups, for instance 1 to 6 groups, independently selected from: halogen atom, nitro, oxo groups (=O), cyano, C1-C6 alkyl, polyfluorinated alkyl, polyfluorinated alkoxy, alkenyl, alkynyl, hydroxyalkyl, hydroxyalkylamino, hydroxyheterocyclyl,aryl, arylalkyl, heterocyclyl, heterocyclyl-alkyl, C3-C7 cycloalkyl, cycloalky-alkyl, alkylaryl, alkyl-heterocyclyl, alkyl-cycloalkyl, alkylaryl-alkyl, alkyl-heterocyclyl-alkyl, alkyl-cycloalkyl-alkyl, alkyl-heterocyclyl-heterocyclyl, heterocyclyl-heterocyclyl, heterocyclyl-alkyl-heterocyclyl, heterocyclyl-alkylamino, alkyl-heterocyclyl-alkyl-amino, , hydroxy, alkoxy, aryloxy, heterocyclyloxy, alkyl-heterocyclyoxy, methylenedioxy, alkylcarbonyloxy, arylcarbonyloxy, cycloalkenyloxy, heterocyclylcarbonyloxy, alkylideneaminooxy, carboxy, alkoxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, heterocyclyloxycarbonyl, amino, ureido, alkylamino, amino-alkylamino, dialkylamino, dialkylamino-heterocyclyl, dialkylamino-alkylamino, arylamino, arylalkylamino, diarylamino, heterocyclylamino, alkyl-heterocyclylamino, alkyl-heterocyclylcarbonyl, formylamino, alkylcarbonylamino, arylcarbonylamino, heterocyclylcarbonylamino, alkyl-heterocyclylcarbonylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, alkoxycarbonylamino, alkoxycarbonylamino-alkylamino, alkoxycarbonylheterocyclyl-alkylamino, hydroxyaminocarbonyl alkoxyimino, alkylsulfonylamino, arylsulfonylamino, heterocyclylsulfonylamino, formyl, alkylcarbonyl, arylcarbonyl, cycloalkylcarbonyl, heterocyclylcarbonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, arylaminosulfonyl, heterocyclylaminosulfonyl, arylthio, alkylthio, phosphonate and alkylphosphonate.
- In their turn, whenever appropriate, each of the above substituent may be further substituted by one or more of the aforementioned groups.
- In this respect, with the term "halogen atom" we intend a fluorine, chlorine, bromine or iodine atom.
- With the term "cyano" we intend a -CN residue.
- With the term "nitro" we intend a -NO2 group.
- With the term "polyfluorinated alkyl or alkoxy" we intend any of the above straight or branched C1-C6 alkyl or alkoxy groups which are substituted by more than one fluorine atom such as, for instance, trifluoromethyl, trifluoroethyl, 1,1,1,3,3,3-hexafluoropropyl, trifluoromethoxy and the like.
- With the term "alkoxy", "cyclyloxy", "aryloxy", "heterocyclyloxy" and derivatives thereof we intend any of the above C1-C6 alkyl, C3-C7 cycloalkyl, aryl or heterocyclyl groups linked to the rest of the molecule through an oxygen atom (-O-). From all of the above, it is clear to the skilled person that any group which name is a composite name such as, for instance, arylamino has to be intended as conventionally construed by the parts from which it derives, e.g. by an amino group which is further substituted by aryl, wherein aryl is as above defined.
- Likewise, any of the terms such as, for instance, alkylthio, alkylamino, dialkylamino, alkoxycarbonyl, alkoxycarbonylamino, heterocyclylcarbonyl, heterocyclylcarbonylamino, cycloalkyloxycarbonyl and the like, include groups wherein the alkyl, alkoxy, aryl, C3-C7 cycloalkyl and heterocyclyl moieties are as above defined.
- Preferably, a compound of the formula (I) is characterized in that R1 is ethynyl-R7, R2 is hydrogen, and R3, R4, R5, R6 and R7 are as defined above.
- Preferably, a compound of the formula (I) is characterized in that R1 is hydrogen, R2 is ethynyl-R7, and R3, R4, R5, R6 and R7 are as defined above.
- More preferably, a compound of the formula (I) is characterized in that R1 is ethynyl-R7, R2 is hydrogen, R3 and R4 are independently hydrogen or an optionally substituted group selected from straight or branched C1-C6 alkyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heterocyclyl and heterocyclyl-alkyl, and R5, R6 and R7 are as defined above.
- More preferably, a compound of the formula (I) is characterized in that R1 is hydrogen, R2 is ethynyl-R7, R3 and R4 are independently hydrogen or an optionally substituted group selected from straight or branched C1-C6 alkyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heterocyclyl and heterocyclyl-alkyl, and R5, R6, and R7 are as defined above.
- Even more preferably, a compound of the formula (I) is characterized in that R1 is ethynyl-R7, wherein R7 is an optionally substituted aryl, R2 is hydrogen, and R3, R4, R5 and R6 are as defined above.
- Even more preferably, a compound of the formula (I) is characterized in that R1 is hydrogen, R2 is ethynyl-R7, wherein R7 is an optionally substituted aryl, and R3, R4, R5 and R6 are as defined above.
- Most preferably, a compound of the formula (I) is characterized in that R1 is ethynyl-R7, wherein R7 is an optionally substituted aryl, R2 is hydrogen, R5 is optionally substituted phenyl, and R3, R4 and R6 are as defined above.
- Most preferably, a compound of the formula (I) is characterized in that R1 is hydrogen, R2 is ethynyl-R7, wherein R7 is an optionally substituted aryl, R5 is optionally substituted phenyl, R3, R4 and R6 are as defined above.
- Specific preferred compounds (cmpds.) of the invention, whenever appropriate in the form of pharmaceutically acceptable salts, are the following:
- 5-[2-Amino-5-(phenylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 1),
- 5-{2-Amino-5-[(3-hydroxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 2),
- 5-{2-Amino-5-[(4-methoxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 3),
- 5-{2-amino-5-[(3-aminophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 4),
- 5-{2-Amino-5-[(2-methoxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 5),
- 5-{2-Amino-5-[(2-aminophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 6),
- 5-{2-Amino-5-[(2,4-difluorophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 7),
- 5-{2-Amino-5-[(4-aminophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 8),
- 5-{2-Amino-5-[(5-amino-2-methoxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 9),
- 5-{2-Amino-5-[(4-amino-2-methoxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 10),
- 5-(2-Amino-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 11),
- 5-[2-Amino-5-({3-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 12),
- 5-(2-Amino-5-{[3-(tetrahydro-2H-pyran-4-ylamino)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 13),
- tert-Butyl (2-{[3-({2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-2-yl]pyrimidin-5-yl}ethynyl)phenyl]amino}ethyl)carbamate (compd. 14),
- 5-[2-Amino-5-({3-[(2-hydroxyethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 15),
- 5-[2-Amino-5-({4-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 16),
- tert-Butyl 3-({[3-({2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-2-yl]pyrimidin-5-yl}ethynyl)phenyl]amino}methyl)azetidine-1-carboxylate (compd. 17),
- 5-(2-Amino-5-{[4-(tetrahydro-2H-pyran-4-ylamino)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 18),
- 5-[2-Amino-5-({4-[(2-hydroxyethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 19),
- tert-Butyl 3-({[4-({2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-2-yl]pyrimidin-5-yl}ethynyl)phenyl]amino}methyl)azetidine-1-carboxylate (compd. 20),
- tert-Butyl (2-{[4-({2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-2-yl]pyrimidin-5-yl}ethynyl)phenyl]amino}ethyl)carbamate (compd. 21),
- 5-[2-Amino-5-({2-methoxy-5-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 22),
- 5-{2-Amino-5-[(4-formylphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 23),
- 5-[2-Amino-5-({3-[(4-methylpiperazin-1-yl)methyl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 24),
- 5-[2-Amino-5-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 25),
- 5-[2-Amino-5-({4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 26),
- 5-[2-Amino-5-({3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 27),
- 5-(2-Amino-5-{[4-(4-hydroxypiperidin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 28),
- 5-[2-Amino-5-({2-methoxy-4-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 29),
- 5-{2-Amino-5-[3-(1,1-dioxidothiomorpholin-4-yl)prop-1-yn-1-yl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 30),
- 5-[2-Amino-5-({4-[(2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 31),
- 5-[2-Amino-5-({3-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 32),
- N-[3-({2-Amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-2-yl]pyrimidin-5-yl}ethynyl)-4-methoxyphenyl]-1-methylpiperidine-4-carboxamide (compd. 33),
- 5-(2-Amino-5-{[2-methoxy-5-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 34),
- 5-{2-Amino-5-[(5-bromo-2-methoxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 35),
- 5-[2-Amino-5-(cyclohexylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 36),
- 5-[2-Amino-5-({2-methoxy-4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 37),
- 5-[2-Amino-5-(cyclopropylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 38),
- 5-[2-Amino-5-(3,3-dimethylbut-1-yn-1-yl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 39),
- 5-{2-Amino-5-[(4-bromophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 40),
- 5-{2-Amino-5-[(4-bromo-2-fluorophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 41),
- 5-(2-Amino-5-{[2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 42),
- 5-[2-Amino-5-({2-[(2-hydroxyethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 43),
- 5-{2-Amino-5-[3-(dimethylamino)prop-1-yn-1-yl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 44),
- 5-{2-Amino-5-[(2-{[2-(dimethylamino)ethyl]amino}phenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 45),
- 5-(2-Amino-5-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 46),
- 5-(2-Amino-5-{[3-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 47),
- 5-[2-Amino-5-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 48),
- 5-(2-Amino-5-{[2-fluoro-5-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 49),
- 5-{2-Amino-5-[3-(4-methylpiperazin-1-yl)prop-1-yn-1-yl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 50),
- 5-(2-Amino-5-{3-[(1-methylpiperidin-4-yl)oxy]prop-1-yn-1-yl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 51),
- 5-[2-Amino-5-({2-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide] (compd. 52),
- 5-[2-Amino-5-(pyridin-3-ylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 53),
- 5-[2-Amino-5-(3-hydroxy-3-methylbut-1-yn-1-yl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 54),
- 5-[2-Amino-5-(3-hydroxybut-1-yn-1-yl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 55),
- 5-(2-Amino-5-{3-[benzyl(methyl)amino]prop-1-yn-1-yl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 56),
- 5-[2-Amino-5-(phenylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-N-methyl-1H-pyrrole-3-carboxamide (compd. 57),
- 5-(2-Amino-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-N-methyl-1H-pyrrole-3-carboxamide (compd. 58),
- 5-[2-Amino-5-({4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 59),
- 5-[2-Amino-5-({4-[4-(dimethylamino)piperidin-1-yl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 60),
- 5-[2-Amino-5-({3-[(azetidin-3-ylmethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 61),
- 5-[2-Amino-5-({4-[(azetidin-3-ylmethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 62),
- 5-[2-Amino-5-({3-[(2-aminoethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 63),
- 5-{2-Amino-5-[(3-{[(1-methylazetidin-3-yl)methyl]amino}phenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 64),
- 5-[2-Amino-5-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 65),
- 5-(2-Amino-5-{[4-(pyrrolidin-1-ylmethyl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 66),
- 5-(2-Amino-5-{[4-(piperidin-1-ylmethyl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 67),
- 5-(2-Amino-5-ethynylpyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 68),
- 5-(2-Amino-pyrimidin-4-yl)-2-(5-chloro-2-methyl-phenyl)-4-phenylethynyl-1H-pyrrole-3-carboxamide (compd. 69),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(3-hydroxyphenyl)ethynyl]-1H-pyrrole-3-carboxamide (compd. 70),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(4-methoxyphenyl)ethynyl]-1H-pyrrole-3-carboxamide (compd. 71),
- 4-[(3-Aminophenyl)ethynyl]-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 72),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(2-methoxyphenyl)ethynyl]-1H-pyrrole-3-carboxamide (compd. 73),
- 4-(2-Amino-phenylethynyl)-5-(2-amino-pyrimidin-4-yl)-2-(5-chloro-2-methyl-phenyl)-1H-pyrrole-3-carboxamide (compd. 74),
- 4-[(4-amino-2-methoxyphenyl)ethynyl]-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 75),
- 4-[(4-Aminophenyl)ethynyl]-5-(2-amino-pyrimidin-4-yl)-2-(5-chloro-2-methyl-phenyl)-1H-pyrrole-3-carboxamide (compd. 76),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(2-methylphenyl)ethynyl]-1H-pyrrole-3-carboxamide (compd. 77),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(4-fluorophenyl)ethynyl]-1H-pyrrole-3-carboxamide (compd. 78),
- 4-[(5-Amino-2-methoxyphenyl)ethynyl]-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 79),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({3-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 80),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({3-[(4-methylpiperazin-1-yl)methyl]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 81),
- 4-({3-[(2-Aminoethyl)amino]phenyl}ethynyl)-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 82),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 83),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({2-[(2-hydroxyethyl)amino]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 84),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 85),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[2-methoxy-5-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 86),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(2-{[2-(dimethylamino)ethyl]amino}phenyl)ethynyl]-1H-pyrrole-3-carboxamide (compd. 87),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[3-(dimethylamino)prop-1-yn-1-yl]-1H-pyrrole-3-carboxamide (compd. 88),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 89),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[3-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 90),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({3-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 91),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 92),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[2-fluoro-5-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 93),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({2-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 94),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 95),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({4-[4-(dimethylamino)piperidin-1-yl]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 96),
- 5-(2-Aminopyrimidin-4-yl)-4-{[4-(1,4'-bipiperidin-1'-yl)phenyl]ethynyl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 97),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 98),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[4-(piperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 99),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 100),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-4-[(2-{[2-(dimethylamino)ethyl]amino}phenyl)ethynyl]-1H-pyrrole-3-carboxamide (compd. 101),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-4-({3-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 102),
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-4-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 103),
- 2-(5-Chloro-2-methylphenyl)-5-[2-(methylamino)-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl]-1H-pyrrole-3-carboxamide (compd. 104),
- 2-(5-Chloro-2-methylphenyl)-5-(5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (compd. 105),
- 2-(5-Chloro-2-methylphenyl)-5-(2-methyl-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (compd. 106),
- 2-(5-Chloro-2-methylphenyl)-5-[2-(methylamino)pyrimidin-4-yl]-4-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 107),
- 2-(5-Chloro-2-methylphenyl)-4-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-5-(pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (compd. 108),
- 2-(5-Chloro-2-methylphenyl)-4-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-5-(2-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide (compd. 109),
- 5-(2-Amino-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxamide (compd. 110),
- 5-[2-Amino-5-(phenylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-ethylphenyl)-N-methyl-1H-pyrrole-3-carboxamide (compd. 111) and
- 5-(2-Amino-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-methyl-1H-pyrrole-3-carboxamide (compd. 112).
- The present invention also provides a process for the preparation of a compound of formula (I) as defined above, by using the reaction routes and synthetic schemes described below, employing the techniques available in the art and starting materials readily available. The preparation of certain embodiments of the present invention is described in the examples that follow, but those of ordinary skill in the art will recognize that the preparations described may be readily adapted to prepare other embodiments of the present invention. For example, the synthesis of non-exemplified compounds according to the invention may be performed by modifications apparent to those skilled in the art, for instance by appropriately protecting interfering groups, by changing to other suitable reagents known in the art, or by making routine modifications of reaction conditions. Alternatively other reactions referred to herein or known in the art will be recognized as having adaptability for preparing other compounds of the invention.
- The compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures. Unless otherwise indicated, the starting materials are known compounds or may be prepared from known compounds according to well known procedures. It will be appreciated that, where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T.W. Greene and P.G.M. Wuts, Protecting Groups in Organic Synthesis, Second Edition, Wiley, New York, 1991, and references cited therein.
- A compound of formula (I) can be prepared according to the general synthetic processes described hereafter in schemes A, B, C, D, E and F.
-
- In the above Scheme R1 is ethynyl-R7, R2 is hydrogen, R3, R4, R5, R6 and R7 are as defined above, and X is halogen.
- All those with ordinary skills in the art will appreciate that any transformation performed according to said methods may require standard modifications such as, for instance, protection of interfering groups, change to other suitable reagents known in the art, or make routine modifications of reaction conditions.
- Accordingly, a process of the present invention comprises the following steps:
- Step 1: metal-catalyzed coupling reactions of a halo derivative of formula (II)
- Step 2: hydrolysis under basic conditions of the resultant compound of formula (IV)
- Step 3: regioselective mono-halogenation of the resultant carboxylic acid of formula (V)
- Step 4: amidation of the resultant mono-halogenated carboxylic acid of formula (VI)
NHR3R4 (VII)
wherein R3 and R4 are as defined above; - Step 5: metal-catalyzed coupling reactions of the resultant mono-halogenated carboxamide of formula (VIII)
optionally converting a compound of the formula (I) into another different compound of the formula (I), and, if desired, converting a compound of the formula (I) into a pharmaceutically acceptable salt thereof or converting a salt into the free compound (I). - According to the Step 1 of Scheme A, the conversion of a halo derivative of general formula (II) into a compound of formula (IV) can be accomplished in a variety of ways. For example a compound of formula (II) can be reacted by metal-catalyzed coupling reactions with an optionally substituted aryl boronic acid of formula (IIIa) or an optionally substituted aryl boronic-ester of formula (IIIb). Preferably, a compound of formula (IV) can be prepared from an intermediate of formula (II) by Pd-catalyzed Suzuki-Miyaura coupling with an optionally substituted aryl boronic acid of formula (IIIa) or an optionally substituted aryl boronic-ester of formula (IIIb). Transition metal-catalyzed couplings of (hetero)aryl halides with aryl boronic acids or boronic-esters are well known to the person skilled in the art, see references: a) Miyaura, Norio; Suzuki, Akira (1979). "Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds". Chemical reviews 95 (7): 2457-2483; b) Suzuki, A. In Metal-Catalyzed Cross-Coupling Reactions, Diederich, F., and Stang, P. J., Eds.; Wiley-VCH: New York, 1998, pp. 49-97. In the so called Suzuki-Miyaura reaction, coupling reaction of aryl boronic acids with (hetero)aryl halides is typically triggered by palladium complex. Phosphine-palladium complexes such as tetrakis(triphenylphosphine)palladium(0) are used for this reaction but also bis(triphenylphosphine)palladium(II) chloride, [1,1'-bis(diphenylphosphino) ferrocene] dichloro palladium(II) may be employed. A base such as potassium phosphate, sodium carbonate, cesium carbonate, potassium carbonate, potassium t-butoxide, tetraethyl ammonium hydroxide, triethylamine is added and tetrahydrofurane, dioxane, N,N-dimethylformamide, ethanol and toluene may be used as reaction media. Typically temperatures range from room temperature to 150 °C. Conventional heating along with microwave irradiation may be employed. Reaction duration ranges from about 30 min to about 96 hours. Various Pd-catalyst/base/solvent combinations have been described in the literature, which allow the fine-tuning of the reaction conditions in order to allow for a broad set of additional functional groups on both coupling partners.
- According to the Step 2 of Scheme A, the hydrolysis of a derivative of formula (IV) into a carboxylic acid of formula (V) can be accomplished in a variety of ways. Typically NaOH or KOH in alcoholic solution is used, at a temperature ranging from room temperature to 150 °C, for a time ranging from about 30 min to about 96 hours.
- According to the Step 3 of Scheme A, the introduction of halogens on a compound of formula (V) may be carried out in a variety of ways and experimental conditions, which are widely known in the art. The reagents that are commonly employed are: NCS, NBS or NIS in solvents such as DMF, THF, AcOH, TFA; CF3COOAg/Br2 or I2 in TFA, DMF, acetonitrile; Phl(OAc)2, I2 in DCM; ICI in AcOH. Temperature ranging from about-40 °C to 100 °C and for a period of time varying from about 1 hour to about 24 hours. The most reactive positions towards sources of electrophylic I+, Br+ and Cl+ in a compound of formula (V) are usually position 5' on the pyrimidine ring together with position 4 on the pyrrole ring but regioselective monohalogenation is often achieved by carefully choosing reaction conditions (see, for example: a) Mitchell, R. H.; Lai, Y-Y., Willams, R. V. N-Bromosuccinimide-Dimethylformamide: A Mild, Selective Nuclear Monobromination Reagent for Reactive Aromatic Compounds. J.Org.Chem. 1979, 44, 4733. b) Aiello, E.; Dattolo, G.; Cirrincione, G.; Almerico, A.M.; D'Asdia, I. Preparation of monohalopyrroles. J. Het. Chem. 1982, 19, 977-979. c) Vanotti E. et al. Regioselective monohalogenation of aminopyrimidinyl-pyrrole carboxylic acid derivatives. Tetr. 2009, 65, 10418 - 10423). In particular, a methodology was developed in order to introduce an iodine on position 5' of the pyrimidine moiety of a derivative of general formula (V) employing CF3COOAg/I2 in DMF at low temperature.
- According to the Step 4 of Scheme A, the conversion of a carboxylic acid of formula (VI) into an amide of formula (VIII) can be accomplished in a variety of ways and experimental conditions, which are widely known in the art for the preparation of carboxamides. As an example, a compound of formula (VI) can be converted into its corresponding acyl chloride in the presence of thionyl chloride or oxalyl chloride, in a suitable solvent, such as toluene, dichloromethane, chloroform, diethyl ether, tetrahydrofuran, dioxane, at a temperature ranging from about -10 °C to reflux and for a period of time varying from about 1 hour to about 96 hours. The acyl chloride can be isolated by evaporation of the solvent and further reacted with 33% ammonium hydroxide solution or with an amine NHR3R4 (VII) in a suitable solvent, such as toluene, dichloromethane, chloroform, diethyl ether, tetrahydrofuran, dioxane, at a temperature ranging from about -10 °C to reflux and for a period of time varying from about 1 hour to about 96 hours. Alternatively, a compound of formula (VI) can be reacted with the ammonium salt of 1-hydroxybenzotriazole or with an amine NHR3R4 (VII) in the presence of a carbodiimide such as dicyclohexyl carbodiimide, diisopropyl carbodiimide, 1-ethyl-3-(3'-dimethylamino)carbodiimide hydrochloric acid salt and hydroxybenzotriazole. Preferably, this reaction is carried out in a suitable solvent such as, for instance, tetrahydrofuran, dichloromethane, toluene, dioxane, N,N-dimethylformamide and in the presence of a proton scavenger such as, for example, triethylamine, N,N-diisopropylethylamine, at a temperature ranging from room temperature to reflux, for a time ranging from about 30 min to about 96 hours.
- According to the Step 5 of Scheme A, the transformation of a compound of formula (VIII) into a compound of formula (I) can be accomplished in a variety of ways and experimental conditions, which are widely known in the art. For example compounds (VIII) can be reacted to give compounds of formula (I) by metal-catalyzed coupling reactions with respectively substituted alkynes of general formula (IX). More particularly, compounds of formula (I) can be prepared from intermediates of formula (VIII) by Pd-catalyzed Sonogashira-Hagihara coupling and Sonogashira-type coupling reactions (including Stephen-Castro couplings and Heck-Cassar alkynylations) with alkynes of general formula (IX). Transition metal-catalyzed couplings of (hetero)aryl halides with alkynes are well known to the person skilled in the art (see references: a) Sonogashira, Y. T.; Hagihara, N. Tetrahedron Lett. 1975, 16, 4467; b) Chinchilla, R.; Najera, C. Chem. Rev. 2007, 107, 874). In the so called Sonogashira reaction, coupling reaction of terminal alkynes with (hetero)aryl halides is typically triggered by a zerovalent palladium complex and a halide salt of copper(I). Phosphine-palladium complexes such as tetrakis(triphenylphosphine)palladium(0) are used for this reaction but also bis(triphenylphosphine)palladium(II) chloride may be employed. An amine is added such as triethylamine or diisopropylethylamine and DMF, acetonitrile or even ether may be used as reaction media. Typically temperatures range from room temperature to 150 °C. Conventional heating along with microwave irradiation may be employed. Reaction duration ranges from about 30 min to about 96 hours. Various Pd-catalyst/co-catalyst/ligand/base/solvent combinations have been described in the literature, which allow the fine-tuning of the reaction conditions in order to allow for a broad set of additional functional groups on both coupling partners. In addition, recently developed procedures employing for example zinc acetylides, alkynyl magnesium salts or alkynyl trifluoroborate salts further broaden the scope of the reaction.
-
- In the above Scheme R1 is ethynyl-R7, R2 is hydrogen, R3, R4, R5, R6 and R7 are as defined above, X is halogen, and PG is a protecting group such as SEM, Boc.
- All those with ordinary skills in the art will appreciate that any transformation performed according to said methods may require standard modifications such as, for instance, protection of interfering groups, change to other suitable reagents known in the art, or make routine modifications of reaction conditions.
- Accordingly, another process of the present invention comprises the following steps:
- Step 6: amidation of the carboxylic acid of formula (V) as defined above, through reaction with an amine of formula (VII) as defined above;
- Step 7: regioselective introduction of a protecting group on the pyrrole nitrogen of the resultant carboxamide of formula (X)
- Step 8: regioselective mono-halogenation of the resultant protected compound of formula (XI)
- Step 9: metal-catalyzed coupling reaction of the resultant mono-halogenated carboxamide of formula (XII)
- Step 10: deprotection of the resultant compound of formula (XIII)
optionally converting a compound of the formula (I) into another different compound of the formula (I), and, if desired, converting a compound of the formula (I) into a pharmaceutically acceptable salt thereof or converting a salt into the free compound (I). - According to the Step 6 of Scheme B, the conversion of a carboxylic acid of formula (V) into an amide of formula (X) can be accomplished in a variety of ways and experimental conditions, already described in Step 4 of Scheme A.
- According to the Step 7 of Scheme B, the regioselective introduction of the protecting group PG on the pyrrole nitrogen of a compound of general formula (X) is possible by carefully controlling the reaction conditions. A wide set of protecting groups is available, which are well known to the person skilled in the art (see for example Green, Theodora W. and Wuts, Peter G.M. - Protective Groups in Organic Synthesis, Third Edition, John Wily & Sons Inc., New York (NY), 1999; Jolicoeur,B.; Chapman, E. E.; Thommpson, A.; Lubell, W. D. Tetrahedron 2006, 62, 11531). Strong bases such as NaH or KH in solvents such as THF, DCM or DMF as well as trialkylamines in DCM or MeCN, sometimes in the presence of DMAP or phase transfer catalysts, are usually employed at temperatures ranging from -40 °C to 50 °C. The pyrrole nitrogen reacts then with an activated source of the protecting group such as benzenesulfonyl chloride (BsCI), toluensulfonyl chloride (TsCI), trimethylsilylethylsulfonyl chloride (SESCI), di-tert-butyldicarbonate (Boc)2O, benzyl bromide (BnBr), 2-(trimethylsilyl)ethoxymethyl chloride (SEMCI), triisopropylsilyltrifluoromethane sulfonate (TIPSOTf), 4-methoxy-benzyl chloride and 2,4-dimethoxybenzyl chloride.
- According to the Step 8 of Scheme B, the mono-halogenation of the compound of formula (XI) to give a halo derivative of formula (XII) may be carried out under the variety of conditions already described in Step 3 of Scheme A.
- According to the Step 9 of Scheme B, the conversion of the halo derivative of formula (XII) into a compound of formula (XIII) may be carried out under the variety of conditions already described in Step 5 of Scheme A.
- According to the Step 10 of Scheme B, the removal of the protecting group PG on the pyrrole ring of a compound of formula (XIII) may be carried out following procedures which are well known in the art (Jolicoeur,B.; Chapman, E. E.; Thommpson, A.; Lubell, W. D. Tetrahedron 2006, 62, 11531). Depending on the protecting group of choice, the following conditions may be employed: benzenesulfonyl (Bs) and toluensulfonyl (Ts) groups may be removed with KOH , NaOH, K2CO3, Triton B, magnesium also in the presence of ammonium chloride in solvents such as MeOH, dioxane at temperatures ranging from room temperature to reflux; trimethylsilylethylsulfonyl (SES) group may be removed using TBAF in THF at room temperature; tert-butoxycarbonyl (Boc) may be removed in the presence of TFA in DCM or by Na2CO3 in DME, DMF at a temperature ranging from room temperature to 130 °C; 4-methoxy-benzyl (MB) and 2,4-dimethoxybenzyl (DMB) groups may be removed by exposure to acid in the presence of anisole to trap the benzyl carbonium ion (e.g. 5% H2SO4 TFA, anisole); 2-(trimethylsilyl)ethoxymethyl (SEM) and triisopropylsilyl (TIPS) may be removed with TBAF, HF, Py or TFA in solvents such as THF, DCM at room temperature or below. The present invention further provides an alternative process for the preparation of a compound of formula (I), wherein R1 is ethynyl or optionally substituted aryl-ethynyl, R2 is hydrogen, R3, R4, R5 and R6 are as defined above, which is shown in Scheme C below.
- In the above Scheme R1 is ethynyl or optionally substituted aryl-ethynyl, R2 is hydrogen, R3, R4, R5, R6, X and PG are as defined above, R7' is trialkylsylyl, R7" is optionally substituted aryl, and X' is bromine or iodine.
- All those with ordinary skills in the art will appreciate that any transformation performed according to said methods may require standard modifications such as, for instance, protection of interfering groups, change to other suitable reagents known in the art, or make routine modifications of reaction conditions.
- Accordingly, another process of the present invention comprises the following steps:
- Step 11: regioselective introduction of a protecting group on the pyrrole nitrogen of the carboxylic ester of formula (IV) as defined above;
- Step 12: regioselective mono-halogenation of the resultant protected carboxylic ester of formula (XIV)
- Step 13: metal-catalyzed coupling reaction of the resultant mono-halogenated carboxylic ester of formula (XV)
- Step 14: hydrolysis under basic conditions of the resultant trialkylsilyl-protected alkyne of formula (XVI)
- Step 15: amidation of the resultant carboxylic acid of formula (XVII)
either - Step 16: metal-catalyzed coupling reaction of the terminal alkyne of the resultant carboxamide of formula (XVIII)
X'-R7" (XIX)
wherein R7" is an optionally substituted aryl group and X' is bromine or iodine; - Step 17: then deprotection of of the resultant compound of formula (XX)
- Step 17a: direct deprotection of the terminal alkyne compound of formula (XVIII) as defined above, to give a compound of general formula (I)
optionally converting a compound of the formula (I) into another different compound of the formula (I), and, if desired, converting a compound of the formula (I) into a pharmaceutically acceptable salt thereof or converting a salt into the free compound (I). - According to Step 11 of Scheme C, the regioselective introduction of protecting group PG on the pyrrole nitrogen of a compound of formula (IV) can be accomplished in a variety of ways and experimental conditions, already described in the Step 7 of Scheme B.
- According to the Step 12 of Scheme C, the mono-halogenation of a compound of formula (XIV) to give a halo derivative of formula (XV) may be carried out under the variety of conditions already described in Step 3 of Scheme A.
- According to the Step 13 of Scheme C, the conversion of a halo derivative of formula (XV) into a compound of formula (XVI) may be carried out under the variety of conditions already described in Step 5 of Scheme A.
- According to the Step 14 of Scheme C, the hydrolysis of a derivative of formula (XVI) into a carboxylic acid of formula (XVII) can be accomplished in a variety of ways, already described in Step 2 of Scheme A. In the mean time removal of trialkylsilyl-protecting group occurs.
- According to the Step 15 of Scheme C, the conversion of a carboxylic acid of formula (XVII) into an amide of formula (XVIII) can be accomplished in a variety of ways and experimental conditions, already described in Step 4 of Scheme A.
- According to the Step 16 of the Scheme C, metal-catalyzed coupling reactions of terminal alkynes of general formula (XVIII) with optionally substituted aryl halides of formula (XIX) may be carried out under the variety of conditions already described in Step 5 of Scheme A.
- According to the Step 17 of Scheme C, the removal of the protecting group PG on the pyrrole ring of a compound of general formula (XX) may be carried out following procedures already described in Step 10 of Scheme B.
- According to the Step 17a of Scheme C, the removal of the protecting group PG on the pyrrole ring of a compound of general formula (XVIII) may be carried out following procedures already described in Step 10 of Scheme B.
-
- In the above Scheme R1 is amino-aryl-ethynyl, R2 is hydrogen, R3, R4, R5, R6, X and PG are as defined above, and R10 and R11 are independently hydrogen or an optionally substituted group selected from straight or branched C1-C6 alkyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, heterocyclyl and heterocyclyl-alkyl, or R10 and R11, taken together with the nitrogen atom to which they are bonded, may form an optionally substituted 5 to 7 membered heterocyclyl group optionally containing one additional heteroatom selected from N, O and S.
- All those with ordinary skills in the art will appreciate that any transformation performed according to said methods may require standard modifications such as, for instance, protection of interfering groups, change to other suitable reagents known in the art, or make routine modifications of reaction conditions.
- Accordingly, another process of the present invention comprises the following steps:
- Step 18: metal-catalyzed coupling reaction of a halo derivative of formula (XXI)
NHR10R11 (XXII)
wherein R10 and R11 are independently hydrogen or an optionally substituted group selected from straight or branched C1-C6 alkyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, heterocyclyl and heterocyclyl-alkyl, or R10 and R11, taken together with the nitrogen atom to which they are bonded, may form an optionally substituted 5 to 7 membered heterocyclyl group optionally containing one additional heteroatom selected from N, O and S; - Step 19: deprotection of the resultant compound of formula (XXIII)
optionally converting a compound of the formula (I) into another different compound of the formula (I), and, if desired, converting a compound of the formula (I) into a pharmaceutically acceptable salt thereof or converting a salt into the free compound (I). - According to the Step 18 of Scheme D, metal-catalyzed coupling reactions of a halo derivative of formula (XXI) with an amine of formula NHR10R11 (XXII) may be carried out in a suitable solvent such as THF or dioxane, and in the presence of catalytic amounts of Pd2(dba)3, 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)-biphenyl and a base such as LiN(TMS)2 at a temperature ranging from room temperature to reflux and for a time ranging from 1 to about 24 hours.
- According to the Step 19 of Scheme D, the removal of the protecting group PG on the pyrrole ring of a compound of formula (XXIII) may be carried out following procedures already described in Step 10 of Scheme B.
-
- In the above scheme R1 is hydrogen, R2 ethynyl-R7, and R3, R4, R5, R6, R7 and X are as defined above.
- All those with ordinary skills in the art will appreciate that any transformation performed according to said methods may require standard modifications such as, for instance, protection of interfering groups, change to other suitable reagents known in the art, or make routine modifications of reaction conditions.
- Accordingly, another process of the present invention comprises the following steps:
- Step 20: regioselective mono-halogenation of a compound of formula (X) as defined above;
- Step 21: metal-catalyzed coupling reaction of the resultant halo derivative of formula (XXIV)
optionally converting a compound of formula (I) into another different compound of formula (I), and, if desired, converting a compound of formula (I) into a pharmaceutically acceptable salt thereof or converting a salt into the free compound of formula (I). - According to the Step 20 of Scheme E, the introduction of halogens on a compound of formula (X) may be carried out in a variety of ways and experimental conditions, already described in the Step 3 of Scheme A.
- According to the Step 21 of Scheme E, the conversion of a halo derivative of general formula (XXIV) into a compound of formula (I) may be carried out under the variety of conditions already described in Step 5 of Scheme A. The present invention further provides an alternative process for the preparation of a compound of formula (I) wherein R1 is ethynyl-R7, R2 is hydrogen, R3, R4, R5, R6 and R7 are as defined above, which is shown in Scheme F below.
- In the above Scheme R1 is ethynyl-R7, R2 is hydrogen, R3, R4, R5, R6 and R7 are as defined above, and X is halogen.
- All those with ordinary skills in the art will appreciate that any transformation performed according to said methods may require standard modifications such as, for instance, protection of interfering groups, change to other suitable reagents known in the art, or make routine modifications of reaction conditions.
- Accordingly, another process of the present invention comprises the following steps:
- Step 22: regioselective mono-halogenation of the carboxylic ester of formula (IV) as defined above;
- Step 23: hydrolysis under basic conditions of the resultant compound of formula (XXV)
- Step 24: amidation of the resultant mono-halogenated carboxylic acid of formula (VI) as defined above through reaction with a derivative of formula (VII) as defined above;
- Step 25: metal-catalyzed coupling reactions of the resultant mono-halogenated carboxamide of formula (VIII) as defined above through reaction with a derivative of formula (IX) as defined above to give a compound of formula (I)
optionally converting a compound of formula (I) into another different compound of formula (I), and, if desired, converting a compound of formula (I) into a pharmaceutically acceptable salt thereof or converting a salt into the free compound of formula (I). - According to the Step 22 of Scheme F, the mono-halogenation of a compound of formula (IV) to give a halo derivative of formula (XXV) may be carried out under the variety of conditions already described in Step 3 of Scheme A.
- According to the Step 23 of Scheme F, the hydrolysis of a derivative of formula (XXV) into a carboxylic acid of formula (VI) can be accomplished in a variety of ways, already described in Step 2 of Scheme A.
- According to the Step 24 of Scheme F, the conversion of a carboxylic acid of formula (VI) into an amide of formula (VIII) can be accomplished in a variety of ways and experimental conditions, already described in Step 4 of Scheme A.
- According to the Step 25 of the Scheme F, metal-catalyzed coupling reactions of terminal alkynes of general formula (IX) with optionally substituted aryl halides of formula (VIII) may be carried out under the variety of conditions already described in Step 5 of Scheme A.
- As indicated above, a compound of formula (I) which is prepared according to the processes object of the invention, can be conveniently converted into another compound of formula (I) by operating according to well-known synthetic conditions, the following being examples of possible conversions:
- Conv. a) converting a compound of formula (I) wherein an amino group is protected as a Boc derivative into the corresponding compound of formula (I) wherein the amino group is free, by hydrolysis of the Boc group;
- Conv. b) converting a compound of formula (I), wherein a primary or secondary amino substituent is present, into the corresponding compound of formula (I), by reaction with a suitable aldehyde or ketone in the presence of a reducing agent;
- Conv. c) converting a compound of formula (I), wherein a substituent like CH=O is present, into the corresponding compound of formula (I) wherein such substituent is CH2NR10R11 group, wherein R10 and R11 are defined above, by reaction with a suitable primary or secondary amine in the presence of a reducing agent:
- From all of the above it is clear to the skilled person that any compound of the formula (I) bearing a functional group which can be further derivatized to another functional group, by working according to methods well known in the art thus leading to other compounds of the formula (I), is intended to be comprised within the scope of the present invention.
- Needless to say, also any of the intermediates of the above described processes could be converted into a different intermediate, if wanted and necessary, by operating in an analogous way as in any one of the conversion reaction here above described.
- From all of the above, it is clear to the skilled person that when preparing the compounds of the formula (I) according to any one of the aforementioned process variants, optional functional groups within the starting materials or the intermediates thereof that could give rise to unwanted side reactions, need to be properly protected according to conventional techniques. Likewise, the conversion of these latter into the free deprotected compounds may be carried out according to known procedures.
- As it will be readily appreciated, if the compounds of the formula (I) prepared according to the process described above are obtained as mixture of isomers, their separation using conventional techniques into the single isomers of the formula (I), is within the scope of the present invention.
- The final compounds may be isolated and purified using conventional procedures, for example chromatography and/or crystallization and salt formation.
- The carboxamides of the formula (I) as defined above can be converted into pharmaceutically acceptable salts. The carboxamides of the formula (I) as defined above, or the pharmaceutically acceptable salts thereof, can be subsequently formulated with a pharmaceutically acceptable carrier or diluent to provide a pharmaceutical composition.
- The synthesis of a compound of formula (I), according to the synthetic process described above, can be conducted in a stepwise manner, whereby each intermediate is isolated and purified by standard purification techniques, like, for example, column chromatography, before carrying out the subsequent reaction. Alternatively, two or more steps of the synthetic sequence can be carried out in a so-called "one-pot" procedure, as known in the art, whereby only the compound resultant from the two or more steps is isolated and purified.
- In cases where a compound of formula (I) contains one or more asymmetric centers, said compound can be separated into the single isomers by procedures known to those skilled in the art. Such procedures comprise standard chromatographic techniques, including chromatography using a chiral stationary phase, or crystallization. General methods for separation of compounds containing one or more asymmetric centers are reported, for instance, in Jacques, Jean; Collet, André; Wilen, Samuel H., - Enantiomers, Racemates, and Resolutions, John Wiley & Sons Inc., New York (NY), 1981 .
- According to any variant of the process for preparing the compounds of the formula (I), the starting materials and any other reactants are known or easily prepared according to known methods.
- The starting materials of the formula (II) can be prepared as described in
WO2007/110344 . - The compounds of the formula (IIIa), (IIIb), (VII), (IX), (IX)', (X), (XIX) and (XXII) are either commercially available or can be prepared with known methods; the compounds of the formula (IIIa) can also be prepared as described in the experimental part below (Preparation A); the compounds of the formula (IX) can also be prepared as described in the experimental part below (Preparations B to P); the compounds of the formula (X) can also be prepared as described in the experimental part below (Preparations Q).
- The compounds of the present invention can be administered either as single agents or, alternatively, in combination with known anticancer treatments such as radiation therapy or chemotherapy regimen in combination with cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents (e.g. angiogenesis inhibitors), farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and the like.
- If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent within the approved dosage range.
- Compounds of the formula (I) may be used sequentially with known anticancer agents when a combination formulation is inappropriate.
- The compounds of the formula (I) of the present invention, suitable for administration to a mammal, e.g., to humans, can be administered by the usual routes and the dosage level depends upon the age, weight, conditions of the patient and administration route.
- For example, a suitable dosage adopted for oral administration of a compound of the formula (I) may range from about 10 to about 500 mg per dose, from 1 to 5 times daily. The compounds of the invention can be administered in a variety of dosage forms, e.g., orally, in the form tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form suppositories; parenterally, e.g., intramuscularly, or through intravenous and/or intrathecal and/or intraspinal injection or infusion.
- The present invention also includes pharmaceutical compositions comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient, which may be a carrier or a diluent.
- The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a suitable pharmaceutical form. For example, the solid oral forms may contain, together with the active compound, diluents, e.g., lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g., silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g., starches, arabic gum, gelatine methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disintegrating agents, e.g., starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. These pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes.
- The liquid dispersions for oral administration may be, e.g., syrups, emulsions and suspensions. As an example, the syrups may contain, as carrier, saccharose or saccharose with glycerine and/or mannitol and sorbitol.
- The suspensions and the emulsions may contain, as examples of carriers, natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., sterile water, olive oil, ethyl oleate, glycols, e.g., propylene glycol and, if desired, a suitable amount of lidocaine hydrochloride. The solutions for intravenous injections or infusions may contain, as a carrier, sterile water or preferably they may be in the form of sterile, aqueous, isotonic, saline solutions or they may contain propylene glycol as a carrier.
- The suppositories may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
- With the aim of better illustrating the present invention, without posing any limitation to it, the following examples are now given.
- For a reference to any specific compound of formula (I) of the invention, optionally in the form of a pharmaceutically acceptable salt, see the experimental section and claims. Referring to the examples that follow, compounds of the present invention were synthesized using the methods described herein, or other methods, which are well known in the art.
- The synthetic preparation of some compounds of the formula (I) of the invention is described in the following examples. The compounds of the present invention, as prepared according to the following examples, were also characterized by 1H NMR and/or by Exact mass data ESI(+).
- 1H-NMR spectrometry was performed on a Mercury VX 400 operating at 400.45 MHz equipped with a 5 mm double resonance probe [1H (15N-31P) ID_PFG Varian]. ESI(+) high resolution mass spectra (HRMS) were obtained on a Waters Q-Tof Ultima directly connected with micro HPLC 1100 Agilent as previously described (M. Colombo, F. Riccardi-Sirtori, V. Rizzo, Rapid Commun. Mass Spectrom. 2004, 18, 511-517). Column chromatography was conducted either under medium pressure on silica (Merck silica gel 40-63 µm) or on prepacked silica gel cartridges (Biotage). Components were visualized by UV light (λ: 254 nm) and by iodine vapor. HPLC was performed on Waters X Terra RP 18 (4.6 x 50 mm, 3.5 µm) column using a Waters 2790 HPLC system equipped with a 996 Waters PDA detector and Micromass mod. ZQ single quadrupole mass spectrometer, equipped with an electrospray (ESI) ion source. Mobile phase A was ammonium acetate 5 mM buffer (pH 5.5 with acetic acid/acetonitrile 95:5), and Mobile phase B was water/acetonitrile (5:95). Gradient from 10 to 90% B in 8 minutes, hold 90% B 2 minutes. UV detection at 220 nm and 254 nm. Flow rate 1 mL/min. Injection volume 10 microL. Full scan, mass range from 100 to 800 amu. Capillary voltage was 2.5 KV; source temperature was 120 °C; cone was 10 V. Retention times (HPLC r.t.) are given in minutes at 220 nm or at 254 nm. Mass are given as m/z ratio.
- When necessary, compounds were purified by preparative HPLC on a Waters Symmetry C18 (19 x 50 mm, 5 µm) column or on a Waters X Terra RP 18 (30 x 150 mm, 5 µm) column using a Waters preparative HPLC 600 equipped with a 996 Waters PDA detector and a Micromass mod. ZQ single quadrupole mass spectrometer, electron spray ionization, positive mode.
- Method 1: Phase A: 0.1% TFA/ACN 95/5; phase B: ACN/H2O 95/5. Gradient from 10 to 90% B in 8 min, hold 90% B 2 min; flow rate 20 mL/min.
- Method 2: Phase A: 0.05% NH4OH/ACN 95/5; Phase B: ACN/H2O 95/5. Gradient from 10 to 100% B in 8 min, hold 100% B 2 min. Flow rate 20 mL/min.
- In the examples below as well as throughout the application, the following abbreviations have the following meanings. If not defined, the terms have their generally accepted meanings.
-
- ACN
- acetonitrile
- AcOH
- acetic acid
- CuI
- copper(I) iodide
- DCM
- dichloromethane
- DIAD
- di-iso-propyl azadicarboxylate
- DIPEA
- N,N-diisopropyethylamine
- DMF
- N,N-dimethylformamide
- DMSO
- dimethyl sulfoxide
- eq
- equivalents
- ESI
- electrospray ionization
- EtOAc
- ethyl acetate
- EDCI
- N-ethyl-N',N'-diisopropyl carbodiimide hydrochloride
- Et2O
- diethyl ether
- EtOH
- ethanol
- g
- gram(s)
- h
- hour(s)
- HCl
- hydrochloric acid
- HOBT
- 1-hydroxybenzotriazole
- HOBT.NH3
- 1H-benzotriazol-1-ol ammonium salt
- HPLC
- high performance liquid chromatography
- K2CO3
- potassium carbonate
- K3PO4
- potassium phosphate
- KOH
- potassium hydroxide
- tBuOK
- potassium tert-butoxide
- LiCl
- lithium chloride
- LiHMDS
- lithium hexamethyldisilazide
- M
- molar
- MeOH
- methanol
- MeNH2
- methylamine
- mg
- milligram(s)
- min
- minutes
- mL
- milliliter(s)
- mmol
- millimole(s)
- mol
- mol(s)
- N
- normal
- NaCl
- sodium chloride
- Na2CO3
- sodium carbonate
- Na2S2O3
- sodium thiosulfate
- Na2SO4
- sodium sulfate
- NaH
- sodium hydride
- NaHCO3
- sodium hydrogen carbonate
- NaOH
- sodium hydroxide
- NH4Cl
- ammonium chloride
- NH4OH
- ammonium hydroxide
- Pd2(dba)3
- tris(dibenzylideneacetone)dipalladium(0)
- Pd(PPh3)2Cl2
- bis(triphenylphosphine)-palladium(II)chloride
- Pd(dppf)Cl2
- [1,1'-bis(diphenylphosphino)ferrocene]palladium(II)chloride
- Ph3P
- triphenylphosphine
- rt
- room temperature
- SnCl2
- tin(II) chloride
- TBAF
- tetrabutyl ammonium fluoride
- TEA
- triethylamine
- TFA
- trifluoroacetic acid
- THF
- tetrahydrofurane
- µL
- microliter(s)
-
- A mixture of 5-chloro-2-ethylaniline (3.35 g, 21.5 mmol), p-toluensulfonic acid (12.29 g, 64.6 mmol) and water (2.15 mL) were ground in a mortar for few minutes, to obtain a homogeneous paste to which solid sodium nitrite (3.71 g, 53.8 mmol) was added and the paste ground for 10 min. Solid potassium iodide (8.94 g, 53.8 mmol) was added and the paste ground for 20 min. The paste was then dissolved in water (50 mL) and treated with sodium sulfite (10% aq. sol.), before being extracted with EtOAc (3 x 100 mL). The combined organic layers were dried over sodium sulfate and the crude was purified by flash chromatography (hexane) to obtain the title compound as a light-yellow oil (4.35 g, 76%).
1H NMR (400 MHz, DMSO-d6) δ ppm 1.12 (t, J=7.51 Hz, 3 H), 2.66 (q, J=7.53 Hz, 2 H), 7.29 - 7.35 (m, 1 H), 7.42 (dd, J=8.30, 2.20 Hz, 1 H), 7.87 (d, J=2.20 Hz, 1 H). - i-Propylmagnesium chloride (2M in THF, 8.98 mL, 17.95 mmol) was added drop wise to a solution of 4-chloro-1-ethyl-2-iodobenzene (4.35 g, 16.3 mmol) in dry THF (40 mL) at -30 °C and the reaction mixture was stirred at the same temperature for 30 min, under argon. After this time, trimethylborate (3.63 mL, 32.6 mmol) was added drop wise and the reaction mixture was stirred at the same temperature for 1.5 h. HCl (1 M, 16 mL) was added and the reaction mixture extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over sodium sulfate and, after removal of the solvent, a solid was obtained, which was triturated with hexane to obtain the title compound as a white solid (2.15 g, 72%).
1H NMR (400 MHz, DMSO-d6) δ 1.12 ppm (t, J=7.51 Hz, 3 H), 2.72 (q, J=7.69 Hz, 2 H), 7.17 (d, J=8.18 Hz, 1 H), 7.25 - 7.32 (m, 1 H), 7.36 (d, J=2.32 Hz, 1 H), 8.19 (s, 2 H). -
- 3-Ethynyl-phenylamine (0.1 mL, 1 mmol) and 1-methyl-piperidin-4-one (0.15 mL, 1.2 mmol) in 1,4-dioxane (4 mL) was treated first with TFA (0.2 mL, 2.6 mmol) and then with sodium triacetoxyborohydride (318 mg, 1.5 mmol). After stirring for 2 h, 10% NH4OH was added to the reaction mixture (15 mL). Extraction with DCM (3 x 25 mL), drying over sodium sulfate, evaporation, purification by flash chromatography over silica gel (DCM/7N NH3 in MeOH 9/1) afforded the title compound (200 mg, 93 %).
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.28 - 1.45 (m, 2 H) 1.85 (d, J=12.57 Hz, 2 H) 2.02 (t, J=10.50 Hz, 2 H) 2.17 (s, 3 H) 2.72 (d, J=11.72 Hz, 2 H) 3.07 - 3.21 (m, 1 H) 3.98 (s, 1 H) 5.59 (d, J=8.06 Hz, 1 H) 6.59 (t, J=8.18 Hz, 2 H) 6.62 - 6.65 (m, 2 H) 7.04 (t, J=7.81 Hz, 1 H). - The above procedure using suitable aldehydes or ketones and amines was employed to synthesize the following compounds:
- N-(3-Ethynylphenyl)tetrahydro-2H-pyran-4-amine
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.24 - 1.39 (m, 2 H) 1.74 - 1.88 (m, 2 H) 3.38 (td, J=10.99, 1.83 Hz, 2 H) 3.54 (s, 1 H) 3.76 - 3.87 (m, 2 H) 5.64 (d, J=8.06 Hz, 1 H) 6.57 (dt, J=7.51, 1.07 Hz, 1 H) 6.59 - 6.62 (m, 1 H) 6.62 - 6.66 (m, 1 H) 7.02 (t, J=7.81 Hz, 1 H). - tert-Butyl {2-[(3-ethynylphenyl)amino]ethyl)carbamate
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.38 (s, 9 H) 3.06 (bs, 4 H) 3.98 (s, 1 H) 5.77 (bs, 1 H) 6.55 - 6.65 (m, 3 H) 6.84 (bs, 1 H) 7.06 (t, J=8.00 Hz, 1 H). - N-(2-{[tert-butyl(dimethyl)silyl]oxy)ethyl)-3-ethynylaniline
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.02 (s, 6 H) 0.86 (s, 9 H) 3.13 (q, J=5.82 Hz, 2 H) 3.69 (t, J=6.04 Hz, 2 H) 3.97 (s, 1 H) 5.69 (t, J=6.04 Hz, 1 H) 6.58 - 6.64 (m, 2 H) 6.64 - 6.67 (m, 1 H) 7.05 (t, J=7.81 Hz, 1 H). - N-(4-Ethynylphenyl)-1-methylpiperidin-4-amine
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.29 - 1.47 (m, 2 H) 1.85 (d, J=11.84 Hz, 2 H) 2.01 (t, J=11.35 Hz, 2 H) 2.17 (s, 3 H) 2.72 (d, J=11.72 Hz, 2 H) 3.08 - 3.24 (m, 1 H) 3.76 (s, 1 H) 5.89 (d, J=7.93 Hz, 1 H) 6.52 (d, J=8.67 Hz, 2 H) 7.15 (d, J=8.67 Hz, 2 H). - tert-Butyl 3-{[(3-ethynylphenyl)amino]methyl)azetidine-1-carboxylate
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.37 (s, 9 H) 2.65 - 2.78 (m, 1 H) 3.19 (d, J=7.20 Hz, 2 H) 3.53 (m, 2 H) 3.89 (m, 2 H) 3.99 (s, 1 H) 5.88 (bs, 1 H) 6.56 - 6.68 (m, 3 H) 7.01 - 7.11 (m, 1 H). - N-(4-Ethynylphenyl)tetrahydro-2H-pyran-4-amine
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.36 (dddd, J=12.82, 11.20, 10.89, 4.39 Hz, 2 H) 1.80 - 1.90 (m, 2 H) 3.40 (td, J=11.47, 2.20 Hz, 2 H) 3.41 - 3.51 (m, 2 H) 3.77 (s, 1 H) 3.85 (dt, J=11.38, 3.52 Hz, 2 H) 5.96 (d, J=7.81 Hz, 1 H) 6.56 (d, J=8.79 Hz, 2 H) 7.16 (d, J=8.67 Hz, 2 H). - N-(2-{[tert-Butyl(dimethyl)silyl]oxy)ethyl)-4-ethynylaniline
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.02 (s, 6 H) 0.85 (s, 9 H) 3.16 (q, J=6.10 Hz, 2 H) 3.69 (t, J=6.04 Hz, 2 H) 3.78 (s, 1 H) 5.97 (t, J=5.98 Hz, 1 H) 6.54 (d, J=8.67 Hz, 2 H) 7.16 (d, J=8.67 Hz, 2 H). - tert-Butyl 3-{[(4-ethynylphenyl)amino]methyl)azetidine-1-carboxylate
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.37 (s, 9 H) 2.68 - 2.80 (m, 1 H) 3.22 (m, J=12.94 Hz, 2 H) 3.53 (br. s., 2 H) 3.78 (s, 1 H) 3.89 (t, J=7.75 Hz, 2 H) 6.15 (t, J=5.92 Hz, 1 H) 6.53 (d, J=8.79 Hz, 2 H) 7.17 (d, J=8.67 Hz, 2 H). - N-(2-Ethynylphenyl)-1-methylpiperidin-4-amine
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.40 - 1.49 (m, 2 H) 1.87 - 1.91 (m, 2 H) 2.04 - 2.11 (m, 2 H) 2.17 (s, 3 H) 2.65 - 2.88 (m, 2 H) 4.44 (s, 1 H) 4.68 - 4.70 (m, 1 H) 6.53 -6.57 (m, 1 H) 6.68 (d, J=8.30 Hz, 1 H) 7.16 - 7.20 (m, 1 H) 7.23 (dd, J=7.57 Hz, 1.59 Hz, 1 H). - N-(2-Chloroethyl)-2-ethynylaniline
1H NMR (400 MHz, DMSO-d 6) δ ppm 3.53 (q, J=6.43 Hz, 2 H) 3.76 (t, J=6.29 Hz, 2 H) 4.44 (s, 1 H) 5.39 - 5.48 (m, 1 H) 6.59 (td, J=7.45, 0.98 Hz, 1 H) 6.71 (d, J=8.18 Hz, 1 H) 7.16 - 7.23 (m, 1 H) 7.25 (dd, J=7.57, 1.59 Hz, 1 H). -
- N-(2-{[tert-Butyl(dimethyl)silyl]oxy}ethyl)-3-ethynylaniline (335 mg, 1.22 mmol) was treated with 1M TBAF in THF (1.5 mL, 1.5 mmol) at room temperature for 5 min. The volatiles were removed and the crude was dissolved in EtOAc (30 mL). The organic phase was washed with water (20 mL) and finally with brine, dried over sodium sulfate and evaporated to give the corresponding alcohol as brownish oil.
1H NMR (600 MHz, DMSO-d 6) δ ppm 3.07 (q, J=5.86 Hz, 2 H) 3.53 (q, J=5.92 Hz, 2 H) 3.97 (s, 1 H) 4.68 (t, J=5.49 Hz, 1 H) 5.68 (t, J=5.49 Hz, 1 H) 6.49 - 6.71 (m, 3 H) 7.05 (t, J=7.78 Hz, 1 H). - The above procedure was employed to synthesize the following compound:
- 2-[(4-Ethynylphenyl)amino]ethanol
1H NMR (600 MHz, DMSO-d 6) δ ppm 3.03 - 3.11 (m, 2 H) 3.53 (q, J=5.80 Hz, 2 H) 3.77 (s, 1 H) 4.70 (t, J=5.40 Hz, 1 H) 5.96 (t, J=5.59 Hz, 1 H) 6.51 - 6.57 (m, 2 H) 7.13 - 7.18 (m, 2 H). -
- N-(2-Chloroethyl)-2-ethynylaniline (0.5 g, 2.79 mmol) in ACN (16 mL) was treated with 2M dimethylamine in THF (4.2 mL, 8.37 mmol), sodium iodide (1.25 g, 8.37 mmol), sodium carbonate (887 mg, 8.37 mmol) and heated in a sealed tube at 80 °C (oil bath temperature) for 15 h, with stirring. EtOAc was added (100 mL) and the organic phase was washed first with water (100 mL) and then with brine. Removal of the volatiles by evaporation, after drying over sodium sulfate and purification of the crude over silica gel (DCM/7N NH3 in MeOH 9/1) afforded the title compound (265 mg, 50%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.19 (s, 6 H) 2.46 - 2.50 (m, 2 H) 3.16 (q, J=5.98 Hz, 2 H) 4.41 (s, 1 H) 5.26 (t, J=5.43 Hz, 1 H) 6.55 (td, J=7.45, 1.10 Hz, 1 H) 6.62 (d, J=8.30 Hz, 1 H) 7.16 - 7.24 (m, 2 H). -
- 3-Ethynylbenzaldehyde (90 mg, 0.69 mmol) and 1-methylpiperazine (92 µL, 0.828 mmol) in 1,4-dioxane (2.6 mL), under a nitrogen atmosphere, at room temperature were treated first with TFA (128 µL, 1.66 mmol), then with sodium triacetoxyborohydride (210 mg, 1.035 mmol) and stirred for 5 h. EtOAc was added to the reaction mixture (20 mL) and 10% NH4OH (15 mL) was added drop wise. The organic layer was separated, dried over sodium sulfate and evaporated. Purification of the crude by flash chromatography over silica gel (DCM/7N NH3 in MeOH 9/1) afforded the title compound (56 mg, 38%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.15 (s, 3 H) 2.33 (bs, 8 H) 3.44 (s, 2 H) 4.15 (s, 1 H) 7.31 - 7.40 (m, 4 H). -
- Ph3P (1.32 g, 5.04 mmol) in DCM (4 mL), under a nitrogen atmosphere, was cooled with an ice bath and treated with neat DIAD (397 µL, 4.6 mmol). After 25 min the solution was added drop wise to 1-methylpiperidin-4-ol hydrochloride (547 g, 4.6 mmol) and 3-ethynylphenol (277 µL, 4.2 mmol) in DCM (8 mL), cooled with an ice bath, under a nitrogen atmosphere, with stirring. The reaction was then stirred at room temperature 4 h. The volatiles were partially removed by evaporation and the residue was purified by flash chromatography (DCM/MeOH 95/5) affording the title compound as a colorless oil (360 mg, 39%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.53 - 1.71 (m, 2 H) 1.90 (m, J=5.86 Hz, 2 H) 2.11 - 2.24 (m, 5 H) 2.60 (m, J=10.62 Hz, 2 H) 4.14 (s, 1 H) 4.31 - 4.44 (m, 1 H) 6.92 - 7.10 (m, 2 H) 7.21 - 7.33 (m, 1 H). - The above procedure was employed to synthesize the following compound:
- 4-(4-Ethynylphenoxy)-1-methylpiperidine
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.61 (m, 2 H) 1.88 (m, 2 H) 2.17 (m, 5 H) 2.64 (m, 2 H) 3.96 (s, 1 H) 4.38 (m, 1 H) 6.91 (d, J=8.91 Hz, 2 H) 7.35 (d, J=8.79 Hz, 2 H). -
- 1-Methylpiperazine (0.66 mL, 6.0 mmol), HOBt (0.84 g, 6.2 mmol) and EDCI (1.15 g, 6.0 mmol) were added to a solution of 4-[(trimethylsilyl)ethynyl]benzoic acid (1.0 g, 4.6 mmol) in dry DCM (45 mL). The mixture was stirred at room temperature for 4 h, washed with saturated aqueous sodium bicarbonate (30 mL), brine, dried over sodium sulphate, and evaporated. The crude was purified by flash chromatography on silica gel (DCM/MeOH 96/4) to afford the title compound (1.29 g, 93%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.24 (s, 9 H) 2.19 (s, 3 H) 2.25 - 2.40 (m, 4 H) 3.18 - 3.73 (m, 4 H) 7.30 - 7.42 (m, 2 H) 7.47 - 7.55 (m, 2 H).
HRMS (ESI) m/z calcd for C17H24N2OSi + H+ 301.1732, found 301.1731. - (4-Methylpiperazin-1-yl){4-[(trimethylsilyl)ethynyl]phenyl}methanone (1.29 g, 4.26 mmol) in MeOH (20 mL) was treated with solid K2CO3 (0.118 g, 0.85 mmol). After stirring at room temperature for 3 h the volatiles were removed by evaporation, the residue was taken up with DCM (40 mL), washed with water (30 mL), brine, dried over sodium sulfate and evaporated. The crude was purified by flash chromatography on silica gel (DCM/MeOH 95/5) to afford the title compound as white solid (0.690 g, 71%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.19 (s, 3 H) 2.22 - 2.41 (m, 4 H) 3.18 - 3.69 (m, 4 H) 4.29 (s, 1 H) 7.36 - 7.41 (m, 2 H) 7.47 - 7.56 (m, 2 H).
HRMS (ESI) m/z calcd for C14H16N2O + H+ 229.1336, found 229.1339. -
- 1-Methylpiperazine (0.58 mL, 5.2 mmol), HOBt (0.70 g, 5.2 mmol) and EDCI (1.0 g, 5.2 mmol) were added to a solution of 3-iodobenzoic acid (1.0 g, 4.0 mmol) in dry DCM (40 mL). The mixture was stirred at room temperature for 16 h, washed with saturated aqueous sodium bicarbonate (30 mL), water (15 mL), brine, dried over sodium sulphate, and evaporated to afford the title compound (1.27 g, 96%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.19 (s, 3 H) 2.22 - 2.42 (m, 4 H) 3.19 - 3.29 (m, 2 H) 3.50 - 3.68 (m, 2 H) 7.19 - 7.28 (m, 1 H) 7.35 - 7.41 (m, 1 H) 7.70 - 7.72 (m, 1 H) 7.80 - 7.82 (m, 1 H).
HRMS (ESI) m/z calcd for C12H15IN2O + H+ 331.0302, found 331.0301. - (3-lodophenyl)(4-methylpiperazin-1-yl)methanone (1.15 g, 3.5 mmol) and ethynyl-trimethyl-silane (0.58 mL, 4.2 mmol) in dry acetonitrile (30 mL) were purged with nitrogen and treated with TEA (0.97 mL, 7.0 mmol, 2 eq.), CuI (0.033 g, 0.17 mmol) and Pd (Ph3P)2Cl2 (0.120 g, 0.17 mmol). The reaction was stirred at room temperature for 2 h, then was diluted with EtOAc (30 mL), washed with water (2 x 20 mL), brine, dried over sodium sulphate, and evaporated. The crude was purified by flash chromatography on silica gel (DCM/MeOH 95/5) to afford the title compound (0.95 g, 91%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.24 (s, 9 H), 2.20 (s, 3 H), 2.25 - 2.45 (m, 4 H), 3.50 - 3.70 (m, 4H), 7.36 - 7.42 (m, 2 H) 7.42 - 7.47 (m, 1 H) 7.50 - 7.54 (m, 1 H).
HRMS (ESI) m/z calcd for C17H24N2OSi + H+ 301.1731, found 301.1732. - 1M TBAF in THF (0.30 mL, 0.30 mmol) was added to a solution of (4-methylpiperazin-1-yl){3-[(trimethylsilyl)ethynyl]phenyl}methanone (90 mg, 0.30 mmol) in dry THF (1.5 mL) and the mixture was stirred at room temperature for 2 h. The solvent was evaporated and the residue taken up with EtOAc (3 mL), washed with brine, dried over sodium sulfate and evaporated to afford the title compound (53 mg, 78%).
HRMS (ESI) m/z calcd for C14H16N2O + H+ 229.2989, found 229.2995. -
- A suspension of [(4-bromophenyl)ethynyl](trimethyl)silane (2.210 g, 8.73 mmol), Pd2(dba)3 (0.400 g, 0.436 mmol), 2-dicyclohexylphosphino-2'-(N,N'-dimethylamino)biphenyl (0.172 g, 0.436 mmol) in anhydrous THF (60 mL) was degassed and backfilled with Argon for three times. 1-Methyl-4-(piperidin-4-yl)piperazine (4.00 g, 21.82 mmol) was added and the mixture was degassed and backfilled with Argon for three times again. Finally LiHMDS 1 M in THF (17.46 mL) was added by a syringe and the mixture was heated to reflux for 2 h. After cooling to room temperature the reaction mixture was filtered on a pad of celite washing with THF (300 mL). The filtrate was evaporated under vacuum and the black oil so obtained was purified by flash chromatography on silica gel (DCM/MeOH/NH4OH 90/10/0.2) to afford the title compound as a yellow solid (2.55 g, 82%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.19 (s, 9 H) 1.35 - 1.49 (m, 2 H) 1.81 (m, J=11.72 Hz, 2 H) 2.13 (s, 3 H) 2.20 - 2.55 (m, 9 H) 2.68 - 2.78 (m, 2 H) 3.72 - 3.83 (m, 2 H) 6.87 (d, J=9.03 Hz, 2 H) 7.18 - 7.28 (m, 2 H).
HRMS m/z calcd for [M + H] 356.2517; found 356.2511. - The above procedure using suitable amines was employed to synthesize the following compounds:
- 1'-{-(4-[(Trimethylsilyl)ethynyl]phenyl}-1,4'-bipiperidine
- 4-(Pyrrolidin-1-yl)-1-{4-[(trimethylsilyl)ethynyl]phenyl}piperidine
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.16 - 0.21 (m, 9 H) 1.46 (d, J=10.50 Hz, 2 H) 1.69 (br. s., 4 H) 1.90 (d, J=11.84 Hz, 2 H) 2.11 - 2.30 (m, 1 H) 2.72 - 2.86 (m, 2 H) 3.71 (d, J=12.82 Hz, 2 H) 6.88 (d, J=8.91 Hz, 2 H) 7.25 (d, J=8.91 Hz, 2 H).
HRMS m/z calcd for [M + H] 327.2251; found 327.2259. - N,N-Dimethyl-1-{4-[(trimethylsilyl)ethynyl]phenyl}piperidin-4-amine
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.19 (s, 9 H) 1.41 (qd, J=11.92, 3.78 Hz, 2 H) 1.81 (d, J=12.33 Hz, 2 H) 2.18 (s, 6 H) 2.25 (br. s., 1 H) 2.72 (td, J=12.36, 2.38 Hz, 2 H) 3.78 (d, J=12.82 Hz, 2 H) 3.88 (s, 1 H) 6.85 - 6.92 (m, 2 H) 7.23 - 7.30 (m, 2 H).
HRMS m/z calcd for [M + H] 301.2095; found 301.2093. - 1-{4-[(Trimethylsilyl)ethynyl]phenyl}piperazine
- 1-{4-[(Trimethylsilyl)ethynyl]phenyl}-4-methylpiperazine
- 1-{4-[(Trimethylsilyl)ethynyl]phenyl}piperidin-4-ol
- (2S)-2-(Pyrrolidin-1-ylmethyl)-1-{4-[(trimethylsilyl)ethynyl]phenyl}pyrrolidine
- A solution of 1-methyl-4-(1-{4-[(trimethylsilyl)ethynyl]phenyl}piperidin-4-yl)piperazine (2.55 g, 7.179 mmol) in anhydrous methanol (25 mL) was treated with powdered anhydrous potassium carbonate (99.2 mg, 0.718 mmol) under stirring at room temperature for 3 h. After removing the solvent under vacuum the residue was taken up with DCM (50 mL) and water (5 mL). The phases were separated, the organic phase was washed with a saturated solution of sodium hydrogencarbonate (3 x 10 mL), brine (3x10 mL), water (10 mL), dried over sodium sulfate and the solvent removed under vacuum. The yellowish solid obtained was purified by chromatography on silica gel (DCM/MeOH/TEA 90/10/0.2) to give the title compound as yellow solid (1.534 g, 76 %).
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.43 (qd, J=11.98, 3.97 Hz, 2 H) 1.81 (m, J=12.21 Hz, 2 H) 2.14 (s, 3 H) 2.20-2.55 (m, 9 H) 2.66 - 2.80 (m, 2 H) 3.67 - 3.84 (m, 4 H) 3.88 (s, 1 H) 6.82 - 6.93 (m, 2 H) 7.20 - 7.32 (m, 2 H).
HRMS m/z calcd for [M + H] 284.2121; found 284.2133. - The above procedure was employed to synthesize the following compounds:
- 1'-(4-Ethynylphenyl)-1,4'-bipiperidine
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.25 - 2.04 (m, 10H) 2.50 (m, 5H) 2.73 (t, J=12.21 Hz, 2 H) 3.90 (s, 1H) 3.81 - 3.95 (m, 2 H) 6.91 (d, J=8.54 Hz, 2 H) 7.29 (d, J=8.79 Hz, 2 H).
HRMS m/z calcd for [M + H] 269.2012; found 269.2002. - 1-(4-Ethynylphenyl)-4-(pyrrolidin-1-yl)piperidine
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.38 - 1.51 (m, 2 H) 1.67 (dt, J=6.65, 3.14 Hz, 4 H) 1.88 (dd, J=12.94, 2.93 Hz, 2 H) 2.09 - 2.20 (m, 1 H) 2.73 - 2.84 (m, 2 H) 3.68 (dt, J=13.03, 3.49 Hz, 2 H) 3.88 (s, 1 H) 6.85 - 6.92 (m, 2 H) 7.24 - 7.29 (m, 2 H).
HRMS m/z calcd for [M + H] 255.1856; found 255.1857. - 1-(4-Ethynylphenyl)-N,N-dimethylpiperidin-4-amine
1H NMR (400 MHz, DMSO-d 6) ppm 1.41 (qd, J=11.92, 3.78 Hz, 2 H) 1.81 (d, J=12.33 Hz, 2 H) 2.19 (s, 6 H) 2.25 (br. s., 1 H) 2.72 (td, J=12.36, 2.38 Hz, 2 H) 3.78 (d, J=12.82 Hz, 2 H) 3.88 (s, 1 H) 6.85 - 6.92 (m, 2 H) 7.23 - 7.30 (m, 2 H).
HRMS m/z calcd for [M + H] 229.1699; found 229.1702. - 1-(4-Ethynylphenyl)piperazine
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.77 - 2.90 (m, 4 H) 3.01 - 3.15 (m, 4 H) 3.89 (s, 1 H) 6.88 (d, J=8.91 Hz, 2 H) 7.23 - 7.38 (m, 2 H).
HRMS m/z calcd for [M + H] 187.123; found 187.1225. - 1-(4-Ethynylphenyl)-4-methylpiperazine
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.23 (s, 3 H) 2.35 -2.55 (m, 4 H) 3.15 - 3.23 (m, 4 H) 3.90 (s, 1 H) 6.90 (d, J=9.03 Hz, 2 H) 7.29 (d, J=8.91 Hz, 2 H).
HRMS m/z calcd for [M + H] 201.1386; found 201.1379. - 1-(3-Ethynylphenyl)-4-methylpiperazine
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.26 (bs, 3 H) 3.16 (bs, 4 H) 4.07 (s, 1 H) 6.82 - 6.90 (m, 1 H) 6.97 - 7.02 (m, 2 H) 7.18 - 7.24 (m, 1 H). - 1-(4-Ethynylphenyl)piperidin-4-ol
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.41 (m, J=12.98, 9.35, 9.35, 3.84 Hz, 2 H) 1.78 (dd, J=9.15, 3.91 Hz, 2 H) 2.91 (ddd, J=13.00, 10.01, 3.11 Hz, 2 H) 3.53 - 3.71 (m, 3 H) 3.88 (s, 1 H) 4.65 (br. s., 1 H) 6.84 - 6.92 (m, 2 H) 7.24 - 7.29 (m, 2 H).
HRMS m/z calcd for [M + H] 202.1227; found 202.1227. - (2S)-1-(4-Ethynylphenyl)-2-(pyrrolidin-1-ylmethyl)pyrrolidine
1H NMR (400 MHz, DMSO-d 6) δ ppm 3.01 - 3.12 (m, 1 H) 3.33 - 3.41 (m, 1 H) 3.82 - 3.83 (m, 1 H) 3.82 - 3.88 (m, 1 H) 6.49 - 6.56 (m, 2 H) 7.23 - 7.29 (m, 2 H).
HRMS m/z calcd for [M + H] 255.1856 ; found 255.185. -
- 1-lodo-2-methoxy-4-nitro-benzene (6.01 g, 21.54 mmol) in absolute ethanol (127 mL) was cooled with an ice bath and treated with SnCl2 (18.83 g, 99.31 mmol). The bath was removed and the mixture was stirred at room temperature for 4 h then poured into ice (300 mL), stirred and treated carefully with saturated aqueous sodium bicarbonate (250 mL) (pH 7-8). The solid was filtered with suction and the panel washed thoroughly with EtOAc (500 mL and 4 x 200 mL). The aqueous layer was separated, dried over sodium sulphate and evaporated. Purification of the crude by flash chromatography on silica gel (hexane/EtOAc 1/1) furnished the title compound (3.17 g, 59%).
- 4-lodo-3-methoxy-phenylamine (3.17 g, 12.7 mmol) and ethynyl-trimethyl-silane (3.5 mL, 25 mmol) in dry acetonitrile were purged with nitrogen and treated with TEA (17.6 mL, 127 mmol), CuI (123 mg, 0.635 mmol) and Pd(Ph3P)2Cl2 (447 mg, 0.635 mmol). The reaction was stirred at room temperature for 2 h. The volatiles were evaporated, the residue was taken up with EtOAc (200 mL), washed with water (50 mL), dried over sodium sulfate and purified by flash chromatography on silica gel (hexane/EtOAc 55/45) to afford the title compound (1.86 g, 66%).
- 3-Methoxy-4-trimethylsilanylethynyl-phenylamine (1.86 g, 8.45 mmol) in MeOH (17 mL) was treated with solid K2CO3 (1.17 g, 8.45 mmol). After stirring at room temperature the volatiles were removed by evaporation, the residue was taken up with EtOAc (50 mL), washed with water (50 mL), brine, dried over sodium sulfate and evaporated. The crude was purified by flash chromatography on silica gel (heptane/EtOAc 65/35) to afford 520 mg of title compound (42% yield).
1H NMR (400 MHz, DMSO-d 6) δ ppm 3.67 (s, 3 H) 4.15 (s, 1 H) 5.32 (s, 2 H) 6.11 (dd, J=8.48, 2.50 Hz, 1 H) 6.26 (d, J=2.44 Hz, 1 H) 7.07 (d, J=8.54 Hz, 1 H). - The above procedure was employed to synthesize the following compound:
- 3-Ethynyl-4-methoxy-phenylamine
1H NMR (400 MHz, DMSO-d 6) δ ppm 3.67 (s, 3 H) 4.04 (s, 1 H) 4.77 (br. s., 2 H) 6.58 (dd, J=8.67, 2.81 Hz,1 H) 6.63 (d, J=2.81 Hz, 1 H) 6.75 (d, J=8.67 Hz, 1 H). -
- 3-Ethynyl-4-methoxyaniline (300 mg, 2 mmol) in DCM (20 mL) was treated in a subsequent manner with HOBt (351 mg, 2.6 mmol), isonipecotic acid hydrochloride (467 mg, 2.6 mmol), DIPEA (906 µL, 5.2 mmol) and finally EDCI (498 mg, 2.6 mmol). The reaction was stirred at room temperature for 1.5 h. The organic phase was washed with saturated sodium hydrogen carbonate solution and dried over sodium sulfate. Evaporation of the solvent left a brownish solid which was employed in the following reaction without further purification.
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.65 (m, J=12.05, 12.05, 3.23 Hz, 2 H) 1.74 (m, J=3.30 Hz, 2 H) 1.88 - 2.02 (m, 2 H) 2.14 - 2.29 (m, 4 H) 2.86 (dt, J=11.35, 3.91 Hz, 2 H) 3.77 (s, 3 H) 4.19 (s, 1 H) 6.98 (d, J=9.03 Hz, 1 H) 7.52 (dd, J=9.03, 2.69 Hz, 1 H) 7.68 (d, J=2.56 Hz, 1 H) 9.76 (s, 1 H). -
- 1-Methylpiperazine (0.58 mL, 5.2 mmol), HOBt (0.70 g, 5.2 mmol.) and EDCI (1.0 g, 5.2 mmol) were added to a solution of 4-hydroxy-3-methoxybenzoic acid (0.69 g, 4.0 mmol.) in dry DCM (40 mL). The mixture was stirred at room temperature for 16 h, washed with saturated aqueous sodium bicarbonate (20 mL), brine, dried over sodium sulphate and evaporated to give the title compound (0.96 g, 96%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.19 (s, 3 H) 2.25 - 2.32 (m, 4 H) 3.42 - 3.55 (m, 4 H) 3.77 (s, 3 H) 6.77 - 6.81 (m, 1 H) 6.81 - 6.84 (m, 1 H) 6.91 - 6.94 (m, 1 H) 9.38 (bs, 1 H).
HRMS (ESI) m/z calcd for C13H18N2O3 + H+ 251.1390, found 251.1386. - Pyridine (1.60 mL, 19.2 mmol) was added to a solution of (4-hydroxy-3-methoxyphenyl)(4-methylpiperazin-1-yl)methanone (0.96 g, 3.84 mmol) in dry DCM (38 mL) at 10 °C. Then triflic anhydride (3.2 mL, 19.2 mmol) was added drop wise and the reaction stirred at the same temperature for 7 h. The mixture was diluted with DCM (50 mL) and the organic layer washed with water (30 mL), brine, dried over sodium sulphate, and evaporated. The crude was purified by flash chromatography on silica gel (DCM/MeOH/7N NH3 in MeOH 95/5/0.5) to afford the title compound as brown oil (0.68 g, 46%).
1H NMR (400 MHz, DMSO-d 6) ppm 2.20 (s, 3 H) 2.23 - 2.45 (m, 4 H) 3.52 - 3.74 (m, 4 H) 3.92 (s, 3 H) 7.06 (dd, J=8.30, 1.95 Hz, 1 H) 7.32 (d, J=1.95 Hz, 1 H) 7.47 - 7.51 (m, 1 H).
HRMS (ESI) m/z calcd for C14H17F3N2O5S + H+ 383.0883, found 383.0884. - To a degassed solution of 2-methoxy-4-[(4-methylpiperazin-1-yl)carbonyl]phenyl trifluoromethanesulfonate (0.570 g, 1.49 mmol) in dry acetonitrile (11 mL) ethynyl(trimethyl)silane (0.312 mL, 2.25 mmol), TEA (0.414 mL, 2.98 mmol.), CuI (0.021 g, 0.11 mmol) and Pd(PPh3)2Cl2 (0.082 g, 0.11 mmol) were added. The mixture was stirred at room temperature for 7 h, then diluted with EtOAc (40 mL), washed with water (20 mL), 10% NH4OH (15 mL), brine, dried over sodium sulphate, and evaporated. The crude was purified by flash chromatography on silica gel (DCM/MeOH/7N NH3 in MeOH 90/10/1) to afford the title compound (0.480 g, 98%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.22 (s, 9 H) 2.18 - 2.20 (m, 3 H) 2.25 - 2.40 (m, 4 H) 3.50 - 3.70 (m, 4 H) 3.83 (s, 3 H) 6.89 (dd, J=7.75, 1.40 Hz, 1 H) 7.00 (d, J=1.40 Hz, 1 H) 7.42 (d, J=7.75 Hz, 1 H).
HRMS (ESI) m/z calcd for C18H26N2O2Si + H+ 331.1837, found 331.1835. - 1M TBAF in THF (1.43 mL, 1.05 mmol) was added to a solution of {3-methoxy-4-[(trimethylsilyl)ethynyl]phenyl}(4-methylpiperazin-1-yl)methanone (0.450 g, 1.36 mmol) in dry THF (7 mL) and the mixture was stirred at room temperature for 2 h. The solvent was evaporated and the residue taken up with EtOAc (30 mL), washed with brine, dried over sodium sulfate and evaporated to afford the title compound (0.263 g, 75%).
-
- To a solution of 2-methoxy-phenylamine (11.27 mL, 12.31 g, 0.1 mol) in glacial acetic acid (250 mL) maintained at about 10 °C a solution of bromine (5.65 mL, 17.58 g, 0.11 mol) in glacial acetic acid (7 mL) was added over 2 h. A purple precipitate was formed, that was filtered on a Buchner funnel and rinsed with glacial acetic acid and petroleum ether (3 x 100 mL) to afford a whitish solid mixture of 4-bromo-2-methoxy-phenylamine and 4,5-dibromo-2-methoxy-phenylamine (26.9 g). The mixture was separated by flash chromatography on silica gel (hexane/EtOAc 40/60) and the desired compound was crystallized from tert-butylmethyl ether (18.73 g, 82.9%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 3.83 (s, 3 H) 6.83 (d, J=8.42 Hz, 1 H) 6.98 (dd, J=8.30, 2.08 Hz, 1 H) 7.11 (d, J=1.95 Hz, 1 H).
HRMS m/z calcd for [M + H] 201.9862; found 201.9866. - 4-Bromo-2-methoxy-phenylamine (2.02 g, 10 mmol) was added to a solution of p-toluensulphonic acid monohydrate (3.80 g, 20 mmol) in acetonitrile (30 mL). The mixture was cooled in an ice bath and treated with an solution of sodium nitrite (0.69 g, 10 mmol) and potassium iodide (4,15 g, 25 mmol) in water (7 mL) over 15 min maintaining the internal temperature below 10 °C. After stirring at that temperature for 15 min and then for 0.5 h at room temperature, the reaction mixture was diluted with water and extracted with EtOAc (5 x 50 mL). The combined organic extracts were washed with 2M sodium thiosulfate (10 mL), brine (4 x 20 mL), water (20 mL), anhydrified over sodium sulphate, and evaporated to dryness affording a black oil that was purified by flash chromatography (petroleum ether/tert-butylmethyl ether 5/1) to yield the title compound (1.63 g, 52.2%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 3.85 (s, 3 H) 6.95 (dd, J=8.24, 2.14 Hz, 1 H) 7.19 (d, J=2.08 Hz, 1 H) 7.69 (d, J=8.18 Hz, 1 H). - To a solution of 4-bromo-1-iodo-2-methoxybenzene (1.634 g, 5.221 mmol) in dry acetonitrile (20 mL) Cul (49.7 mg, 0.261 mmol) and Pd(Ph3P)2Cl2 (183.2 mg, 0.261 mmol) were added under Argon atmosphere and the mixture was degassed and backfilled with Argon for three times. TEA (0.728 mL, 5.221 mmol) and (ethynyl)trimethylsilane(1.48 mL, 1.03 g, 10.442 mmol) were added with a syringe and the reaction mixture, that darkened within 10 min, was stirred at room temperature for 1 h. The solvent was removed under vacuum and the residue was taken up with EtOAc (100 mL), washed with brine (3 x 20 mL), water (20 mL), dried over sodium sulphate and evaporated to dryness. The crude was purified by chromatography on silica gel (petroleum ether/diethyl ether 9/1) to yield the title compound as an orange solid (1.426 g, 96.5%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.21 (s, 9 H) 3.83 (s, 3 H) 7.11 (dd, J=8.18, 1.83 Hz, 1 H) 7.26 (d, J=1.83 Hz, 1 H) 7.31 (d, J=8.06 Hz, 1 H). - The above procedure was employed to synthesize the following compounds:
- [(4-Bromo-2-fluorophenyl)ethynyl](trimethyl)silane
- [(5-Bromo-2-methoxyphenyl)ethynyl](trimethyl)silane
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.22 (s, 9 H) 3.81 (s, 3 H) 6.97 - 7.06 (m, 1 H) 7.42 - 7.58 (m, 2 H). - [(5-Bromo-2-fluorophenyl)ethynyl](trimethyl)silane
- A solution of [(4-bromo-2-methoxyphenyl)ethynyl](trimethyl)silane (1.426 g, 5.035 mmol) in dry THF (25 mL) was degassed and backfilled with argon for three times. Pd2(dba)3 (230.5 mg, 0.252 mmol) and 2-dicyclohexylphosphino-2-(N,N'-dimethylamino)biphenyl (79,3 mg, 0.201 mmol) were added under argon atmosphere and the mixture was degassed and backfilled with argon for three times. Then 1 M LiHMDS in THF (12.1 mL, 12.084 mmol) and N-methylpiperazine (1,34 mL, 1.21 g, 12.083 mmol) were added by a syringe and the mixture was degassed and backfilled with Argon for three times. The reaction mixture was heated to reflux for 1 h. After cooling to room temperature the reaction mixture was filtered on a pad of celite washing with THF (200 mL). The filtrate was evaporated under vacuum and the black oil so obtained was purified by chromatography on silica gel (DCM/MeOH 9/1) to afford the title compound as a brownish solid (1.042 g, 68.4%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.18 (s, 9 H) 2.22 (s, 3 H) 2.43 (m, 4 H) 3.18 - 3.24 (m, 4 H) 3.78 (s, 3 H) 6.44 (dd, 1 H) 6.48 (d, J=2.20 Hz, 1 H) 7.15 (d, J=8.54 Hz, 1 H).
HRMS m/z calcd for [M + H] 303.1887; found 303.1892. - The above procedure was employed to synthesize the following compounds:
- 1-{3-Fluoro-4-[(trimethylsilyl)ethynyl]phenyl}-4-methylpiperazine
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.21 (m, 9 H) 2.21 (s, 3 H) 2.37 - 2.43 (m, 2 H) 3.21 - 3.26 (m, 2 H) 6.71 (dd, J=8.79, 2.44 Hz, 1 H) 6.77 (dd, J=13.79, 2.44 Hz, 1 H) 7.27 (t, J=8.73 Hz, 1 H). - 1-{4-Methoxy-3-[(trimethylsilyl)ethynyl]phenyl-4-methylpiperazine
- 1-{4-Fluoro-3-[(trimethylsilyl)ethynyl]phenyl}-4-methylpiperazine
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.23 (s, 9 H) 2.22 (s, 3 H) 2.43 (m, J=5.00 Hz, 4 H) 2.95 - 3.14 (m, 4 H) 6.95 (dd, J=5.86, 3.17 Hz, 1 H) 6.97 - 7.04 (m, 1 H) 7.07 - 7.14 (m, 1 H). - 1-Methyl-4-{4-[(trimethylsilyl)ethynyl]phenyl}piperazine
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.20 (s, 9 H) 2.22 (s, 3 H) 2.39 - 2.47 (m, 4 H) 3.16 - 3.22 (m, 4 H) 6.88 (d, J=8.91 Hz, 2 H) 7.27 (d, J=8.91 Hz, 2 H).
HRMS m/z calcd for [M + H] 273.1782; found 273.1776. - A solution of 1-{3-methoxy-4-[(trimethylsilyl)ethynyl]phenyl-4-methylpiperazine (583 mg, 1.927 mmol) in anhydrous methanol (12 mL) is treated with powdered anhydrous potassium carbonate under stirring at room temperature for 1.5 h. After removing the solvent under vacuum the residue was taken up with EtOAc (80 mL) and water (5 mL). The phases were separated, the organic phase was washed with brine (3x10 mL), water (10 mL), dried over sodium sulfate and the solvent removed under vacuum. The dark oil obtained was purified by chromatography on silica gel (DCM/MeOH/TEA 90/10/0.1) to give the title compound as brownish solid (374 mg, 84.2%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.22 (s, 3 H) 2.39 - 2.46 (m, 4 H) 3.16 - 3.25 (m, 4 H) 3.79 (s, 3 H) 3.92 (s, 1 H) 6.45 (dd, 1H) 6.46 (d, 1 H) 7.18 (d, J=8.42 Hz, 1 H).
HRMS m/z calcd for [M + H] 231.1492; found 231.1496. - The above procedure was employed to synthesize the following compounds:
- 1-(4-Ethynyl-3-fluorophenyl)-4-methylpiperazine
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.20 (s, 3 H) 2.35 - 2.43 (m, 4 H) 3.17 - 3.24 (m, 4 H) 4.16 (s, 1 H) 6.72 (dd, J=8.73, 2.50 Hz, 1 H) 6.78 (dd, J=13.79, 2.44 Hz, 1 H) 7.29 (t, J=8.67 Hz, 1 H).
HRMS m/z calcd for [M + H] 219.1292; found 219.1292. - 4-Bromo-1-ethynyl-2-fluorobenzene
- 1-(3-Ethynyl-4-methoxyphenyl)-4-methylpiperazine
HRMS m/z calcd for [M + H] 231.1492; found 231.1501. - 4-Bromo-2-ethynyl-1-methoxybenzene
1H NMR (400 MHz, DMSO-d 6) δ ppm 3.82 (s, 3 H) 4.35 (s, 1 H) 6.72 - 7.11 (m, 1 H) 7.51 - 7.58 (m, 2 H). - 4-Bromo-1-ethynyl-2-methoxybenzene
- 4-Bromo-2-ethynyl-1-fluorobenzene
- 1-(3-Ethynyl-4-fluorophenyl)-4-methylpiperazine
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.21 (s, 3 H) 2.40 - 2.46 (m, 4 H) 3.03 - 3.11 (m, 4 H) 4.39 (s, 1 H) 6.96 - 7.05 (m, 2 H) 7.09 - 7.16 (m, 1 H). -
- To 2-iodo-1-methoxy-4-nitrobenzene (485 mg, 1.74 mmol) suspended in methanol (6 mL) a solution of NH4Cl (465 mg, 8.69 mmol) in water (4.9 mL) and powdered Fe (290 mg, 5.192 mmol) were added and the mixture was heated to reflux for 3 h. The precipitate formed was filtered off and the filtrate was evaporated until the methanol was eliminated. After diluting with water and alkalinization with sodium carbonate the mixture was extracted with EtOAc (4 x 20 mL). The combined organic extracts were washed with brine (3 x 10 mL), water (10 mL), dried over sodium sulfate and the solvent was removed under vacuum. The crude dark oil was purified by flash chromatography on silica gel (hexane/EtOAc 1/1) to afford 400 mg of solid that was crystallized from n-pentane and diethyl ether to yield the title compound (363 mg, 83%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 3.66 (s, 3 H) 4.79 (s, 2 H) 6.56 (dd, J=8.61, 2.62 Hz, 1 H) 6.73 (d, J=8.67 Hz, 1 H) 7.02 (d, J=2.69 Hz, 1 H) - To a solution of 3-iodo-4-methoxyaniline (180 mg, 0723 mmol) in DCM (5 mL) 1-methyl-4-piperidone (0.116 mL, 106 mg, 0.940 mmol), TFA (0.290 mL, 429 mg, 3.760 mmol) and tetramethylammonium triacetoxyborohydride (285 mg, 1.084 mmol) were added in sequence. The reaction is completed in 30 min. The reaction mixture was diluted with DCM, washed with saturated solution of sodium hydrogen carbonate (3 x 5 mL), brine (3 x 5 mL), dried over sodium sulfate and the solvent was removed under vacuum. The solid crude so obtained was purified by flash chromatography (EtOAc/TEA 99/1) to afford a beige solid that was crystallized from diethylether to afford the title compound as a whitish solid (197 mg, 79%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.32 (qd, J=11.50, 3.60 Hz, 2 H) 1.82 (d, J=11.96 Hz, 2 H) 1.99 (t, J=11.17 Hz, 2 H) 2.15 (s, 3 H) 2.70 (d, J=11.96 Hz, 2 H) 2.99 - 3.13 (m, 1 H) 3.67 (s, 3 H) 5.14 (d, J=8.54 Hz, 1 H) 6.57 (dd, J=8.79, 2.69 Hz, 1 H) 6.77 (d, J=8.79 Hz, 1 H) 7.01 (d, J=2.81 Hz, 1 H).
HRMS m/z calcd for [M + H] 347.0615; found 347.0627. - The above procedure was employed to synthesize the following compound:
- N-(4-Iodo-3-methoxyphenyl)-1-methylpiperidin-4-amine
- Into a flask maintained under argon atmosphere N-(3-iodo-4-methoxyphenyl)-1-methylpiperidin-4-amine (180 mg, 0.52 mmol), CuI (9.9 mg, 0.052 mmol) and Pd(Ph3P)Cl2 (36.5 mg, 0.052 mmol) were added and dissolved in acetonitrile (5 mL) and dioxane (5 mL). The solution was degassed and backfilled with argon for three times. TEA (0.725 mL, 526 mg, 5.2 mmol) and (ethynyl)trimethylsilane (0.147 mL, 0.102 mg, 1.04 mmol) were added with a syringe and the solution was stirred at room temperature for 75 min. The volatiles were evaporated and the residue was taken up with EtOAc (30 mL), washed with water (3 x 5 mL), dried over sodium sulfate and the solvent was removed under vacuum.
- The black oil obtained was purified by flash chromatography on silica gel (EtOAc/MeOH/33% NH4OH) to afford the title compound as brown solid (155 mg, 94%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.20 (s, 9 H) 1.51 (bs, 2 H) 1.99 (d, J=11.35 Hz, 2 H) 2.64 (bs, 3 H) 2.88 (bs, 2 H) 3.69 (s, 3 H) 5.24 (d, J=7.57 Hz, 1 H) 6.57 - 6.67 (m, 2 H) 6.82 (d, J=9.76 Hz, 1 H) 9.25 (bs, 1 H).
HRMS m/z calcd for [M + H] 317.2044; found 317.2053. - The above procedure was employed to synthesize the following compound:
- N-{3-Methoxy-4-[(trimethylsilyl)ethynyl]phenyl}-1-methylpiperidin-4-amine
- To a solution of N-{4-methoxy-3-[(trimethylsilyl)ethynyl]phenyl)-1-methylpiperidin-4-amine (128 mg, 0.404 mmol) in methanol (2 mL) powdered anhydrous potassium carbonate (56 mg, 0.404 mmol) was added and the mixture was stirred at room temperature for 1 h. The solvent was removed under vacuum and the residue was taken up with EtOAc (30 mL). The solution obtained was washed with brine, (3 x 5 mL), water (5 m), dried over sodium sulfate and the solvent was removed under vacuum. The dark brown oil was purified by flash chromatography (EtOAc/MeOH/33%NH4OH 90/10/0.1) to yield the title compound as a yellow solid (85 mg, 86%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.27 - 1.42 (m, 2 H) 1.83 (m, J=2.93 Hz, 2 H) 1.94 - 2.09 (m, 2 H) 2.17 (s, 3 H) 2.67 - 2.79 (m, 2 H) 3.08 (m, J=2.81 Hz, 1 H) 3.68 (s, 3 H) 4.06 (s, 1 H) 5.08 (d, J=8.30 Hz, 1 H) 6.54 - 6.67 (m, 2 H) 6.73 - 6.85 (m, 1 H).
HRMS m/z calcd for [M + H] 245.1649; found 245.1652. - The above procedure was employed to synthesize the following compound:
- N-(4-Ethynyl-3-methoxyphenyl)-1-methylpiperidin-4-amine
-
- A solution of 1-methylpiperidin-4-ol (1.15 g, 10.0 mmol) in dry THF (5 mL) was added drop wise to a suspension of NaH (60% dispersion in mineral oil, 0.400 g, 10.0 mmol) in dry THF (5 mL) at 0 °C. The reaction was kept at the same temperature for 15 min then stirred at room temperature for 1 h. 3-Bromoprop-1-yne (0.75 mL, 10.0 mmol), was slowly added and the mixture was stirred at room temperature for 16 h. After solvent removal, the residue was taken up with DCM (50 mL), washed with water (50 mL), dried over sodium sulfate and purified by flash chromatography on silica gel (DCM/MeOH/TEA 90/10/0.1) to afford the title compound (0.140 g, 9%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.35 - 1.50 (m, 2 H) 1.75 - 1.85 (m, 2 H) 1.95 - 2.05 (m, 2 H) 2.13 (s, 3 H) 2.54 - 2.62 (m, 2 H) 3.35 (t, J=2.44 Hz, 1 H) 3.39 - 3.47 (m, 1 H) 4.13 (d, J=2.44 Hz, 2 H).
HRMS (ESI) m/z calcd for C9H15NO + H+ 154.1227, found 154.1230. -
- A solution of 3-bromoprop-1-yne (1.70 mL, 22.5 mmol in acetone (7 mL) was added to a suspension of 1-methylpiperazine (3.77 mL, 33.7 mmol) and K2CO3 (4.66 g, 33.7 mmol) in acetone (40 mL) at 0 °C. The mixture was stirred at room temperature for 4 h and then filtered. The filtrate was evaporated to dryness and the residue was taken up with water (80 mL) and extracted with DCM (2 x 20 mL). The separated organic phase was washed with brine (3 x 5 mL), dried over sodium sulfate and evaporated to afford the title compound as brown oil (1.60 g, 51%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 2.24 - 2.37 (m, 4 H) 2.38 - 2.48 (m, 4 H) 3.11 (t, J=2.44 Hz, 1 H) 3.23 (d, J=2.44 Hz, 2 H).
HRMS (ESI) m/z calcd for C8H14N2 + H+ 139.1230, found 139.1227. -
- To a mixture of 2-(5-chloro-2-methyl-phenyl)-1H-pyrrole-3-carbonitrile (1.80 g, 8.28 mmol) in DCM (40 mL) was added acetyl chloride (0.936 mL, 13.14 mmol) at room temperature, under nitrogen. The resultant mixture was cooled to 0 °C and anhydrous aluminum trichloride (2.62 g, 19.8 mmol) was added in small portions during a period of 10 min, keeping the internal temperature below 5 °C. Upon complete addition, the mixture was brought to room temperature and allowed to stir for 30 min. Then, the mixture was slowly poured in a solution of ice-cooled 1 M HCl (18 mL). The aqueous layer was separated and extracted twice with DCM (40 mL). The combined organic extracts were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The crude material was chromatographed on silica gel (10 to 20% EtOAc /hexane) to afford the title compound (2.0 g, 86%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.24 (s, 3 H) 2.43 (s, 3 H) 7.38 - 7.42 (m, 1 H) 7.43 (d, J=2.32 Hz, 1 H) 7.46 - 7.50 (m, 1 H) 7.60 (s, 1 H) 12.89 (bs, 1 H).
HRMS (ESI) calcd for C14H11ClN2O + H+ 259.0633, found 259.0638. - To a suspension of 5-acetyl-2-(5-chloro-2-methyl-phenyl)-1H-pyrrole-3-carbonitrile (1.98 g, 7.66 mmol) in DMF (10 mL) was added N,N-dimethylformamide diisopropyl acetal (4.8 mL, 23.0 mmol). The mixture was allowed to stir overnight at 90 °C. The mixture was evaporated in vacuo and used in the next step without further purification.
- To a suspension of the crude 2-(5-chloro-2-methyl-phenyl)-5-(E)-3-dimethylamino-acryloyl)-1H-pyrrole-3-carbonitrile coming from the previous step in DMF (10 mL) was added methylguanidine hydrochloride (920 mg, 8.4 mmol) and K2CO3 (1.27 g, 9.16 mmol). The mixture was heated to 110 °C overnight under efficient stirring. The resultant mixture was concentrated and chromatographed on silica gel (10 to 30% EtOAc/hexane) to afford the title compound (1.19 g, 48%, 2 steps).
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.28 (s, 3 H) 2.88 (d, J=4.52 Hz, 3 H) 6.83 - 6.95 (m, 1 H) 6.95 - 7.03 (m, 1 H) 7.36 - 7.41 (m, 1 H) 7.41 - 7.46 (m, 1 H) 7.46 - 7.53 (m, 3 H) 8.27 (d, J=4.64 Hz, 1 H) 12.53 (bs, 1 H).
HRMS (ESI) calcd for C17H14ClN5 + H+ 324.1011, found 324.1013. - According to this step, but using guanidine carbonate, the following compound was prepared:
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carbonitrile
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.28 (s, 3 H) 7.05 (bs, 1 H) 7.14 (d, J=5.74 Hz, 1 H) 7.41 - 7.46 (m, 1 H) 7.46 - 7.54 (m, 3 H) 8.30 (d, J=5.74 Hz, 1 H) 12.79 (bs, 1 H).
HRMS (ESI) calcd for C16H12ClN5 + H+ 310.0854, found 310.0853. - According to this step, but using formamidine acetate, the following compound was prepared:
- 2-(5-Chloro-2-methyl-phenyl)-5-(pyrimidin-4-yl)-1H-pyrrole-3-carbonitrile
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.30 (s, 3 H) 7.40 - 7.45 (m, 1 H) 7.46 - 7.53 (m, 2 H) 7.61 (s, 1 H) 7.90 (dd, J=5.43, 1.28 Hz, 1 H) 8.79 (d, J=5.37 Hz, 1 H) 9.13 (d, J=1.22 Hz, 1 H) 12.98 (bs, 1 H).
HRMS (ESI) calcd for C17H14N5O + H+ 295.0745, found 295.0750. - According to this step, but using acetamidine acetate, the following compound was prepared:
- 2-(5-Chloro-2-methylphenyl)-5-(2-methylpyrimidin-4-yl)-1H-pyrrole-3-carbonitrile
1H NMR (600 MHz, DMSO-d 6) δ ppm 2.28 (s, 3 H), 2.61 - 2.64 (m, 3 H), 7.39 - 7.45 (m, 1 H), 7.46 - 7.52 (m, 2 H), 7.55 (s, 1 H), 7.68 (d, J=5.31 Hz, 1 H), 8.67 (d, J=5.31 Hz, 1 H), 12.84 (bs, 1 H).
ESI (+) MS: m/z 309 (MH+). - To a solution of 2-(5-chloro-2-methyl-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-pyrrole-3-carbonitrile (1.15 g, 3.55 mmol) in TFA (15.0 mL) were sequentially added water (2.25 mL) and 98% sulfuric acid (4.5 mL) under efficient stirring. The mixture was allowed to stir for 8 h at 70 °C and then was diluted by drop wise addition of water (45 mL). The reaction mixture was made basic (pH 10-12) by adding 30% aqueous ammonia (15 mL) under stirring. The precipitated solid was collected by filtration, washed with water and finally dried in a vacuum oven at 50 °C affording the title compound as an off-white solid (1.07 g, 88%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.12 (s, 3 H) 2.88 (d, J=4.15 Hz, 3 H) 6.67 - 6.83 (m, 1 H) 6.88 (d, J=5.13 Hz, 1 H) 7.19 (bs, 1 H) 7.26 - 7.32 (m, 2 H) 7.34 - 7.38 (m, 1 H) 7.39 (s, 1 H) 8.20 (d, J=5.37 Hz, 1 H) 11.87 (bs, 1 H). HRMS (ESI) calcd for C17H16ClN5O + H+ 342.1116, found 342.1118. - The above procedure was employed to synthesize the following compounds:
- 2-(5-Chloro-2-methyl-phenyl)-5-(pyrimidin-4-yl)-1H-pyrrole-3-carboxamide
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.13 (s, 3 H) 6.81 (bs, 1 H) 7.19 - 7.33 (m, 3 H) 7.33 - 7.40 (m, 1 H) 7.57 (d, J=2.69 Hz, 1 H) 7.74 (dd, J=5.43, 1.40 Hz, 1 H) 8.70 (d, J=5.49 Hz, 1 H) 9.04 (d, J=1.10 Hz, 1 H) 12.22 (bs, 1 H). HRMS (ESI) calcd for C16H13N4O + H+ 313.0851, found 313.0853. - 2-(5-Chloro-2-methylphenyl)-5-(2-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.12 (s, 3 H) 2.59 (s, 3 H) 6.80 (bs, 1 H) 7.24 - 7.31 (m, 2 H) 7.33 (bs, 1 H) 7.34 - 7.38 (m, 1 H) 7.50 - 7.58 (m, 2H) 8.59 (d, J=5.34 Hz, 1H) 12.13 (bs, 1H).
HRMS (ESI) calcd for C16H13N4O + H+ 327.1007, found 327.1011. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.12 (s, 3H), 6.35 (bs, 2H), 6.73 (bs, 1H), 6.93 (d, J=5.24 Hz, 1H), 7.22 (bs, 1H), 7.25-7.30 (m, 2H), 7.32-7.36 (m, 2H), 8.20 (d, J=5.24 Hz, 1H), 11.85 (bs, 1H).
HRMS (ESI) m/z calcd for C16H14ClN5O + H+ 328.0960, found 328.0959. -
- To a solution of ethyl 5-(2-aminopyrimidin-4-yl)-2-bromo-1H-pyrrole-3-carboxylate (prepared according to
WO2007/110344 , 2.0 g, 6.43 mmol) dissolved in EtOH (20 mL) and toluene (20 mL), LiCl (408 mg, 9.64 mmol), 1 M aq Na2CO3 (17 mmol), 5-chloro-2-methylphenylboronic acid (1.423 g, 8.35 mmol) and Pd(Ph3P)2Cl2 (470 mg, 0.67 mmol) were added and the reaction mixture was heated at 100 °C for 5 h. After cooling to room temperature, the precipitate was filtered and the filtrate was evaporated under reduced pressure, dissolved in DCM and washed with water. The organic layer was then dried over sodium sulfate and concentrated. The crude material was chromatographed on silica gel (DCM/EtOAc 50/50) to afford the title compound (1.99 g, 87%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.09 (t, J=7.14 Hz, 3 H) 2.11 (s, 3 H) 4.04 (q, J=7.12 Hz, 2 H) 6.41 (s, 2 H) 7.01 (d, J=5.25 Hz, 1 H) 7.25 - 7.36 (m, 3 H) 7.37 - 7.43 (m, 1 H) 8.21 (d, J=5.13 Hz, 1 H) 12.17 (bs, 1 H). - According to the above procedure, but starting from the suitable aryl boronic acid, the following compounds were prepared:
- Ethyl 5-(2-aminopyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate (IV)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.04 (t, J=7.14 Hz, 3 H) 2.21 (s, 3 H) 4.02 (q, J=7.04 Hz, 2 H) 6.41 (s, 2 H) 7.01 (d, J=5.25 Hz, 1 H) 7.32 (d, J=2.44 Hz, 1 H) 7.54 (d, J=8.06 Hz, 1 H) 7.59 (d, J=1.46 Hz, 1 H) 7.70 (dd, J=8.06, 1.46 Hz, 1 H) 8.21 (d, J=5.25 Hz, 1 H) 12.24 (bs, 1 H). - Ethyl 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxylate (IV)
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.97 (t, J=7.57 Hz, 3 H) 1.06 (t, J=7.08 Hz, 3 H) 2.44 (q, J=7.57 Hz, 2 H) 4.03 (q, J=7.08 Hz, 2 H) 7.21 (d, J=6.10 Hz, 1 H) 7.32 (d, J=2.32 Hz, 1 H) 7.38 (d, J=8.42 Hz, 1 H) 7.47 (dd, J=8.30, 2.32 Hz, 1 H) 7.50 (d, J=2.56 Hz, 1 H) 8.25 (d, J=5.98 Hz, 1 H) 12.52 (bs, 1 H). - Ethyl 5-(2-aminopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate (IV)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.01 (t, J=7.15 Hz, 6 H) 2.54 (q, J=7.60 Hz, 2 H) 4.00 (q, J=7.08 Hz, 2 H) 6.41 (bs, 2 H) 7.01 (d, J=5.25 Hz, 1 H) 7.31 (d, J=2.56 Hz, 1 H) 7.56 (d, J=1.60 Hz, 1 H) 7.58 (d, J=8.20 Hz, 1 H) 7.74 (dd, J=8.12, 1.53 Hz, 1 H) 8.21 (d, J=5.13 Hz, 1 H) 12.27 (bs, 1 H). - Ethyl 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxylate (1.0 g, 2.80 mmol) was treated with a 1.5 M solution of potassium hydroxide in 95% EtOH (32.4 mL, 20 eq) under reflux for 20 h. After cooling, the residue was concentrated, dissolved in water and washed with DCM. To the aqueous phase cooled to 5 °C, a solution of 2 N HCl was added, under agitation. The resultant precipitate was collected by filtration to give the title compound (0.92 g, 95%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.12 (s, 3 H) 7.28 - 7.37 (m, 3 H) 7.40 - 7.45 (m, 1 H) 7.59 (d, J=2.56 Hz, 1 H) 7.77 (bs, 1 H) 8.28 (d, J=6.44 Hz, 1 H) 12.06 (s, 1 H) 12.54 (bs, 1 H). - 5-(2-Amino-pyrimidin-4-yl)-2-(5-chloro-2-methyl-phenyl)-1H-pyrrole-3-carboxylic acid (0.70 g, 2.13 mmol) and Iodine (1.134 g, 4.47 mmol) in dry DMF (5 mL), under a nitrogen atmosphere, were stirred at -40 °C (internal temperature) and treated drop wise with silver trifluoroacetate (0.987 g, 4.47 mmol) in DMF (5 mL). The mixture was stirred at -40 °C for 7 h and then filtered over a short plug of celite. The panel was washed with DMF (5 mL) and the filtrate was collected in a flask containing 10% Na2S2O3 (50 mL). Precipitation of a pale yellow solid occurred. Dilution with water (50 mL) and filtration of the solid afforded 0.79 g of crude product, which was reacted in the next step with no further purification.
- According to the above procedure the following compound was prepared:
- 5-(2-Amino-5-iodo-pyrimidin-4-yl)-2-phenyl-1H-pyrrole-3-carboxylic acid (VI)
- Crude 5-(2-amino-5-iodo-pyrimidin-4-yl)-2-(5-chloro-2-methyl-phenyl)-1H-pyrrole-3-carboxylic acid (691 mg, 1.52 mmol) in DMF (5 mL) and DIPEA (1.06 mL, 6.08 mmol) was stirred at 0° C. EDCI (582 mg, 3.04 mmol) and HOBT.NH3 (469 mg, 3.04 mmol) were added and the reaction mixture was stirred for 2 h at room temperature. The reaction mixture was poured into saturated solution of sodium hydrogen carbonate. The solid was filtered with suction and the panel washed thoroughly with water and dried under vacuum in an oven at 50 °C. The crude compound may be purified by flash chromatography (DCM/MeOH 95/5) to give the title compound (518 mg, 75%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.13 (s, 3 H) 6.53 (bs, 2 H) 6.78 (bs, 1 H) 7.11 (bs, 1 H) 7.28 (d, J=2.32 Hz, 1 H) 7.29 (d, J=8.30 Hz, 1 H) 7.36 (dd, J=8.30, 2.32 Hz, 1 H) 7.77 (d, J=2.69 Hz, 1 H) 8.50 (s, 1 H) 11.53 (bs, 1 H). - According to this step, but starting from 5-(2-amino-5-iodo-pyrimidin-4-yl)-2-phenyl-1H-pyrrole-3-carboxylic acid, the following compound was prepared:
- 5-(2-Amino-5-iodo-pyrimidin-4-yl)-2-phenyl-1H-pyrrole-3-carboxamide (VIII)
1H NMR (400 MHz, DMSO-d 6) δ ppm 6.63 (bs, 2 H), 6.90 (bs, 1 H), 7.28 (bs, 1 H), 7.33 - 7.39 (m, 1 H), 7.39 - 7.45 (m, 2 H), 7.64 - 7.69 (m, 3 H), 8.50 - 8.52 (m, 1 H), 11.27 (bs, 1 H). - According to the above procedure, but starting from ethyl 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxylate, the following compound was prepared:
- 5-(2-Amino-5-iodo-pyrimidin-4-yl)-2-(5-chloro-2-ethyl-phenyl)-1H-pyrrole-3-carboxamide (VIII)
ESI (+) MS: m/z 468 (MH+). - According to the above procedure, but starting from ethyl 5-(2-aminopyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate, the following compound was prepared:
- 5-(2-Amino-5-iodo-pyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide (VIII)
ESI (+) MS: m/z 488 (MH+). - According to the above procedure, but starting from ethyl 5-(2-aminopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate, the following compound was prepared:
- 5-(2-Amino-5-iodo-pyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide (VIII)
ESI (+) MS: m/z 502 (MH+). - According to the above procedure, but employing the suitable amine, the following compound was prepared:
- 5-(2-Amino-5-iodopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-N-methyl-1H-pyrrole-3-carboxamide (VIII)
HRMS (ESI) calcd for C17H15ClIN5O + H+ 468.7012, found 468.7018. - According to the above procedure, but starting from ethyl 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxylate and employing the suitable amine, the following compound was prepared:
- 5-(2-Amino-5-iodo-pyrimidin-4-yl)-2-(5-chloro-2-ethyl-phenyl)-N-methyl-1H-pyrrole-3-carboxamide (VIII)
ESI (+) MS: m/z 482 (MH+). - According to the above procedure, but starting from ethyl 5-(2-aminopyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate and employing the suitable amine, the following compound was prepared:
- 5-(2-Amino-5-iodo-pyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-N-methyl-1H-pyrrole-3-carboxamide (VIII)
ESI (+) MS: m/z 502 (MH+). - According to the above procedure, but starting from ethyl 5-(2-aminopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate and employing the suitable amine, the following compound was prepared:
- 5-(2-Amino-5-iodo-pyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-N-methyl-1H-pyrrole-3-carboxamide (VIII)
ESI (+) MS: m/z 516 (MH+). - 5-(2-Amino-5-iodo-pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (100 mg, 0.22 mmol, 1 eq) in dry ACN (4 mL) was treated with the alkyne (0.44 mmol, 2 eq) and TEA (0.31 mL, 2.2 mmol, 10 eq). The flask was stirred and purged with nitrogen and then solid CuI (0.011 mmol, 0.05 eq) and Pd(Ph3P)2Cl2 (0.011 mmol, 0.05 eq) were added. The reaction was then either refluxed or heated under microwave irradiation at 80 °C until full conversion of the starting material was observed (typically from 1 to several h were required). If precipitation of the product occurred upon cooling, the solid was filtered, washed in sequence with ACN (3 x 1 mL), H2O/MeOH 9/1 (2 x 1 mL) and finally dried under vacuum at 50 °C. Conversely, the reaction was diluted with DCM (20 mL), washed with water (5 mL), dried over sodium sulfate and evaporated. The residue was then purified by flash chromatography, typically, DCM/MeOH 95/5 under gradient conditions or reverse phase purification (Phase A: 0.05 NH4OH/ACN 95/5; Phase B : ACN/H2O 95/5 Gradient: 10-70 in 10 CV).
- The above procedure was employed to synthesize the following compounds:
- 5-[2-Amino-5-(phenylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = phenylethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 1)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 6.79 (bs, 3 H) 6.99 (bs, 1 H) 7.30 (d, J=8.30 Hz, 1H) 7.31 (d, J=2.44 Hz, 1 H) 7.37 (dd, J=8.30, 2.32 Hz, 1 H) 7.83 (d, J=2.69 Hz, 1 H) 8.45 (s, 1 H) 11.66 (bs, 1 H).
HRMS (ESI) calcd for C24H18ClN5O + H+ 428.1273, found 428.1278. - 5-{2-Amino-5-[(3-hydroxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = (3-hydroxyphenyl)ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 2)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 6.78 (bs, 1 H) 6.81 (ddd, J=8.21, 2.47, 0.92 Hz, 1H) 6.85 (bs, 1 H) 6.93 (bs, 1 H) 6.94 (dd, J=2.14, 1.65 Hz, 1 H) 7.04 (dt, J=7.69, 1.10 Hz, 1 H) 7.18 - 7.25 (m, 1 H) 7.31 (d, J=2.30 Hz, 1 H) 7.30 (d, J=8.10 Hz, 1 H) 7.36 (dd, J=8.06, 2.20 Hz, 1 H) 7.79 (d, J=2.56 Hz,1 H) 8.44 (s, 1 H) 9.66 (s, 1 H) 11.64 (bs, 1 H).
HRMS (ESI) calcd for C24H18ClN5O2 + H+ 444.1222, found 444.1220. - 5-{2-Amino-5-[(4-methoxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = (4-methoxyphenyl)ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 3)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 3.80 (s, 3 H) 6.99 (d, J=8.91 Hz, 2 H) 7.31 (d, J=2.30 Hz, 1 H) 7.30 (d, J=8.10 Hz, 1 H) 7.37 (dd, J=8.10, 2.30 Hz, 1 H) 7.55 (d, J=8.91 Hz, 2 H) 7.81 (d, J=2.56 Hz, 1 H) 8.42 (s, 1 H) 11.63 (d, J=1.46 Hz, 1 H).
HRMS (ESI) calcd for C25H20ClN5O2 + H+ 458.1379, found 458.1371. - 5-{2-amino-5-[(3-aminophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = (3-aminophenyl)ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 4)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 5.18 (bs, 2 H) 6.60 (ddd, J=8.12, 2.26, 0.98 Hz, 1 H) 6.73 -6.79 (m, 2 H) 6.78 - 6.94 (bs, 3 H) 7.05 (t, J=7.75 Hz, 1 H) 7.30 (d, J=8.10 Hz, 1 H) 7.32 (d, J=2.20 Hz, 1 H) 7.37 (dd, J=8.10, 2.30 Hz, 1 H) 7.79 (d, J=2.69 Hz, 1 H) 8.40 (s, 1 H) 11.63 (bs, 1 H).
HRMS (ESI) calcd for C24H19ClN6O + H+ 443.1382, found 443.1384. - 5-{2-Amino-5-[(2-methoxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = (2-methoxyphenyl)ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 5)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 3.82 (s, 3 H) 6.75 (bs, 2 H) 6.82 (bs, 2 H) 6.99 (td, J=7.48, 0.92 Hz, 1 H) 7.09 (dd, J=8.48, 0.67 Hz, 1 H) 7.30 (d, J=8.20 Hz, 1 H) 7.32 (d, J=2.20 Hz, 1 H) 7.37 (dd, J=8.20, 2.20 Hz, 2 H) 7.38 (ddd, J=8.42, 7.32, 1.71 Hz, 2 H) 7.53 (dd, J=7.57, 1.59 Hz, 1 H) 7.95 (d, J=2.69 Hz, 1 H) 8.41 (s, 1 H) 11.55 (bs, 1 H).
HRMS (ESI) calcd for C25H20ClN5O2 + H+ 458.1379, found 458.1375. - 5-{2-Amino-5-[(2-aminophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = (2-aminophenyl)ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 6)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 5.47 (s, 2 H) 6.55 (td, J=7.45, 0.98 Hz, 1 H) 6.74 (dd, J=8.24, 0.67 Hz, 1 H) 7.07 (ddd, J=8.24, 7.14, 1.59 Hz, 1 H) 7.29 (d, J=8.20 Hz, 1 H) 7.31 (d, J=2.20 Hz, 1 H) 7.32 (dd, J=7.60, 1.40 Hz, 1 H) 7.36 (dd, J=8.20, 2.20 Hz, 1 H) 7.84 (d, J=2.56 Hz, 1 H) 8.57 (s, 1 H) 11.62 (s, 1 H).
HRMS (ESI) calcd for C24H19ClN6O + H+ 443.1382, found 443.1376. - 5-{2-Amino-5-[(2,4-difluorophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = (2,4-difluorophenyl)ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 7)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.13 (s, 3 H) 6.79 (bs, 2 H) 6.83 (bs, 1 H) 6.95 (bs, 1 H) 7.19 (m, J=8.54, 8.54, 2.56, 0.85 Hz,1 H) 7.28 (d, J=8.20 Hz, 1 H) 7.29 (d, J=2.20 Hz, 1 H) 7.36 (dd, J=8.20, 2.20 Hz, 1 H) 7.42 (td, J=9.64, 2.69 Hz, 1 H) 7.75 (td, J=8.54, 6.59 Hz, 1 H) 7.80 (d, J=2.56 Hz, 1 H) 8.45 (s, 1 H) 11.65 (bs, 1 H).
HRMS (ESI) calcd for C24H16ClF2N5O + H+ 464.1084, found 464.1081. - 5-{2-Amino-5-[(4-aminophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = (4-aminophenyl)ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 8)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 5.53 (bs, 2 H) 6.57 (d, J=8.67 Hz, 2 H) 6.63 (bs, 2 H) 6.79 (bs, 1 H) 6.90 (bs, 1 H) 7.26 (d, J=8.67 Hz, 2 H) 7.30 (d, J=8.20 Hz, 1 H) 7.32 (d, J=2.32 Hz, 1 H) 7.36 (dd, J=8.20, 2.20 Hz, 1 H) 7.80 (d, J=2.56 Hz, 1 H) 8.36 (s, 1 H) 11.57 (bs, 1 H).
HRMS (ESI) calcd for C24H19ClN6O + H+ 443.1382, found 443.1378. - 5-{2-Amino-5-[(5-amino-2-methoxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = (5-amino-2-methoxyphenyl)ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 9)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 3.67 (s, 3 H) 4.76 (bs, 2 H) 6.61 (dd, J=8.67, 2.81 Hz,1 H) 6.73 (bs, 3 H) 6.76 (d, J=2.81 Hz, 1 H) 6.80 (d, J=8.79 Hz, 1 H) 6.85 (bs, 1 H) 7.29 (d, J=8.42 Hz, 1 H) 7.32 (d, J=2.20 Hz, 1 H) 7.36 (dd, J=8.18, 2.32 Hz, 1 H) 7.95 (d, J=2.56 Hz, 1 H) 8.38 (s, 1 H) 11.52 (bs, 1 H).
HRMS (ESI) calcd for C25H21ClN6O2 + H+ 473.1488, found 473.1483. - 5-{2-Amino-5-[(4-amino-2-methoxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = (4-amino-2-methoxyphenyl)ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 10)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 3.70 (s, 3 H) 5.49 (bs, 2 H) 6.17 (dd, J=8.61, 2.50 Hz, 1 H) 6.32 (d, J=2.44 Hz, 1 H) 6.65 (bs, 2 H) 6.80 (bs, 1 H) 6.88 (bs, 1 H) 7.25 (d, J=8.54 Hz, 1 H) 7.29 (d, J=8.69 Hz, 1 H) 7.31 (d, J=2.32 Hz, 1 H) 7.36 (dd, J=8.06, 2.32 Hz, 1 H) 7.82 (d, J=2.69 Hz, 1 H) 8.53 (s, 1 H) 11.59 (bs, 1 H).
HRMS (ESI) calcd for C25H21ClN6O2 + H+ 473.1488, found 473.1481. - 5-(2-Amino-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = [4-(4-methylpiperazin-1-yl)phenyl]ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 11)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 2.22 (s, 3 H) 2.42 - 2.47 (m, 4 H) 3.19 - 3.25 (m, 4 H) 6.68 (bs, 2 H) 6.78 (bs, 1 H) 6.91 - 6.99 (m, 3 H) 7.26 - 7.35 (m, 2 H) 7.35 - 7.38 (m, 1 H) 7.40 - 7.48 (m, 2 H) 7.81 (d, J=2.56 Hz, 1 H) 8.40 (s, 1 H) 11.60 (s, 1 H).
HRMS (ESI) calcd for C29H28ClN7O + H+ 526.2117, found 526.2121. - 5-[2-Amino-5-({3-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {3-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 12)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.30 - 1.45 (m, 2 H) 1.86 (bs, 2 H) 1.96 - 2.06 (m, 2 H) 2.11 - 2.17 (m, 6 H) 2.64 - 2.76 (m, 2 H) 3.14 - 3.23 (m, 1 H) 5.56 (d, J=8.06 Hz, 1 H) 6.58 - 6.64 (m, 2 H) 6.72 - 6.76 (m, 2 H) 7.08 (t, J=8.06 Hz, 1 H) 7.27 - 7.33 (m, 2 H) 7.34 - 7.39 (m, 1 H) 7.79 (d, J=2.44 Hz, 1 H) 8.42 (s, 1 H) 11.62 (bs, 1 H). HRMS (ESI) calcd for C30H30ClN7O + H+ 540.2273, found 540.2279. - 5-(2-Amino-5-{[3-(tetrahydro-2H-pyran-4-ylamino)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = [3-(tetrahydro-2H-pyran-4-ylamino)phenyl]ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 13)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.29 - 1.44 (m, 2 H) 1.85 -1.92 (m, 2 H) 2.15 (s, 3 H) 3.39 - 3.46 (m, 2 H) 3.47 - 3.54 (m, 1 H) 3.77 - 3.90 (m, 2 H) 5.64 (d, J=7.66 Hz, 1 H) 6.65 (dd, J=8.24, 2.14 Hz, 1 H) 6.74 - 6.80 (m, 2 H) 6.84 (bs, 3 H) 7.09 (t, J=7.81 Hz, 1 H) 7.27 - 7.35 (m, 2 H) 7.35 - 7.40 (m, 1 H) 7.81 (d, J=2.56 Hz, 1 H) 8.42 (s, 1 H) 11.63 (s, 1 H).
HRMS (ESI) calcd for C29H27ClN6O2 + H+ 527.1957, found 527.1961. - tert-Butyl (2-{[3-({2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-2-yl]pyrimidin-5-yl}ethynyl)phenyl]amino}ethyl)carbamate [(I), R1 = tert-butyl {2-[(3-ethynylphenyl)amino]ethyl}carbamate, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 14)
ESI (+) MS: m/z 586 (MH+). - 5-[2-Amino-5-({3-[(2-hydroxyethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {3-[(2-hydroxyethyl)amino]phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 15)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 3.12 (q, J=5.94 Hz, 2 H) 3.56 (q, J=5.90 Hz, 2 H) 4.68 (t, J=5.49 Hz, 1 H) 5.65 (t, J=5.68 Hz, 1 H) 6.64 (ddd, J=8.30, 2.32, 0.85 Hz, 1 H) 6.74 - 6.80 (m, 2 H) 7.06 - 7.12 (m, 1 H) 7.28 - 7.33 (m, 2 H) 7.35 - 7.39 (m, 1 H) 7.83 (d, J=2.69 Hz, 1 H) 8.42 (s, 1 H) 11.63 (s, 1 H).
HRMS (ESI) calcd for C26H23ClN6O2 + H+ 487.1644, found 487.1644. - 5-[2-Amino-5-({4-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {4-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 16)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.33 - 1.48 (m, 2 H) 1.88 (d, J=11.96 Hz, 2 H) 2.02 (t, J=10.86 Hz, 2 H) 2.14 (s, 3 H) 2.17 (s, 3 H) 2.73 (d, J=11.11 Hz, 2 H) 3.13 - 3.27 (m, 1 H) 5.94 (d, J=7.81 Hz, 1 H) 6.58 (d, J=8.79 Hz, 2 H) 6.63 (bs, 2 H) 6.79 (bs, 1 H) 6.89 (bs, 1 H) 7.27 - 7.31 (m, 3 H) 7.32 (d, J=2.32 Hz, 1 H) 7.34 - 7.39 (m, 1 H) 7.80 (d, J=2.69 Hz, 1 H) 8.36 (s, 1 H) 11.57 (s, 1 H).
HRMS (ESI) calcd for C30H30ClN7O + H+ 540.2273, found 540.2278. - tert-Butyl 3-({[3-({2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-2-yl]pyrimidin-5-yl}ethynyl)phenyl]amino}methyl)azetidine-1-carboxylate [(I), R1 = tert-butyl 3-{[(3-ethynylphenyl)amino]methyl}azetidine-1-carboxylate, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 17)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.37 (s, 9 H) 2.14 (s, 3 H) 2.70 - 2.80 (m, 1 H) 3.21 - 3.27 (m, 2 H) 3.52 - 3.60 (m, 2 H) 3.90 (t, J=8.85 Hz, 2 H) 5.88 (t, J=5.60 Hz, 1 H) 6.62 (ddd, J=8.24, 2.26, 0.85 Hz, 1 H) 6.74 (bs, 3 H) 6.75 - 6.80 (m, 2 H) 6.90 (bs, 1 H) 7.06 - 7.14 (m, 1 H) 7.28 - 7.31 (m, 1 H) 7.32 (d, J=2.32 Hz, 1 H) 7.34 - 7.40 (m, 1 H) 7.82 (d, J=2.69 Hz, 1 H) 8.42 (s, 1 H) 11.63 (d, J=2.20 Hz, 1 H).
HRMS (ESI) calcd for C30H30ClN7O + H+ 612.2485, found 612.2492. - 5-(2-Amino-5-{[4-(tetrahydro-2H-pyran-4-ylamino)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = [4-(tetrahydro-2H-pyran-4-ylamino)phenyl]ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 18)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.33 - 1.44 (m, 2 H) 1.84 - 1.91 (m, 2 H) 2.14 (s, 3 H) 3.42 (td, J=11.53, 2.20 Hz, 2 H) 3.45 - 3.54 (m, 1 H) 3.87 (ddd, J=11.47, 3.78, 3.42 Hz, 2 H) 6.01 (d, J=7.93 Hz, 1 H) 6.63 (bs, 2 H) 6.62 (d, J=8.79 Hz, 2 H) 6.80 (bs, 1 H) 6.89 (bs, 1 H) 7.27 - 7.34 (m, 4 H) 7.34 - 7.39 (m, 1 H) 7.80 (d, J=2.56 Hz, 1 H) 8.36 (s, 1 H) 11.58 (d, J=1.95 Hz, 1 H).
HRMS (ESI) calcd for C29H27ClN6O2 + H+ 527.1957, found 527.1961. - 5-[2-Amino-5-({4-[(2-hydroxyethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {4-[(2-hydroxyethyl)amino]phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 19)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 3.13 (q, J=5.90 Hz, 2 H) 3.56 (q, J=5.90 Hz, 2 H) 4.70 (t, J=5.49 Hz, 1 H) 6.03 (t, J=5.80 Hz, 1 H) 6.60 (d, J=8.91 Hz, 2 H) 6.63 (bs, 2 H) 6.79 (bs, 1 H) 6.90 (bs, 1 H) 7.28 - 7.34 (m, 4 H) 7.34 - 7.38 (m, 1 H) 7.81 (d, J=2.69 Hz, 1 H) 8.36 (s, 1 H) 11.57 (s, 1 H).
HRMS (ESI) calcd for C26H23ClN6O2 + H+ 487.1644, found 487.1651. - tert-Butyl 3-({[4-({2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-2-yl]pyrimidin-5-yl}ethynyl)phenyl]amino}methyl)azetidine-1-carboxylate [(I), R1 = tert-butyl 3-{[(4-ethynylphenyl)amino]methyl}azetidine-1-carboxylate, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 20)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.37 (s, 9 H) 2.14 (s, 3 H) 2.70 - 2.80 (m, 1 H) 3.22 - 3.28 (m, 2 H) 3.55 (t, J=5.90 Hz, 2 H) 3.91 (t, J=8.12 Hz, 2 H) 6.21 (t, J=5.90 Hz, 1 H) 6.59 (d, J=8.79 Hz, 2 H) 6.64 (bs, 2 H) 6.79 (bs, 1 H) 6.90 (bs, 1 H) 7.27 - 7.34 (m, 4 H) 7.35 - 7.39 (m, 1 H) 7.80 (d, J=2.69 Hz, 1 H) 8.36 (s, 1 H) 11.58 (s, 1 H).
HRMS (ESI) calcd for C33H34ClN7O3 + H+ 612.2485, found 612.2485. - tert-Butyl (2-{[4-({2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-2-yl]pyrimidin-5-yl}ethynyl)phenyl]amino}ethyl)carbamate [(I), R1 = tert-butyl {2-[(4-ethynylphenyl)amino]ethyl}carbamate, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 21)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.39 (s, 9 H) 2.14 (s, 3 H) 3.10 (bs, 4 H) 6.09 (t, J=5.25 Hz, 1 H) 6.58 (d, J=8.67 Hz, 2 H) 6.63 (bs, 2 H) 6.79 (bs, 1 H) 6.84 - 6.90 (m, 1 H) 6.91 (bs, 1 H) 7.28 - 7.34 (m, 4 H) 7.34 - 7.39 (m, 1 H) 7.80 (d, J=2.56 Hz, 1 H) 8.37 (s, 1 H) 11.57 (bs, 1 H).
HRMS (ESI) calcd for C31H32ClN7O3 + H+ 586.2328, found 586.2322. - 5-[2-Amino-5-({2-methoxy-5-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {2-methoxy-5-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 22)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.29 - 1.42 (m, 2 H) 1.82 - 1.90 (m, 2 H) 1.95 - 2.05 (m, 2 H) 2.14 (s, 3 H) 2.16 (s, 3 H) 2.67 - 2.74 (m, 2 H) 3.08 - 3.17 (m, 1 H) 3.68 (s, 3 H) 5.06 (d, J=8.42 Hz, 1 H) 6.63 (dd, J=8.91, 2.93 Hz, 1 H) 6.73 (d, J=2.81 Hz, 2 H) 6.84 (d, J=9.03 Hz, 2 H) 7.26 - 7.34 (m, 2 H) 7.34 - 7.40 (m, 1 H) 7.95 (d, J=2.69 Hz, 1 H) 8.40 (s, 1 H) 11.53 (s, 1 H).
HRMS (ESI) calcd for C31H32ClN7O2 + H+ 570.2379, found 570.2375. - 5-{2-Amino-5-[(4-formylphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = (4-formylphenyl)ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 23)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.13 - 2.15 (m, 3 H) 6.81 - 7.07 (m, 4 H) 7.26 - 7.33 (m, 2 H) 7.35 - 7.40 (m, 1 H) 7.77 - 7.85 (m, 3 H) 7.92 - 7.98 (m, 2 H) 8.50 (s, 1 H) 10.03 (s, 1 H) 11.73 (d, J=2.07 Hz, 1 H).
HRMS (ESI) calcd for C25H18ClN5O2 + H+ 456.1222, found 456.1219. - 5-[2-Amino-5-({3-[(4-methylpiperazin-1-yl)methyl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {3-[(4-methylpiperazin-1-yl)methyl]phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 24)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.15 (s, 3 H) 2.17 (s, 3 H) 2.27 - 2.45 (m, 8 H) 3.48 (s, 2 H) 7.28 - 7.41 (m, 5 H) 7.47 - 7.52 (m, 2 H) 7.83 (d, J=2.56 Hz, 1 H) 8.46 (s, 1 H) 11.67 (s, 1 H).
HRMS (ESI) calcd for C30H30ClN7O + H+ 540.2273, found 540.2278. - 5-[2-Amino-5-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 25)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.38 - 1.53 (m, 2 H) 1.82 (m, J=11.47 Hz, 2 H) 2.14 (s, 3 H) 3.78 - 3.91 (m, 2 H) 6.96 (d, J=9.15 Hz, 2 H) 7.28 - 7.33 (m, 2 H) 7.34 - 7.40 (m, 1 H) 7.43 (d, J=8.54 Hz, 2 H) 7.81 (d, J=2.69 Hz, 1 H) 8.39 (s, 1 H) 9.32 (bs, 1 H) 11.61 (bs, 1 H).
HRMS (ESI) calcd for C34H37ClN8O + H+ 609.2852, found 609.2850. - 5-[2-Amino-5-({4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 26)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.35 - 1.58 (m, 2 H) 1.73 (bs, 4 H) 1.95 (m, J=10.99 Hz, 2 H) 2.14 (s, 3 H) 2.56 - 2.74 (m, 2 H) 2.82 (t, J=11.11 Hz, 2 H) 3.77 (m, J=7.32 Hz, 2 H) 6.68 (bs., 2 H) 6.78 (bs, 1 H) 6.92 (bs, 1 H) 6.96 (d, J=8.91 Hz, 2 H) 7.21 - 7.34 (m, 2 H) 7.34 - 7.39 (m, 1 H) 7.43 (d, J=8.91 Hz, 2 H) 7.81 (d, J=2.56 Hz, 1 H) 8.39 (s, 1 H) 11.61 (bs, 1 H).
HRMS (ESI) calcd for C33H34ClN7O + H+ 580.2586, found 580.2579. - 5-[2-Amino-5-({3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 27)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 2.19 (s, 3 H) 2.25 - 2.41 (m, 4 H) 3.62 (bs, 2 H) 6.79 (bs, 2 H) 7.28 - 7.32 (m, 2 H) 7.34 - 7.41 (m, 2 H) 7.47 - 7.53 (m, 1 H) 7.56 (t, J=1.34 Hz, 1 H) 7.67 (dt, J=7.81, 1.34 Hz, 1 H) 7.82 (d, J=2.69 Hz, 1 H) 8.47 (s, 1 H) 11.67 (s, 1 H).
HRMS (ESI) calcd for C30H28ClN7O2 + H+ 554.2066, found 554.2071. - 5-(2-Amino-5-{[4-(4-hydroxypiperidin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = [4-(4-hydroxypiperidin-1-yl)phenyl]ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 28)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.34 - 1.53 (m, 2 H) 1.80 (m, J=8.54 Hz, 2 H) 2.14 (s, 3 H) 2.95 (ddd, J=12.91, 10.10, 2.99 Hz, 2 H) 3.54 - 3.73 (m, 3 H) 4.66 (bs, 1 H) 6.67 (bs, 2 H) 6.78 (bs, 1 H) 6.88 - 6.98 (m, 3 H) 7.27 - 7.33 (m, 2 H) 7.34 - 7.39 (m, 1 H) 7.39 - 7.45 (m, 2 H) 7.81 (d, J=2.56 Hz, 1 H) 8.39 (s, 1 H) 11.60 (s, 1 H).
HRMS (ESI) calcd for C29H27Cl6O2 + H+ 527.1957, found 527.1954. - 5-[2-Amino-5-({2-methoxy-4-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {2-methoxy-4-[(1-methylpiperidin-4-yl)amino]phenyl} ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 29)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.13 (s, 3 H) 3.76 (s, 3 H) 5.02 (d, J=8.06 Hz, 1 H) 6.20 - 6.32 (m, 3 H) 6.70 (bs, 2 H) 6.85 (bs, 2 H) 7.23 - 7.32 (m, 2 H) 7.34 - 7.40 (m, 1 H) 7.76 (d, J=2.44 Hz, 1 H) 8.47 (s, 1 H) 11.63 (s, 1 H). HRMS (ESI) calcd for C31H32ClN7O2 + H+ 570.2379, found 570.2372. - 5-{2-Amino-5-[3-(1,1-dioxidothiomorpholin-4-yl)prop-1-yn-1-yl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = 3-(1,1-dioxidothiomorpholin-4-yl)prop-1-yn-1-yl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 30)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.13 (s, 3 H) 3.05 (m, J=5.37 Hz, 4 H) 3.16 (m, J=5.61 Hz, 4 H) 3.81 (s, 2 H) 6.69 (bs, 2 H) 6.93 (br, 3 H) 7.23 - 7.32 (m, 2 H) 7.32 - 7.39 (m, 1 H) 7.70 (d, J=2.69 Hz, 1 H) 8.32 (s, 1 H) 11.59 (d, J=1.83 Hz, 1 H).
HRMS (ESI) calcd for C23H23ClN6O3S + H+ 499.1314, found 499.1309. - 5-[2-Amino-5-({4-[(2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {4-[(2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 31)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.80 - 2.10 (m, 8H) 2.14 (s, 3 H) 2.45 (bs, 2 H) 2.61 (bs, 2 H) 3.11 (m, J=6.59 Hz, 2 H) 3.37 - 3.47 (m, 2 H) 3.76 - 4.05 (m, 1 H) 6.62 (bs, 4 H) 6.81 (bs, 3 H) 7.26 - 7.34 (m, 3 H) 7.35 - 7.39 (m, 1 H) 7.41 (m, J=2.69 Hz, 1 H) 7.81 (d, J=2.56 Hz, 1 H) 8.38 (s, 1 H) 11.59 (bs, 1 H).
HRMS (ESI) calcd for C33H34ClN7O + H+ 580.2586, found 580.2579. - 5-[2-Amino-5-({3-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {3-[(1-methylpiperidin-4-yl)oxy]phenyl} ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 32)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.54 - 1.71 (m, 2 H) 1.93 (dd, J=10.86, 6.84 Hz, 2 H) 2.09 - 2.26 (m, 8 H) 2.55-2.64 (m, 2 H) 4.37 - 4.47 (m, 1 H) 6.79 (bs, 2 H) 6.98 (ddd, J=8.33, 2.53, 0.98 Hz, 1 H) 7.12 - 7.19 (m, 1 H) 7.26 - 7.33 (m, 2 H) 7.34 - 7.40 (m, 1 H) 7.81 (d, J=2.69 Hz, 1 H) 8.45 (s, 1 H) 11.65 (bs, 1 H).
HRMS (ESI) calcd for C30H29ClN6O2 + H+ 541.2114, found 541.2108. - N-[3-({2-Amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-2-yl]pyrimidin-5-yl}ethynyl)-4-methoxyphenyl]-1-methylpiperidine-4-carboxamide [(I), R1 = {5-methoxy-3-[(4-methylpiperidin-1-yl) carbonylamino]phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 33)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.54 - 1.71 (m, 2 H) 1.93 (dd, J=10.86, 6.84 Hz, 2 H) 2.09 - 2.26 (m, 8 H) 2.55 - 2.64 (m, 2 H) 4.37 - 4.47 (m, 1 H) 6.79 (bs, 2 H) 6.98 (ddd, J=8.33, 2.53, 0.98 Hz, 1 H) 7.12 - 7.19 (m, 1 H) 7.26 - 7.33 (m, 2 H) 7.34 - 7.40 (m, 1 H) 7.81 (d, J=2.69 Hz, 1 H) 8.45 (s, 1 H) 11.65 (bs, 1 H).
HRMS (ESI) calcd for C32H32ClN7O3 + H+ 598.2328, found 598.2322. - 5-(2-Amino-5-{[2-methoxy-5-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = [2-methoxy-5-(4-methylpiperazin-1-yl)phenyl]ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] R2 = H, R3 = NH2, R4 = CH3, R5 = Cl] (compd. 34)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 2.23 (s, 3 H) 2.47 (m, J=3.91 Hz, 4 H) 3.02 - 3.10 (m, 4 H) 3.75 (s, 3 H) 6.74 (bs, 1 H) 6.83 (bs, 2 H) 6.92 - 7.01 (m, 2 H) 7.10 (d, J=1.71 Hz, 1 H) 7.26 - 7.34 (m, 2 H) 7.34 - 7.40 (m, 1 H) 7.91 - 7.98 (m, 1 H) 8.41 (s, 1 H) 11.55 (s, 1 H).
HRMS (ESI) calcd for C30H30ClN7O2 + H+ 556.2223, found 556.2228. - 5-{2-Amino-5-[(5-bromo-2-methoxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = (5-bromo-2-methoxyphenyl)ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 35)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 3.84 (s, 3 H) 6.65 - 6.91 (m, 4 H) 7.07 (d, J=9.03 Hz, 1 H) 7.26 - 7.33 (m, 2 H) 7.34 - 7.39 (m, 1 H) 7.53 (dd, J=8.91, 2.56 Hz, 1 H) 7.70 (d, J=2.56 Hz, 1 H) 7.93 (d, J=2.69 Hz, 1 H) 8.44 (bs, 1 H) 11.57 (bs, 1 H).
HRMS (ESI) calcd for C25H19BrClN5O2 + H+ 536.0484, found 536.0490. - 5-[2-Amino-5-(cyclohexylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = cyclohexylethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 36)
1H NMR (400 MHz, DMSO- d 6) δ ppm 1.23 - 1.40 (m, 3 H) 1.52 (m, J=9.52 Hz, 3 H) 1.70 (m, J=6.10 Hz, 2 H) 1.84 - 1.96 (m, 2 H) 2.14 (s, 3 H) 2.69 - 2.78 (m, 1 H) 6.58 (bs, 2 H) 6.80 (bs, 1 H) 6.87 (bs, 1 H) 7.26 - 7.32 (m, 2 H) 7.34 - 7.39 (m, 1 H) 7.73 (d, J=2.56 Hz, 1 H) 8.25 (s, 1 H) 11.48 (bs, 1 H).
HRMS (ESI) calcd for C24H24ClN5O + H+ 434.1742, found 434.1744. - 5-[2-Amino-5-({2-methoxy-4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {2-methoxy-4-[(4-methylpiperazin-1-yl)carbonyl] phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 37)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.17 (s, 3 H) 2.20 (s, 3 H) 3.86 (s, 3 H) 6.78 (bs, 2 H) 6.84 (bs, 2 H) 6.97 (dd, J=7.75, 1.40 Hz, 1 H) 7.05 (d, J=1.34 Hz, 1 H) 7.12 - 7.18 (m, 1 H) 7.27 - 7.40 (m, 2 H) 7.57 (d, J=7.81 Hz, 1 H) 7.94 (s, 1 H) 8.43 (s, 1 H) 11.57 (bs, 1 H).
HRMS (ESI) calcd for C31H30ClN7O3 + H+ 584.2172, found 584.2166. - 5-[2-Amino-5-(cyclopropylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = cyclopropylethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 38)
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.75 - 0.94 (m, 4 H) 1.59 - 1.70 (m, 1 H) 2.14 (s, 3 H) 6.56 (bs, 2 H) 6.80 (bs, 1 H) 6.92 (bs, 1 H) 7.24 - 7.32 (m, 2 H) 7.33 - 7.38 (m, 1 H) 7.61 - 7.66 (m, 1 H) 8.14 - 8.30 (m, 1 H) 11.50 (bs, 1 H). HRMS (ESI) calcd for C21H18ClN5O + H+ 392.1273, found 392.1266. - 5-[2-Amino-5-(3,3-dimethylbut-1-yn-1-yl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = 3,3-dimethylbut-1-yn-1-yl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 39)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.35 (s, 9 H) 2.14 (s, 3 H) 6.56 (bs, 2 H) 6.80 (bs, 2 H) 7.24 - 7.34 (m, 2 H) 7.34 - 7.39 (m, 1 H) 7.76 (d, J=2.56 Hz, 1 H) 8.23 (bs, 1 H) 11.50 (bs, 1 H).
HRMS (ESI) calcd for C22H22ClN5O + H+ 408.1586, found 408.1578. - 5-{2-Amino-5-[(4-bromophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = (4-bromophenyl)ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 40)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 6.79 (bs, 3 H) 7.04 (bs, 1 H) 7.26 - 7.33 (m, 2 H) 7.34 - 7.39 (m, 1 H) 7.51 - 7.58 (m, 2 H) 7.60 - 7.68 (m, 2 H) 7.78 (d, J=2.56 Hz, 1 H) 8.46 (s, 1 H) 11.66 (bs, 1 H).
HRMS (ESI) calcd for C24H17BrClN5O + H+ 506.0378, found 506.0373. - 5-{2-Amino-5-[(4-bromo-2-fluorophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = (4-bromo-2-fluorophenyl)ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 41)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.13 (s, 3 H) 6.59 - 7.15 (m, 4 H) 7.26 - 7.33 (m, 2 H) 7.33 - 7.40 (m, 1 H) 7.71 (dd, J=9.28, 1.83 Hz, 1 H) 7.80 (d, J=2.56 Hz, 1 H) 8.46 (s, 1 H) 11.66 (bs, 1 H).
HRMS (ESI) calcd for C24H16BrClFN5O + H+ 524.0284, found 524.0277. - 5-(2-Amino-5-{[2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = [2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 42)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 2.23 (s, 3 H) 2.44 (bs, 4 H) 6.46 - 6.96 (m, 6 H) 7.25 - 7.32 (m, 2 H) 7.32 - 7.39 (m, 1 H) 7.45 (t, J=8.73 Hz, 1 H) 7.81 (d, J=2.56 Hz, 1 H) 8.39 (s, 1 H) 11.59 (s, 1 H).
HRMS (ESI) calcd for C29H27ClFN7O + H+ 544.2023, found 544.2018. - 5-[2-Amino-5-({2-[(2-hydroxyethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {2-[(2-hydroxyethyl)amino]phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 43)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 3.20 - 3.26 (m, 2 H) 3.60 (q, J=5.74 Hz, 2 H) 4.84 (t, J=5.25 Hz, 1 H) 5.41 (t, J=5.61 Hz, 1 H) 6.60 (td, J=7.45, 0.98 Hz, 1 H) 6.70 (d, J=7.93 Hz, 1 H) 6.92 (bs, 4 H) 7.15 - 7.23 (m, 1 H) 7.27 - 7.32 (m, 2 H) 7.34 - 7.41 (m, 2 H) 7.80 (d, J=2.69 Hz, 1 H) 8.51 (s, 1 H) 11.63 (s, 1 H).
HRMS (ESI) calcd for C26H23ClN6O2 + H+ 487.1644, found 487.1634. - 5-{2-Amino-5-[3-(dimethylamino)prop-1-yn-1-yl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = 3-(dimethylamino)prop-1-yn-1-yl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 44)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.13 (s, 3 H) 2.26 (s, 6 H) 3.57 (s, 2 H) 6.64 (bs, 2 H) 6.79 (bs, 1 H) 7.01 (bs, 1 H) 7.25 - 7.30 (m, 2 H) 7.33 - 7.38 (m, 1 H) 7.76 (d, J=2.69 Hz, 1 H) 8.32 (s, 1 H) 11.54 (bs, 1 H).
HRMS (ESI) calcd for C21H21ClN6O + H+ 409.1538, found 409.1532. - 5-{2-Amino-5-[(2-{[2-(dimethylamino)ethyl]amino}phenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = (2-{[2-(dimethylamino)ethyl] amino} phenyl)ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 45)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 2.18 (s, 6 H) 3.18 (q, J=5.86 Hz, 2 H) 5.55 (t, J=5.00 Hz, 1 H) 6.51 - 6.64 (m, 1 H) 6.66 (d, J=8.18 Hz, 1 H) 6.79 (bs, 2 H) 6.95 (bs, 1 H) 7.16 - 7.25 (m, 1 H) 7.25 - 7.33 (m, 2 H) 7.34 - 7.43 (m, 2 H) 7.84 (d, J=2.56 Hz, 1 H) 8.46 (s, 1 H) 11.64 (s, 1 H).
HRMS (ESI) calcd for C28H28ClN7O + H+ 514.2117, found 514.2111. - 5-(2-Amino-5-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = [2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 46)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 2.24 (s, 3 H) 2.46 (bs, 4 H) 3.22 - 3.28 (m, 4 H) 3.78 (s, 3 H) 6.49 - 6.56 (m, 2 H) 7.27 - 7.34 (m, 3 H) 7.35 - 7.38 (m,1 H) 7.92 (d, J=2.56 Hz,1 H) 8.36 (s,1 H) 11.49 (d, J=1.95 Hz,1 H). HRMS (ESI) calcd for C30H30ClN7O2 + H+ 556.2223, found 556.2215. - 5-(2-Amino-5-{[3-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = [3-(4-methylpiperazin-1-yl)phenyl]ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 47)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 2.26 (bs, 3 H) 3.19 (bs, 4 H) 6.81 (bs, 4 H) 6.93 - 7.04 (m, 2 H) 7.11 - 7.16 (m, 1 H) 7.22 - 7.27 (m, 1 H) 7.28 - 7.33 (m, 1H) 7.34 - 7.40 (m, 1 H) 7.85 (d, J=2.69 Hz, 1 H) 8.43 (s, 1 H) 11.64 (s, 1 H).
HRMS (ESI) calcd for C29H28ClN7O + H+ 526.2117, found 526.2122. - 5-[2-Amino-5-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {4-[(1-methylpiperidin-4-yl)oxy]phenyl} ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 48)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.64 (m, 2 H) 1.94 (m, 2 H) 2.18 (m, 8 H) 2.62 (m, 2 H) 4.24 - 4.54 (m, 1 H) 6.72 (bs, 2 H) 6.94 - 7.03 (m, 2 H) 7.26 - 7.33 (m, 2 H) 7.33 - 7.39 (m, 1 H) 7.45 - 7.60 (m, 2 H) 7.80 (d, J=2.56 Hz, 1 H) 8.41 (s, 1 H) 11.62 (s, 1 H).
HRMS (ESI) calcd for C30H29ClN6O2 + H+ 541.2114, found 541.2121. - 5-(2-Amino-5-{[2-fluoro-5-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = [2-fluoro-5-(4-methylpiperazin-1-yl)phenyl] ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 49)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 2.22 (s, 3 H) 2.46 (m, J=4.88 Hz, 4 H) 3.06 - 3.17 (m, 4 H) 6.84 (bs, 4 H) 7.01 (dt, J=7.75, 4.42 Hz, 1 H) 7.11 - 7.19 (m, 2 H) 7.27 - 7.32 (m, 2 H) 7.34 - 7.39 (m, 1 H) 7.85 (d, J=2.56 Hz, 1 H) 8.44 (s, 1 H) 11.65 (s, 1 H)
HRMS (ESI) calcd for C29H27ClFN7O + H+ 544.2023, found 544.2022. - 5-{2-Amino-5-[3-(4-methylpiperazin-1-yl)prop-1-yn-1-yl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = (4-methylpiperazin-1-yl)prop-1-yn-1-yl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 50)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.13 (s, 3 H) 3.63 - 3.80 (m, 2 H) 6.68 (bs, 2 H) 6.85 (bs, 1 H) 6.97 (bs, 1 H) 7.28 (d, J=1.95 Hz, 2 H) 7.34 - 7.40 (m, 1 H) 7.73 (d, J=2.56 Hz, 1 H) 8.34 (s, 1 H) 11.60 (bs, 1 H).
HRMS (ESI) calcd for C24H26ClN7O + H+ 464.1960, found 464.1965. - 5-(2-Amino-5-{3-[(1-methylpiperidin-4-yl)oxy]prop-1-yn-1-yl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = 3-[(1-methylpiperidin-4-yl)oxy]prop-1-yn-1-yl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 51)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.41 - 1.56 (m, 2 H) 1.82 - 1.91 (m, 2 H) 1.98 - 2.07 (m, 2 H) 2.10 - 2.18 (m, 6 H) 2.56 - 2.65 (m, 2 H) 3.53 - 3.62 (m, 1 H) 4.51 - 4.56 (m, 2 H) 7.25 - 7.31 (m, 2 H) 7.33 - 7.38 (m, 1 H) 7.68 - 7.72 (m, 1 H) 8.32 (s, 1 H) 11.58 (bs, 1 H).
HRMS (ESI) calcd for C25H27ClN6O2 + H+ 479.1957, found 479.1942. - 5-[2-Amino-5-({2-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {2-[(1-methylpiperidin-4-yl)amino] phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 52)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.49 (q, J=9.64 Hz, 2 H) 1.90 (d, J=10.74 Hz, 2 H) 2.13 (s, 3 H) 4.89 (d, J=8.30 Hz, 1 H) 6.61 (t, J=7.57 Hz, 1 H) 6.72 (d, J=8.42 Hz, 1 H) 6.78 (bs, 2 H) 6.89 (bs, 2 H) 7.14 - 7.22 (m, 1 H) 7.27 - 7.31 (m, 2 H) 7.34 - 7.38 (m, 1 H) 7.38 - 7.41 (m, 1 H) 7.78 (d, J=2.56 Hz, 1 H) 8.49 (s,1 H) 11.65 (d, J=1.95 Hz,1 H). HRMS (ESI) calcd for C30H30ClN7O + H+ 540.2273, found 540.2269. - 5-[2-Amino-5-(pyridin-3-ylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = pyridin-3-ylethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 53)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 6.81 (bs, 3 H) 7.12 (bs, 1 H) 7.26 - 7.32 (m, 2 H) 7.34 - 7.38 (m, 1 H) 7.47 - 7.55 (m, 1 H) 7.83 (d, J=2.69 Hz, 1 H) 8.03 (d, J=8.18 Hz, 1 H) 8.50 (s, 1 H) 8.63 (bs, 1 H) 8.87 (bs, 1 H) 11.71 (bs, 1 H).
HRMS (ESI) calcd for C23H17ClN6O + H+ 429.1225, found 429.1218. - 5-[2-Amino-5-(3-hydroxy-3-methylbut-1-yn-1-yl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = 3-hydroxy-3-methylbut-1-yn-1-yl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 54)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.53 (s, 6 H) 2.13 (s, 3 H) 5.54 (s, 1 H) 6.63 (bs, 1 H) 6.84 (s, 2 H) 7.25 - 7.31 (m, 2 H) 7.33 - 7.38 (m, 1 H) 7.83 (d, J=2.56 Hz, 1 H) 8.26 (bs, 1 H) 11.55 (bs, 1 H).
HRMS (ESI) calcd for C21H20ClN5O2 + H+ 410.1379, found 410.1377. - 5-[2-Amino-5-(3-hydroxybut-1-yn-1-yl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = 3-hydroxybut-1-yn-1-yl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 55)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.45 (d, J=6.59 Hz, 3 H) 2.13 (s, 3 H) 4.67 - 4.76 (m, 1 H) 5.52 (d, J=5.49 Hz, 1 H) 6.63 (bs, 2 H) 6.88 (bs, 2 H) 7.25 - 7.32 (m, 2 H) 7.32 - 7.37 (m, 1 H) 7.80 (d, J=2.56 Hz, 1 H) 8.28 (bs, 1 H) 11.56 (bs, 1 H).
HRMS (ESI) calcd for C20H18ClN5O2 + H+ 396.1222, found 396.1225. - 5-(2-Amino-5-{3-[benzyl(methyl)amino]prop-1-yn-1-yl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = 3-[benzyl(methyl)amino]prop-1-yn-1-yl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 56)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.13 (s, 3 H) 2.29 (s, 3 H) 3.61 (bs, 2 H) 3.65 (bs, 2 H) 6.67 (bs, 2 H) 6. 79 (bs, 1 H) 6.99 (bs, 1 H) 7.20 - 7.39 (m, 9 H) 7.76 (d, J=2.56 Hz, 1 H) 8.36 (bs, 1 H) 11.56 (bs, 1 H).
HRMS (ESI) calcd for C27H25ClN6O + H+ 485.1851, found 485.1844. - According to this step, but starting from 5-(2-amino-5-iodo-pyrimidin-4-yl)-2-(5-chloro-2-methyl-phenyl)-N-methyl-1H-pyrrole-3-carboxamide, the following compounds were prepared:
- 5-[2-Amino-5-(phenylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-N-methyl-1H-pyrrole-3-carboxamide [(I), R1 = phenylethynyl, R2 = H, R3 = CH3, R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 57)
ESI (+) MS: m/z 442 (MH+). - 5-(2-Amino-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-N-methyl-1H-pyrrole-3-carboxamide [(I), R1 = [4-(4-methylpiperazin-1-yl)phenyl]ethynyl, R2 = H, R3 = CH3, R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 58)
ESI (+) MS: m/z 540 (MH+). - According to this step, but starting from 5-(2-amino-5-iodo-pyrimidin-4-yl)-2-(5-chloro-2-ethyl-phenyl)-N-methyl-1H-pyrrole-3-carboxamide, the following compounds were prepared:
- 5-[2-Amino-5-(phenylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-ethylphenyl)-N-methyl-1H-pyrrole-3-carboxamide [(I), R1 = phenylethynyl, R2 = H, R3 = CH3, R4 = H, R5 = 5-chloro-2-ethylphenyl, R6 = NH2] (compd. 111)
ESI (+) MS: m/z 456 (MH+). - 5-(2-Amino-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-methyl-1H-pyrrole-3-carboxamide [(I), R1 = [4-(4-methylpiperazin-1-yl)phenyl]ethynyl, R2 = H, R3 = CH3, R4 = H, R5 = 5-chloro-2-ethylphenyl, R6 = NH2] (compd. 112)
ESI (+) MS: m/z 564 (MH+). -
- A solution of 5-(2-amino-pyrimidin-4-yl)-2-(5-chloro-2-methyl-phenyl)-1H-pyrrole-3-carboxylic acid (11.62 g, 30.4 mmol) in DMF (100 mL) and DIPEA (21.2 mL, 121.6 mmol) was stirred at 0 °C. EDCI (11.64 g, 60.8 mmol) and HOBT.NH3 (9.38 g, 60.8 mmol) were added and the reaction mixture was stirred for 3 h at room temperature. The mixture was diluted with water and the resultant precipitate was collected by filtration to afford the title compound (8.17 g, 82%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.12 (s, 3H), 6.35 (bs, 2H), 6.73 (bs, 1H), 6.93 (d, J=5.24 Hz, 1H), 7.22 (bs, 1H), 7.25-7.30 (m, 2H), 7.32-7.36 (m, 2H), 8.20 (d, J=5.24 Hz, 1H), 11.85 (bs, 1H).
HRMS (ESI) m/z calcd for C16H14ClN5O + H+ 328.0960, found 328.0959. - NaH (60% dispersion in mineral oil, 0.452 g, 11.3 mmol) was added to a suspension of 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (2.62 g, 8.0 mmol) in dry THF (25 mL) at 0 °C. The reaction was kept at the same temperature for 20 min then 2-(chloromethoxy)ethyl](trimethyl)silane (2.0 mL, 11.3 mmol) was added and the mixture was stirred at room temperature for 2 h. Saturated aqueous NaCl (30 mL) was added at 0 °C and the mixture was extracted with EtOAc (2 x 35 mL). The separated organic phase was dried over sodium sulfate and the solvent evaporated. The crude was purified by flash chromatography on silica gel (DCM/EtOH 94/6) to afford the title compound (1.39 g, 38%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.17 (s, 9 H) 0.54 - 0.72 (m, 2 H) 2.02 (s, 3 H) 3.16 - 3.23 (m, 2 H) 5.47 (d, J=10.13 Hz, 1 H) 5.77 (d, J=10.13 Hz, 1 H) 6.60 (s, 2 H) 6.80 (bs, 1 H) 6.83 (d, J=5.25 Hz, 1 H) 7.13 (bs, 1 H) 7.20 - 7.23 (m, 1 H) 7.29 - 7.36 (m, 2 H) 7.37 - 7.43 (m, 1 H) 8.23 (d, J=5.25 Hz, 1 H).
HRMS (ESI) m/z calcd for C22H28ClN5O2Si + H+ 458.1774, found 458.1774. - N-iodosuccinimide (720 mg, 3.2 mmol) was added to a solution of 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-3-carboxamide (1.39 g, 3.0 mmol) in dry DMF (6 mL). The reaction mixture was heated at 65 °C for 7 h, allowed to cool to room temperature and then diluted with EtOAc (30 mL), washed with water (2 x 20 mL) brine, dried over sodium sulphate, and evaporated. The crude was purified by flash chromatography on silica gel (DCM/MeOH 97/3) to afford the title compound as yellow solid (1.07 g, 60%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.13 (s, 9 H) 0.51 - 0.66 (m, 2 H) 2.04 (s, 3 H) 3.03 (m, 2 H) 5.07 (d, J=10.74 Hz, 1 H) 5.26 (d, J=10.74 Hz, 1 H) 6.78 (bs, 1 H) 6.89 (s, 2 H) 7.11 (bs, 1 H) 7.17 - 7.19 (m, 1 H) 7.20 (s, 1 H) 7.31 - 7.35 (m, 1 H) 7.38 - 7.42 (m, 1 H) 8.58 (s, 1 H).
HRMS (ESI) m/z calcd for C22H27ClIN5O2Si + H+ 584.0740, found 584.0744. - To a degassed solution of 5-(2-amino-5-iodopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-{[2-(trimethylsilyl)ethoxy] methyl}-1H-pyrrole-3-carboxamide (140 mg, 0.24 mmol), (4-ethynylphenyl)(4-methylpiperazin-1-yl)methanone (98 mg, 0.43 mmol) and TEA (0.335 mL, 2.4 mmol) in dry ACN (2.5 mL) were added copper iodide (2.5 mg, 0.012 mmol) and Pd(PPh3)2Cl2 (8.4 mg, 0.012 mmol). The mixture was heated at 80 °C for 2 h, then the solvent was evaporated. The crude was purified by flash chromatography on silica gel (DCM/MeOH/7N NH3 in MeOH 95/4/1) to afford the title compound (131 mg, 80%).
1H NMR (400 MHz, DMSO-d6 ) δ ppm 0.20 (s, 9 H) 0.48 - 0.65 (m, 2 H) 2.04 (s, 3 H) 2.83 (s, 3 H) 3.11 (t, J=8.24 Hz, 2 H) 3.15 - 3.52 (m, 8H) 5.30 (d, J=10.38 Hz, 1 H) 5.62 (d, J=10.38 Hz, 1 H) 6.80 (bs, 1 H) 7.03 (bs, 1 H) 7.13 - 7.30 (m, 3 H) 7.31 - 7.37 (m, 1 H) 7.39 - 7.45 (m, 1 H) 7.46 - 7.52 (m, 2 H) 7.55 - 7.61 (m, 2 H) 7.68 (s, 1 H) 8.41 - 8.54 (s, 1 H).
HRMS (ESI) m/z calcd for C36H42ClN7O3Si + H+ 684.2880, found 684.2884. - The above procedure was employed to synthesize the following compound:
- 5-{2-Amino-5-[(4-bromophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1-{[2-(trimethylsilyl) ethoxy]methyl}-1H-pyrrole-3-carboxamide (XIII)
ESI (+) MS: m/z 637 (MH+). - Trifluoroacetic acid (1.4 mL) was added to a solution of 5-[2-amino-5-({4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-3-carboxamide (0.110 g, 0.14 mmol) in dry DCM (2.8 mL) and stirred for 4 h at room temperature. After solvent removal, the residue was treated with EtOH (3 mL), 33% NH4OH (0.4 mL) and stirred for 0.5 h. The solvent was evaporated to dryness and the residue was purified by flash-chromatography on silica gel (DCM/MeOH/7N NH3 in MeOH 94/5/1) to afford the title compound as white solid (0.055 g, 71%).
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.14 (s, 3 H) 2.20 (s, 3 H) 2.27 - 2.41 (m, 4 H) 3.44 - 3.69 (m, 4 H) 6.81 (bs, 3 H) 7.02 (bs, 1 H) 7.22 - 7.33 (m, 2 H) 7.33 - 7.39 (m, 1 H) 7.40 - 7.46 (m, 2 H) 7.63 - 7.69 (m, 2 H) 7.80 - 7.83 (m, 1 H) 8.47 (s, 1 H) 11.68 (s, 1H).
HRMS (ESI) m/z calcd for C30H28CIN7O2 + H+ 554.2066, found 554.2068. - The above procedure was employed to synthesize the following compound:
- 5-[2-Amino-5-({4-[4-(dimethylamino)piperidin-1-yl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {4-[4-(dimethylamino)piperidin-1-yl]phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 60)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 1.37 - 1.53 (m, 2 H) 1.79 - 1.88 (m, 2 H) 2.14 (s, 3 H) 2.22 (bs, 6 H) 2.27 - 2.35 (m, 1H) 2.71 - 2.81(m, 2 H) 3.78 - 3.88(m, 2 H) 6.67 (bs, 3 H) 6.79 (bs, 1 H) 6.91 - 6.99 (m, 2 H) 7.27 - 7.33 (m, 2 H) 7.34 - 7.39 (m, 1 H) 7.40 - 7.46 (m, 2 H) 7.81 (d, J=2.56 Hz, 1 H) 8.39 (bs, 1 H) 11.55 - 11.65 (m, 1 H).
HRMS (ESI) m/z calcd for C31H32CIN7O + H+ 554.2430, found 554.2428. -
- tert-Butyl 3-({[3-({2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-2-yl]pyrimidin-5-yl}ethynyl)phenyl] amino}methyl)azetidine-1-carboxylate (190 mg, 0.311 mmol) in DCM (2.2 mL) and TFA (240 µL, 3.1 mmol) was stirred at room temperature for 48 h, then DCM (25 mL), water (25 mL) and 2 mL of 10% NH4OH were added. The organic layer was separated and the aqueous phase was further extracted employing DCM/MeOH. After drying over sodium sulfate, evaporation of the solvent, purification by flash chromatography over silica gel (DCM/7N NH3 in MeOH 8/2) and crystallization from Et2O/MeOH, the title compound was obtained as a light yellow solid (113 mg, 71%).
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.15 (s, 3 H) 2.83 - 2.97 (m, 1 H) 3.43 (dd, J=9.52, 6.96 Hz, 2 H) 3.74 (t, J=8.48 Hz, 2 H) 5.85 (t, J=5.68 Hz, 1 H) 6.62 (ddd, J=8.24, 2.20, 0.79 Hz, 1 H) 6.75 (bs, 2 H) 6.75 - 6.80 (m, 2 H) 6.90 (bs, 2 H) 7.07 - 7.14 (m, 1 H) 7.28 - 7.34 (m, 2 H) 7.35 - 7.40 (m, 1 H) 7.84 (s, 1 H) 8.42 (s, 1 H) 11.59 (bs, 1 H). HRMS (ESI) m/z calcd for C28H26ClN7O + H+ 512.1960, found 512.1962. - The above procedure was employed to synthesize the following compounds:
- 5-[2-Amino-5-({4-[(azetidin-3-ylmethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {4-[(azetidin-3-ylmethyl)amino]phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 62)
HRMS (ESI) m/z calcd for C28H26ClN7O + H+ 512.1960, found 512.1968. - 5-[2-Amino-5-({3-[(2-aminoethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = {3-[(2-aminoethyl)amino]phenyl}ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 63)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.15 (s, 3 H) 2.73 (t, J=6.29 Hz, 2 H) 3.04 (q, J=6.10 Hz, 2 H) 5.72 (t, J=5.74 Hz, 1 H) 6.63 (dt, J=8.94, 1.27 Hz, 1 H) 6.75 - 6.79 (m, 2 H) 6.74 - 6.79 (m, 2 H) 7.10 (t, J=8.12 Hz, 1 H) 7.28 - 7.33 (m, 2 H) 7.34 - 7.39 (m, 1 H) 7.83 (s, 1 H) 8.42 (s, 1 H).
HRMS (ESI) calcd for C26H24CIN7O + H+ 486.1804, found 486.1809. -
- 5-[2-Amino-5-({3-[(azetidin-3-ylmethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (55 mg, 0.11 mmol) in DMF (1 mL), under a nitrogen atmosphere, was treated with formaldehyde 37 wt % in water (9 µL, 0.13 mmol) and sodium triacetoxyborohydride (35 mg, 0.165 mmol). After 45 minutes the reaction mixture was added drop wise to 10 % NH4OH (25 mL) and left at 4°C for 2 h. The solid was filtered, washed with water and dried at 40 °C, under vacuum. Purification by reverse phase chromatography (Phase A: 0.05 NH4OH%/AC 95/5; Phase B: ACN/H2O 95/5. Gradient: 10-100% of phase B) afforded the title compound (20 mg, 35%).
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.15 (s, 3 H) 2.19 (s, 3 H) 2.53 - 2.59 (m, 1 H) 2.88 (t, J=6.23 Hz, 2 H) 3.16 - 3.25 (m, 4 H) 5.76 (t, J=5.55 Hz, 1 H) 6.58 - 6.63 (m, 1 H) 6.72 - 6.78 (m, 2 H) 6.80 - 6.97 (m, 4 H) 7.09 (t, J=7.81 Hz, 1 H) 7.25 - 7.34 (m, 2 H) 7.33 - 7.40 (m, 1 H) 7.82 (d, J=2.56 Hz, 1 H) 8.42 (s, 1 H) 11.63 (bs, 1 H).
HRMS (ESI) calcd for C29H28CIN7O + H+ 526.2117, found 526.2110. -
- 5-{2-Amino-5-[(4-formylphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (53 mg, 0.1176 mmol) and 1-methylpiperazine (16 µL, 0.1411 mmol) in 1,4-dioxane (2 mL) and DMF (0.5 mL), under a nitrogen atmosphere, were treated first with AcOH (24 µL, 0.4234 mmol) and then with sodium triacetoxyborohydride (37 mg, 0.1764 mmol, 1.5 eq.). After stirring for 1 h, DCM (20 mL) was added and the organic phase was washed subsequently with 10% NH4OH (15 mL) and brine, dried over sodium sulfate and evaporated. The crude was purified by flash chromatography over silica gel (DCM/MeOH/7N NH3 in MeOH 9/1/0.1) to afford the title compound as a white solid (28 mg, 44%).
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.14 (s, 3 H) 2.17 (s, 3 H) 2.27 - 2.46 (m, 8 H) 3.49 (s, 2 H) 7.27 - 7.40 (m, 5 H) 7.53 - 7.58 (m, 2 H) 7.82 (d, J=2.69 Hz, 1 H) 8.44 (s, 1 H) 11.61 - 11.68 (m, 1 H).
HRMS (ESI) calcd for C30H30CIN7O + H+ 540.2273, found 540.2271. - According to this procedure, but using the suitable amine, the following compounds were prepared:
- 5-(2-Amino-5-{[4-(pyrrolidin-1-ylmethyl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = [4-(pyrrolidin-1-ylmethyl)phenyl]ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 66)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 1.54 - 1.80 (m, 4 H) 2.14 (s, 3 H) 2.45 (bs, 4 H) 3.61 (bs, 1 H) 6.78 (bs, 2 H) 6.99 (bs, 1 H) 7.25 - 7.33 (m, 2 H) 7.33 - 7.40 (m, 3 H) 7.52 - 7.58 (m, 2 H) 7.82 (d, J=2.69 Hz, 1 H) 8.44 (s, 1 H) 11.64 (s, 1H).
HRMS (ESI) calcd for C29H27CIN6O + H+ 511.2008, found 511.2010. - 5-(2-Amino-5-{[4-(piperidin-1-ylmethyl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = [4-(piperidin-1-ylmethyl)phenyl]ethynyl, R2 = R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 67)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 1.34 - 1.44 (m, 2 H) 1.50 (quin, J=5.52 Hz, 4 H) 2.14 (s, 3 H) 2.27 - 2.38 (m, 4 H) 3.45 (s, 2 H) 6.78 (bs, 3 H) 6.98 (bs, 1 H) 7.26 - 7.39 (m, 5 H) 7.52 - 7.59 (m, 2 H) 7.82 (d, J=2.69 Hz, 1 H) 8.44 (s, 1 H) 11.64 (s, 1 H).
HRMS (ESI) calcd for C30H29ClN6O + H+ 525.2164, found 525.2159. -
- To a solution of ethyl 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxylate (1.0 g, 2.8 mmol) in dry THF (40 mL) cooled to 0 °C NaH 60% (1.342 g, 3.36 mmol) was added portion wise and the reaction mixture stirred for 30 min. (2-Chloromethoxy-ethyl)-trimethyl-silane (0.417 mL, 3.36 mmol) was added drop wise. The reaction mixture was allowed to warm up slowly to room temperature and stirred for 2 h. Saturated aqueous NaCl (30 mL) was added at 0 °C and the mixture was extracted with EtOAc (2 x 35 mL). The separated organic phase was dried over sodium sulfate and the solvent evaporated. The crude was purified by flash chromatography on silica gel (DCM/MeOH 98/2) to afford the title compound as an orange oil (0.80 g, 57%).
1H NMR (400 MHz, DMSO-d6 ) δ ppm -0.17 (s, 9 H) 0.59 - 0.69 (m, 2 H) 1.01 (t, J=7.08 Hz, 3 H) 2.02 (s, 3 H) 3.23 (t, J=8.30 Hz, 2 H) 4.00 (q, J=7.16 Hz, 2 H) 5.54 (d, J=10.01 Hz, 1 H) 5.82 (d, J=10.01 Hz, 1 H) 6.63 (s, 2 H) 6.98 (d, J=5.25 Hz, 1 H) 7.25 (s, 1 H) 7.27 (d, J=2.32 Hz, 1 H) 7.36 (d, J=8.18 Hz, 1 H) 7.44 (dd, J=8.18, 2.20 Hz, 1 H) 8.22 (d, J=5.25 Hz, 1 H). - N-iodosuccinimide (356 mg, 1.58 mmol) was added to a solution of ethyl 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-{[2-(trimethylsilyl)ethoxy]methyl)-1H-pyrrole-3-carboxylate (700 mg, 1.44 mmol) in DMF (15 mL). The reaction mixture was heated at 60 °C for 4 h, allowed to cool to room temperature, concentrated and then diluted with EtOAc (30 mL). The organic phase was washed with sodium sulfite, water, brine, dried over sodium sulphate, and evaporated to afford the title compound as yellow solid (0.70 g, 79%).
1H NMR (400 MHz, DMSO-d6 ) δ ppm -0.14 (s, 9 H) 0.59 (ddd, J=10.41, 6.26, 2.87 Hz, 2 H) 1.01 (t, J=7.08 Hz, 3 H) 2.04 (s, 3 H) 3.06 (qd, J=8.56, 2.62 Hz, 2 H) 4.01 (q, J=7.08 Hz, 2 H) 5.15 (d, J=10.74 Hz, 1 H) 5.36 (d, J=10.74 Hz, 1 H) 6.92 (bs, 2 H) 7.11 (s, 1 H) 7.22 (d, J=2.32 Hz, 1 H) 7.37 (d, J=8.30 Hz, 1 H) 7.45 (dd, J=8.30, 2.32 Hz, 1 H) 8.60 (s, 1 H). - In a sealed tube filled with argon, a mixture of ethyl 5-(2-amino-5-iodopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-3-carboxylate (612 mg, 1.0 mmol), Pd(PPh3)2Cl2 (70 mg, 0.1 mmol), CuI (19 mg, 0.1 mmol), ethynyl(trimethyl)silane (0.415 mL, 3 mmol) and triethylamine (10 mmol) in degassed ACN (10 mL) was stirred at room temperature overnight. To the reaction mixture was added N,N,N',N'-tetramethylethylenediamine (0.3 mL, 2 mmol) and the reaction mixture stirred at the same temperature for 15 min. The solvent was evaporated under vacuum and the residue purified by flash chromatography (hexane/EtOAc 8/2) to obtain the title compound (495 mg, 85%).
1H NMR (400 MHz, DMSO-d6 ) δ ppm -0.18 (s, 9 H) 0.22 (s, 2 H) 0.51 - 0.66 (m, 2 H) 1.06 (t, J=7.08 Hz, 3 H) 2.03 (s, 3 H) 3.06 - 3.17 (m, 2 H) 4.02 (q, J=7.08 Hz, 2 H) 5.43 (d, J=10.25 Hz, 1 H) 5.70 (d, J=10.25 Hz, 1 H) 7.16 (s, 2 H) 7.25 (d, J=2.32 Hz, 1 H) 7.37 (d, J=8.18 Hz, 1 H) 7.45 (dd, J=8.18, 2.32 Hz, 1 H) 7.64 (s, 1 H) 8.40 (s, 1 H). - Ethyl 5-{2-amino-5-[(trimethylsilyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1-{[2-(trimethylsilyl)ethoxy] methyl}-1H-pyrrole-3-carboxylate (466 mg, 0.8 mmol) was treated with a 1.5 M solution of potassium hydroxide in 95% EtOH (5.33 mL, 8 mmol) and stirred at 50 °C overnight. After cooling, the residue was concentrated, dissolved in water and washed with DCM. The aqueous layer was acidified until pH<1 with the addition of 2 N HCl and extracted with EtOAc (3x). The combined organic layers were dried over Na2SO4 and the solvent evaporated under vacuum to obtain the title compound as an orange oil (367 mg, 95%).
1H NMR (400 MHz, DMSO-d6 ) δ ppm -0.17 (s, 9H) 0.54-0.63 (m, 2H) 2.04 (s, 3H) 3.11 (td, J=8.24, 1.95 Hz, 2H) 4.41 (s, 1H) 5.37 (d, J=10.25 Hz, 1H) 5.64 (d, J=10.25 Hz, 1H) 7.13 (s, 2H) 7.25 (d, J=2.32 Hz, 1H) 7.36 (d, J=8.30 Hz, 1H) 7.43 (dd, J=8.30, 2.32 Hz, 1H) 7.51 (s, 1H) 8.43 (s, 1H) 11.94 (bs, 1H). - A solution of 5-(2-amino-5-ethynylpyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-3-carboxylic acid (338 mg, 0.7 mmol) in dry THF (5 mL) and DIPEA (0.48 mL, 2.8 mmol) was stirred at 0°C. EDCI (268 mg, 1.4 mmol), HOBT.NH3 (213 mg, 1.4 mmol) were added and the reaction mixture was stirred at room temperature overnight. The solvent was evaporated, the residue taken-up in saturated solution of NaHCO3 and extracted with EtOAc. The combined organic layers were dried over sodium sulfate to obtain the title compound as a light-orange oil (334 mg, 99%).
1H NMR (400 MHz, DMSO-d6 ) δ ppm -0.17 (s, 9 H) 0.53 - 0.63 (m, 2 H) 2.04 (s, 3 H) 3.08 (td, J=8.24, 1.45 Hz, 2H) 4.32 (s, 1 H) 5.28 (d, J=10.50 Hz, 1 H) 5.55 (d, J=10.38 Hz, 1 H) 6.79 (bs, 1 H) 7.01 (bs, 1 H) 7.11 (s, 2 H) 7.22 (d, J=2.20 Hz, 1 H) 7.34 (d, J=8.20 Hz, 1 H) 7.41 (dd, J=8.20, 2.30 Hz, 1 H) 7.50 (s, 1 H) 8.42 (s, 1 H). - In a sealed tube filled with argon, a mixture of 5-(2-amino-5-ethynylpyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-3-carboxamide (120 mg, 0.25 mmol), Pd(PPh3)2Cl2 (21 mg, 0.03 mmol), Cul (6 mg, 0.03 mmol), iodobenzene (153 mg, 0.75 mmol) and TEA (0.348 mL, 2.5 mmol) in degassed ACN (2.5 mL) was stirred at room temperature overnight. To the reaction mixture was added N,N,N',N'-tetramethylethylenediamine (0.075 mL, 0.5 mmol) and the reaction mixture stirred at the same temperature for 15 min. The solvent was evaporated under vacuum and the residue purified by flash chromatography (hexane/EtOAc 1/1 + 1% TEA), to obtain the title compounds (91 mg, 65%).
1H NMR (400 MHz, DMSO-d6 ) δ ppm -0.20 (s, 9H) 0.50 - 0.65 (m, 2H) 2.04 (s, 3H) 3.10 (td, J=8.27, 1.40 Hz, 2H) 5.29 (d, J=10.50 Hz, 1H) 5.61 (d, J=10.50 Hz, 1H) 6.79 (bs, 1H) 7.06 (bs, 1H) 7.15 (s, 2H) 7.23 (d, J=2.20 Hz, 1H) 7.34 (d, J=8.20 Hz, 1H) 7.37 - 7.45 (m, 4 H) 7.59 - 7.63 (m, 2 H) 7.67 (s, 1H) 8.52 (s, 1 H). - Trifluoroacetic acid (1.4 mL) was added to a solution of 5-[2-amino-5-(phenylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-3-carboxamide (78 mg, 0.14 mmol) in dry DCM (2.8 mL) and stirred for 4 h at room temperature. After solvent removal, the residue was treated with EtOH (3 mL), 33% NH4OH (0.4 mL) and stirred for 0.5 h. The solvent was evaporated to dryness and the residue was purified by flash-chromatography on silica gel (DCM/MeOH/7N NH3 in MeOH 94/5/1) to afford the title compound as white solid (45 mg, 75%).
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.14 (s, 3 H) 6.79 (bs, 3 H) 6.99 (bs, 1 H) 7.30 (d, J=8.30 Hz, 1H) 7.31 (d, J=2.44 Hz, 1 H) 7.37 (dd, J=8.30, 2.32 Hz, 1 H) 7.83 (d, J=2.69 Hz, 1 H) 8.45 (s, 1 H) 11.66 (bs, 1 H).
HRMS (ESI) calcd for C24H18ClN5O + H+ 428.1273, found 428.1278. -
- Trifluoroacetic acid (1.4 mL) was added to a solution of 5-(2-amino-5-ethynylpyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-3-carboxamide (67 mg, 0.14 mmol) in dry DCM (2.8 mL) and stirred for 4 h at room temperature. After solvent removal, the residue was treated with EtOH (3 mL), 33% NH4OH (0.4 mL) and stirred for 0.5 h. The solvent was evaporated to dryness and the residue was purified by flash-chromatography on silica gel (DCM/MeOH/7N NH3 in MeOH 94/5/1) to afford the title compound as white solid (42 mg, 85%).
ESI (+) MS: m/z 352 (MH+). -
- A suspension of 5-{2-amino-5-[(4-bromophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1-{[2-(trimethyl silyl)ethoxy]methyl}-1H-pyrrole-3-carboxamide (prepared according to Example 2 step 9, 554 mg, 0.87 mmol), Pd2(dba)3 (40 mg, 0.043 mmol), 2-dicyclohexylphosphino-2-(N,N'-dimethylamino)biphenyl (17 mg, 0.043 mmol) in anhydrous THF (6 mL) was degassed and backfilled with Argon for three times. 1-Methyl-4-piperazine (0.242 mL, 2.18 mmol) was added and the mixture was degassed and backfilled with Argon for three times again. Finally LiHMDS 1 M in THF (1.74 mL) was added by a syringe and the mixture was heated to reflux for 2 h. After cooling to room temperature the reaction mixture was filtered on a pad of celite washing with THF (30 mL). The filtrate was evaporated under vacuum and the black oil so obtained was purified by flash chromatography on silica gel (DCM/MeOH 90/10) to afford the title compound (428 mg, 75%).
ESI (+) MS: m/z 656 (MH+). - Trifluoroacetic acid (1.4 mL) was added to a solution of 5-(2-amino-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-3-carboxamide (92 mg, 0.14 mmol) in dry DCM (2.8 mL) and stirred for 4 h at room temperature. After solvent removal, the residue was treated with EtOH (3 mL), 33% NH4OH (0.4 mL) and stirred for 0.5 h. The solvent was evaporated to dryness and the residue was purified by flash-chromatography on silica gel (DCM/MeOH/7N NH3 in MeOH 94/5/1) to afford the title compound as white solid (52 mg, 71%).
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.14 (s, 3 H) 2.22 (s, 3 H) 2.42 - 2.47 (m, 4 H) 3.19 - 3.25 (m, 4 H) 6.68 (bs, 2 H) 6.78 (bs, 1 H) 6.91 - 6.99 (m, 3 H) 7.26 - 7.35 (m, 2 H) 7.35 - 7.38 (m, 1 H) 7.40 - 7.48 (m, 2 H) 7.81 (d, J=2.56 Hz, 1 H) 8.40 (s, 1 H) 11.60 (s, 1 H).
HRMS (ESI) calcd for C29H28CIN7O + H+ 526.2117, found 526.2121. -
- 5-(2-Amino-pyrimidin-4-yl)-2-(5-chloro-2-methyl-phenyl)-1H-pyrrole-3-carboxamide (1.1 g, 3.36 mmol) in dry DMF (6 mL) was treated with solid N-iodosuccinimide (830 mg, 3.69 mmol), stirred at room temperature for 4.5 h and poured into iced water (150 mL). The solid was then filtered with suction, washed thoroughly with water, dried in an oven under vacuum at 50 °C and purified by flash chromatography over silica gel (DCM/MeOH/7 N NH3 in MeOH 95/5/0.5) to afford the title compound (654 mg, 43%).
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.20 (s, 3 H) 6.41 (bs, 2 H) 7.00 (bs, 1 H) 7.13 (bs, 1 H) 7.30 (d, J=8.30 Hz, 1 H) 7.31 (d, J=5.25 Hz, 1 H) 7.34 (d, J=2.30 Hz, 1 H) 7.36 (dd, J=8.30, 2.30 Hz, 1 H) 8.29 (d, J=5.25 Hz, 1 H) 11.90 (s, 1H). - The above procedure was employed to synthesize the following compound:
- 5-(2-Amino-pyrimidin-4-yl)-2-(5-chloro-2-ethyl-phenyl)-4-iodo-1H-pyrrole-3-carboxamide (XXIV)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 1.01 (t, J=7.57 Hz, 3 H) 6.59 (bs, 2 H) 6.96 (bs, 1 H) 7.13 (bs, 1 H) 7.30 - 7.37 (m, 3 H) 7.38 - 7.45 (m, 1 H) 8.29 (d, J=5.37 Hz, 1 H) 11.99 (s, 1 H). - 5-(2-Amino-pyrimidin-4-yl)-2-(5-chloro-2-methyl-phenyl)-4-iodo-1H-pyrrole-3-carboxamide (45 mg, 0.1 mmol, 1 eq.) in dry ACN (1 mL) was treated with the alkyne (0.2 mmol, 2 eq.) and TEA (0.14 mL, 1 mmol, 10 eq.). The flask was stirred, purged with nitrogen and then solid Cul (0.005 mmol, 0.05 eq) and Pd (Ph3P)2Cl2 (0.005 mmol, 0.05 eq) were added. The reaction was then either refluxed or heated under microwave irradiation at 80 °C until full conversion of the starting material was observed (typically from 1 to several hours were required). If precipitation of the product occurred upon cooling, the solid was filtered, washed in sequence with ACN (3 x 1 mL), H2O/MeOH 9/1 (2 x 1 mL) and finally dried under vacuum at 50 °C. Conversely, the reaction was diluted with DCM (20 mL), washed with water (5 mL), dried over sodium sulfate and evaporated. The residue was then purified by flash chromatography. Typically, DCM/MeOH 95/5 under gradient conditions or reverse phase purification (Phase A: 0.05 NH4OH/ACN 95/5; Phase B: ACN/H2O 95/5 Gradient: 10-70 in 10 CV).
- The above procedure was employed to synthesize the following compounds:
- 5-(2-Amino-pyrimidin-4-yl)-2-(5-chloro-2-methyl-phenyl)-4-phenylethynyl-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = phenylethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 69)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.16 (s, 3 H) 6.37 (bs, 2 H) 7.05 (bs, 1 H) 7.22 (bs, 1 H) 7.29 (d, J=8.40 Hz, 1 H) 7.30 (d, J=2.20 Hz, 1 H) 7.36 (dd, J=8.40, 2.20 Hz, 1 H) 7.42 - 7.47 (m, 3 H) 7.48 (d, J=5.25 Hz, 1 H) 7.55 - 7.60 (m, 2 H) 8.36 (d, J=5.25 Hz, 1 H) 12.06 (bs, 1 H).
HRMS (ESI) calcd for C24H18ClN5O + H+ 428.1273, found 428.1274. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(3-hydroxyphenyl)ethynyl]-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = (3-hydroxyphenyl)ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 70)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.15 (s, 3 H) 6.32 (bs, 2 H) 6.82 (ddd, J=8.18, 2.44, 0.73 Hz, 1 H) 6.93 (dd, J=2.14, 1.65 Hz, 2 H) 6.98 (dt, J=7.60, 1.14 Hz, 1 H) 7.02 (bs, 1 H) 7.17 (bs, 1 H) 7.24 (t, J=7.87 Hz, 1 H) 7.27 (d, J=7.90 Hz, 1 H) 7.28 (d, J=2.00 Hz, 1 H) 7.34 (dd, J=7.93, 2.00 Hz, 1 H) 7.45 (d, J=5.25 Hz, 1 H) 8.32 (d, J=4.88 Hz, 1 H) 9.77 (bs, 1 H) 12.03 (bs, 1 H).
HRMS (ESI) calcd for C24H18ClN5O2 + H+ 444.1222, found 444.1219. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(4-methoxyphenyl)ethynyl]-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = (4-methoxyphenyl)ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 71)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.15 (s, 3 H) 3.81 (s, 3 H) 6.35 (bs, 2 H) 7.02 (d, J=8.91 Hz, 2 H) 7.04 (bs, 1 H) 7.21 (bs, 1 H) 7.28 (d, J=8.30 Hz, 1 H) 7.29 (d, J=2.32 Hz, 1 H) 7.36 (dd, J=8.20, 2.20 Hz, 1 H) 7.48 (d, J=5.25 Hz, 1 H) 7.52 (d, J=8.91 Hz, 2 H) 8.34 (d, J=5.25 Hz, 1 H) 12.00 (s, 1 H).
HRMS (ESI) calcd for C25H20ClN5O2 + H+ 458.1379, found 458.1378. - 4-[(3-Aminophenyl)ethynyl]-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = (3-aminophenyl)ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 72)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.15 (s, 3 H) 5.27 (br. s., 2 H) 6.36 (bs, 2 H) 6.62 (ddd, J=8.09, 2.29, 0.98 Hz, 1 H) 6.70 (dt, J=7.63, 1.13 Hz, 1 H) 6.75 (t, J=1.77 Hz, 1 H) 7.01 (bs, 1 H) 7.08 (t, J=7.87 Hz, 1 H) 7.22 (bs, 1 H) 7.27 - 7.31 (m, 2 H) 7.33 - 7.39 (m, 1 H) 7.48 - 7.50 (m, 1 H) 8.35 (d, J=5.25 Hz, 1 H) 12.02 (s, 1 H).
HRMS (ESI) calcd for C24H19CIN6O + H+ 443.1382, found 443.1379. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(2-methoxyphenyl)ethynyl]-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = (2-methoxyphenyl)ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 73)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.12 (s, 3 H) 3.92 (s, 3 H) 6.35 (bs, 2 H) 7.03 (td, J=7.48, 0.92 Hz, 1 H) 7.13 (d, J=8.06 Hz, 1 H) 7.26 - 7.29 (m, 2 H) 7.34 - 7.37 (m, 1 H) 7.38 (bs, 2 H) 7.39 - 7.45 (m, 1 H) 7.51 - 7.54 (m, 1 H) 7.66 (d, J=5.25 Hz, 1 H) 8.39 (d, J=5.25 Hz, 1 H) 12.08 (bs, 1 H).
HRMS (ESI) calcd for C25H20ClN5O2 + H+ 458.1379, found 458.1373. - 4-(2-Amino-phenylethynyl)-5-(2-amino-pyrimidin-4-yl)-2-(5-chloro-2-methyl-phenyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = (2-aminophenyl)ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 74)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.18 (s, 3 H) 5.74 (s, 2 H) 6.34 (bs, 2 H) 6.55 (td, J=7.45, 0.98 Hz, 1 H) 6.61 (bs, 1 H) 6.73 (dd, J=8.30, 0.61 Hz, 1 H) 7.08 (ddd, J=8.27, 7.17, 1.53 Hz, 1 H) 7.18 (bs, 1 H) 7.26 (dd, J=7.63, 1.40 Hz, 1 H) 7.33 (d, J=8.30 Hz, 1 H) 7.37 (d, J=2.32 Hz, 1 H) 7.40 (dd, J=8.30, 2.32 Hz, 1 H) 7.54 (d, J=5.25 Hz, 1 H) 8.34 (d, J=5.13 Hz, 1 H) 11.99 (s, 1 H).
HRMS (ESI) calcd for C24H19ClN6O + H+ 443.1382, found 443.1379. - 4-[(4-amino-2-methoxyphenyl)ethynyl]-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = (4-amino-2-methoxyphenyl)ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 75)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.17 (s, 3 H) 3.71 (s, 3 H) 5.78 (s, 2 H) 6.17 (dd, J=8.48, 2.50 Hz, 1 H) 6.30 (d, J=2.44 Hz, 1 H) 6.32 (bs, 2 H) 6.60 (bs, 1 H) 7.16 (bs, 1 H) 7.18 (d, J=8.54 Hz, 1 H) 7.32 (d, J=8.30 Hz, 1 H) 7.36 (d, J=2.32 Hz, 1 H) 7.39 (dd, J=8.30, 2.32 Hz, 1 H) 7.54 (d, J=5.25 Hz, 1 H) 8.33 (d, J=5.25 Hz, 1 H) 11.93 (s, 1 H).
HRMS (ESI) calcd for C25H21CIN6O2 + H+ 473.1488, found 473.1492. - 4-[(4-Aminophenyl)ethynyl]-5-(2-amino-pyrimidin-4-yl)-2-(5-chloro-2-methyl-phenyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = (4-aminophenyl)ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 76)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.14 (s, 3 H) 5.60 (bs, 2 H) 6.31 (bs, 2 H) 6.60 (d, J=8.54 Hz, 2 H) 7.05 (bs, 1 H) 7.19 (bs, 1 H) 7.24 (d, J=8.67 Hz, 2 H) 7.27 (d, J=2.32 Hz, 1 H) 7.28 (d, J=8.30 Hz, 1 H) 7.35 (dd, J=8.30, 2.32 Hz, 1 H) 7.50 (d, J=5.25 Hz, 1 H) 8.33 (d, J=5.25 Hz, 1 H) 11.91 (s, 1 H).
HRMS (ESI) calcd for C24H19ClN6O + H+ 443.1382, found 443.1385. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(2-methylphenyl)ethynyl]-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = (2-methylphenyl)ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 77)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.17 (s, 3 H) 6.37 (bs, 2 H) 7.05 (bs, 1 H) 7.23 - 7.34 (m, 5 H) 7.37 (dd, J=8.30, 2.32 Hz, 1 H) 7.52 (d, J=5.13 Hz, 1 H) 7.53 (d, J=7.32 Hz, 1 H) 8.35 (d, J=5.25 Hz, 1 H) 12.06 (s, 1 H).
HRMS (ESI) calcd for C25H20ClN5O + H+ 442.1429, found 442.1427. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(4-fluorophenyl)ethynyl]-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = (4-fluorophenyl)ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 78) 1H
NMR (401 MHz, DMSO-d6) δ ppm 2.13 (s, 3 H) 6.34 (bs, 2 H) 7.01 (bs, 1 H) 7.17 (bs, 1 H) 7.24 - 7.31 (m, 4 H) 7.33 (dd, J=8.60, 2.55 Hz, 1 H) 7.42 (d, J=5.13 Hz, 1 H) 7.59 - 7 63 (m, 2 H) 8.32 (d, J=5.25 Hz, 1 H) 12.03 (s, 1 H).
HRMS (ESI) calcd for C24H17ClFN5O + H+ 446.1179, found 446.1184. - 4-[(5-Amino-2-methoxyphenyl)ethynyl]-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = (5-amino-2-methoxyphenyl)ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 79)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.12 (s, 3 H) 3.78 (s, 3 H) 4.81 (bs, 2 H) 6.34 (bs, 2 H) 6.64 (dd, J=8.79, 2.81 Hz, 1 H) 6.75 (d, J=2.81 Hz, 1 H) 6.84 (d, J=8.79 Hz, 1 H) 7.26 (d, J=2.20 Hz, 1 H) 7.27 (d, J=8.12 Hz, 1 H) 7.35 (dd, J=8.12, 2.26 Hz, 2 H) 7.65 (d, J=5.25 Hz, 1 H) 8.36 (d, J=5.37 Hz, 1 H) 12.04 (bs, 1 H).
HRMS (ESI) calcd for C25H21ClN6O2 + H+ 473.1488, found 473.1485. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({3-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = {3-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 80)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 1.34 - 1.46 (m, 2 H) 1.89 (d, J=11.72 Hz, 2 H) 1.97 - 2.09 (m, 2 H) 2.15 (s, 3 H) 2.18 (s, 3 H) 2.68 - 2.81 (m, 2 H) 3.20 (d, J=7.08 Hz, 2 H) 5.67 (d, J=8.06 Hz, 1 H) 6.36 (bs, 2 H) 6.58 - 6.67 (m, 1 H) 6.67 - 6.72 (m, 1 H) 6.72 - 6.75 (m, 1 H) 7.02 (bs, 1 H) 7.12 (t, J=7.87 Hz, 1 H) 7.22 (bs, 1 H) 7.26 - 7.31 (m, 3 H) 7.33 - 7.38 (m, 1 H) 7.45 - 7.51 (m, 1 H) 8.33 (d, J=5.25 Hz, 1 H) 12.03 (bs, 1 H).
HRMS (ESI) calcd for C30H30ClN7O + H+ 540.2273, found 540.2271. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({3-[(4-methylpiperazin-1-yl)methyl]phenyl}ethynyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = {3-[(4-methylpiperazin-1-yl)methyl]phenyl}ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 NH2] (compd. 81)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.16 (s, 3 H) 2.19 (s, 3 H) 2.32-2.47 (m, 10 H) 6.38 (bs, 2 H) 7.04 (bs, 1 H) 7.22 (bs, 1 H) 7.27 - 7.51 (m, 8 H) 8.35 (d, J=5.13 Hz, 1 H) 12.06 (bs, 1 H).
HRMS (ESI) calcd for C30H30ClN7O + H+ 540.2273, found 540.2266. - 4-({3-[(2-Aminoethyl)amino]phenyl}ethynyl)-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = {3-[(2-aminoethyl)amino]phenyl}ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 82)
Obtained from tert-butyl {2-[(3-{[2-(2-aminopyrimidin-4-yl)-4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-3-yl]ethynyl}phenyl)amino]ethyl}carbamate after treatment with TFA in DCM (69% yield).
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.15 (s, 3 H) 2.80 (t, J=6.29 Hz, 2 H) 3.11 (q, J=6.10 Hz, 2 H) 5.83 (t, J=5.55 Hz, 1 H) 6.36 (bs, 2 H) 6.63 - 6.68 (m, 1 H) 6.71 - 6.79 (m, 2 H) 7.02 (bs, 1 H) 7.15 (t, J=7.93 Hz, 2 H) 7.22 (bs, 1 H) 7.26 - 7.31 (m, 3 H) 7.33 - 7.38 (m, 2 H) 7.46 - 7.53 (m, 2 H) 8.34 (d, J=5.25 Hz, 1 H).
HRMS (ESI) calcd for C26H24CIN7O + H+ 486.1804, found 486.1799. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = [4-(4-methylpiperazin-1-yl)phenyl]ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 83)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 2.23 (s, 3 H) 2.41 - 2.47 (m, 4 H) 3.20 - 3.27 (m, 4 H) 6.33 (bs, 2 H) 6.98 (d, J=9.03 Hz, 2 H) 7.05 (bs, 1 H) 7.21 (bs, 1 H) 7.25 - 7.30 (m, 2 H) 7.33 - 7.37 (m, 1 H) 7.38 - 7.44 (m, 2 H) 7.47 - 7.56 (m, 1 H) 8.33 (d, J=5.25 Hz, 1 H) 11.96 (s, 1 H).
HRMS (ESI) calcd for C29H28CIN7O + H+ 526.2117, found 526.2116. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({2-[(2-hydroxyethyl)amino]phenyl}ethynyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = {2-[(2-hydroxyethyl)amino]phenyl}ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 84)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.19 (s, 3 H) 3.22 - 3.27 (m, 2 H) 3.65 (q, J=5.94 Hz, 2 H) 4.86 (t, J=5.74 Hz, 1 H) 5.89 (t, J=5.55 Hz, 1 H) 6.35 (bs, 2 H) 6.59 (td, J=7.42, 0.92 Hz, 1 H) 6.64 (bs, 1 H) 6.68 (d, J=8.30 Hz, 1 H) 7.10 - 7.24 (m, 2 H) 7.30 - 7.36 (m, 2 H) 7.36 - 7.44 (m, 2 H) 7.55 (d, J=5.25 Hz, 1 H) 8.36 (d, J=5.25 Hz, 1 H) 12.03 (s, 1 H).
HRMS (ESI) calcd for C26H23CIN6O2 + H+ 487.1644, found 487.1648. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = [2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 NH2] (compd. 85)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.14 (s, 3 H) 2.22 (s, 3 H) 2.40 - 2.46 (m, 4 H) 3.24 - 3.28 (m, 4 H) 6.34 (bs, 2 H) 6.82 (dd, J=8.79, 2.44 Hz, 1 H) 6.88 (dd, J=13.79, 2.32 Hz, 1 H) 7.04 (bs, 1 H) 7.26 (bs, 1 H) 7.26 - 7.30 (m, 2 H) 7.33 - 7.37 (m, 1 H) 7.41 (t, J=8.73 Hz, 1 H) 7.53 (d, J=5.25 Hz, 1 H) 8.31 (d, J=5.25 Hz, 1 H) 12.02 (s, 1 H).
HRMS (ESI) calcd for C29H27CIFN7O + H+ 544.2023, found 544.2028. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[2-methoxy-5-(4-methylpiperazin-1-yl)phenyl] ethynyl}-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = [2-methoxy-5-(4-methylpiperazin-1-yl)phenyl]ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 NH2] (compd. 86)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.12 (s, 3 H) 2.24 (s, 3 H) 2.46 - 2.49 (m, 4 H) 3.07 - 3.11 (m, 4 H) 3.85 (s, 3 H) 6.35 (bs, 2 H) 6.89 - 7.09 (m, 3 H) 7.26 - 7.30 (m, 2 H) 7.32 - 7.40 (m, 2 H) 7.66 (d, J=5.25 Hz, 1 H) 8.38 (d, J=5.25 Hz, 1 H) 12.06 (s, 1 H).
HRMS (ESI) calcd for C30H30CIN7O2 + H+ 556.2223, found 556.2217. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(2-{[2-(dimethylamino)ethyl]amino}phenyl)ethynyl]-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = (2-{[2-(dimethylamino)ethyl]amino)phenyl)ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 NH2] (compd. 87)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.16 (s, 6 H) 2.18 (s, 3 H) 5.83 (t, J=5.19 Hz, 1 H) 6.35 (bs, 2 H) 6.60 (t, J=7.38 Hz, 1 H) 6.66 (d, J=8.18 Hz, 1 H) 7.16 - 7.24 (m, 2 H) 7.29 - 7.37 (m, 3 H) 7.37 - 7.42 (m, 1 H) 7.54 (d, J=5.37 Hz, 1 H) 8.34 (d, J=5.25 Hz, 1 H) 12.02 (s, 1 H).
HRMS (ESI) calcd for C28H28CIN7O + H+ 514.2117, found 514.2110. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[3-(dimethylamino)prop-1-yn-1-yl]-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = 3-(dimethylamino)prop-1-yn-1-yl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 88)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.14 (s, 3 H) 2.53 - 2.62 (m, 6 H) 3.94 (bs, 2 H) 6.37 (bs, 2 H) 6.90 (bs, 1 H) 7.20 (bs, 1 H) 7.26 - 7.32 (m, 2 H) 7.33 - 7.40 (m, 2 H) 8.28 (d, J=5.25 Hz, 1 H) 12.01 (bs, 1 H).
HRMS (ESI) calcd for C21H21ClN6O + H+ 409.1538, found 409.1543. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = [2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 89)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.11 (s, 3 H) 2.28 (bs, 3 H) 2.50 - 2.55 (m, 4 H) 3.90 (s, 3 H) 6.31 (bs, 2 H) 6.55 - 6.60 (m, 2 H) 7.24 - 7.30 (m, 2 H) 7.30 - 7.37 (m, 3 H) 7.39 (bs, 1 H) 7.66 (d, J=5.25 Hz, 1 H) 8.36 (d, J=5.13 Hz, 1 H) 11.95 (s, 1 H).
HRMS (ESI) calcd for C30H30ClN7O2 + H+ 556.2223, found 556.2220. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[3-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = [3-(4-methylpiperazin-1-yl)phenyl]ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 90)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.15 (s, 3 H) 2.24 (s, 3 H) 2.44 - 2.49 (m, 4 H) 3.10 - 3.23 (m, 4 H) 6.36 (bs, 2 H) 6.90 - 7.09 (m, 4 H) 7.23 (bs, 0 H) 7.25 - 7.31 (m, 3 H) 7.33 - 7.39 (m, 1 H) 7.46 - 7.50 (m, 1 H) 8.35 (d, J=5.25 Hz, 1H) 12.04 (s, 1H).
HRMS (ESI) calcd for C29H28ClN7O + H+ 526.2117, found 526.2120. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({3-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = {3-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 91)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.58 -1.72 (m, 2 H) 1.88 -1.99 (m, 2 H) 2.16 (s, 3 H) 2.19 (s, 3H) 2.15 - 2.24 (m, 2H) 2.57 - 2.66 (m, 2 H) 4.30 - 4.52 (m, 1 H) 6.37 (bs, 2 H) 7.04 (d, J=2.44 Hz, 1 H) 7.08 - 7.11 (m, 1 H) 7.13 (d, J=7.69 Hz, 1 H) 7.22 (bs, 1 H) 7.26 - 7.39 (m, 4 H) 7.46 (d, J=5.25 Hz, 1 H) 8.35 (d, J=5.25 Hz, 1 H) 12.06 (bs, 1 H).
HRMS (ESI) calcd for C30H29ClN6O2 + H+ 541.2114, found 541.2109. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = {4-[(1-methylpiperidin-4-yl)oxy]phenyl)ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 92)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 1.53 - 1.73 (m, 2 H) 1.90 -1.99 (m, 2 H) 2.15 (s, 3 H) 2.19 (s, 3 H) 2.18 - 2.25 (m, 2 H) 2.58 - 2.66 (m, 2 H) 4.35 - 4.52 (m, 1 H) 6.35 (bs, 2 H) 6.91 - 7.08 (m, 3 H) 7.20 (bs, 1 H) 7.25 - 7.32 (m, 2 H) 7.33 - 7.38 (m, 1 H) 7.42 - 7.54 (m, 3 H) 8.26 - 8.43 (m, 1 H) 12.01 (bs, 1 H).
HRMS (ESI) calcd for C30H29CIN6O2 + H+ 541.2114, found 541.2110. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[2-fluoro-5-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = [2-fluoro-5-(4-methylpiperazin-1-yl)phenyl]ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 NH2] (compd. 93)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.15 (s, 3 H) 2.25 (s, 5 H) 2.47 - 2.51 (m, 4H) 3.03 - 3.18 (m, 4 H) 6.37 (bs, 2 H) 7-00 - 7.09 (m, 3 H) 7.20 (t, J=9.03 Hz, 1 H) 7.23 - 7.34 (m, 3 H) 7.34 - 7.39 (m, 1 H) 7.51 (d, J=5.25 Hz, 1 H) 8.32 (d, J=5.13 Hz, 1 H) 12.12 (s, 1 H).
HRMS (ESI) calcd for C29H27CIFN7O + H+ 544.2023, found 544.2017. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({2-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = {2-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 94)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.68 - 1.83 (m, 2 H) 1.94 - 2.05 (m, 2 H) 2.20 (s, 3 H) 2.97 - 3.18 (m, 4 H) 4.42 -4.51 (m, 1 H) 5.66 (d, J=7.81 Hz, 1 H) 6.35 (bs, 2 H) 6.52 (bs, 1 H) 6.60 (t, J=7.69 Hz, 1 H) 6.73 (d, J=8.42 Hz, 1 H) 7.10 (bs, 1 H) 7.14 - 7.23 (m, 1 H) 7.30 - 7.45 (m,4 H) 7.56 (d, J=5.25 Hz, 1 H) 8.36 (d, J=5.25 Hz, 1 H) 12.02 (bs, 1 H).
HRMS (ESI) calcd for C30H30ClN7O + H+ 540.2273, found 544.2069. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl)ethynyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = {4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 NH2] (compd. 95)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 1.40 - 1.55 (m, 2 H) 1.83 (d, J=11.47 Hz, 2 H) 2.14 (s, 3 H) 2.18 (s, 3 H) 2.25 - 2.44 (m, 5 H) 2.71 - 2.84 (m, 2 H) 3.84 (d, J=12.69 Hz, 2 H) 6.33 (bs, 2 H) 6.95 - 7.00 (m, 2 H) 7.05 (bs, 1 H) 7.21 (bs, 1 H) 7.26 - 7.30 (m, 2 H) 7.34 - 7.36 (m, 1 H) 7.37 - 7.41 (m, 2 H) 7.47 - 7.51 (m, 1 H) 8.33 (d, J=5.27 Hz, 1 H) 11.97 (bs, 1H).
HRMS (ESI) calcd for C34H37CIN8O + H+ 609.2852, found 609.2858. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({4-[4-(dimethylamino)piperidin-1-yl]phenyl}ethynyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = {4-[4-(dimethylamino)piperidin-1-yl]phenyl}ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 96)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 1.43 - 1.62 (m, 2 H) 1.85 - 2.02 (m, 2 H) 2.12 - 2.16 (m, 3 H) 2.47 (bs, 6 H) 2.72 - 2.83 (m, 2 H) 3.91 (d, J=12.45 Hz, 2 H) 6.33 (bs, 2 H) 7.00 (d, J=9.03 Hz, 2 H) 7.04 (bs, 1 H) 7.21 (bs, 1 H) 7.26 - 7.31 (m, 2 H) 7.32 - 7.38 (m, 1 H) 7.40 (d, J=8.79 Hz, 2 H) 7.46 - 7.51 (m, 1 H) 8.33 (d, J=5.25 Hz, 1 H) 11.97 (s, 1H).
HRMS (ESI) calcd for C31H32ClN7O + H+ 554.2430, found 554.2437. - 5-(2-Aminopyrimidin-4-yl)-4-{[4-(1,4'-bipiperidin-1'-yl)phenyl]ethynyl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = [4-(1,4'-bipiperidin-1'-yl)phenyl]ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 97)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 1.32 - 1.62 (m, 8 H) 1.82 (bs, 2 H) 2.14 (s, 3 H) 2.75 (t, J=11.41 Hz, 2 H) 3.87 (d, J=11.60 Hz, 2 H) 6.33 (bs, 2 H) 6.98 (d, J=9.03 Hz, 2 H) 7.04 (bs, 1 H) 7.21 (bs, 1 H) 7.26 - 7.30 (m, 2 H) 7.34 - 7.37 (m, 1 H) 7.39 (d, J=8.91 Hz, 2 H) 7.46 - 7.51 (m, 1 H) 8.33 (d, J=5.25 Hz, 1 H) 11.96 (bs, 1 H).
HRMS (ESI) calcd for C34H36ClN7O + H+ 594.2743, found 594.2739. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}ethynyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = {4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 NH2] (compd. 98)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.42 - 1.62 (m, 6 H) 1.82 (bs, 2 H) 2.14 (s, 3 H) 2.82 (t, J=11.41 Hz, 2 H) 3.84 - 3.92 (m, 2 H) 6.33 (bs, 2 H) 6.93 -7.03 (m, 2 H) 7.04 (bs, 1 H) 7.21 (bs, 1 H) 7.26 - 7.30 (m, 2 H) 7.34 - 7.43 (m, 3 H) 7.46 - 7.51 (m, 1 H) 8.33 (d, J=5.25 Hz, 1 H) 11.98 (bs, 1 H).
HRMS (ESI) calcd for C33H34CIN7O + H+ 580.2586, found 580.2578. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[4-(piperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = [4-(piperazin-1-yl)phenyl]ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = NH2] (compd. 99)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.12 (s, 3 H) 3.07 - 3.13 (m, 4 H) 6.31 (bs, 2 H) 7.00 (d, J=9.03 Hz, 3 H) 7.18 (bs, 1 H) 7.23 - 7.28 (m, 2 H) 7.29 - 7.36 (m, 1 H) 7.42 (d, J=8.79 Hz, 2 H) 7.44 - 7.50 (m, 1 H) 8.30 (d, J=5.26 Hz, 1 H) 11.96 (bs, 1 H).
HRMS (ESI) calcd for C28H26CIN7O + H+ 512.1960, found 512.1964. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({4-[(4-methylpiperazin-1-yl)carbonyl]phenyl)ethynyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = {4-[(4-methylpiperazin-1-yl)carbonyl] phenyl}ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 NH2] (compd. 100)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.16 (s, 3 H) 2.21 (s, 3 H) 2.25 - 2.42 (m, 4 H) 3.46 - 3.69 (m, 2 H) 6.39 (bs, 2 H) 7.05 (bs, 1 H) 7.22 (bs, 1 H) 7.27 - 7.33 (m, 2 H) 7.33 - 7.39 (m, 1 H) 7.43 - 7.48 (m, 3 H) 7.61 - 7.65 (m, 2 H) 8.36 (d, J=5.25 Hz, 1 H) 12.11 (bs, 1 H).
HRMS (ESI) calcd for C30H28CIN7O2 + H+ 554.2066, found 554.2064. - According to this procedure, but starting from 5-(2-amino-pyrimidin-4-yl)-2-(5-chloro-2-ethyl-phenyl)-4-iodo-1H-pyrrole-3-carboxamide, the following compounds were prepared:
- 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-4-[(2-{[2-(dimethylamino)ethyl]amino}phenyl)ethynyl]-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = (2-{[2-(dimethylamino)ethyl]amino}phenyl)ethynyl, R3 = R4 = H, R5 = 5-chloro-2-ethylphenyl, R6 = NH2] (compd. 101)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.02 (t, J=7.57 Hz, 3 H) 2.17 (s, 6 H) 3.20 - 3.30 (m, 4 H) 5.83 - 5.89 (m, 1 H) 6.34 (bs, 2 H) 6.60 (td, J=7.45, 0.98 Hz, 1 H) 6.64 - 6.68 (m., 1 H) 6.65 (s, 1 H) 7.16 (bs, 2 H) 7.18 - 7.23 (m, 1 H) 7.31 - 7.39 (m, 3 H) 7.43 - 7.47 (m, 1 H) 7.54 (d, J=5.25 Hz, 1 H) 8.34 (d, J=5.25 Hz, 1 H) 12.06 (bs, 1 H).
HRMS (ESI) calcd for C29H30CIN7O + H+ 528.2273, found 528.2280. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-4-({3-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = {3-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl, R3 = R4 = H, R5 = 5-chloro-2-ethylphenyl, R6 = NH2] (compd. 102)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.00 (t, J=7.57 Hz, 3 H) 1.58 - 1.70 (m, 2 H) 1.89 -1.98 (m, 2 H) 2.19 (s, 3 H) 2.20 - 2.24 (m, 2 H) 2.58 - 2.65 (m, 2 H) 4.40 - 4.47 (m, 1 H) 6.36 (bs, 2 H) 6.99 (bs, 1 H) 7.03 (dd, J=8.12, 2.26 Hz, 1 H) 7.11 (d, J=2.44 Hz, 1 H) 7.13 (d, J=7.69 Hz, 1 H) 7.20 (bs, 1 H) 7.27 (d, J=2.32 Hz, 1 H) 7.31 - 7.38 (m, 1 H) 7.39 - 7.43 (m, 1 H) 7.46 (d, J=5.25 Hz, 1 H) 8.34 (d, J=5.25 Hz, 1 H) 12.10 (s, 1 H).
HRMS (ESI) calcd for C31H31CIN6O2 + H+ 555.2270, found 555.2272. - 5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-4-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide [(I), R1 = H, R2 = [4-(4-methylpiperazin-1-yl)phenyl]ethynyl, R3 = R4 = H, R5 = 5-chloro-2-ethylphenyl, R6 = NH2] (compd. 103)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.00 (t, J=7.57 Hz, 3 H) 2.23 (s, 3 H) 2.43 - 2.47 (m, 4 H) 3.21 - 3.25 (m, 4 H) 6.32 (bs, 2 H) 6.99 (d, J=9.03 Hz, 2 H) 7.01 (bs, 1 H) 7.18 (bs, 1 H) 7.25 (d, J=2.32 Hz, 1 H) 7.28 - 7.34 (m, 1 H) 7.38 - 7.43 (m, 3 H) 7.48 - 7.52 (m, 1 H) 8.33 (d, J=5.13 Hz, 1 H) 12.00 (s, 1 H).
HRMS (ESI) calcd for C30H30CIN7O + H+ 540.2273, found 540.2275. -
- NaH (60% dispersion in mineral oil, 160 mg, 4.0 mmol) was added to a suspension of 2-(5-chloro-2-methyl-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (1.0 g, 2.92 mmol) in dry THF (15 mL) at 0 °C. The reaction was kept at the same temperature for 20 min then 2-(chloromethoxy)ethyl](trimethyl)silane (0.714 mL, 4.0 mmol) was added and the mixture was stirred at room temperature for 2 h. Saturated aqueous NaCl (20 mL) was added at 0 °C and the mixture was extracted with EtOAc (2 x 30 mL). The separated organic phase was dried over sodium sulfate and the solvent evaporated. The crude was purified by flash chromatography on silica gel (DCM/EtOH 94/6) to afford the title compound (620 mg, 45%).
ESI (+) MS: m/z 472 (MH+). - N-iodosuccinimide (301 mg, 1.34 mmol) was added to a solution of 2-(5-chloro-2-methyl-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (600 mg, 1.27 mmol) in dry DMF (5 mL). The reaction mixture was heated at 65 °C for 7 h, allowed to cool to room temperature and then diluted with EtOAc (10 mL), washed with water (2x5 mL) brine, dried over sodium sulphate, and evaporated. The crude was purified by flash chromatography on silica gel (DCM/MeOH 97/3) to afford the title compound as yellow solid (520 mg, 65%).
ESI (+) MS: m/z 598 (MH+). - To a degassed solution of 2-(5-chloro-2-methylphenyl)-5-[5-iodo-2-(methylamino)pyrimidin-4-yl]-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-3-carboxamide 5 (0.143 g, 0.24 mmol), 1-(4-ethynylphenyl)-4-methylpiperazine (86 mg, 0.43 mmol) and TEA (0.335 mL, 2.4 mmol) in dry ACN (2.5 mL) were added copper iodide (2.5 mg, 0.012 mmol) and Pd(PPh3)2Cl2 (8.4 mg, 0.012 mmol). The mixture was heated at 80 °C for 2 h, then the solvent was evaporated. The crude was purified by flash chromatography on silica gel (DCM/MeOH/7N NH3 in MeOH 95/4/1) to afford the title compound (139 mg, 85%).
ESI (+) MS: m/z 670 (MH+). - Trifluoroacetic acid (1.4 mL) was added to a solution of 2-(5-chloro-2-methylphenyl)-5-[2-(methylamino)-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl]-1-{[3-(trimethylsilyl)propoxy]methyl}-1H-pyrrole-3-carboxamide (96 mg, 0.14 mmol) in dry DCM (2.8 mL) and stirred for 4 h at room temperature. After solvent removal, the residue was treated with EtOH (3 mL), 33% NH4OH (0.4 mL) and stirred for 0.5 h. The solvent was evaporated to dryness and the residue was purified by flash-chromatography on silica gel (DCM/MeOH/7N NH3 in MeOH 94/5/1) to afford the title compound as white solid (63 mg, 85%).
ESI (+) MS: m/z 540 (MH+). - According to this procedure, but starting from 2-(5-chloro-2-methyl-phenyl)-5-(pyrimidin-4-yl)-1H-pyrrole-3-carboxamide, the following compound was prepared:
- 2-(5-Chloro-2-methylphenyl)-5-(5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-1H-pyrrole-3-carboxamide [(I), R1 = [4-(4-methylpiperazin-1-yl)phenyl]ethynyl, R2 = H, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = H] (compd. 105)
ESI (+) MS: m/z 511 (MH+). - According to this procedure, but starting from 2-(5-chloro-2-methylphenyl)-5-(2-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide, the following compound was prepared:
- 2-(5-Chloro-2-methylphenyl)-5-(2-methyl-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-1H-pyrrole-3-carboxamide [(I), R1 = [4-(4-methylpiperazin-1-yl)phenyl]ethynyl, R2 = H, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = CH3]* (compd. 106)
ESI (+) MS: m/z 525 (MH+). -
- N-iodosuccinimide (301 mg, 1.34 mmol) was added to a solution of 2-(5-chloro-2-methylphenyl)-5-[2-(methylamino)pyrimidin-4-yl]-1H-pyrrole-3-carboxamide (433 mg, 1.27 mmol) in dry DMF (5 mL). The reaction mixture was stirred at room temperature for 5 h and poured into iced water (50 mL). The solid was then filtered with suction, washed thoroughly with water, dried in an oven under vacuum at 50 °C and purified by flash chromatography over silica gel (DCM/MeOH/7 N NH3 in MeOH 95/5/0.5) to afford the title compound (344 mg, 58%).
ESI (+) MS: m/z 468 (MH+). - The above procedure was employed to synthesize the following compounds:
- 2-(5-Chloro-2-methylphenyl)-4-iodo-5-(pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (XXIV)
ESI (+) MS: m/z 439 (MH+). - 2-(5-Chloro-2-methylphenyl)-4-iodo-5-(2-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide (XXIV)
ESI (+) MS: m/z 453 (MH+). - 2-(5-Chloro-2-methylphenyl)-4-iodo-5-[2-(methylamino)pyrimidin-4-yl]-1H-pyrrole-3-carboxamide (47 mg, 0.1 mmol) in dry ACN (1 mL) was treated with 1-(4-ethynylphenyl)-4-methylpiperazine (40 mg, 0.2 mmol) and TEA (0.14 mL, 1 mmol). The flask was stirred and purged with nitrogen and then solid Cul (1.0 mg, 0.005 mmol) and Pd(Ph3P)2Cl2 (3.5 mg, 0.005 mmol) were added. The reaction was refluxed for 2 h, then the solvent was evaporated. The crude was purified by flash chromatography on silica gel (DCM/MeOH/7N NH3 in MeOH 95/4/1) to afford the title compound (41 mg, 76%).
ESI (+) MS: m/z 540 (MH+). - According to this step, but starting from 2-(5-chloro-2-methylphenyl)-4-iodo-5-(pyrimidin-4-yl)-1H-pyrrole-3-carboxamide, the following compound was prepared:
- 2-(5-Chloro-2-methylphenyl)-4-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-5-(pyrimidin-4-yl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R = [4-(4-methylpiperazin-1-yl)phenyl]ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = H] (compd. 108)
ESI (+) MS: m/z 511 (MH+). - According to this step, but starting from 2-(5-chloro-2-methylphenyl)-4-iodo-5-(2-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide, the following compound was prepared:
- 2-(5-Chloro-2-methylphenyl)-4-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-5-(2-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide [(I), R1 = H, R = [4-(4-methylpiperazin-1-yl)phenyl]ethynyl, R3 = R4 = H, R5 = 5-chloro-2-methylphenyl, R6 = CH3] (compd. 109)
ESI (+) MS: m/z 525 (MH+). -
- Ethyl 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxylate (450 mg, 1.21 mmol) in DMF (7.5 mL) was treated with N-bromosuccinimide (216 mg, 1.21 mmol). The mixture was stirred overnight at room temperature, then poured into water, extracted with EtOAc (2 x 30 mL). The separated organic phase was dried over sodium sulfate and the solvent evaporated. Crystallization from diethyl ether afforded the title compound (420 mg, 77%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.98 (t, J=7.57 Hz, 3 H), 1.04 (t, J=7.08 Hz, 3 H), 2.43 (q, J=7.57 Hz, 2 H), 4.03 (q, J=7.08 Hz, 2 H), 6.56 (bs, 2 H), 7.27 (d, J=2.20 Hz, 1 H), 7.35 (d, J=8.30 Hz, 1 H), 7.44 (dd, J=8.30, 2.32 Hz, 1 H), 7.67 (d, J=2.69 Hz, 1 H), 8.38 (s, 1 H), 12.02 (bs, 1 H). - According to this step, but starting from ethyl 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxylate, the following compound was prepared:
- Ethyl 5-(2-amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxylate (XXV)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.07 (t, J=7.08 Hz, 3 H), 2.10 (s, 3 H), 4.01 - 4.09 (m, 2 H), 6.57 (bs, 2 H), 7.30 - 7.34 (m, 2 H), 7.38 - 7.42 (m, 1 H), 7.67 (d, J=2.69 Hz, 1 H), 8.38 (s, 1 H), 12.00 (bs, 1 H). - According to this step, but starting from ethyl 5-(2-aminopyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate, the following compound was prepared:
- Ethyl 5-(2-amino-5-bromopyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate (XXV)
ESI (+) MS: m/z 470 (MH+). - According to this step, but starting from ethyl 5-(2-aminopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate, the following compound was prepared:
- Ethyl 5-(2-amino-5-bromopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate (XXV)
ESI (+) MS: m/z 484 (MH+). - According to this step, but starting from ethyl 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxylate and using N-chlorosuccimide instead of N-bromosuccinimide, the following compound was prepared:
- Ethyl 5-(2-amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxylate (XXV)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 1.07 (t, J=7.14 Hz, 3 H), 2.10 (s, 3 H), 4.05 (q, J=7.08 Hz, 2 H), 6.55 (bs, 2 H), 7.32 (d, J=8.30 Hz, 1 H), 7.31 (d, J=1.95 Hz, 1 H), 7.40 (dd, J=8.30, 2.56 Hz, 1 H), 7.55 (d, J=2.56 Hz, 1 H), 8.30 (s, 1 H), 12.04 (bs, 1H). - According to this step, but starting from ethyl 5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxylate and using N-chlorosuccimide instead of N-bromosuccinimide, the following compound was prepared:
- Ethyl 5-(2-amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxylate (XXV)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 0.97 (t, J=7.57 Hz, 3 H), 1.04 (t, J=7.08 Hz, 3 H), 2.43 (q, J=7.65 Hz, 2 H), 4.03 (q, J=7.12 Hz, 2 H), 6.54 (bs, 2 H), 7.27 (d, J=2.32 Hz, 1 H), 7.35 (d, J=8.30 Hz, 1 H), 7.44 (dd, J=8.30, 2.32 Hz, 1 H), 7.55 (d, J=2.69 Hz, 1 H), 8.30 (s, 1 H), 12.07 (bs, 1 H). - According to this step, but starting from ethyl 5-(2-aminopyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate and using N-chlorosuccimide instead of N-bromosuccinimide, the following compound was prepared:
- Ethyl 5-(2-amino-5-chloropyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate (XXV)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 1.03 (t, J=7.08 Hz, 3 H), 2.20 (s, 3 H), 4.03 (q, J=7.04 Hz, 2 H), 6.56 (bs, 2 H), 7.53 (d, J=8.06 Hz, 1 H), 7.56 - 7.59 (m, 1 H), 7.58 (d, J=2.69 Hz, 1 H), 7.70 (dd, J=7.99, 1.77 Hz, 1 H), 8.31 (s, 1 H), 12.16 (bs, 1 H). - According to this step, but starting from ethyl 5-(2-aminopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate and using N-chlorosuccimide instead of N-bromosuccinimide, the following compound was prepared:
- Ethyl 5-(2-amino-5-chloropyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate (XXV)
ESI (+) MS: m/z 439 (MH+). - Ethyl 5-(2-amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxylate (400 mg, 0.89 mmol) was treated with a 1.5 M solution of potassium hydroxide in 95% EtOH (11.86 mL, 20 eq) under reflux overnight. After cooling, the residue was concentrated, dissolved in water and washed with DCM. To the aqueous phase cooled to 5 °C, a solution of 2 N HCl was added, under agitation. The resultant precipitate was collected by filtration to give the title compound (356 mg, 95%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.99 (t, J=7.57 Hz, 3 H), 2.45 (q, J=7.61 Hz, 2 H), 6.54 (bs, 2 H), 7.27 (d, J=2.32 Hz, 1 H), 7.34 (d, J=8.30 Hz, 1 H), 7.42 (dd, J=8.30, 2.30 Hz, 1 H), 7.68 (d, J=2.81 Hz, 1 H), 8.36 (s, 1 H), 11.88 (bs, 1H). - The above procedure was employed to synthesize the following compounds:
- 5-(2-Amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxylic acid (VI)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 2.12 (s, 3 H), 6.54 (bs, 2 H), 7.31 (d, J=8.30 Hz, 1 H), 7.30 (d, J=2.20 Hz, 1 H), 7.38 (dd, J=8.30, 2.32 Hz, 1 H), 7.55 (s, 1 H), 8.29 (s, 1 H), 11.90 (bs, 1 H). - 5-(2-Amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxylic acid (VI)
1H NMR (400 MHz, DMSO-d6 ) δ ppm 0.98 (t, J=7.63 Hz, 3 H), 2.45 (q, J=7.57 Hz, 2 H), 6.54 (bs, 2 H), 7.27 (d, J=2.32 Hz, 1 H), 7.34 (d, J=8.30 Hz, 1 H), 7.42 (dd, J=8.30, 2.32 Hz, 1 H), 7.55 (d, J=2.69 Hz, 1 H), 8.29 (s, 1 H), 11.85 (bs, 1 H), 11.93 (bs, 1 H). - 5-(2-Amino-5-chloropyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylic acid (VI)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.23 (s, 3 H), 6.51 (bs, 2 H), 7.50 (d, J=8.18 Hz, 1 H), 7.55 (bs, 2 H), 7.65 (dd, J=8.18, 1.71 Hz, 1 H), 8.27 (s, 1 H), 11.80 (bs, 1 H). - Crude 5-(2-amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxylic acid (200 mg, 0.47 mmol) in DMF (2 mL) and DIPEA (0.332 mL, 1.89 mmol) was stirred at 0° C. EDCI (180 mg, 0.94 mmol) and HOBT.NH3 (143 mg, 0.94 mmol) were added and the reaction mixture was stirred for 2 h at room temperature. The reaction mixture was poured into saturated solution of sodium hydrogen carbonate. The solid was filtered with suction and the panel washed thoroughly with water and dried under vacuum in an oven at 50 °C. The crude compound may be purified by flash chromatography (DCM/MeOH 95/5) to give the title compound (336 mg, 85%).
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.98 (t, J =7.57 Hz, 3 H), 2.45 (q, J=7.61 Hz, 2 H), 6.52 (bs, 2 H), 6.76 (bs, 1 H), 7.17 (bs, 1 H), 7.24 (d, J =2.20 Hz, 1 H), 7.32 (d, J =8.30 Hz, 1 H), 7.41 (dd, J =8.30, 2.32 Hz, 1 H), 7.76 (d, J =2.56 Hz, 1 H), 8.35 (s, 1 H), 11.60 (bs, 1 H). - According to the above procedure, but starting from ethyl 5-(2-amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxylate, the following compound was synthesized:
- 5-(2-Amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (VIII)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.12 (s, 3 H), 6.53 (bs, 2 H), 6.78 (bs, 1 H), 7.23 (bs, 1 H), 7.27 (d, J=2.32 Hz, 1 H), 7.28 (d, J=8.20 Hz, 1 H), 7.36 (dd, J=8.20, 2.32 Hz, 1 H), 7.75 (d, J=2.56 Hz, 1 H), 8.35 (s, 1 H), 11.57 (bs, 1 H). - According to the above procedure, but starting from ethyl 5-(2-amino-5-bromopyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate, the following compound was synthesized:
- 5-(2-Amino-5-bromopyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide (VIII)
ESI (+) MS: m/z 441 (MH+). - According to the above procedure, but starting from ethyl 5-(2-amino-5-bromopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate, the following compound was synthesized:
- 5-(2-Amino-5-bromopyrimidin-4-yl)-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide (VIII)
ESI (+) MS: m/z 455 (MH+). - According to the above procedure, but starting from ethyl 5-(2-amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxylate, the following compound was synthesized:
- 5-(2-Amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (VIII)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.11 (s, 3 H), 6.50 (bs, 2 H), 6.77 (bs, 1 H), 7.28 (bs, 1 H), 7.27 (d, J=2.32 Hz, 1 H), 7.28 (d, J=8.30 Hz, 1 H), 7.35 (dd, J=8.30, 2.32 Hz, 1 H), 7.69 (d, J=2.69 Hz, 1 H), 8.26 (s,1 H), 11.60 (bs, 1 H). According to the above procedure, but starting from ethyl 5-(2-amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxylate, the following compound was synthesized: - 5-(2-Amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxamide (VIII)
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.97 (t, J=7.57 Hz, 3 H), 2.45 (q, J=7.57 Hz, 2 H), 6.50 (bs, 5 H), 6.75 (bs, 1 H), 7.23 (bs, 1 H), 7.24 (d, J=2.32 Hz, 1 H), 7.32 (d, J=8.30 Hz, 1 H), 7.40 (dd, J=8.30, 2.32 Hz, 1 H), 7.70 (d, J=2.69 Hz, 1 H), 8.26 (s, 1 H), 11.63 (bs, 1 H). - According to the above procedure, but starting from ethyl 5-(2-amino-5-chloropyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate, the following compound was synthesized:
- 5-(2-Amino-5-chloropyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide (VIII)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.21 (s, 3 H), 6.50 (bs, 2 H), 6.77 (bs, 1 H), 7.41 (bs, 1 H), 7.49 (d, J=7.69 Hz, 1 H), 7.52 (d, J=1.34 Hz, 1 H), 7.64 (dd, J=7.99, 1.53 Hz, 1 H), 7.73 (d, J=2.56 Hz, 1 H), 8.27 (s,1 H), 11.74 (bs, 1 H). According to the above procedure, but starting from ethyl 5-(2-amino-5-chloropyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylate, the following compound was synthesized: - 5-(2-Amino-5-chloropyrimidin-4-yl)-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide (VIII)
ESI (+) MS: m/z 410 (MH+). - According to the above procedure, but employing the suitable amine in the step 24, the following compounds were synthesized:
- 5-(2-Amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-N-methyl-1H-pyrrole-3-carboxamide (VIII)
ESI (+) MS: m/z 421 (MH+). - 5-(2-Amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-methyl-1H-pyrrole-3-carboxamide (VIII)
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.96 (t, J=7.57 Hz, 3 H), 2.43 (q, J=7.57 Hz, 2 H), 2.62 (d, J=4.52 Hz, 3 H), 6.52 (bs, 2 H), 7.22 (d, J=2.32 Hz, 1 H), 7.31 (d, J=8.30 Hz, 1 H), 7.40 (dd, J=8.30, 2.30 Hz, 1 H), 7.74 (d, J=2.56 Hz, 1 H), 7.81 (q, J=4.60 Hz, 1 H), 8.35 (s, 1 H), 11.58 (bs, 1 H). - 5-(2-Amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-ethyl-1H-pyrrole-3-carboxamide (VIII)
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.96 (t, J=7.57 Hz, 3 H), 1.01 (t, J=7.14 Hz, 3 H), 2.43 (q, J=7.57 Hz, 2 H), 3.12 (qd, J=7.14, 5.68 Hz, 2 H), 6.53 (bs, 2 H), 7.24 (d, J=2.32 Hz, 1 H), 7.31 (d, J=8.30 Hz, 1 H), 7.40 (dd, J=8.30, 2.30 Hz, 1 H), 7.74 (d, J= 2.56 Hz, 1 H), 7.79 (t, J= 5.61 Hz, 1 H), 8.35 (s, 1 H), 11.58 (bs, 1 H). - 5-(2-Amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-(2-hydroxyethyl)-1H-pyrrole-3-carboxamide (VIII)
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.97 (t, J=7.63 Hz, 3 H), 2.43 (q, J=7.61 Hz, 2 H), 3.17 (q, J=6.06 Hz, 2 H), 3.39 (q, J=6.27 Hz, 2 H), 4.60 (t, J=5.49 Hz, 1 H), 6.53 (bs, 2 H), 7.23 (d, J= .32 Hz, 1 H), 7.31 (d, J= .32 Hz, 1 H), 7.40 (dd, J=8.32, 2.32 Hz, 1 H), 7.73 (t, J=5.61 Hz, 1 H), 7.76 (d, J=2.56 Hz, 1 H), 8.35 (s, 1 H), 11.60 (bs, 1 H). - 5-(2-Amino-5-bromopyrimidin-4-yl)-[2-ethyl-5-(trifluoromethyl)phenyl]-N-methyl-1H-pyrrole-3-carboxamide (VIII)
ESI (+) MS: m/z 469 (MH+). - 5-(2-Amino-5-bromopyrimidin-4-yl)-[2-ethyl-5-(trifluoromethyl)phenyl]-N-ethyl-1H-pyrrole-3-carboxamide (VIII)
ESI (+) MS: m/z 483 (MH+). - 5-(2-Amino-5-bromopyrimidin-4-yl)-[2-ethyl-5-(trifluoromethyl)phenyl]-N-(2-hydroxyethyl)-1H-pyrrole-3-carboxamide (VIII)
ESI (+) MS: m/z 499 (MH+). - 5-(2-Amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-N-methyl-1H-pyrrole-3-carboxamide (VIII)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.09 (s, 3 H), 2.63 (d, J=4.52 Hz, 3 H), 6.50 (bs, 2 H), 7.25 (d, J=2.44 Hz, 1 H), 7.27 (d, J=8.40 Hz, 1 H), 7.35 (dd, J=8.30, 2.32 Hz, 1 H), 7.67 (d, J=2.56 Hz, 1 H), 7.87 (q, J=4.35 Hz, 1 H), 8.27 (s, 1 H), 11.61 (d, J=0.73 Hz, 1 H). - 5-(2-Amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-N-(2-hydroxyethyl)-1H-pyrrole-3-carboxamide (VIII)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.09 (s, 3 H), 3.18 (q, J=6.14 Hz, 2 H), 3.41 (q, J=5.94 Hz, 2 H), 4.62 (t, J=5.49 Hz, 1 H), 6.51 (bs, 2 H), 7.26 (d, J=2.07 Hz, 1 H), 7.27 (d, J=7.57 Hz, 1 H), 7.35 (dd, J=8.18, 2.20 Hz, 1 H), 7.70 (d, J=2.56 Hz, 1 H), 7.83 (t, J=5.74 Hz, 1 H), 8.27 (s, 1 H), 11.62 (bs, 1 H). - 5-(2-Amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-methyl-1H-pyrrole-3-carboxamide (VIII)
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.96 (t, J 7.63 Hz, 3 H), 2.43 (q, J=7.57 Hz, 2 H), 2.62 (d, J=4.52 Hz, 3 H), 6.49 (bs, 2 H), 7.22 (d, J=2.20 Hz, 1 H), 7.30 (d, J=8.30 Hz, 1 H), 7.39 (dd, J=8.30, 2.30 Hz, 1 H), 7.67 (d, J=2.44 Hz, 1 H), 7.84 (q, J=4.19 Hz, 1 H), 8.26 (s, 1 H), 11.62 (bs, 1 H). - 5-(2-Amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-ethyl-1H-pyrrole-3-carboxamide (VIII)
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.96 (t, J=7.57 Hz, 3 H), 1.02 (t, J=7.14 Hz, 3 H), 2.43 (q, J=7.53 Hz, 2 H), 3.12 (qd, J=7.16, 5.61 Hz, 2 H), 6.49 (bs, 2 H), 7.23 (d, J=2.32 Hz, 1 H), 7.31 (d, J=8.30 Hz, 1 H), 7.40 (dd, J=8.30, 2.30 Hz, 1 H), 7.68 (d, J=2.56 Hz, 1 H), 7.83 (t, J=5.61 Hz, 1 H), 8.27 (s, 1 H), 11.61 (bs, 1 H). - 5-(2-Amino-5-chloropyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-(2-hydroxyethyl)-1H-pyrrole-3-carboxamide (VIII)
1H NMR (400 MHz, DMSO-d 6) δ ppm 0.96 (t, J=7.57 Hz, 3 H), 2.43 (q, J=7.61 Hz, 2 H), 3.17 (q, J=6.10 Hz, 2 H), 3.40 (q, J=6.06 Hz, 2 H), 4.61 (t, J=5.49 Hz, 1 H), 6.50 (bs, 2 H), 7.23 (d, J=2.32 Hz, 1 H), 7.31 (d, J=8.30 Hz, 1 H), 7.40 (dd, J=8.30, 2.30 Hz, 1 H), 7.70 (d, J=2.56 Hz, 1 H), 7.79 (t, J=5.55 Hz, 1 H), 8.27 (s, 1 H), 11.63 (bs, 1 H). - 5-(2-Amino-5-chloropyrimidin-4-yl)-N-methyl-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide (VIII)
1H NMR (400 MHz, DMSO-d 6) δ ppm 2.19 (s, 3 H), 2.63 (d, J=4.52 Hz, 3 H), 6.50 (bs, 2 H), 7.48 (d, J=7.81 Hz, 1 H), 7.51 (d, J=1.46 Hz, 1 H), 7.64 (dd, J=7.99, 1.65 Hz, 1 H), 7.70 (d, J=2.56 Hz, 1 H), 7.94 (q, J=4.64 Hz, 1 H), 8.27 (s, 1 H), 11.74 (bs, 1 H). - 5-(2-Amino-5-chloropyrimidin-4-yl)-N-ethyl-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide (VIII)
1H NMR (400 MHz, DMSO-d 6) δ ppm 1.03 (t, J=7.20 Hz, 3 H), 2.20 (s, 3 H), 3.13 (qd, J=7.18, 5.43 Hz, 2 H), 6.50 (bs, 2 H), 7.48 (d, J=7.93 Hz, 1 H), 7.52 (d, J=1.46 Hz, 1 H), 7.64 (dd, J=7.93, 1.59 Hz, 1 H), 7.70 (d, J=2.56 Hz, 1 H), 7.95 (t, J=5.61 Hz, 1 H), 8.28 (s, 1 H), 11.73 (bs, 1 H). - 5-(2-Amino-5-chloropyrimidin-4-yl)-[2-ethyl-5-(trifluoromethyl)phenyl]-N-methyl-1H-pyrrole-3-carboxamide (VIII)
ESI (+) MS: m/z 424 (MH+). - 5-(2-Amino-5-chloropyrimidin-4-yl)-[2-ethyl-5-(trifluoromethyl)phenyl]-N-ethyl-1H-pyrrole-3-carboxamide (VIII)
ESI (+) MS: m/z 438 (MH+). - 5-(2-Amino-5-chloropyrimidin-4-yl)-[2-ethyl-5-(trifluoromethyl)phenyl]-N-(2-hydroxyethyl)-1H-pyrrole-3-carboxamide (VIII)
ESI (+) MS: m/z 454 (MH+). - 5-(2-Amino-5-bromopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxamide (252 mg, 0.599 mmol) in dry ACN (5 mL) was treated with 1-(4-ethynylphenyl)-4-methylpiperazine (180 mg, 0.89 mmol) and TEA (0.83 mL, 5.99 mmol). The flask was stirred and purged with nitrogen and then solid CuI (5.7 mg, 0.029 mmol) and Pd(Ph3P)2Cl2 (21.0 mg, 0.029 mmol) were added. The reaction was then refluxed for 2 h. The reaction mixture was diluted with DCM, washed with water, dried over sodium sulfate and evaporated. The crude was purified by flash chromatography on silica gel (DCM/MeOH/7N NH3 in MeOH 95/4/1) to afford the title compound (155 mg, 48%).
ESI (+) MS: m/z 540 (MH+). - General Principle - Specific JAK2, JAK1 or JAK3 peptide subtrates are trans-phosphorylated by JAK kinases in the presence of ATP traced with 33P-γ-ATP. At the end of the phosphorylation reaction, the unreacted ATP, cold and radioactive, is captured by an excess of dowex ion exchange resin that eventually settles by gravity to the bottom of the reaction plate. The supernatant is subsequently withdrawn and transferred into a counting plate that is then evaluated by β-counting.
- Dowex resin preparation - 500 g of wet resin (SIGMA, custom prepared resin DOWEX 1x8 200-400 mesh, 2.5 Kg) are weighed out and diluted 2 to 1 in 150 mM sodium formate, pH 3.00. The resin is allowed to settle down overnight and then the supernatant is discarded. After three washes as above over a couple of days, the resin is allowed to settle and two volumes (with respect to the resin volume) of 150 mM sodium formate buffer are added.
- Kinase Buffer (KB) - Kinase buffer was composed of 50 mM HEPES pH 7.5 containing 10 mM MgCl2, 2.5 mM DTT, 10 (µM Na3VO4 and 0.2 mg/mL BSA.
- Enzyme - Assays were performed with the commercially available JAK2 kinase domain (Invitrogen, Eugene, OR) that showed a linear kinetic without prephosphorylation.
- Assay conditions - The JAK2 kinase assay was run with a final enzyme concentration of 1 nM, in the presence of 60 µM ATP, 3 nM 33P-γ-ATP and 64 µM of substrate BioDBn*306 (Aminoacid sequence: LPLDKDYYWREPGO - SEQ ID NO: 1). The peptidic substrate was purchased from American Peptide Company (Sunnyvale, CA).
- Enzyme - Assays were performed with the JAK1 kinase domain (residues 861-1152 of the 1154 amino acid long full-length sequence, accession number P23458 of UniProtKB/Swiss-Prot database).
- The JAK1 kinase domain was preactivated with ATP for 1 h at 28 °C in order to obtain a linear kinetic.
- Assay conditions - The JAK1 kinase assay was run with a final pre activated enzyme concentration of 2.5 nM, in the presence of 100 µM ATP, 2 nM 33P-γ-ATP and 154 µM of substrate BioDBn*333 (Aminoacid sequence: KKHTDDGYMPMSPGVA - SEQ ID NO: 2). The peptidic substrate was purchased from American Peptide Company (Sunnyvale, CA).
- Enzyme - Assays were performed with the JAK3 kinase domain (residues 781-1124 of the 1124 amino acid long full-length sequence, accession number P52333 of UniProtKB/Swiss-Prot databse) that showed a linear kinetic without prephosphorylation.
- Assay conditions - The JAK3 kinase assay was run with a final enzyme concentration of 1 nM, in the presence of 22 µM ATP, 1 nM 33P-γ-ATP and 40 µM of substrate BioDBn*306 (Aminoacid sequence: LPLDKDYYWREPGO - SEQ ID NO: 1). The peptidic substrate was purchased from American Peptide Company (Sunnyvale, CA).
- General Principle - Specific Lck and Lyn subtrates are trans-phosphorylated by Lck and Lyn kinases in the presence of ATP traced with 33P-γ-ATP. At the end of the phosphorylation reaction, the unreacted ATP, cold and radioactive, is captured by an excess of dowex ion exchange resin that eventually settles by gravity to the bottom of the reaction plate. The supernatant is subsequently withdrawn and transferred into a counting plate that is then evaluated by β-counting.
- Enzyme - The assay has been performed using Lck full length (accession number P06239 of UniProtKB/Swiss-Prot database). The Lck full-length protein showed a linear kinetic without prephosphorylation.
- Lck Kinase Buffer (KB) - Kinase buffer was composed of 50 mM HEPES pH 7.5 containing 3 mM MgCl2, 3 mM MnCl2, 1 mM DTT, 3 µM Na3VO4, and 0.2 mg/mL BSA.
- Assay conditions - The Lck kinase assay was run with a final enzyme concentration of 1.4 nM, in the presence of 6 µM ATP, 3 nM 33P-γ-ATP and 5 µM of substrate Myelin Basic Protein (MBP). The MBP was purchased from Sigma (Sigma-Aldrich St. Louis, MO; cod. M-1891)
- Enzyme - The assay has been performed using Lyn full length (accession number P07948 of UniProtKB/Swiss-Prot database). The Lyn full-length protein showed a linear kinetic without prephosphorylation.
- Lyn Kinase Buffer (KB) - Kinase buffer was composed of 50 mM HEPES pH 7.5 containing 3 mM MgCl2, 1 mM DTT, 3 µM Na3VO4, and 0.2 mg/mL BSA.
- Assay conditions - The Lyn kinase assay was run with a final enzyme concentration of 1 nM, in the presence of 25 µM ATP, 1.5 nM 33P-γ-ATP and 250 µM of substrate ABI 1 (Aminoacid sequence: EAIYAAPFAKKK- SEQ ID NO: 3). The peptidic substrate was purchased from American Peptide Company (Sunnyvale, CA).
- Compound Dilution - For IC50 determination, test compounds are received as a 1 mM solution in 100% DMSO, distributed into 96 well plates: compounds are then plated into the first column of a microtiter plate (A1 to G1), 100 µL/well.
- An automated station for serial dilutions (Biomek FX, Beckman) is used for producing 1:3 dilutions in 100 % DMSO, from line A1 to A10, and for all the compounds in the column. Moreover, 4-5 copies of daughter plates are prepared by reformatting 5 µL of this first set of 100% DMSO dilution plates into 384 deep well-plates: one of these plates with the serial dilutions of test compounds will be thawed the day of the experiments, reconstituted at a 3X concentration with water and used in the IC50 determination assays. In a standard experiment, the highest concentration (3X) of all compounds is 30 µM, while the lowest one is 1.5 nM. Each 384 well-plate will contain at least one curve of the standard inhibitor staurosporine and reference wells (total enzyme activity vs. no enzymatic activity) for the Z' and signal to background evaluation.
- Assay Scheme - 384-well plates, V bottom (test plates) are prepared with 5 µL of the compound dilution (3X) and then placed onto a PlateTrak 12 robotized station (Perkin Elmer; the robot has one 384-tip pipetting head for starting the assay plus one 96-tip head for dispensing the resin) together with one reservoir for the Enzyme mix (3X) and one for the ATP mix (3X). At the start of the run, the robot aspirates 5 µL of ATP mix, makes an air gap inside the tips (3 µl) and aspirates 5 µL of JAK2 mix. The following dispensation into the plates plus 3 cycles of mixing, done by the robot itself, starts the kinase reaction. At this point, the correct concentrations are restored for all the reagents. The robot incubates the plates for 60 minutes at room temperature, and then stops the reaction by pipetting 60 µL of dowex resin suspension into the reaction mix. In order to avoid tip clogging, wide bore tips are used to dispense the resin suspension. Three cycles of mixing are done immediately after the addition of the resin. Another mixing cycle is performed after all the plates are stopped, this time using normal tips: the plates are then allowed to rest for about one hour in order to allow resin sedimentation. At this point, 27 µL of the supernatant are transferred into 384-Optiplates (Perkin-Elmer), with 50 µL of Microscint 40 (Perkin-Elmer); after 5 min of orbital shaking the plates are read on a Perkin-Elmer Top Count radioactivity counter.
- Data Fitting - Data are analyzed by an internally customized version of the SW package "Assay Explorer" that provides sigmoidal fitting of the ten-dilutions curves for IC50 determination in the secondary assays/hit confirmation routines.
- Cell lines: The JAK2 dependent human megakaryoblastic leukemia cell line SET-2 (DSMZ, Braunschweig GERMANY) and the JAK2 independent human chronic myelogenous leukaemia cell line K562 (ECACC, Wiltshire, UK) were cultured in RPMI-1640 medium-Glutamax (Gibco BRL, Gaithesburg, MD, USA), supplemented with 10% fetal bovine serum (FBS) at 37 °C and 5% CO2.
- Cell proliferation assay: Approximately 5x103 cells were plated into 384 microtiter plate wells in 50 µL of growth media with different concentrations of inhibitors. The cells were incubated at 37 °C and 5 % CO2 for 72 hours, then the plates were processed using CellTiter-Glo assay (Promega, Madison, WI, USA) following the manufacturer's instruction. Briefly 25 µL/well reagent solution is added to each well and after 5 minutes shaking the micro-plates are read by Envision luminometer (PerkinElmer, Waltham, MA, USA).
- Data Fitting - Data are analyzed by Symix Assay Explorer software (Symix Technologies Inc.) that provides sigmoidal fitting algorithm of the 8 points dilutions curves for IC50 determination.
- In biochemical assays, the compounds of formula (I) tested as described above demonstrate a remarkably potent JAK and SFK inhibitory activity, typically lower than 0.1 µM. See, as an example, the following Table A wherein are reported experimental data (IC50) of the compounds of the invention obtained for representative enzymes of JAK (i.e. JAK2) and Src (i.e. Lyn) family Kinases.
- In cellular assays, the compounds of formula (I) tested as described above show a remarkably high activity in JAK2 dependent SET-2 cell line (see Table A).
Table A Compd. JAK2 IC50 µM Lyn IC50 µM SET-2 IC50 µM 1 0.002 0.30 2 0.002 0.006 0.52 4 0.001 0.001 0.15 5 0.005 0.75 6 0.001 0.003 0.24 8 0.001 0.002 0.14 9 0.001 0.010 0.34 11 0.004 0.008 0.09 12 0.001 0.50 13 0.004 0.008 15 0.002 0.005 0.24 22 0.002 0.009 0.43 24 0.002 0.005 0.33 25 0.002 0.010 0.17 26 0.001 0.29 27 0.001 0.001 0.58 28 0.001 0.001 0.33 31 0.001 0.31 32 0.004 0.006 0.16 34 0.005 0.020 0.67 38 0.002 0.57 40 0.085 2.48 42 0.011 0.009 0.24 43 0.013 0.96 44 0.011 0.46 45 0.010 0.56 46 0.006 0.018 0.29 47 0.003 0.006 0.22 48 0.006 0.008 0.16 49 0.005 0.020 0.14 50 0.007 0.026 1.38 53 0.002 0.11 54 0.016 0.78 63 0.003 0.005 0.10 65 0.001 0.08 66 0.001 0.001 0.19 67 0.001 0.001 0.19 69 0.008 0.020 1.45 72 0.002 0.010 0.42 74 0.004 0.013 0.12 76 0.003 0.008 0.50 80 0.006 0.78 81 0.006 0.003 0.54 82 0.007 0.011 0.29 83 0.008 0.009 0.51 86 0.001 0.001 0.21 87 0.013 0.024 0.29 89 0.006 0.004 0.26 90 0.003 0.005 0.30 91 0.005 0.114 0.26 92 0.005 0.039 0.22 93 0.005 0.093 0.23 94 0.032 0.661 0.29 95 0.008 0.281 0.40 96 0.004 0.093 0.21 97 0.012 0.293 0.74 98 0.036 0.208 1.64 99 0.002 0.026 0.41 101 0.005 0.025 0.20 102 0.001 0.006 0.24 103 0.004 0.023 0.18 - So far, the novel compounds of the invention are endowed with a potent JAK and Src family kinases inhibitory activity and are thus particularly advantageous, in therapy, against cancer and metastasis, cell proliferative disorders, viral infections, immune disorders, neurodegenerative disorders, cardiovascular diseases and bone related diseases.
-
- <110> Nerviano Medical Sciences S.r.l.
- <120> Alkynyl substitued pyrimidinyl-pyrroles active as kinases inhibitors
- <130> NMS 086
- <150>
EP11175736
<151> 2011-07-28 - <160> 3
- <170> PatentIn version 3.3
- <210> 1
<211> 15
<212> PRT
<213> Artificial - <220>
<223> Peptide substrate - <400> 1
- <210> 2
<211> 16
<212> PRT
<213> Artificial - <220>
<223> Peptide substrate - <400> 2
- <210> 3
<211> 12
<212> PRT
<213> Artificial - <220>
<223> Peptide substrate - <400> 3
Claims (14)
- A compound of formula (I):one selected from R1 and R2 is hydrogen and the other is ethynyl-R7, wherein:R7 is hydrogen, trialkylsylyl or an optionally substituted group selected from straight or branched C1-C6 alkyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heterocyclyl and heterocyclyl-alkyl;R3 and R4 are independently hydrogen or an optionally substituted group selected from straight or branched C1-C6 alkyl, straight or branched C2-C6 alkenyl, straight or branched C2-C6 alkynyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl and heterocyclyl-alkyl, or R3 and R4, taken together with the nitrogen atom to which they are bonded, may form an optionally substituted 5 to 7 membered heterocyclyl group optionally containing one additional heteroatom selected from N, O and S;R5 is an optionally substituted aryl;R6 is hydrogen, an optionally substituted straight or branched C1-C6 alkyl or NR8R9, wherein:R8 and R9 are independently hydrogen or an optionally substituted group selected from straight or branched C1-C6 alkyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, heterocyclyl and heterocyclyl-alkyl, or R8 and R9, taken together with the nitrogen atom to which they are bonded, may form an optionally substituted 5 to 7 membered heterocyclyl group optionally containing one additional heteroatom selected from N, O and S;or a pharmaceutically acceptable salt thereof.
- A compound of formula (I) as defined in claim 1 wherein:R1 is ethynyl-R7 and R2 is hydrogen.
- A compound of formula (I) as defined in claim 2 wherein:R3 and R4 are independently hydrogen or an optionally substituted group selected from straight or branched C1-C6 alkyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heterocyclyl and heterocyclyl-alkyl.
- A compound of formula (I) as defined in claims 2 or 3 wherein:R7 is an optionally substituted aryl.
- A compound of formula (I) as defined in claim 1 wherein:R1 is hydrogen and R2 is ethynyl-R7.
- A compound of formula (I) as defined in claim 5 wherein:R3 and R4 are independently hydrogen or an optionally substituted group selected from straight or branched C1-C6 alkyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heterocyclyl and heterocyclyl-alkyl.
- A compound or a pharmaceutically acceptable salt thereof which is selected from the group consisting of:5-[2-Amino-5-(phenylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 1),5-{2-Amino-5-[(3-hydroxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 2),5-{2-Amino-5-[(4-methoxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 3),5-{2-amino-5-[(3-aminophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 4),5-{2-Amino-5-[(2-methoxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 5),5-{2-Amino-5-[(2-aminophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 6),5-{2-Amino-5-[(2,4-difluorophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 7),5-{2-Amino-5-[(4-aminophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 8),5-{2-Amino-5-[(5-amino-2-methoxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 9),5-{2-Amino-5-[(4-amino-2-methoxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 10),5-(2-Amino-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 11),5-[2-Amino-5-({3-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 12),5-(2-Amino-5-{[3-(tetrahydro-2H-pyran-4-ylamino)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 13),tert-Butyl (2-{[3-({2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-2-yl]pyrimidin-5-yl}ethynyl)phenyl]amino}ethyl)carbamate (compd. 14),5-[2-Amino-5-({3-[(2-hydroxyethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 15),5-[2-Amino-5-({4-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 16),tert-Butyl 3-({[3-({2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-2-yl]pyrimidin-5-yl}ethynyl)phenyl]amino}methyl)azetidine-1-carboxylate (compd. 17),5-(2-Amino-5-{[4-(tetrahydro-2H-pyran-4-ylamino)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 18),5-[2-Amino-5-({4-[(2-hydroxyethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 19),tert-Butyl 3-({[4-({2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-2-yl]pyrimidin-5-yl}ethynyl)phenyl]amino}methyl)azetidine-1-carboxylate (compd. 20),tert-Butyl (2-{[4-({2-amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-2-yl]pyrimidin-5-yl}ethynyl)phenyl]amino}ethyl)carbamate (compd. 21),5-[2-Amino-5-({2-methoxy-5-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 22),5-{2-Amino-5-[(4-formylphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 23),5-[2-Amino-5-({3-[(4-methylpiperazin-1-yl)methyl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 24),5-[2-Amino-5-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 25),5-[2-Amino-5-({4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 26),5-[2-Amino-5-({3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 27),5-(2-Amino-5-{[4-(4-hydroxypiperidin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 28),5-[2-Amino-5-({2-methoxy-4-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 29),5-{2-Amino-5-[3-(1,1-dioxidothiomorpholin-4-yl)prop-1-yn-1-yl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 30),5-[2-Amino-5-({4-[(2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 31),5-[2-Amino-5-({3-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 32),N-[3-({2-Amino-4-[4-carbamoyl-5-(5-chloro-2-methylphenyl)-1H-pyrrol-2-yl]pyrimidin-5-yl}ethynyl)-4-methoxyphenyl]-1-methylpiperidine-4-carboxamide (compd. 33),5-(2-Amino-5-{[2-methoxy-5-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 34),5-{2-Amino-5-[(5-bromo-2-methoxyphenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 35),5-[2-Amino-5-(cyclohexylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 36),5-[2-Amino-5-({2-methoxy-4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 37),5-[2-Amino-5-(cyclopropylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 38),5-[2-Amino-5-(3,3-dimethylbut-1-yn-1-yl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 39),5-{2-Amino-5-[(4-bromophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 40),5-{2-Amino-5-[(4-bromo-2-fluorophenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 41),5-(2-Amino-5-{[2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 42),5-[2-Amino-5-({2-[(2-hydroxyethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 43),5-{2-Amino-5-[3-(dimethylamino)prop-1-yn-1-yl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 44),5-{2-Amino-5-[(2-{[2-(dimethylamino)ethyl]amino}phenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 45),5-(2-Amino-5-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 46),5-(2-Amino-5-{[3-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 47),5-[2-Amino-5-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 48),5-(2-Amino-5-{[2-fluoro-5-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 49),5-{2-Amino-5-[3-(4-methylpiperazin-1-yl)prop-1-yn-1-yl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 50),5-(2-Amino-5-{3-[(1-methylpiperidin-4-yl)oxy]prop-1-yn-1-yl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 51),5-[2-Amino-5-({2-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide] (compd. 52),5-[2-Amino-5-(pyridin-3-ylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 53),5-[2-Amino-5-(3-hydroxy-3-methylbut-1-yn-1-yl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 54),5-[2-Amino-5-(3-hydroxybut-1-yn-1-yl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 55),5-(2-Amino-5-{3-[benzyl(methyl)amino]prop-1-yn-1-yl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 56),5-[2-Amino-5-(phenylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-N-methyl-1H-pyrrole-3-carboxamide (compd. 57),5-(2-Amino-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-N-methyl-1H-pyrrole-3-carboxamide (compd. 58),5-[2-Amino-5-({4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 59),5-[2-Amino-5-({4-[4-(dimethylamino)piperidin-1-yl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 60),5-[2-Amino-5-({3-[(azetidin-3-ylmethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 61),5-[2-Amino-5-({4-[(azetidin-3-ylmethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 62),5-[2-Amino-5-({3-[(2-aminoethyl)amino]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 63),5-{2-Amino-5-[(3-{[(1-methylazetidin-3-yl)methyl]amino}phenyl)ethynyl]pyrimidin-4-yl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 64),5-[2-Amino-5-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}ethynyl)pyrimidin-4-yl]-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 65),5-(2-Amino-5-{[4-(pyrrolidin-1-ylmethyl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 66),5-(2-Amino-5-{[4-(piperidin-1-ylmethyl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 67),5-(2-Amino-5-ethynylpyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 68),5-(2-Amino-pyrimidin-4-yl)-2-(5-chloro-2-methyl-phenyl)-4-phenylethynyl-1H-pyrrole-3-carboxamide (compd. 69),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(3-hydroxyphenyl)ethynyl]-1H-pyrrole-3-carboxamide (compd. 70),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(4-methoxyphenyl)ethynyl]-1H-pyrrole-3-carboxamide (compd. 71),4-[(3-Aminophenyl)ethynyl]-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 72),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(2-methoxyphenyl)ethynyl]-1H-pyrrole-3-carboxamide (compd. 73),4-(2-Amino-phenylethynyl)-5-(2-amino-pyrimidin-4-yl)-2-(5-chloro-2-methyl-phenyl)-1H-pyrrole-3-carboxamide (compd. 74),4-[(4-amino-2-methoxyphenyl)ethynyl]-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 75),4-[(4-Aminophenyl)ethynyl]-5-(2-amino-pyrimidin-4-yl)-2-(5-chloro-2-methyl-phenyl)-1H-pyrrole-3-carboxamide (compd. 76),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(2-methylphenyl)ethynyl]-1H-pyrrole-3-carboxamide (compd. 77),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(4-fluorophenyl)ethynyl]-1H-pyrrole-3-carboxamide (compd. 78),4-[(5-Amino-2-methoxyphenyl)ethynyl]-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 79),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({3-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 80),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({3-[(4-methylpiperazin-1-yl)methyl]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 81),4-({3-[(2-Aminoethyl)amino]phenyl}ethynyl)-5-(2-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 82),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 83),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({2-[(2-hydroxyethyl)amino]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 84),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[2-fluoro-4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 85),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[2-methoxy-5-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 86),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[(2-{[2-(dimethylamino)ethyl]amino}phenyl)ethynyl]-1H-pyrrole-3-carboxamide (compd. 87),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-[3-(dimethylamino)prop-1-yn-1-yl]-1H-pyrrole-3-carboxamide (compd. 88),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 89),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[3-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 90),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({3-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 91),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({4-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 92),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[2-fluoro-5-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 93),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({2-[(1-methylpiperidin-4-yl)amino]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 94),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 95),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({4-[4-(dimethylamino)piperidin-1-yl]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 96),5-(2-Aminopyrimidin-4-yl)-4-{[4-(1,4'-bipiperidin-1'-yl)phenyl]ethynyl}-2-(5-chloro-2-methylphenyl)-1H-pyrrole-3-carboxamide (compd. 97),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 98),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-{[4-(piperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 99),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-4-({4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 100),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-4-[(2-{[2-(dimethylamino)ethyl]amino}phenyl)ethynyl]-1H-pyrrole-3-carboxamide (compd. 101),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-4-({3-[(1-methylpiperidin-4-yl)oxy]phenyl}ethynyl)-1H-pyrrole-3-carboxamide (compd. 102),5-(2-Aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-4-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 103),2-(5-Chloro-2-methylphenyl)-5-[2-(methylamino)-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl]-1H-pyrrole-3-carboxamide (compd. 104),2-(5-Chloro-2-methylphenyl)-5-(5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (compd. 105),2-(5-Chloro-2-methylphenyl)-5-(2-methyl-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (compd. 106),2-(5-Chloro-2-methylphenyl)-5-[2-(methylamino)pyrimidin-4-yl]-4-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-1H-pyrrole-3-carboxamide (compd. 107),2-(5-Chloro-2-methylphenyl)-4-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-5-(pyrimidin-4-yl)-1H-pyrrole-3-carboxamide (compd. 108),2-(5-Chloro-2-methylphenyl)-4-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}-5-(2-methylpyrimidin-4-yl)-1H-pyrrole-3-carboxamide (compd. 109),5-(2-Amino-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1H-pyrrole-3-carboxamide (compd. 110),5-[2-Amino-5-(phenylethynyl)pyrimidin-4-yl]-2-(5-chloro-2-ethylphenyl)-N-methyl-1H-pyrrole-3-carboxamide (compd. 111) and5-(2-Amino-5-{[4-(4-methylpiperazin-1-yl)phenyl]ethynyl}pyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-methyl-1H-pyrrole-3-carboxamide (compd. 112).
- A process for preparing a compound of formula (I) as defined in claim 1 or the pharmaceutically acceptable salts thereof, characterized in that the process comprises the following steps:Step 1: metal-catalyzed coupling reactions of a halo derivative of formula (II)Step 2: hydrolysis under basic conditions of the resultant compound of formula (IV)Step 3: regioselective mono-halogenation of the resultant carboxylic acid of formula (V)Step 4: amidation of the resultant mono-halogenated carboxylic acid of formula (VI)
NHR3R4 (VII)
wherein R3 and R4 are as defined in claim 1;Step 5: metal-catalyzed coupling reactions of the resultant mono-halogenated carboxamide of formula (VIII)Step 6: amidation of the carboxylic acid of formula (V) as defined above, through reaction with an amine of formula (VII) as defined above;Step 7: regioselective introduction of a protecting group on the pyrrole nitrogen of the resultant carboxamide of formula (X)Step 8: regioselective mono-halogenation of the resultant protected compound of formula (XI)Step 9: metal-catalyzed coupling reaction of the resultant mono-halogenated carboxamide of formula (XII)Step 10: deprotection of the resultant compound of formula (XIII)Step 11: regioselective introduction of a protecting group on the pyrrole nitrogen of the carboxylic ester of formula (IV) as defined above;Step 12: regioselective mono-halogenation of the resultant protected carboxylic ester of formula (XIV)Step 13: metal-catalyzed coupling reaction of the resultant mono-halogenated carboxylic ester of formula (XV)Step 14: hydrolysis under basic conditions of the resultant trialkylsilyl-protected alkyne of formula (XVI)Step 15: amidation of the resultant carboxylic acid of formula (XVII)
eitherStep 16: metal-catalyzed coupling reaction of the terminal alkyne of the resultant carboxamide of formula (XVIII)
X'-R7" (XIX)
wherein R7" is an optionally substituted aryl group and X' is bromine or iodine;Step 17: then deprotection of the resultant compound of formula (XX)
orStep 17a: direct deprotection of the terminal alkyne compound of formula (XVIII) as defined above, to give a compound of general formula (I)Step 18: metal-catalyzed coupling reaction of a halo derivative of formula (XXI)
NHR10R11 (XXII)
wherein R10 and R11 are independently hydrogen or an optionally substituted group selected from straight or branched C1-C6 alkyl, C3-C7 cycloalkyl, cycloalkyl-alkyl, heterocyclyl and heterocyclyl-alkyl, or R10 and R11, taken together with the nitrogen atom to which they are bonded, may form an optionally substituted 5 to 7 membered heterocyclyl group optionally containing one additional heteroatom selected from N, O and S;Step 19: deprotection of the resultant compound of formula (XXIII)
alternatively,Step 20: regioselective mono-halogenation of a compound of formula (X) as defined above;Step 21: metal-catalyzed coupling reaction of the resultant halo derivative of formula (XXIV)Step 22: regioselective mono-halogenation of the carboxylic ester of formula (IV) as defined above;Step 23: hydrolysis under basic conditions of the resultant compound of formula (XXV)Step 24: amidation of the resultant mono-halogenated carboxylic acid of formula (VI) as defined above through reaction with a derivative of formula (VII) as defined above;Step 25: metal-catalyzed coupling reactions of the resultant mono-halogenated carboxamide of formula (VIII) as defined above through reaction with a derivative of formula (IX) as defined above to give a compound of formula (I)
optionally converting a compound of formula (I) into another different compound of formula (I), and, if desired, converting a compound of formula (I) into a pharmaceutically acceptable salt thereof or converting a salt into the free compound of formula (I). - An in vitro method for inhibiting the JAK and/or Src family kinase proteins activity which comprises contacting the said protein with an effective amount of a compound of formula (I) as defined in claim 1.
- A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, and at least one pharmaceutically acceptable excipient, carrier and/or diluent.
- A pharmaceutical composition according to claim 10 further comprising one or more chemotherapeutic agents.
- A product comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
- A compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, for use as a medicament.
- A compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, for use in a method of treating cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12737280.3A EP2736514B1 (en) | 2011-07-28 | 2012-07-18 | Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11175736 | 2011-07-28 | ||
EP12737280.3A EP2736514B1 (en) | 2011-07-28 | 2012-07-18 | Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors |
PCT/EP2012/064056 WO2013014039A1 (en) | 2011-07-28 | 2012-07-18 | Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2736514A1 EP2736514A1 (en) | 2014-06-04 |
EP2736514B1 true EP2736514B1 (en) | 2017-10-18 |
Family
ID=46545383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12737280.3A Active EP2736514B1 (en) | 2011-07-28 | 2012-07-18 | Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors |
Country Status (4)
Country | Link |
---|---|
US (1) | US8912200B2 (en) |
EP (1) | EP2736514B1 (en) |
JP (1) | JP6016915B2 (en) |
WO (1) | WO2013014039A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
JP5970537B2 (en) * | 2011-04-19 | 2016-08-17 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Substituted pyrimidinyl-pyrroles active as kinase inhibitors |
EP3049110A2 (en) * | 2013-09-23 | 2016-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for targeting tumor microenvironment and for preventing metastasis |
DK3322706T3 (en) | 2015-07-16 | 2021-02-01 | Array Biopharma Inc | SUBSTITUTED PYRAZOLO [1,5-A] PYRIDINE COMPOUNDS AS RIGHT CHINESE INHIBITORS |
AU2016344058A1 (en) | 2015-10-26 | 2018-05-17 | Array Biopharma Inc. | Point mutations in Trk inhibitor-resistant cancer and methods relating to the same |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
CA3019671C (en) | 2016-04-04 | 2024-02-20 | Loxo Oncology, Inc. | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
WO2017176744A1 (en) | 2016-04-04 | 2017-10-12 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
KR102566858B1 (en) | 2016-05-18 | 2023-08-11 | 어레이 바이오파마 인크. | (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl Method for producing )-3-hydroxypyrrolidine-1-carboxamide |
CN107840842A (en) * | 2016-09-19 | 2018-03-27 | 北京天诚医药科技有限公司 | Alkynes is for heterocyclic compound, its preparation method and its in application pharmaceutically |
JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
JOP20190092A1 (en) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
TWI812649B (en) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
TWI791053B (en) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
JP7060694B2 (en) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Substituted pyrolo [2,3-D] pyrimidine compounds as RET kinase inhibitors |
JP7061195B2 (en) | 2018-01-18 | 2022-04-27 | アレイ バイオファーマ インコーポレイテッド | Substituted pyrazolo [3,4-d] pyrimidine compound as a RET kinase inhibitor |
TWI727152B (en) * | 2018-03-16 | 2021-05-11 | 大陸商北京天誠醫藥科技有限公司 | Alkynyl heterocyclic compound, its preparation method and its application in medicine |
EP3829543A1 (en) | 2018-07-31 | 2021-06-09 | Loxo Oncology, Inc. | Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide |
ES2922314T3 (en) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Fused Heterocyclic Compounds as RET Kinase Inhibitors |
US20220081438A1 (en) | 2018-12-19 | 2022-03-17 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
US20220041579A1 (en) | 2018-12-19 | 2022-02-10 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases |
CN109776331A (en) * | 2019-04-02 | 2019-05-21 | 宁夏大学 | A kind of preparation method of 3- methoxyl group -4- Iodoaniline |
AU2020413333A1 (en) | 2019-12-27 | 2022-06-16 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
EP4211140A1 (en) | 2020-09-10 | 2023-07-19 | Schrödinger, Inc. | Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer |
JP2024503661A (en) * | 2021-01-12 | 2024-01-26 | ベイジン・イノケア・ファーマ・テク・カンパニー・リミテッド | Method for producing (S)-1-(1-acryloylpyrrolidin-3-yl)-3-((3,5-dimethoxyphenyl)ethynyl)-5-(methylamino)-1H-pyrazole-4-carboxamide |
JP2024505890A (en) | 2021-01-26 | 2024-02-08 | シュレーディンガー, インコーポレイテッド | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
TW202300150A (en) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | Cyclic compounds and methods of using same |
KR20230165833A (en) | 2021-04-02 | 2023-12-05 | 네르비아노 메디칼 사이언시스 에스.알.엘. | Substituted pyrrole carboxamides, process for their preparation and use as kinase inhibitors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0546082B1 (en) * | 1990-08-29 | 1996-12-18 | E.I. Du Pont De Nemours And Company | Herbicidal pyrrolesulfonylureas |
CA2379064A1 (en) * | 1999-07-15 | 2001-01-25 | Pharmacopeia, Inc. | Bradykinin b1 receptor antagonists |
US7776869B2 (en) * | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
US7812022B2 (en) * | 2004-12-21 | 2010-10-12 | Glaxosmithkline Llc | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors |
EP1924566B1 (en) * | 2005-09-01 | 2016-01-13 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
NZ572202A (en) | 2006-03-27 | 2012-05-25 | Nerviano Medical Sciences Srl | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors |
WO2008062276A2 (en) * | 2006-11-20 | 2008-05-29 | Glenmark Pharmaceuticals S.A. | Acetylene derivatives as stearoyl coa desaturase inhibitors |
TWI426074B (en) | 2008-04-30 | 2014-02-11 | Nerviano Medical Sciences Srl | Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1h-pyrrole-3-carboxamides |
EP2323992B1 (en) * | 2008-07-29 | 2016-07-20 | Boehringer Ingelheim International GmbH | 5-alkynyl-pyrimidines |
US8658662B2 (en) * | 2009-11-11 | 2014-02-25 | Nerviano Medical Sciences S.R.L. | Crystalline CDC7 inhibitor salts |
TW201127384A (en) * | 2009-11-18 | 2011-08-16 | Nerviano Medical Sciences Srl | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent |
-
2012
- 2012-07-18 JP JP2014522036A patent/JP6016915B2/en active Active
- 2012-07-18 WO PCT/EP2012/064056 patent/WO2013014039A1/en active Application Filing
- 2012-07-18 US US14/235,477 patent/US8912200B2/en active Active
- 2012-07-18 EP EP12737280.3A patent/EP2736514B1/en active Active
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
US8912200B2 (en) | 2014-12-16 |
JP2014521621A (en) | 2014-08-28 |
EP2736514A1 (en) | 2014-06-04 |
US20140194406A1 (en) | 2014-07-10 |
WO2013014039A1 (en) | 2013-01-31 |
JP6016915B2 (en) | 2016-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2736514B1 (en) | Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors | |
US9283224B2 (en) | Substituted pyrimidinyl-pyrroles active as kinase inhibitors | |
US10479779B2 (en) | Substituted pyrroles active as kinases inhibitors | |
JP5976778B2 (en) | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | |
JP5925808B2 (en) | Tricyclic derivatives, their preparation and their use as kinase inhibitors | |
CA2835478C (en) | Substituted indazole derivatives active as kinase inhibitors | |
US8846701B2 (en) | Pyrazolo-quinazolines | |
EP2598508B1 (en) | Isoxazolo-quinazolines as modulators of protein kinase activity | |
EP2417125B1 (en) | N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as mps1 kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140220 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20160817 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20170517 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 937333 Country of ref document: AT Kind code of ref document: T Effective date: 20171115 Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012038668 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20171018 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 937333 Country of ref document: AT Kind code of ref document: T Effective date: 20171018 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180118 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180118 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180218 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180119 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012038668 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 |
|
26N | No opposition filed |
Effective date: 20180719 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180718 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20180731 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180731 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180731 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180718 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180718 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20120718 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171018 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171018 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230720 Year of fee payment: 12 Ref country code: GB Payment date: 20230727 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230725 Year of fee payment: 12 Ref country code: DE Payment date: 20230727 Year of fee payment: 12 |